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Abstract 
Organ transplantation remains the best treatment for many patients with end 
organ disease. However, there is a discrepancy between organ supply and 
demand. Many donor organs are not used for transplantation because of risk 
attributes in the deceased donor ranging from infectious risks to specific risks 
associated with the cause of death.  
The aims of this thesis were to identify the number of deceased donors with 
risk attributes and then quantify the risks associated with using organs from 
such donors. This information was then used to provide evidence to the 
transplant community on which to base their decisions on using organs from 
such donors. 
This thesis used data in the UK Transplant Registry, which prospectively 
collects data on the clinical characteristics and follow-up of all donors and 
transplant recipients in the UK, and the Potential Donor Audit, which is a 
prospectively populated registry including all patients who die in UK critical 
care units of donation age.  
The main findings of this thesis were that there are a large number of 
deceased donors with risk attributes, in particular donors with increased risk 
behaviour for blood borne viral disease or with hepatitis C virus infection, 
whose organs are currently not used for transplantation, but that could safely 
be used. The thesis also describes that the transmission of 
meningitis/encephalitis from deceased donors to transplant recipients is a rare 
but serious complication of transplantation, but that transplantation of usually 
excellent organs from such donors should not be contraindicated. Different 
transplant centres display marked variations in practice in using organs from 
donors with different risk attributes, but centres that display greater risk 
appetite in using organs from higher risk donors do not have worse transplant 
outcomes compared to centres with lower risk appetites.  
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Transplantation of organs from higher risk donors can result in excellent 
transplant outcomes. Wide variations in practice are seen across the UK, and 
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1.1 Organ Donation and Transplantation 
Organ transplantation remains a highly successful form of therapy for selected 
patients, either as lifesaving or life enhancing treatment (1).  
However, in the United Kingdom (UK) there remains a large discrepancy 
between organ supply and demand (1). There are currently around 7000 
people awaiting a solid organ transplant and of that number around 400 die 
every year on the transplant waiting list (Figure 1.1) (1). Every day an 
estimated 3 people die secondary to the shortage of organs available for 
transplantation and around 1 in 6 of those listed for a heart, lung or liver 
transplant die or become too unwell to receive a transplant (1,2). Due to this 
discrepancy between supply and demand it is imperative that organs from 
donors are not discarded unnecessarily, and it is important to assess groups 
of donors where utilization of organs could be improved.  
 
Figure 1.1. Number of deceased donors and transplants in the UK, 1st April 2006-
31st March 2016, and patients active on the transplant list, taken from the NHSBT 
Organ Donation & Transplantation Activity report (3). 
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1.2 Waiting list mortality- Balancing of risks 
The risk of using solid organs from donors considered to be of suboptimal 
quality because of donor factors such as older age or infection needs to be 
balanced against the risk of the patient dying following listing for organ 
transplantation (4). This consideration is important for all organ types, since 
although transplantation of livers, lungs or hearts is lifesaving as there is 
currently no viable alternative to transplantation, kidney transplantation has 
been shown to considerably improve a patient’s quality and length of life 
compared to dialysis (4). As such, in the United States (US), 20-40% of 
patients listed for a solid organ transplant have died or been removed from 
the waiting list within 3 years (5). 
The biggest risk of death for patients with end-stage renal failure awaiting a 
kidney transplant relates mainly to the negative health effects of renal dialysis, 
with some studies demonstrating patients on dialysis have up to a 30-fold 
increased risk of mortality compared to a matched healthy population (6,7,8). 
Dialysis has known severe effects on a patient’s cardiovascular function and 
around 20% of deaths of patients on dialysis is secondary to cardiovascular 
disease (9). This effect of dialysis is seen most acutely in patients on dialysis 
with diabetes where mortality 5 years after starting dialysis can be upwards of 
50% for certain age groups (9). Patients are also at increased risk for infection 
whilst on dialysis, in particular sepsis secondary to bacteraemia (9). However, 
dialysis remains a successful treatment and patients can be maintained for 
years successfully. Hence, the risk of not transplanting a kidney from a donor 
with risk attributes is very different to not transplanting other solid organs as 
dialysis is a viable treatment option.  
The burden of liver disease in the UK is increasing, and liver disease is a 
common cause of death in the UK in those aged between 18 and 64 (10). The 
majority of liver disease is secondary to alcohol abuse, with obesity and viral 
hepatitis following alcohol as the second and third commonest reasons for 
liver failure (10-12). The median time from listing for a liver transplant to 
successful transplantation is around 150 days with some variation observed 
between different UK transplant centres. In the UK, of patients listed for a liver 
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transplant in the financial year 2012 to 2013, 68% of patients would have 
been transplanted within 1-year, 17% would still be waiting for a liver, 4% 
would have been removed from the list, and 11% will have died whilst 
awaiting a transplant (10-12). To be listed for a liver transplant, your 1 year 
risk of death of without a transplant should exceed the risk of death after 
transplantation, currently around 8%. Listed candidates are expected to have 
a greater than 50% chance of survival 5 years following transplantation with a 
quality of life that is acceptable to that candidate (10). Mortality on the liver 
transplant waiting list is mainly secondary to progression of the patient’s 
disease and there being no viable treatment in lieu of transplantation (4). 
Hence there is a pressing need to increase the number of liver transplants 
performed due to ongoing high risk of mortality on the transplant waiting list. 
However, one of the major reasons for non-utilisation of livers is because of 
non-desirable risk attributes of the donor (13). As the deceased donor 
population changes, and more donors possess these undesirable risk 
attributes, it is imperative that the livers that can be safely used are not 
discarded (14). In addition, there is also a growing body of evidence that livers 
from donors with risk attributes may function as well as livers without such 
attributes (13,15).  
Heart transplantation is an excellent treatment for patients with end stage 
heart failure, but due to the shortage of suitable hearts available for 
transplantation it remains a potential treatment option only for a select number 
of patients (16). In the UK, over the last 20 years,  there have been increases 
in the number of patients on the heart transplant waiting list, but the number of 
heart transplants being performed has not increased at a similar rate (16). 
One of the major difficulties in heart transplantation is balancing the allocation 
of hearts to the sickest patients requiring transplantation, but also to ensure 
that the patients are well enough to survive the operation and the 
complications following transplantation (16). Current evidence seems to 
suggest that patients with stable heart failure might not necessarily benefit 
from transplantation (17).The number of patients on ventricular assist devices 
(VAD) has increased the number of patients on the heart transplant waiting 
list. VADs can be implanted in patients who otherwise would be likely to wait a 
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long time for a heart transplant, thus using the VAD as a bridge to transplant; 
VADs can reverse end-stage heart failure so that these patients can be 
discharged home. As well as the above group of patients, some patients who 
were not suitable transplant candidates, after a period of support on a VAD, 
may become transplantable. There are now a large number of patients with 
VADs on the heart transplant waiting list. This has increased transplant list 
numbers well beyond the numbers of performed transplants. However, most 
patients with VADs will be re-admitted to hospital with serious complications 
following insertion, so they are not free of complications (17). One of the 
major challenges to heart transplantation is the lack of suitable donors, and 
despite the UK reporting record numbers of deceased donors, only a small 
number of these donors will donate a heart for transplantation (3,17).  
Lung transplantation is the gold-standard therapy for patients with end-stage 
lung disease (18,19). At present, suitable donor allografts are scarce. As 
such, organ allocation strategies are required to best allocate this limited 
resource (19). Lung transplant survival rates are lower than for other solid 
organ transplants, but as the patients listed for a lung transplant in the UK are 
a heterogeneous group across differing disease types, patients with different 
lung pathologies may derive varying levels of benefit from transplantation 
(18). An important consideration in lung transplantation is that some patients 
may be suitable for a single lung transplant or a bilateral lung transplant. The 
patients treated with a single lung transplant may be considered partially 
treated and may have reduced survival but due to lack of donor lungs single 
lung transplantation allows more patients to benefit from this scarce resource 
(18). 
The risk of mortality on the waiting list varies for each patient and between 
organ types. Heart, liver and lung transplantation are lifesaving procedures, 
but not all patients will necessarily derive benefit from transplantation or 
derive benefit from the transplantation of any quality donor organ. Whilst not 
necessarily lifesaving, kidney transplantation confers a survival advantage 
compared to dialysis. The decision to utilise organs from donors with risk 
attributes, be it attributes that may affect organ function (e.g. older age, 
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comorbid disease) or may result in disease transmission (e.g. infection, 
malignancy) is always being weighed up against the risk of the patient dying 
without transplantation. 
1.3 Deceased donation 
The mainstay of organ transplantation is the use of organs from deceased 
donors. There are two main circumstances of deceased donation: Donation 
following brain stem death (DBD) and donation following circulatory death 
(DCD).  
Brain stem death testing, also called neurological determination of death, has 
become an acceptable and common means of verifying death in the UK (20). 
The criteria require the patient to be deeply comatose, unresponsive, 
ventilated and have a known aetiology for their brain injury with potential 
reversible causes for their coma excluded (e.g. metabolic disturbances, 
hypothermia, sedative drugs, other neurological disorders etc.) (20). The 
donor must also have been shown to have no functioning brain stem reflexes. 
These conditions must be tested by two experienced doctors at separate 
times. DBD donors provide the majority of donor organs, despite brain stem 
death being relatively rare. An increasing number of donor organs are now 
coming from DCD donors. Prior to the acceptance of brain stem criteria for 
verifying death in 1979, all deceased donors were DCD donors. When brain 
stem testing became accepted, practice changed, recognising that the 
additional warm ischaemic insult that the donor organs are subjected to was 
deleterious to their subsequent outcome. Despite these concerns, over the 
last decade the number of organs from DCD donors being used for 
transplantation has continued to increase, with several large retrospective 
studies now demonstrating that for kidneys, the results are comparable to 
those for kidneys transplanted from DBD donors following adjustment for 
additional donor and recipient factors (21). Kidneys from DCD donors now 
make up 42.9% of the total number of renal transplants performed in the UK 
(3). While the use of livers from DCD donors is now part of standard UK 
transplant practice, despite the additional ischaemic injury being shown to 
have a higher incidence of graft failure, post-operative complications and 
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ischaemic cholangiopathy (22). The use of lungs from DCD donors provide a 
valuable resource of lungs for transplantation with good results being 
observed (23,24). However, they still make up a smaller proportion (~20%) of 
the total of deceased lung donors in the UK (24). Historically, the use of 
hearts from DCD donors is thought to be associated with poor outcomes (25). 
However, modern perfusion techniques mean this might become a viable 
option to help increase the number of heart transplants performed in the UK. 
Several studies demonstrate that the use of hearts from selected DCD donors 
convey good outcomes for patients (25-28). 
There are two principal types of DCD donor, controlled and uncontrolled. 
Uncontrolled DCD refers to organ retrieval after a cardiac arrest that is 
unexpected and from which the patient cannot or should not be 
resuscitated(29,30), Controlled DCD takes place after death which follows 
planned withdrawal of life-sustaining treatment. The clinical circumstances of 
DCD are described by the Maastricht classification, and there are 4 major 
sub-types of DCD donor described by the Maastricht categories (Table 1.1) 
(29). Although some units in the UK have supported uncontrolled DCD, the 
vast majority of DCD donors in the UK are from controlled Maastricht category 
three patients (29,30). 
Category Type Circumstances Typical Location 
1 Uncontrolled Dead on arrival Emergency Department 
2 Uncontrolled Unsuccessful resuscitation Emergency Department 
3 Controlled Cardiac arrest follows planned 
withdrawal of life sustaining 
treatments 
Intensive Care Unit 
4 Either Cardiac arrest in a patient who is 
brain dead 
Intensive Care Unit 
Table 1.1. The Maastricht classification of Donation after Circulatory Death (adapted 
from Summers et al 2015 (29).  
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1.4 Living donation 
The use of kidneys from living donors has been taking place since 1954, 
when the first successful kidney transplant was performed by transplanting a 
kidney from a living donor into his identical twin. Improvements in 
immunosuppression in organ transplantation have resulted in transplantation 
being possible between non-genetically identical individuals and receiving a 
live donor kidney is now viewed as the gold standard in kidney 
transplantation. It is well documented that the use of kidneys from such 
donors results in improved outcomes for transplant recipients. While living 
kidney donation results in excellent transplant outcomes, it remains a complex 
ethical and moral issue. Living kidney donation is not without risk, but the risks 
are well quantified and low such that they are usually outweighed by the huge 
benefit experienced by the recipient. However, very few studies have 
assessed the mid to long term risks that living kidney donors could face. A 
recent systematic review and meta-analysis looking at the long-term 
outcomes of living kidney donors demonstrated that whilst all-cause mortality, 
cardiovascular disease and diabetes risk were similar for living kidney donors 
and the rest of the population, there was an increased risk of end stage renal 
disease, although this risk was still small (31). The review also demonstrated 
that female living kidney donors may have an increased risk of pre-eclampsia, 
albeit small in absolute terms (31). The findings of this analysis have 
implications on the consent process for living kidney donation and also on the 
follow-up of living kidney donors.  
Living donor liver transplants remain uncommon in the UK, representing 3% 
of liver transplants performed, but living liver donation is the predominant form 
of liver transplantation in India and across Asia (32-34). In the UK they are 
performed for both Adult and Paediatric recipients, although this form of liver 
transplantation has been more common for paediatric recipients (34). The 
risks associated with living liver donation are significantly higher than for living 
kidney donation, with a complication rate in the donor around 21% (34-36). 
True mortality rates for living liver donors are unknown but in the US the 
mortality rate is roughly 0.2% (34). Reported outcomes from living liver donors 
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have been promising, and living liver donation remains a viable method by 
which to increase the number of liver transplants performed in the UK (34).  
1.5 Allocation 
1.5.1 National and Local Organ Allocation 
Deceased donor organ allocation in the UK may be patient-specific offering, 
where the offering scheme has been developed with specific aims in mind 
using available evidence (e.g. kidney, pancreas, liver) or centre based 
offering, where the organ is deemed to be the responsibility of the transplant 
centre in whose zone the donor hospital lies, with the local transplant 
clinicians taking on the responsibility of selecting the most eligible recipient 
from their waiting list. In the latter situation transplant centres develop their 
own centre based allocation policies. Both types of organ allocation present 
different problems (37,38). Patient specific offering means that offers of 
organs from donors with specific risks may be declined, not because of the 
donor but because of the recipient. Centre-specific offering results in a large 
amount of responsibility being left to the transplanting clinicians to ensure fair 
allocation and the decision to accept an offered organ; in particular organs 
with potential infection transmission are often declined for transplantation 
(37,38). Solid organ allocation has undergone several changes over the last 
20 years, with different allocation/offering schemes being introduced to try and 
reduce inadequacies or inequities in transplantation observed in prior 
schemes. A summary of the major changes in abdominal organ allocation in 
the UK is shown in Figure 1.2.  
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Figure 1.2. Timeline of major changes to abdominal organ allocation in the UK from 
1996-2016. 
1.5.2 Super-urgent recipients and fast-track of organs 
For some patients awaiting organ transplantation, the severity of their organ 
failure may lead to death within a few days in the absence of successful 
transplantation. The most common situation this applies to is for liver 
recipients or heart recipients. Allocation schemes can recognise the urgent 
need for transplantation for such recipients and allocate the next organ 
available nationally to these recipients (39).  
Fast-tracking of deceased donor organs refers to simultaneous offering of 
deceased donor organs to all UK transplant centres which have opted in to 
such schemes. The aims of the fast-track scheme are to reduce cold 
ischaemic time on deceased donor organs and also to improve utilisation of 
organs. The fast-track scheme for kidneys was introduced in November 2012 
for kidneys from DBD donors and in March 2013 was expanded to include 
kidneys from DCD donors. The UK kidney fast-track scheme has resulted 
several hundred successful kidney transplants, and early allograft outcomes 
are favourable (40).  
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1.5.3 Human Leucocyte Antigen (HLA)-matching and compatibility 
Immediately following consent for organ donation by the donor’s next of kin, 
blood is taken from the potential donor, sent to a tissue typing laboratory, and 
the donor’s HLA type and blood group determined. HLA is the human form of 
the major histocompatibility complex (MHC) (41). The HLAs corresponding to 
the MHC Class 1 are HLA-A, HLA-B and HLA-C. HLA is glycoprotein on the 
surface of cells that plays a major role in adaptive immunity(41). In 
transplantation, HLA class 1 and HLA class 2 play an important role. HLA 
class 1 is found on the surface of all nucleated cells and consists of a trans-
membrane polymorphic heavy chain stabilized by a non-polymorphic surface 
structure the b-2 microglobulin. The heavy chain has three immunoglobulin 
like domains, a1, a2,, and a3. The a1 and a2 domains form a groove consisting 
of 2 a- helices and a b-pleated sheet which holds fragments of intracellular 
peptide. The a1 and a2 domains are incredibly polymorphic, whereas the a3 
domain is highly conserved and interacts with CD8 co-receptor of T-cells (42). 
There are several major sub-types of Class II HLA, namely HLA-DP, -DQ and 
–DR. Class II HLA molecules consist of two transmembrane glycoprotein 
chains, the a and b chains. Class II molecules are found on immune cells and 
they express endogenous peptide to CD4 T-helper cells (43). The major 
mechanisms by which a transplant candidate will have developed antibodies 
to non-self HLA is via blood transfusion, having been pregnant or had a 
previous transplant (41,44). If they have been exposed to non-self HLA by 
one of the above means they may develop anti-HLA antibodies. If they 
receive a transplant bearing HLA to which they have developed a prior 
antibody, this may result in hyper-acute rejection (within minutes of 
transplantation) or early acute antibody mediated rejection which can occur a 
few days after transplantation (41,45). 
1.5.4 Kidney allocation 
Due to the complexities and importance of HLA-matching in kidney 
transplantation, kidney allocation schemes have been developed to ensure 
that this national resource of donor kidneys are used for the best recipients. 
There have been several iterations of kidney allocation schemes in the UK. 
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The first national allocation system came into place in 1998 as the National 
Kidney Allocation scheme (NKAS) for heart beating donors (DBD donors) 
(46). This allocation hoped to compromise between equity and utility and 
kidneys were allocated based on tiers of HLA-matching (46,47). This 
allocation scheme was found to result in continued inequity of access to 
kidney transplantation for highly sensitised patients and patients of non-white 
ethnic origin. The 2006 NKAS replaced the 1998 NKAS because of this 
recognised inequity, and is still in place today. The main aim of the 2006 
NKAS was equity of access to transplantation among all patients regardless 
of geographical location, ethnicity and rareness of HLA type. The 2006 
scheme gave absolute priority to well matched patients, but that within that 
group, paediatric patients (<18 years) received absolute priority over adults. 
This allocation scheme improved access to transplantation, however inequity 
remained for highly sensitised and patients of non-white ethnicity. A new 
proposed kidney offering scheme has since been developed and will seek to 
address this (48). 
Kidneys are only retrieved from a potential DCD donor when an implanting 
kidney transplant centre has indicated that they are provisionally prepared to 
transplant them, on the basis of the available donor information, including 
age, comorbidity, and risk of disease transmission (Figure 1.3) (49,50). There 
is marked variation between transplant centres in their willingness to use 
kidneys from DCD donors in the United Kingdom (51). Pre-2014, most DCD 
donor kidneys were allocated to patients living within the region associated 
with the donor hospital. From September 2014 one of the pair of DCD kidneys 
is allocated nationally and one donor kidney is retained for local use.  
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Figure 1.3. Summary of organ donation timeline from offer to transplant/discard. 
(modified from Summers et al. Kidney International 2015) (29).  
1.5.5 Other organ allocation 
Listing for liver, heart and lung transplantation is based on criteria that have 
been agreed and published nationally and an appeals panel exists to allow for 
exceptions to the agreed criteria(10,52-54).  Each transplant unit has a 
designated zone in the UK, and the size of the zone is adjusted annually to 
ensure that the proportion of candidates on the Unit’s waiting list is 
proportional to the proportion of deceased donors in the UK. There is 
considerable centre variation both in the numbers of patients on the wait list, 
the number of transplants done and the rates of acceptance (3). It is the 
responsibility of each Unit to decide whether to accept the offered liver, heart 
or lung and select the most appropriate recipient (54).  
The sequence of offering of DBD livers is shown in Figure 1.4.  
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Figure 1.4. Summary of liver allocation in the UK under new 2015 National Liver 
Allocation scheme (54). 
1.6 Infections in organ donation and transplantation 
The prevention, diagnosis, and management of infectious disease in both 
organ donors and solid organ transplant recipients are some of the main 
contributors to the improved allograft outcomes observed in organ 
transplantation (55,56). The risk of serious infections in organ recipients is 
determined by a combination of factors, including the patients exposure to 
different infections and their level of immunosuppression. Donor transmission 
of infection is another factor that determines a transplant recipient’s infection 
burden post-transplant, with the outcome of transmitted infections varying in 
severity (56,57). A timeline created by Fishman et al summarises the major 
infections that affect transplant recipients, and when post-transplant the 
patients might experience such infections (Figure 1.5) (58). 
New quantitative molecular microbial assays and therapies have improved 
detection of infection in organ donors and transplant recipients and have 
helped to improve prevention and treatment of infection. Major hurdles that 
will likely impact on infection in transplant candidates include the shifting 
worldwide epidemiology of infections, in particular recent viral outbreaks in 
South America and Africa (58). Increasing antimicrobial resistance poses a 
major threat to organ transplantation. Several studies have now demonstrated 
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poor outcomes of transplant patients infected with multi-drug resistant 
organisms (MDRO), and also donor transmission of MDRO to transplant 
recipients (59,60). Other hurdles are suboptimal assays for the microbiological 
screening of organ donors, and virus-associated malignancies for which 
patient specific susceptibility is yet to be fully explored (61).  
1.6.1 Current Microbiological screening in organ donors 
The advisory committee for the safety of blood, tissues and organs (SaBTO) 
stipulate both mandatory and recommended screening of donor blood, tissues 
and organs. As demonstrated by Table 1, the requirements vary depending 
on what is being donated. Currently in the UK, all patients who have been 
consented for organ donation are screened for the presence of the following 
transmissible infections (63): 
• Human immunodeficiency virus (HIV)  
• Hepatitis C virus (HCV)  
• Hepatitis B virus (HBV)  
• Human T-lymphotropic virus (HTLV) (1 and 2)  
• Toxoplasma gondii (Toxoplasmosis) 
• Treponema Pallidum (syphilis)  
• Epstein-Barr Virus (EBV) 










Infection  Serological 
Test  










HIV1/2  Anti- 
HIV1/2Ab/HIV 
Ag combo  
M  M  M  M  
HBV  HBsAg  M  M  M  M  
 
Anti-HBc  M  M  M  M  
HCV  Anti-HCV IgG  M  M  M  M  
HTLV1/2  Anti- HTLV1/2  R  M  M  M  
Syphilis  Anti-T. 
pallidum 
antibody  





R  NR  R NR  
CMV  Anti-CMV IgG  R  NR  R  R  
EBV  Anti-EBV IgG  R  NR  R  NR  
HEV  HEV RNA  R  R  R  NR  
Chlamydia 
trachomatis  
n/a  NR  NR  NR  M  
M= Mandatory test; R= Recommended test; NR= Not required/ not applicable. 
Table 1.2 Mandatory and recommended screening of organ, tissue and cell donors 








Figure 1.5. Timeline of infections following organ transplantation (adapted from 
Fishman et al (58). 
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1.6.2 Interpretation of microbiological results in transplantation 
Following exposure to, and infection by a microbiological agent there is a 
period of time during which no microbe can be readily recovered from the 
host; this is classically called the eclipse period (Figure 1.6) (64-67). 
Donations taken during this period are unlikely to be infectious but in practice 
this would not be safe (63). The time from infection to the onset of detectable 
infectivity depends upon the method used for detection of infection. This 
period of infectivity which cannot be detected is colloquially called a “window” 
and represents the duration of undetectable infectivity. This “window” is 
shortest for genomic (nucleic acid technology testing (NAT)) and antigen 
tests, and longest for antibody tests. For practical purposes, the time from 
infection to first detection of a marker is referred to as the “window period” 
(58,65,67). 
 
Figure 1.6. Demonstrating of the eclipse, antigen/NAT window, and antibody window 
period following infection. Modified from SaBTO 2017(63) 
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1.6.3 Common donor derived infections 
If a potential donor is found to have either anti-EBV or anti-CMV antibodies, it 
does not immediately represent a contraindication for donation, as 
transmission of these viral infections has become an accepted part of 
transplant practice, largely due to the high prevalence in the donor population 
(63). Transmission of these viruses can, however, result in severe 
consequences for the transplant recipients (68-70). Transmission of EBV can 
result in post-transplant lymphoproliferative disorder (PTLD). The incidence of 
PTLD in the solid organ transplant recipients has never been accurately 
determined. Different incidences are reported depending on the organ that 
has been transplanted and the recipient’s EBV serostatus pre-transplant (68-
70). CMV, when transmitted or reactivated in the transplant recipient, can 
cause a whole host of inflammatory processes notably colitis and pneumonitis 
and can often prove fatal if treatment does not resolve the viraemia. It is also 
becoming more common for CMV to develop resistance to both valganciclovir 
and foscarnet through the mutations in UL54 and UL-97, resulting in 
significant morbidity or mortality in the recipient (71-73).  
1.7 Increased risk organ donors 
1.7.1 The impact of blood borne viral infections on donation and 
transplantation 
A group of donors whose organs are often not used for transplantation are 
donors who have proven infectious diseases, particularly blood borne viral 
diseases (BBV) such as HCV, HBV, HTLV, and HIV. This is because of the 
likely transmission of the virus to the immunocompromised recipient.  
1.7.2 HTLV 
HTLV-1 is a retrovirus, in which infection in around 5-8% of non-
immunocompromised patients results in one of two clinical disorders: HTLV-
associated myelopathy and adult T-cell associated leukaemia / lymphoma 
(74). The impact that HTLV transmission has on immunocompromised 
individuals is not well understood, with several case reports suggesting rapid 
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progression of HTLV-associated myelopathy, but recent UK transmissions 
from a single donor to three recipients showed early infectious spread but no 
development of disease (74-76). Detection of antibodies to either HTLV-1 or –
2 is a contraindication to organ and tissue donation in the UK (62,77,78).  
1.7.3  Hepatitis C virology and epidemiology in donation and 
Transplantation 
HCV is a RNA virus of the family Flavaviridae. Exposure to HCV can result in 
acute infection which in around 80% of individuals will result in chronic 
infection. The global prevalence of HCV (based on the presence of anti-HCV 
antibodies) is estimated to be around 1.6% (roughly 115 million people), with 
estimates of the global viraemic prevalence (i.e. the number of people with 
detectable HCV RNA) estimated at 1%, although these estimates may be an 
underestimate (79,80).  
Prevalence of HCV infection shows variation across the globe. The countries 
with the highest prevalence for HCV are those with the greatest exposure to 
iatrogenic transmission of HCV. Currently around 250,000 people in the UK 
are thought to be infected with HCV and with increasing demand for organs 
for transplantation it is possible that selected Hepatitis C positive donors 
(HCVpos) may represent a source of organs for transplantation (Figure 1.7). 
However western countries account for a minority of the global prevalence of 
HCV (79). HCV infection also shows marked age distributions. In countries 
where the major route of transmission is through intravenous drug use (IVDU) 
the age of people infected is considerably lower than those who are infected 













Figure 1.7. Viraemic prevalence of HCV around the world (from Manns, M. P. et al. 
(2017) (79)9 
HCV is primarily transmitted through percutaneous blood exposure, such as 
through medical procedures or through the sharing of devices for IVDU. 
Vertical transmission and sexual transmission have also been reported, but 
are far less common. In the UK, iatrogenic spread of HCV has been 
significantly reduced since screening of blood products was introduced and 
through leucodepletion of blood products, leaving IVDU as the major route of 
HCV transmission (78). Other important risk factors for HCV include 
occupational exposure (i.e. working in healthcare and sustaining a needle 
stick injury) and tattooing. Nevertheless, in many cases no risk factor is 
identified.  
HCV is a very heterogeneous virus with seven main genotypes, designated 1-
7.  These genotypes have many subtypes identified by lower case letters (e.g. 
2a,2b…). The HCV genotype influences disease course and response to 
treatment.  
1.7.4 Diagnosis of HCV 
In organ transplantation, HCV is often identified through the presence of anti-
HCV antibodies in the donor blood. Following detection of these anti-HCV 
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antibodies the transplant centre will then test for HCV RNA or detectable HCV 
antigen via PCR or NAT testing. There is often a window period following 
infection until detection of HCV antibodies can occur (the antibody window 
period) (Figure 1.7). Due to this infection window period the history of the 
donor for any behaviour that would place them at increased risk of blood 
borne viral disease is heavily relied upon for donor characterisation and 
assessing the safety of the organs for transplantation. This behavioural history 
therefore influences a clinician’s likelihood of accepting the organs from an 
RNA negative HCV antibody positive individual (81,82). 
1.7.5 HCV and transplantation 
The progression of chronic HCV infection is from hepatic fibrosis to cirrhosis 
and hepatocellular carcinoma. HCV infection is a common cause of liver 
failure and requirement for transplantation (10). In addition to the hepatic 
complications seen in HCV there are a number of extrahepatic complications 
including cryoglobulinaemia, renal failure secondary to cryoglobulins or 
glomerulonephritis (GN) (in particular type 1 mesangiocapillary GN), and 
Hodgkin’s lymphoma (79). In addition, patients have increased insulin 
resistance leading to diabetes mellitus, as well as increased cardiovascular 
disease and risk of stroke (83). The role HCV plays in end organ damage is 
therefore multifactorial and patients with chronic HCV can often require 
transplantation of organs other than the liver. At present, organs from HCV 
antibody positive (HCVpos) deceased donors are seldom used for 
transplantation because of the high probability of disease transmission, with 
an accelerated risk of cirrhosis and liver failure. National guidance in the US 
and UK currently strongly cautions against the use of organs from HCVpos 
donors (55,57,62). Until recently, treatment of HCV in the allograft recipient 
was expensive, toxic and relatively ineffective (84). However, the advent of 
highly effective direct acting anti-viral agents (DAA) has greatly improved the 
outcome for HCV infected patients, with over 95% achieving sustained 
virological response (SVR) (85,86). Hence, transmission of HCV could come 
to be viewed in a similar light to EBV and CMV transmission (87).  
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1.7.6 Mechanism of action of DAA 
There are four classes of DAAs, defined by their mechanism of action and 
target. The four classes are non-structural proteins 3/4A (NS3/4A) protease 
inhibitors (PIs), NS5B nucleoside polymerase inhibitors. The NS3/4A 
protease was identified as a major target for antiviral intervention, as its 
blockade shuts down the intracellular life cycle by inhibiting maturation of 
the viral polyprotein (79). Replication has been identified as a major target 
for antiviral drugs. Replication can be directly inhibited by NS5B inhibitors. 
These include nucleotide analogues, which function as RNA chain 
terminators, and non-nucleoside inhibitors of NS5B that target allosteric 
sites of the enzyme and make it non-functional. NS5A inhibitors alter the 
regulatory role of NS5A and seem to disorganize the replication complex 
thereby inhibiting HCV replication in a potent manner, enhanced by their 
ability to also inhibit viral assembly and release (79).  
1.7.7 Hepatitis B virus 
HBV is a double stranded enveloped virus of the hepadnaviridae, with its 
primary replication occurring in the liver, hence the risk of transmission is 
highest following liver transplantation. Recently, there has been a trend 
towards using organs from donors who test positive for HBV as around 1/3rd 
of the global population has serological evidence of past infection or current 
infection. An estimated 400 million people are infected with HBV worldwide, 
with variation in prevalence depending on geographic region (88). Despite 
effective measures to prevent HBV infection via immunization and also 
effective anti-viral therapy, HBV infection remains a common blood borne viral 
disease and an important cause of end stage liver failure and requirement for 
liver transplantation (89). The first advances in HBV treatment were with 
Hepatitis B immunoglobulin and lamivudine which resulted in improved 
survival rates for patients with HBV. Following this, nucleoside(tide) 
analogues have demonstrated that they can prevent the need for liver 
transplantation for some patients by preventing end stage liver disease. 
These analogues also have meant that recurrence of HBV post-liver 
transplant is now rare. Deceased donors who are anti-HB virus core antibody 
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positive are being increasingly used for liver transplantation. However, without 
effective prophylaxis, HBV transmission has been estimated to be as high as 
86% (89).  
1.7.8 Human Immunodeficiency virus (HIV) 
The presence of HIV infection in an organ donor is currently a contraindication 
to donation in the UK except in exceptional or lifesaving circumstances (63). 
Despite this guidance indicating there are situations where the organs from 
these donors could be used, there remains a reluctance to use organs from 
such donors. Over the last decade there has been an increasing number of 
reports describing successful organ transplantation of HIV positive donor 
organs to HIV positive recipients. Current epidemiological analysis suggests 
that since the introduction of highly active anti-retroviral therapy, life 
expectancy with treated HIV is roughly two-thirds that of the general 
population (90,91). Although several reports indicate that episodes of acute 
rejection are significantly higher in HIV infected individuals, in general 
transplant outcomes were favourable (92).  As an increasing number of 
patients with HIV develop ESRD, the use of HIV positive donor organs for 
transplantation could become more common in order to address the 
discrepancy between organ supply and demand. It has also been proposed 
that HIV infected patients on the waiting list could be allocated HIV infected 
organs. Preliminary experience of transplanting kidneys from HIV infected 
donors to HIV infected transplant recipients in South Africa has been 
reassuring and the first UK case of transplanting HIV infected kidneys to two 
HIV infected recipients has demonstrated that it is safe and effective (93).  
1.7.9 Increased ischaemic risk donors 
Death secondary to hanging, drowning or carbon monoxide (CO) inhalation 
results in global tissue hypoxia, and may have severe detrimental effects on 
organs that might be used for transplantation (94,95). However, thus far there 
has been no convincing evidence to refute or uphold this assertion. As such, 
there is no current guidance in the US, UK or Europe as to whether organs 
from such donors should be used for transplantation. 
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Suicide by hanging is one of the most common suicide methods and suicide 
remains a common cause of death, especially in the younger population 
(96,97). During hanging there is compression of the carotid arteries, jugular 
veins and the trachea resulting in raised intracranial pressure, cerebral 
oedema and brain death. In addition to the above, the suicide victim also 
develops pulmonary oedema and multi-organ failure secondary to global 
tissue hypoxia (94,98). Hence, donors who died by the above mechanism 
may have greater risk for hypoxia driven organ damage. There are also 
concerns regarding the amount of down time that the patient may have had 
prior to organ retrieval, and hence an unknown amount of ischaemic insult to 
the organs. With regards to the lungs from donors who have drowned, there is 
concern about possible infectious complications (99). 
The effect that these causes of death have on the quality of donor organs has 
never been fully established and due to the ongoing shortage of organs 
available for transplantation, organs from these donors have been used for 
transplantation. 
1.7.10 Other donor diseases 
There is growing concern over the possibility of transmission of donor 
autoimmunity to the recipient (100-102). The risks that these donors pose, in 
particular donors with immune thrombocytopaenia (ITP), has never before 
been quantified.  
There is also concern over the presence of donor connective tissue disease 
such as Ehlers-Danlos and Marfans and how this may affect the organ and 
the ability of the surgeon to implant it. The presence of these conditions may 
also result in graft dysfunction or failure (103). 
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1.8 PhD Aims 
1.8.1 PhD project objectives 
The objectives for this PhD were to: 
1. Describe the proportion of organ donors in the UK who died of 
meningitis and encephalitis and their corresponding transplant recipient 
outcomes 
2. Describe the rate of autoimmune disease transmission from donors 
with ITP 
3. Describe the different types of behaviour associated with increased risk 
of viral transmission in the UK donor population and to what extent 
their use results in unexpected blood borne viral disease transmission 
4. Describe the UK experience of using organs from donors with HCV and 
evaluate the benefit in organ donation and transplantation if organs 
from these donors could be used.  
5. Evaluate the effect that donor death by ligature asphyxiation has on 
renal transplant outcomes. 
6. Describe how variations in risk appetite between renal transplant 





1.9 The UK Transplant Registry 
Information is collected about the donor, the transplant procedure and the 
recipient for every transplant carried out in the UK and this is recorded in the 
UK Transplant Registry (UKTR). These data are collected from a variety of 
different sources including specialist nurses in organ donation (SNODs), 
donor and recipient transplant coordinators, transplant surgeons and 
clinicians and the staff involved in tissue-typing. This information is then 
relayed, often in paper form, to National Health Service Blood and Transplant 
(NHSBT) for input into the registry. In addition to the above, NHSBT formely 
employed data collectors who were given authorisation to access transplant 
follow-up data (graft and patient survival). This has since been replaced, and 
most centres now report their own follow-up to NHSBT. While much 
information is entered into specific fields, a large amount of information on 
deceased organ donors and recipients is recorded in the UKTR as free text 
entries. For deceased donors, this typically includes information about specific 
medications the donor may have been taking, causes of death that are not 
coded in the registry, and any other information deemed to be important by 
the transplant team to record at time of donation. With regards to transplant 
recipients, information held in the free text entries often relates to pre-
transplant organ failure that is not coded in the registry and any causes of 
post-transplant organ failure or death that don’t correspond to a specific cause 
stated in the UKTR. These free text entries could be accessed and analysed 
through coding for specific search terms, followed by manual review of the 
notes of the deceased donors or recipients identified from the code. Specific 
statistical code to search the free-text entries is shown in Appendix 1. 
1.10 The Potential Donor Audit 
The Potential Donor Audit (PDA) is a prospective registry of all patients aged 
less than 80 years who died in critical care units of acute hospitals in the UK, 
irrespective of their medical suitability to become organ donors.  The PDA 
was established to determine the potential number of solid organ donors and 
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provide information regarding different hospital practices about donation, as 
one of a series of measures aimed to improve organ donation in the UK. For 
the present analysis information from the PDA was only analysed from 2009 
onwards when the coded reasons for why potential donors did not proceed to 
donation was made more comprehensive with a choice of 24 coded 
‘contraindications’ to donation (e.g. Haematological malignancy; HIV) and 14 
‘reasons’ why organ donation did not proceed (e.g. family refusal; coroner 
refusal). Up to 2013 only deaths in critical care units of patients up to the age 
of 75 years were included in the PDA, but from 2013 the age limit was 
increased to 80 years.  
Initially patients who died in cardiothoracic intensive care units were not 
included in the audit, but from 2013 such patients have also been included in 
the audit.  
1.11 Incident Reporting 
Prior to 2010, recipient centres were expected, according to UK guidance, to 
report any adverse outcomes in recipients relating directly to the organ 
donation process to NHSBT, including, in the case of donors with 
meningitis/encephalitis, transmission of the causal agent. This reporting 
requirement became mandatory when the 2010 European Union Organ 
Donation Directive (EUODD) was written into UK law in the Quality and Safety 
of Organs for Transplantation Regulations (2012).  
1.12 Changes in SaBTO guidance 
Over the last 18 years the SaBTO guidance has changed three times to 
reflect changes in transplant practice. These guidelines have therefore 
changed over the course of the study periods for each results chapter. In 
order to present the findings of the results chapters in the context of 
guidelines at the time, the major changes in SaBTO guidance are 
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in the UK 
Study period 
1st January 





transplantation if no visible 
damage or local infection in 
organ at retrieval-donation 
acceptable with appropriate 
recipient antibiotic 
prophylaxis covering donor 
organism.                
Bacterial meningitis  
No significant change 
Bacterial Meningitis      




Not specifically mentioned 
but included in the following: 
Donor has any history of 
neurodegenerative disease 
of unknown aetiology-
Donations can never be 
accepted from a donor with a 
degenerative neurological 
disease of unknown 
aetiology 
 
Meningitis unknown aetiology 
Change: Material from 
meningitis cases from whom no 
organism is cultured should not 
be used for donation 
Meningitis unknown aetiology        
Change: Material from cases of 
death from meningo-encephalitis 
where no organism is cultured 
should not be used for donation, 
except in the circumstance that 
the following conditions are met: 
- The infection is thought 
due to a bacterium by 
clinicians caring for the 
patient. 
- Microbiological cultures 
are negative because 
they were taken after 
antibiotics had been 
started. 
- Appropriate and 
adequate antibiotic 
treatment has been given 
to the recipient. 
- Expert microbiological 
advice has been 
obtained. 




Herpes simplex (HSV) or 
varicella zoster infection 
(VZV)- contraindication to 
donation unless HSV/VZV 
treated for 7+days, if treated 
less then 7 days, recipient 
should have anti-viral 
prophylaxis 
Other aetiology, donor not 
abroad- careful expert case 
consideration by case 
assessment required 
Other aetiology, donor 
abroad recently-
contraindication to donation. 
Viral meningo-encephalitis  
Change: If HSV or VZV CNS 
infection is diagnosed as a 
manifestation of systemic viral 
infection (as seen in neonates 
and the immunosuppressed), 
donation of organs, tissues and 
cells is contraindicated as the 
viruses may be disseminated 
widely with associated viraemia. 
HSV encephalitis without 
evidence of systemic infection 
can be treated with antiviral 
therapy and the likelihood of 
disseminated infection in the 
donor is small, even without 
antiviral therapy. In this situation 
antiviral prophylaxis should be 
considered for the recipient.  
Eyes must not be donated if the 
donor has a past history of, or 
active infection with, either HSV 
or VZV. 
Viral Meningo-encephalitis 






















2003 to 31st 
December 
2015 
Cautions against use if risk 
behaviour identified within 
preceding 12 months. 
Information on donors to 
be collected: 
The following information 
should be gained from living 
donors or, for dead donors or 
living donors not capable of 
discussing these matters, 
from their most relevant life 
partner or close family 
member.  
Is the donor or their partner 
known to have HIV, Hepatitis 
B or Hepatitis C ?  
For men, has the donor ever 
had sex with another man?  
Has the donor ever received 
money or drugs in payment 
for sex?  
Has the donor ever injected 
or snorted drugs, even 
once?  
In the last 12 months, has 
the donor had sex with:  
someone who is, or may be, 
HIV positive?  
 a man who has had sex with 
another man (if the donor is 
female)?  
a person who receives 
money or drugs in payment 
for sex?  
anyone who has ever 
injected or snorted drugs?  
anyone who has been 
sexually active in parts of the 
world where the main route 
of HIV infection is 
heterosexual sex?  
Change: No advice on 
appropriateness of patients for 
organ donation 
Information on donors to be 
collected: 
Change: Any behavioural 
history that could have put the 
donor at risk of blood-borne 
viruses. This will include 
questions about risk behaviours 
such as recreational drug use, 
men who have sex with men 
(MSM), and risks such as 
accidental body fluid exposure;  
 
Change: Advises specific consent 
on additional risk that donor poses 
and said discussion to be 
recorded in patients notes 
Information on donors to be 
collected: 
Change: Behavioural history that 
could have put the donor at risk of 
transmissible pathogens This will 
include questions about risk 
behaviours such as recreational 
drug use, men who have sex with 
men (MSM), sex with commercial 
sex workers, sex with a partner 
know to have a sexually 
transmissible disease, 










2000 to 1st 
January 2016 
 
Donor HCV antibody 
Contraindication to donation. 
Consider only in life-saving 
situations (after discussing 
all implications with organ 
recipient or those close to 
the patient) if the patient is 
already infected with HCV 
Donor HCV RNA/NAT 
positive 
Not addressed in guidance 
Donor HCV antibody/antigen 
positive and Donor HCV 
RNA/NAT positive 
Change: Contraindication to 
donation- caveat in exceptional 
circumstances, a life-preserving 
donation from an infected donor 
may be released for clinical use 
in a recipient who also is 
infected with or has cleared 
HCV in accordance with. In 
exceptional circumstances a life-
preserving donation from a 
donor whose serum is 
concordantly repeatably reactive 
for, or contains, anti-HCV may 
be released for clinical use 
providing HCV RNA is 
Donor HCV IgG antibody 
positive- Relative contraindication 
to donation  
Donor HCV RNA NAT or HCV 
combination Ab/Ag (”combo”) 
test  
Relative contraindication to 
donation  
Change: New "HCV infection in 
the potential donor does not 
amount to an absolute 
contraindication to donation of 
material for life-preserving 
transplantation, however the net 
benefit of transplantation must be 
considered against the risk of not 
receiving that specific transplant. 
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undetectable, bearing in mind 
that this does not absolutely 
exclude infectivity. Consider 
seeking expert advice 
concerning HCV management in 
recipient. 
This risk/benefit analysis allows 
for the potential use of a 
transplant from a HCV infected 
donor to a non-infected recipient" 
(63). 
Table 2.1.  Summary of the changes in SaBTO guidance (2000-2017) as pertains to 
each relevant results chapter.   
1.13 Donor Risk Indices 
In order to estimate the potential graft survival of discarded donor kidneys the 
UK Kidney Donor Risk Index was used (UKKDRI). This risk index takes into 
account variables that significantly impacted on graft survival and uses 
coefficients from a multivariate analysis to generate an equation that is used 
to predict the risk of graft failue.  
UKKDRI was calculated by the following equation: 
UKKDRI = exp{0.245 x (donor age <40)+ 0.396 x (donor age ³60) + 
0.265 x (history of hypertension) + 0.0253 x [donor weight (kg) 75 ]/10) + 
0.00461 x (days in hospital)+  0.0465 x (adrenaline)(104). 
Similarly, an equation has been generated in order to predict the likelihood of 
liver graft failure post transplanted. The UK Donor Liver Index (DLI) is 
calculated using the following equation: 
DLI = exp{1.61 + 0.0084 x age − 0.012 x height[m] − (0.17 if female) + (0.64 if 
DCD) + (0.49 if split liver) + (0.16 if smoker) + 0.0092 x bilirubin [in µmol/L] 
(105). 
There is currently no UK donor cohort validated risk index for heart, lung, or 
multi-visceral deceased organ donors. The Pancreas Donor risk index 
constructed using the Scientific Registry of Transplant Recipients in the US, 
has been validated on the UK donor population to predict allograft survival 
following simultaneous kidney-pancreas (SPK) transplantation (106). It did not 
predict allograft survival following pancreas transplant alone or pancreas after 
kidney transplantation (106). 
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1.14 Estimated glomerular filtration rate (eGFR)  
Calculated from the modification of diet in renal disease calculation (MDRD) 
equation (107): 
=186 x (Creat / 88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black) 
1.15 HLA, UKELD and MELD definitions 
HLA-mismatch level was defined according to UK allocation policy for kidneys 
from brain-death donors and was based on the mismatch between donor and 
recipient at the HLA-A, -B, and -DR loci: level 1 was a 000 HLA-A, -B, and -
DR mismatch; level 2 was a 0 HLA-DR plus 0 or 1 HLA-B mismatch; level 3 
was a 0 HLA-DR plus 2 HLA-B mismatch or a 1 HLA-DR plus 0 or 1 HLA-B 
mismatch; and level 4 was a 2 HLA-DR or a 1 HLA-DR plus 2 HLA-B 
mismatch (50).  
The United Kingdom End-Stage Liver Disease (UKELD) and Model of End 
Stage Liver Disease (MELD) scores were used when assessing differences in 
liver recipient characteristics. UKELD score is calculated based on the 
patient’s international normalized ratio (INR) of prothrombin times, serum 
creatinine, serum bilirubin, and serum sodium (108). MELD score is 
calculated based on recipient serum bilirubin and creatinine levels, INR and 
underlying cause of liver disease (109,110) 
1.16 Statistical Analysis 
1.16.1 Univariate Analysis 
Principal univariate analysis was carried out using t-test for parametric 
continuous data and Wilcoxon for non-parametric continuous data. To test for 
normality the Anderson-Farling method was used. 
Fisher’s exact test and chi-squared (2) were used to compare categorical 
data.  
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1.16.2 Survival Analysis and Kaplan-Meier tables 
Survival data in medicine is concerned with the time it takes an individual to 
reach an end point of interest. The survival analyses in this paper are 
concerned with the time it takes a transplant patient to die following organ 
transplantation (patient survival) or the time it takes for the patient’s transplant 
allograft to fail (graft survival). Survival data is characterized by two features:  
1. Length of time for the patient to reach the end point of interest 
(e.g. death) 
2. Censoring of the data 
Survival times reflect the time from the ‘starting point’ (for most of this work 
that will be the time of transplantation) until the outcome of interest is reached. 
Often it is not known when this endpoint of interest is reached, only that the 
patient remained free of this endpoint over the specified study period (i.e. the 
patient may have experienced graft loss following the study period or it may 
not be known if the graft failed because the patient was lost to follow-up). 
These patients are described as being ‘right-censored’. ‘Right-censored’ 
means the patients were known to not have reached the endpoint of interest 
when they were last followed-up. ‘Left-censored’ data refers to when follow-up 
for the study begins after the baseline date.  
Kaplan-Meier (KM) estimates of survival curves were first proposed in 1958 
by Kaplan and Meier (111).The Kaplan-Meier method of calculating survival 
curves give the cumulative probability (the survival probability) of an individual 
remaining free of the endpoint at any time after the baseline (Figure 2.1). The 
survival probability changes when a specific endpoint is reached, giving the 
KM curve a stepped like appearance. 
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Figure 2.1. Example KM curve showing 5-year death censored graft survival of 
recipients of kidneys from DBD donors compared to DCD donors. 
As Figure 2.1 demonstrates it is often required to compare the survival 
between two cohorts of patients. This thesis will often compare the survival of 
recipients based on the presence/absence of a risk attribute in the deceased 
donor. To statistically assess whether or not there is a difference between the 
survival of the two groups the log-rank test or regression methods can be 
used. The log-rank test is used throughout this thesis to describe differences 
in mortality curves, and the test works by detecting a consistently different 
event rate between the groups, with the null hypothesis being that there is no 
difference between the two groups. This generates a p-value as shown in 
Figure 2.1. For this thesis, all p-values less than 0.05 were deemed to be 
statistically significant, unless otherwise stated in the chapter.  
1.16.3 Multivariate Analysis of survival data 
The limit of the log-rank test is that it cannot assess the independent role of 
more than one factor at a time on survival. In order to do this multivariable 
regression models can be used to quantify the relationships between one or 
more factors on survival. The model used throughout this piece of work is 
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Cox-proportional hazards model. This model can test the independent effects 
of a number of explanatory variables to a hazard.  This regression takes the 
form of:    hi(t) = exp(β
′xi)h0(t) 
where hi(t) is the hazard for an individual i at time t, h0(t) is a baseline hazard 
and xi are the explanatory variables in the model and β are the corresponding 
coefficients of these variables. From this model we are then able to get 
hazard ratios. These ratios give the estimated hazard of a disease for the 
variable xj = x+ 1 relative to the individual with variable xj=x +0, while 
adjusting for all the other variables in the equation. The hazard ratio is 
interpreted as: >1 raised hazard, <1 decreased hazard, 0:  no increase or 
decrease in hazard at the endpoint.  
An important assumption of Cox proportional hazards regression model is the 
proportionality of hazards i.e. a hazard remains constant throughout time for 
the variables included in the model. To assess proportionality of hazards log-
cumulative hazard plots were used.  
1.16.4 Logistic regression 
Logistic regression is a regression model that can be used when your 
outcome is a binary variable (e.g presence/ absence of a condition) and there 
are a large number of explanatory variables. Logistic regression is used 
extensively throughout this thesis, primarily to investigate the role that 
different donor risk attributes have on the likelihood of a deceased donor to 
proceed or not proceed to organ donation, or to have their organs used/ not 
used for transplantation. In these situations, not proceed/ not transplant=0 
and proceed/transplant=1. The logistic regression equation appears as 
follows: 
Logit(p)=a +b1x1+b2x2+…bkxk. 
Where xi is the ith explanatory variable e.g. (1 or 2 in the equation above); p is 
the value of b the true probability that the individual has the disease/ outcome 
of interest, given their values for x; a is a constant term; and b is the estimated 
logistic regression coefficients. The exponential of these particular b 
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coefficients results in the estimate of the odds ratio. As with the hazards ratio, 
the odds ratio gives estimates of odds of a diseases for values of x. i.e. the 
odds for a disease of x+1 relative to x + 0, whilst adjusting for all the other x’s 
in the equation, hence resulting in a an adjusted odds ratio. Again, like for the 
hazards ratio an odds ratio >1 corresponds to increased odds of having the 
outcome of interest, and a value below 1 indicates decreased odds.  
1.16.5 Multivariable analysis-building the models 
Multivariable analysis was carried out using logistic regression analysis for 
binary outcomes, linear regression for assessing the impact of different 
factors on post-transplant eGFR and creatinine, and for survival Cox 
proportional hazards. These methods have been used extensively throughout 
this thesis.  
Both multivariate techniques require you to build a model in a step-wise 
manner or with donor and/or recipient characteristics that have been deemed 
important clinically. For both logistic regression and Cox-proportional hazards 
regression the model is assessed following the addition of each new variable 
through Akaike’s information criterion (AIC): 
AIC= -2logL + aq 
The AIC decreases as your model improves. In this equation -2logL, is -2x the 
logarithm of the likelihood of estimates, ‘aq’= a constant multiplied by the 
number of unknown ‘b’ parameters included in the model. As changes in -
2LogL have a 2 distribution, the change in -2LogL following the addition of 
each new variable can be used to assess the significance of said variable in 
the model.  
1.17 Multiple Imputation 
In order to handle the missing data in the registry multiple imputation was 
performed when stated. Multiple imputation replaces each missing 
observation with a set of plausible values that represent the uncertainty about 
the right value to impute. The use of multiple imputation allows for analysis of 
the imputed data sets with no missing information. The imputation method 
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depends on the pattern of the missing data. A monotone missing pattern 
infers that once a missing variable is observed for a group/unit, all variables 
following this will also be missing. An arbitrary missing pattern can be either 
monotone or non-monotone, and was the pattern for most missing data in the 
UKTR. The FCS method of imputation was used using FCS regression for 
continual variables, FCS logistic regression for binary/ordinal variables and 
FCS discriminant function in SAS for binary/nominal variables.  
The imputation models should be congenial to, or consistent with, your 
analytic model, Including, at least, the same variables as the analytic model.  
Multiple imputation assumes the data are missing at random given the 
covariates in the model.  
1.18 Statistical Software 
The software used for data analysis for this research was Statistical Analyses 
Software 9.3 (SAS 9.3), from SAS institutes in Cary, North Carolina (112). It is 
a code based program that has three main functions. Firstly, it allows SQL 
programming, and hence easy interaction with the databases such as those 
that compose the NHSBT UKTR. Secondly it has a powerful statistics 
package. Thirdly, it has a macro language that enables extensive 
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1.19 Background 
The demand for organs for transplantation far exceeds supply and increasing 
consideration is being given to the use of organs from sub-optimal donors, 
including those perceived to pose a potential increased risk of disease 
transmission to the recipients (113). Donors who have a died as a result of 
meningitis and encephalitis are of potential concern because of the risk of 
transmitting life threatening meningitis or encephalitis to the 
immunocompromised recipient (57,113,114) . This risk was highlighted by a 
recent case in the UK where a donor who died of an encephalitis of unknown 
cause transmitted a fatal encephalitis to two renal transplant recipients (115). 
Cases of meningitis and encephalitis transmission have been observed in the 
US and Europe, with the transmission often proving fatal (116-122). The risk 
of disease transmission, however, needs to be evaluated and balanced 
against the potential benefit of additional donor organs for transplantation to 
the recipient population.   
UK guidelines from the SaBTO (2017) state that ‘if there is any possibility of 
acquisition of a neurotropic infection from abroad the donation is 
contraindicated owing to the risk of rabies, West Nile virus or other exotic 
neurotropic infections’ (63). The guidelines also state that ‘Material from cases 
of meningo-encephalitis for which no infection is identified should not be used 
for donation’. However, there is a caveat in the guidance that recognises there 
may be a clinical need for transplantation of such urgency that it is appropriate 
to consider the use of organs and tissues for life-preserving purposes from 
donors who would not otherwise be considered eligible to donate, due to a 
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known or perceived risk of disease transmission (123). SaBTO guidance also 
states that ‘if bacterial meningitis has been confirmed, but there is no visible 
damage or local infection in the organ or tissues required at retrieval, the 
donation of the organs, tissues and cells are acceptable’ for transplantation 
(123). US guidance (2013) also states that donors dying of encephalitis 
without a proven cause should be avoided; the two exceptions to this general 
caution include donors with proven bacterial meningitis and donors with 
proven Naegleria fowlerii meningoencephalitis’ (57).  The UK and US 
guidance is mirrored by that from the Council of Europe (2015), which states 
‘if the aetiology of an active infection cannot be established the donor is not a 
suitable candidate for donation’ (124). Despite current guidance, organs from 
donors where the cause of meningitis and encephalitis is not known continue 
to be used for transplantation, as clinicians balance the risk of donor 
transmitted disease against that of death on the waiting list whilst awaiting a 
graft. I reviewed the UK experience, to better understand the extent to which 
organs from deceased donors with meningitis and encephalitis (of both known 
and unknown cause) have been used for transplantation, and to determine 
the associated recipient outcomes. 
1.20 Methods 
1.20.1 Identification of deceased donors who died of Meningitis and 
Encephalitis 
The UKTR was examined to identify deceased donors between 1st January 
2003 and 31st December 2014, where the cause of death was meningitis 
and/or encephalitis, and who donated one or more organs for transplantation. 
All UK deceased donors whose cause of death was coded in the UKTR as 
‘meningitis’ were readily identified. However, the designated codes for cause 
of death in the UKTR are limited to any one of 65 possible causes and there is 
no code for encephalitis on the registry currently, leaving the data entry team 
the option of coding cases of encephalitis as ‘meningitis’, ‘infection-type 
unclassified’, ‘other’, ‘other-please specify’ and ‘unknown’ and using the free 
text entry to specify encephalitis as the cause of death. All free text entries in 
the registry for donors whose primary cause of death was coded as 
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‘meningitis,’ were fully reviewed to identify if the infection had been recorded 
as viral, bacterial, was not known or was unstated, and whether the causal 
infectious agent had been recorded. For deaths coded as ‘infection-type 
unclassified’, ‘other’, ‘other-please specify’ and ‘unknown’, free text entries 
were searched using the search terms ‘Meningitis’, ‘Encephalitis’, ‘Meningo-
encephalitis’, and common misspellings of these terms to identify any 
additional donors where the cause of death was meningitis/encephalitis and to 
find whether the causal agent had been identified. The information on organ 
donors entered into the UKTR is that entered at time of donation, and any 
subsequent changes in cause of death or in causative agent for meningitis or 
encephalitis are relayed to the recipient centres but not changed on the 
registry. 
1.20.2 Identification of potential donors who died of meningitis and 
encephalitis 
The PDA was examined to identify all non-proceeding potential donors who 
died of meningitis and encephalitis over the study period. Potential organ 
donors were identified in the same way as those in the UKTR, with cause of 
death coding supplemented by free-text searches. 
1.20.3 Identification of recipients who received organs from donors who died 
of known and unknown causes of meningitis and encephalitis 
Recipients of organs from donors who died of known and unknown causes of 
meningitis/encephalitis in the UK between 1st January 2003 and 31st 
December 2014 were identified using the UKTR. Information on recipient 
survival and death censored graft survival was collected from the UKTR.  
1.20.4 Statistical Analysis 
Principal univariate analyses reported deceased donor and recipient 
characteristics by donor meningitis and encephalitis status (known cause 
meningitis and encephalitis (KME), unknown cause meningitis and 
encephalitis (UKME), other) using percentages, means or medians and 
standard deviations or interquartile ranges as appropriate. Univariate analysis 
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was carried out using t-test for continuous data. Comparisons between groups 
were made using 2–tests for categorical data, and unpaired difference tests 
for continuous data (one-way ANOVA if normality can be assumed, Kruskal-
Wallis test otherwise).  
Kaplan-Meier curves were used to compare death-censored graft survival and 
patient survival across donor cause of death groups. The univariate log-rank 
test was used to calculate p-values from this.  
Cox proportional hazards regression model was fitted in a stepwise selection 
method in order to identify the combined effect of factors on patient and graft 
survival. Log cumulative hazard plots were drawn and proportionality of 
hazards was checked using log-log plots of the hazard. There was no 
evidence of non-proportionality of hazards.  
Donor related variables included in the multivariate model were donor age, 
donor type (DBD or DCD), ethnic group, gender, past medical history of 
diabetes and hypertension, liver disease, cardiac disease, previous drug 
abuse, smoking history and if the donor died of a known or unknown cause of 
meningitis/encephalitis. Recipient factors included were recipient age, 
ethnicity, gender, sensitization (for the renal model), primary renal, liver or 
heart disease, HLA group, and cold ischaemic time (CIT). 
1.21 Results 
1.21.1 Identification of donors who died from meningitis and encephalitis 
A total of 258 (2.4%) of the 11,530 deceased donors, who donated one or 
more organs for transplantation, were identified as having died of a meningitis 
and encephalitis over the 12-year study period. Of the 258 organ donors 
identified, 214 (1.9%) were directly coded by the UKTR as having died of 
meningitis (Figure 3.1). A further 44 donors were not coded as meningitis but 
it was clear from free text entries that they had died of meningitis or 
encephalitis/meningo-encephalitis.  Further analysis of free text entries in the 
UKTR for these donors showed that 85.7% had meningitis and the remaining 
14.3% had encephalitis or meningo-encephalitis.  
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There were 221 organ donors who died from meningitis of which 169 (76.5%) 
had a bacterial cause, 2 (1.4%) a viral cause and in 50 cases (22.6%) the 
aetiology was unknown or unstated (Figure 3.1). Thirty-seven donors died 
from encephalitis and/or meningo-encephalitis, of which a bacterial cause was 
thought to be responsible in 11 (29.7%), a viral cause in 6 (16.2%) and in 20 
(54.1%) of cases, the cause was unknown or unstated. Where the cause of 
meningitis and encephalitis was thought to be known, the causative infectious 
organism was stated in 63% of meningitides and 19% of encephalitides 
(Table 3.1). Most of the bacterial meningitides were attributed to a 
streptococcal or meningococcal cause.  
                                                             Meningitis 
Bacterial n = 140 Viral n = 1 
Streptococcal                  85 Varicella-Zoster Virus                1 
Meningococcal 32   
Staphylococcal 7   
Other gram positive organism  6   
Listeria    4   
Other gram negative organism 3   
Klebsiella 2   
Enterococcus 1   
    
                                                            Encephalitis 
Bacterial n = 6 Viral n = 1 
Streptococcal 4 Varicella-Zoster Virus 1 
Meningococcal 2   
Table 3.1. Causal infectious agents in organ donors who died from meningitis and 
encephalitis. Of the 258 donors who died from meningitis/ encephalitis 148 (57.4%) 




Figure 3.1. Flow diagram for organ donors identified as dying from meningitis and 
encephalitis 
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The UK PDA was scrutinized to identify patients less than 80 years with 
meningitis and encephalitis that did not proceed to organ donation and 
therefore were not entered on the organ donor transplant registry. 
Over the 12-year study period, a total of 668 patients died of 
meningitis/encephalitis did not donate organs for transplantation. Whereas the 
number of patients who died of meningitis and encephalitis was greater in the 
latter part of the study period, the number of actual organ donors dying of 
meningitis and encephalitis remained relatively constant throughout the study 
period (Figure 3.2). Clinical details in the PDA of why potential donors did not 
proceed to organ donation were limited. Analysis of the reasons coded in the 
database or available in free text entries indicated that 85 (12.7%) of the 668 
potential organ donors were declined based on their cause of death, i.e. 
meningitis and encephalitis. 
Figure 3.2. The number of non-proceeding potential organ donors with meningitis 
and encephalitis and, the number of actual organ donors with meningitis and 
encephalitis. 
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1.21.2 Characteristics of donors who died of meningitis and encephalitis 
The clinical characteristics of the 221 organ donors with meningitis and the 37 
donors with encephalitis were very similar and were, therefore, combined and 
compared to those who died of all other causes during the study period 
(Table 3.2). Organ donors who died of meningitis/encephalitis were younger 
and there were more DBD than DCD donors. They also, on average, donated 
more organs and more of the donated organs were transplanted. Overall, 
donors with meningitis/encephalitis had a lower body mass index (BMI) and 
lower incidence of hypertension, cardiac disease, and were less often 
smokers.  
1.21.3 Characteristics of recipients receiving organs from donors who died of 
meningitis and encephalitis 
The 258 organ donors with meningitis and encephalitis provided a total of 899 
solid organs that were transplanted (455 kidneys, 237 livers, 71 hearts, 44 
lungs, 7 heart and lung, 72 pancreata (including simultaneous kidney 
pancreas transplant (SPK)) and 13 other solid organ transplants). The types 
of organs transplanted were similar in deceased donors with known and 




All other deceased 
donors 
(n = 11272) 
Donors with Meningitis 
and Encephalitis 
(n = 258) 
P value 
Age (y)* 48.0 ± 16.6 34.0 ± 19.9 <0.001 
Male/ Female (%) 54/ 46 52/ 48 0.602 
DBD/ DCD (%) 69/ 31 88/ 12 <0.001 
Number of Organs 
donated/donor 
3.5 ± 1.5 4.0 ± 1.7 <0.001 
Number of Organs 
Transplanted/donor 
3.0 ± 1.5 4 ± 1.5 <0.001 
BMI 26.3 ± 5.6 25.1 ± 6.9 <0.001 
Diabetes   
0.767 Yes/ No 714 (6%)/10182 (90%) 13 (5%)/239 (93%) 
Missing/Unknown 376 (3%) 6 (2%) 
Hypertension   <0.001 
Yes/ No 2902 (26%)/ 7891 (70%) 22 (9%)/230 (89%)  
Missing/Unknown 479 (4%) 6 (2%)  
Cardiac Disease**   0.019 
Yes/No 1129 (10%)/9637 (85%) 13 (5%)/240 (93%)  
Missing/Unknown 506 (5%) 5 (2%)  
Liver disease   0.125 
Yes/No 367 (3%)/10316 (92%) 3 (1%)/249 (97%)  
Missing/Unknown 589 (5%) 6 (2%)  
Alcohol Abuse   0.022 
Yes/No 1563 (14%)/9280 (82%) 21 (8%)/230 (89%)  
Missing/Unknown 429 (4%) 7 (3%)  
Drug Abuse   0.301 
Yes/No 663 (6%)/10151 (90%) 10 (4%)/242 (94%)  
Missing 458 (4%) 6 (2%)  
Smoking History   <0.001 
Yes/No 5065 (45%)/5846 (52%) 79 (31%)/174 (67%)  
Missing 361 (3%) 5 (2%)  
Cause of death stated as 
Cerebrovascular accident 
or Hypoxic brain injury 
8485 (75%) 0  
Table 3.2 Clinical characteristics of organ donors who died of known and unknown 
causes of meningitis and encephalitis and donors who died from all other causes 
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UK centres transplanted a total of 455 kidneys from donors who died of 
known and unknown causes of meningitis and encephalitis.  All 24 UK 
transplant centres accepted kidneys from donors with both KME and UKME 
(Figure 3.3). Over the entire study period, these comprised 1-11% of the total 
number of renal transplants performed (Figure 3.3). There was no clear 
relationship between the volume of transplant activity at a particular centre 
and the proportion of transplants performed using kidneys from donors with 
KME and UKME. The clinical characteristics of recipients who received 
kidneys from donors who died with an unknown cause and those with a 
known cause (bacterial or viral) of meningitis and encephalitis are shown 
separately and are compared with the recipients of non-
meningitis/encephalitis organs (Table 3.3). There were no major clinical 
differences between recipients who received kidneys from donors who died of 
known and unknown causes of meningitis and encephalitis. Overall, however, 
recipients who received kidneys from donors with meningitis and encephalitis 
were markedly younger than those who received kidneys from deceased 
donors who died from other causes. The recipients of kidneys from donors 
with UKME and KME received kidneys, which had a better HLA-match than 
those from donors who died from other causes. 
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Table 3.3. Clinical characteristics of kidney transplant recipients from organ donors 
who died of known and unknown causes of meningitis and encephalitis, and from 
donors who died of all other causes. 
 Transplant 
recipients from 




donors with KME 
(n= 333) 
Transplant recipients 




Age (y)* 40.6 ± 15 41.1 ± 16.9 47.6 ± 14.9 <0.001 
Gender    0.884 
Male 83 (68%) 202 (61%) 11847 (62%)  
Female 39 (32%) 131 (39%) 7235 (38%)  
Not stated 0 0 10 (0.5%)  
Ethnicity    0.466 
White 102 (83%) 261 (78%) 15165 (79%)  
Other/Not specified 20 (16%) 72 (22%) 3927 (21%)  
cRF>85%** 12 (10%) 37 (11%) 1677 (9%) 0.309 
Wait time 531 (996) 638 (1085) 770 (1075) 0.004 
Previous Transplants 19 (16%) 65 (20%) 2858 (15%) 0.131 
HLA Mismatch    0.005 
1 (well matched) 20 (16%) 52 (16%) 2570 (13%)  
2 44 (36%) 126 (38%) 6202 (33%)  
3 42 (35%) 102 (31%) 7944 (42%)  
4 (poorly matched) 15 (12%) 50 (15%) 2316 (12%)  
Missing/Unspecified 1 (1%) 3 (1%) 60 (<0.5%)  
Primary Renal Disease    0.041 
Glomerulonephritis 10 (8%) 36 (11%) 2788 (15%)  
Polycystic Kidney Disease 11 (9%) 30 (9%) 2066 (11%)  
Diabetes (types 1 and 2) 20 (16%) 42 (13%) 2823 (15%)  
Other/Not reported 81 (66%) 225 (67%) 11404 (59%)  
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Figure 3.3.  Total number of deceased donor kidneys transplanted in UK renal transplant centres from the 1st January 2003 to 1st of January 
2015. 
For each centre, the number of kidneys transplanted from donors with known and unknown causes of meningitis and encephalitis are shown as 
a percentage of the total number of deceased donor kidney transplants performed.
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1.21.4 Liver Transplant Recipients 
The clinical characteristics of the 237 liver transplant recipients who received 
livers from organ donors with KME and UKME are shown in Table 3.4 along 
with the characteristics of recipients of livers from donors who died of all other 
causes. The recipients of livers from KME donors and UKME donors were 
significantly younger than recipients of livers from donors who died of all other 
causes. Livers from UKME donors were more frequently allocated to 
recipients on the super-urgent waiting list (the most urgent category).  
Table 3.4. Clinical characteristics of liver transplant recipients from organ donors 
who died of known and unknown causes of meningitis and encephalitis, and from 
















Age (y) 36.4 ± 23.0 33.4 ± 23.7 45.2 ± 18.6 <0.001 
Gender    0.415 









Not Stated 0 0 1 (<0.5%)  
Ethnicity    0.182 
White /  








Previous Transplants 9 (13%) 14 (8%) 806 (9%) 0.990 
UKELD  54 ± 7 54 ± 6 54 ± 6 0.889 
Urgent status 16 (23%) 27 (16%) 1220 (14%) 0.151 
Primary Liver Disease    0.828 
Primary Biliary cholangitis 10 (14%) 6 (4%) 597 (7%)  
Hepatitis C liver cirrhosis 6 (9%) 15 (9%) 1023 (13%)  
Alcoholic Liver disease 7 (10%) 18 (11%) 1540 (18%)  
Other/Not stated 47 (67%) 128 (76%) 5086 (62%)  
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1.21.5 Heart Transplant Recipients 
Over the study period 71 hearts were transplanted from donors who died of 
meningitis and encephalitis (Table 3.5). Recipients from donors who died of 
meningitis/encephalitis were younger, and were much more likely to require a 
heart urgently in comparison to recipients of hearts from donors who died of 
all other causes (Table 3.5). 
 
Table 3.5. Clinical characteristics of heart transplant recipients from organ donors 
who died of known and unknown causes of meningitis and encephalitis, and from 
donors who died of all other causes 
1.21.6 Recipient outcomes after transplantation 
Of the 899 recipients who received transplants from donors with UKME and 
KME there were 2 early deaths attributable to donor transmission of 













all other cause 
of death donors 
(n=1482) 
P-value 
Age (y)* 31.4 ± 26.6 31.2 ± 23.8 38.5 ± 18.7 <0.008 








 441 (30%) 
 
Ethnicity    0.197 
White 12 (80%) 53 (95%) 1304 (88%)  
Other/Not specified 3 (20%) 3 (5%) 178 (12%)  
Previous Transplants 0 0 30 (2%) 0.481 
Urgent status 9 (60%) 40 (71%) 750 (50%) 0.008 
Primary Heart Disease    0.935 
Idiopathic Dilated 
Cardiomyopathy 
7(46%) 14 (25%) 524 (35%)  
Congenital Heart 
Disease 
1 (7%) 8 (14%) 133 (9%)  
Coronary Heart 
Disease 
1 (7%) 8 (14%) 234 (16%)  
Other/Not stated 6 (40%) 26 (46%) 591 (40%)  
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meningo-encephalitis of unknown aetiology. The renal recipients, males aged 
67 and 42, died of encephalitis 17 days and 19 days respectively following 
transplantation. On post-mortem examination, the transmitted organism was 
found to be the nematode infection Halicephalobus gingivalis. It is the first 
documented UK case and first documented human-to-human transmission of 
this organism, and only the 6th, 7th and 8th documented cases of human 
infection. The UKTR did not include any other reports of death, graft loss or 
major morbidity secondary to disease transmission from any of the other 
donors with UKME or KME. Only one other of the 455 recipients of kidneys 
from donors with UKME or KME died within 30 days of transplantation, and 
death in this case was attributed to cardiovascular disease, giving a thirty day 
mortality of 0.7%, which is similar to the thirty-day mortality in renal transplant 
recipients who received kidneys from donors who died of all other causes 
(153 deaths in 19,095 recipients (0.8%)). In the 444 recipients of non-renal 
organs from donors with UKME and KME, there were 14 deaths within 30 
days (3.2% 30 day mortality rate vs. 3.7% in recipients of organs from donors 
without UKME or KME), of which 3 deaths were attributed to a neurological 
cause and in all of these death followed a cerebrovascular accident (CVA). Of 
the three deaths from CVA, one recipient died of an ischemic stroke 11 days 
after receiving a liver from a donor with an unknown cause of encephalitis 
who also donated 2 kidneys for transplantation, one recipient died of a stroke 
(type unstated) 28 days after receiving a liver from a donor with a unknown 
cause of meningitis who also donated 2 kidneys for transplantation, and one 
recipient died of a haemorrhagic stroke 12 days after receiving a heart from a 
donor with E.coli meningitis who donated 2 kidneys and a liver for 
transplantation. In none of these three patients was any mention made in the 
free text entries to suggest the CVAs were in any way related to the 
transmission of infection.  
Overall patient survival was significantly better in recipients of kidneys from 
donors with KME (p=0.002). After adjustment using Cox proportional hazard 
model the survival advantage was secondary to lower donor age, lower 
recipient age, a greater proportion being DBD donors and the donors 
possessing fewer comorbidities (p=0.06). Death censored graft survival for 
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recipients of kidneys from donors with KME was greater than that for 
recipients of kidneys from donors who died of any other cause of death, but 
this difference failed to reach statistical significance (Figure 3.4).  Patient and 
graft survival was similar for kidney recipients from UKME donors and 
recipients from donors who died from other causes.  
Death-censored graft survival and patient survival were comparable for heart 
and liver recipients from UKME and KME donors when compared to all other 




Figure 3.4. Patient and death censored Graft Survival for recipients of kidneys from 
organ donors who died of known and unknown causes of meningitis and 
encephalitis, and organ donors who died from all other causes. P-value corresponds 
to score test of the overall null hypothesis that there are no differences in survival 
curves for all groups i.e. comparing survival for all groups. 
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Figure 3.5. Patient and death censored Graft survival for recipients of livers from 
organ donors who died of unknown and known causes of meningitis and 
encephalitis, and organ donors who died from all other causes. P-value corresponds 
to score test of the overall null hypothesis that there are no differences in survival 
curves for all groups i.e. comparing survival for all groups 
 
Figure 3.6. Patient and death censored Graft Survival for recipients of hearts from 
organ donors who died of unknown and known causes of meningitis and 
encephalitis, and organ donors who died of all other causes. P-value corresponds to 
score test of the overall null hypothesis that there are no differences in survival 
curves for all groups i.e. comparing survival for all groups. 
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1.22 Discussion 
The analysis was undertaken to determine the extent to which organs from 
deceased donors who died of meningitis or encephalitis were transplanted in 
the UK, and to determine the outcome of recipients who received such 
organs.  Over the 12-year study period, a total of 899 organs were 
transplanted from 258 donors who died of meningitis or encephalitis. The 
number of actual organ donors who died of meningitis or encephalitis over the 
12-year study period remained relatively constant, and all UK transplant units 
accepted organs from such donors for transplantation. In the case of kidney 
transplants, there was evidence that the threshold for accepting kidneys from 
donors who died of meningitis or encephalitis varied between centres.  
However, such variability did not correlate with the volume of transplant 
activity undertaken by the centre.  
While donors with meningitis or encephalitis comprised only a small 
proportion (2.3%) of the total number of deceased organ donors over the 
study period, they made an important contribution to transplant activity, 
leading to 455 kidney transplants and 444 non-renal transplants.  Moreover, 
such donors tended to be younger with favourable donor characteristics and 
overall they donated more organs per donor. The majority (66%) of the entire 
donor cohort in this analysis who died of meningitis had a known cause of 
meningitis and therefore the use of their organs for transplantation was not, 
according to current UK guidelines, contraindicated. Nevertheless, a large 
proportion (34%) of those who donated organs died of an unknown or 
unstated cause of meningitis or encephalitis.  Use of organs from such donors 
is cautioned in the UK guidelines, although it is recognised that their use in life 
saving situations may be appropriate. In the present study, donors with an 
unknown cause of meningo-encephalitis donated not only lifesaving organs 
but most (91%) donated at least one kidney for transplantation. We cannot 
exclude the possibility that, at least in some of these donors, additional 
reassuring clinical information relating to the aetiology of the meningo-
encephalitis (e.g. expert opinion suspecting a bacterial cause that could not 
be proven) may have been made available to the transplanting centres, but 
was not recorded in the registry.  
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In the present analysis, there was no recorded incidence of transmission of 
the causative agent for meningitis or encephalitis from any of the donors 
where the causative agent was identified prior to donation. It is important to 
appreciate that clinical decision making informed the use of organs from 
donors with meningitis or encephalitis/meningo-encephalitis and it cannot be 
assumed that if organs from the potential, rather than actual, organ donors 
with a known cause of meningitis had been used that they also would not 
have posed a risk of disease transmission. One (2.7%) of the 37 organ donors 
with encephalitis (representing one (5%) of the 20 organ donors with an 
unknown cause of their encephalitis) transmitted infection to two renal 
allograft recipients.  In both cases the transmitted infection, which was 
subsequently shown to be the nematode H. gingivalis, was fatal.  There were 
no other recorded cases of disease transmission for patients who died of an 
unknown cause of meningitis and encephalitis. Overall, recipients of organs 
from donors who died as a result of a meningitis or encephalitis (known or 
unknown causes) had similar patient and graft survival to that observed in 
recipients of organs from donors who died from other causes. Where a 
bacterial cause of donor meningitis or encephalitis/ meningo-encephalitis was 
identified, this information would have been available to the recipient 
transplant centres and it is likely that most, if not all, recipients of such organs 
would have received prophylactic antibiotic treatment in keeping with clinical 
guidelines. 
The number of actual organ donors with meningitis or encephalitis was 
around a third of the number of potential donors identified from the UK PDA 
dying with meningitis or encephalitis but whose organs were not used for 
transplantation. This figure is considerably higher than the overall percentage 
of actual to potential organ donors identified from the UK PDA (51). 
Unfortunately, the data available in the UK PDA was not sufficiently detailed 
to allow us to determine precisely why potential donors with meningitis and 
encephalitis did not proceed to become actual organ donors, but in at least 
18.7% of cases the reason cited was the underlying cause of death, and 
presumably concern by recipient centres about disease transmission. It is 
impossible to estimate how many of these unused potential organ donors 
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could have transmitted a fatal disease to recipients, and hence how many 
potential lives were saved through not using these organs for transplantation.  
The findings arising from the present analysis may allow clinicians at 
transplanting centres to make a more informed decision about the risks of 
disease transmission when considering the use of organs from potential 
donors with meningitis and encephalitis.  The decision to transplant an organ 
from a donor with meningitis and/or encephalitis, especially where the cause 
is unknown, should be taken after fully informing the potential recipient of the 
associated risks.  
There are several published case studies that describe examples of donor-
derived infection causing meningitis and encephalitis in transplant recipients 
(116-122).  A wide range of pathogens responsible for such disease 
transmission have been implicated and often it had not been clear before 
organ transplantation that the donors had meningitis and encephalitis (116-
122). An emerging concern in the US is the transmission of West Nile Virus 
(WNV) from affected donors to transplant recipients, which has been seen in 
8 different clusters. Transmission of Lymphocytic Choriomeningitis Virus 
(LCMV), Balamuthia Mandirallis and Rabies have also been reported (116-
122). In the clusters of donor derived infection of meningitis and encephalitis, 
a wide variety of causes of death of the donors were reported, ranging from 
urinary tract infection, diabetic ketoacidosis, trauma and stroke (119,120,125).  
The current literature suggests that the risk of donor transmission of 
meningitis and encephalitis is omnipresent and exclusion of such donors, who 
are often relatively young and previously healthy, would not fully address this 
risk because, in reported cases, the cause of donor death was not always 
known to be meningitis and encephalitis. It was not possible from the analysis 
undertaken for the present analysis to determine the number of donors with 
unrecognized meningitis or encephalitis. 
There are also other limitations to the present analysis: encephalitis and 
meningo-encephalitis were not specifically coded as a cause of death in the 
UKTR. Nor are the definitions made clear so there may have been some lack 
of consistency and accuracy between the diagnosis of encephalitis, meningitis 
and meningo-encephalitis. There is a possibility that the numbers quoted in 
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this chapter are an underestimate of those who died from these causes. 
Attempts were made to minimize this possibility by using multiple search 
terms (and common misspellings of these), and careful review of the free text 
entries. There is a possibility that cases of disease transmission from donors 
with meningitis or encephalitis were not reported to NHSBT, as the reporting 
requirement only became part of UK law in 2012. However, over the entire 
study period NHSBT has had close oversight of all UK transplant units and it 
is very unlikely that any transmission of meningitis or encephalitis occurred 
without NHSBT being made aware of this. Moreover, analysis of the causes of 
death in the 14 patients who died within 30 days after receiving organs from 
donors with UKME or KME showed that only 3 were listed as dying from 
neurological cause (all CVA), and in none of these was infection noted as a 
contributory cause of death.  A further limitation of this analysis is its 
applicability to the wider global transplant community. Given the relatively 
limited geographical area of the UK there is limited variation in infectious 
pathogens. Hence, in other much larger countries, such as the US, where 
different infectious agents vary geographically and by time of year, additional 
consideration should be given to the risk that donors with meningitis or 
encephalitis may pose and what organism could be causing their illness.  
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Organ donors who die from Immune Thrombocytopaenia in 
the UK: What risk do they pose to transplant recipients 
Publications from this work: Trotter et al. Donors with Immune Thrombocytopenia: Do they 
pose a risk to transplant recipients?   
American Journal of Transplantation. 2017;17(3):796-802. 
1.23 Background 
The transfer of immunocompetent donor lymphocytes originating from 
transplanted organs, notably the liver, may result in the development of graft 
versus host disease (GVHD)(126). GVHD following liver transplantation has 
been reported in between 0.1-2% of liver transplant recipients and may 
progress to a fatal multi-system disease (126,127). Donor plasma cells or B-
lymphocytes transmitted with an allograft are also known to cause transient 
haemolysis when donor specific antibodies react against recipient red cells 
(the passenger lymphocyte syndrome (PLS)) (128,129). In addition to GVHD 
and PLS, there have been very occasional case reports documenting the 
transmission of ITP from organ donors to liver transplant recipients with 
serious consequences (130-132).  
Primary ITP is an autoimmune disorder characterized by isolated 
thrombocytopenia (peripheral blood platelet count <100 x 109/L) in the 
absence of other causes or disorders that may be associated with 
thrombocytopenia.  ITP may also be secondary, when associated with other 
conditions such as infection, immunodeficiency syndromes, systemic 
autoimmune disease or malignancy.  There is currently no definitive clinical or 
laboratory parameters that can define ITP and this remains a diagnosis of 
exclusion after considering alternative causes of thrombocytopenia such as 
liver disease, medications or bone marrow disorders (133,134). However, 
there are a number of antibodies to specific platelet glycoproteins that have 
been identified in patients with ITP. Testing for these antibodies is not 
recommended as platelet associated IgG is not specific to ITP, and has been 
detected in non-immune thrombocytopaenia (134). ITP typically presents with 
bruising and mucosal bleeding. Although many patients have no bleeding or 
minimal bruising, serious and sometimes fatal intracranial or gastrointestinal 
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bleeding can occur (135). Primary ITP is a rare disorder with an age-adjusted 
prevalence of 9.5 per 100,000 in the United States (US) and an incidence of 
2.7 per 100,000 in Northern Europe (136). In children, ITP may follow viral 
infection and resolve spontaneously.  In contrast, ITP in adults can have a 
subtle onset and is usually chronic in nature. 
First line treatment for ITP is usually steroids or intravenous immunoglobulins 
(IVIg).  Subsequent therapy may involve immunosuppression (e.g. rituximab, 
mycophenolate or azathioprine), surgical splenectomy or thrombopoietin 
receptor agonists (e.g. eltrombopag or romiplostim) (134).  
In Transplant-Mediated Alloimmune Thrombocytopaenia (TMAT), donor 
leucocytes from an organ donor with ITP produce anti-platelet antibodies that 
bind platelet membrane epitopes such as glycoprotein (GP) IIb/IIIa common to 
both donor and recipient. Only 5 cases of TMAT have been previously 
reported, all following liver transplantation. In all cases TMAT was 
distinguished by severe and sudden onset thrombocytopaenia with platelets 
<10 x 109/l within three days of liver transplantation (130-132). While TMAT is 
a rare complication of liver transplantation, there has been no attempt to 
estimate the risk of disease transmission from organ donors with recent or 
past history of ITP. Consequently, there is no current guidance in the UK or 
the US with regards to the safety of using organs from donors with ITP. To 
help inform policy on the use of organs from donors with a history of ITP we 
undertook a retrospective registry analysis to establish the number of donors 
with ITP from which organs were used for transplantation and their associated 
recipient outcomes.  
1.24 Methods 
1.24.1 Identification of Donors who died of ITP 
The UKTR was used to identify all organ donors with a diagnosis of ITP. The 
UKTR was interrogated using the search terms ‘ITP’ ‘Idiopathic 
Thrombocytopaenic Purpura’, ‘Immune Thrombocytopaenia’ (and common 
misspellings and alternative combinations of these words) for all UK deceased 
and living organ donors between 1st January 2000 and 31st December 2015. 
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In donors identified as having a pre-donation diagnosis of ITP, a search was 
made of their records to establish: the duration of ITP, what treatments (if any) 
had been received and their platelet counts at time of death. A diagnosis or a 
past medical history of ITP recorded in the UKTR meant that the donor was 
included in the analysis.  
1.24.2 Identification of Recipients from Donors with ITP 
The recipients of organs from donors who had ITP were identified from the 
UKTR.  Information regarding patient and graft survival was collected from the 
registry. The platelet count on the third post-operative day and any 
subsequent history of TMAT or ITP in the transplant recipient was obtained 
from the recipient’s respective transplant centre. 
1.25 Results 
1.25.1 Organ Donors with ITP 
Over the 16-year study period there were 20,440 potential deceased donors 
of which 24 had diagnosis of ITP at the time of organ donation. None of 
11,843 living donors over this time period were known to have ITP. Of the 24 
deceased donors with history of ITP, information on whether specific 
treatment was given for ITP was available for 14 of them. Of these, two of the 
patients with ITP died of ICH before any specific treatment was administered. 
Of the remaining 12 patients, treatment comprised IVIg and/or steroids (n=9), 
splenectomy alone or splenectomy plus rituximab, eltrombopag and 
romplistim (n=2), and IVIg plus rituximab (n=1). Twenty-one of the 24 potential 
deceased donors with ITP proceeded to organ donation.  Three donors with 
ITP did not proceed to organ donation, because of withdrawal of family 
consent (n=1), positive Human T-Lymphotropic Virus (HTLV) n=1), and 
prolonged time to asystole after withdrawal of life supporting treatment (n=1). 
1.25.2 Clinical Characteristics of Donors with ITP 
Compared with deceased organ donors who did not have ITP, organ donors 
with ITP were of similar age (median 49, Interquartile range (IQR) (23-63) vs. 
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49 (36-59), p=0.520), and gender (10 (48%) male vs. 7400 (54%) male, 
p=0.666). Donors with ITP were significantly more likely to have died from 
ICH (18 (85%) vs. 7864 (57%), p<0.001) and have a lower platelet count at 
donation (median 56 x109/l IQR (33-90) vs. median 203 x 109/l IQR (147- 
267), p<0.001) compared to donors without ITP. Donors with ITP donated 
organs, which led to 49 organ transplants [31 kidney transplants (including 3 
simultaneous kidney-pancreas (SPK) transplants), 14 liver transplants and 4 
heart transplants]. 
1.25.3 Clinical Characteristics of Kidney transplant recipients 
The 31 kidney transplant recipients from organ donors with ITP and recipients 
of kidneys from those without ITP were of similar age (median 43.0 IQR (35-
58) vs. median 48.0 IQR (37-58), p=0.272), gender (17(55%) male vs.14165 
(62%), p=0.875), ethnicity (22 (71%) white vs. 18260 (80%) white, p=0.214), 
and HLA mismatch level (39% mismatch level 1 and 2 vs. 49% mismatch 
level 1 and 2, p=0.545).  None of the 31 recipients developed ITP or TMAT in 
the early post-transplant period, although one recipient developed what was 
assumed to be sporadic ITP 8 years post-transplantation. The median platelet 
count on day-three after transplantation with a kidney from a donor with ITP 
was 179 x109/l (IQR 124-210).  
Survival analysis comparing renal transplant recipients from donors with ITP 
and from all other deceased donors demonstrated no difference in 10-year 




Figure 4.1. Patient and Graft survival of renal transplant recipients from organ 
donors with ITP and all other deceased organ donors 
1.25.4 Clinical Characteristics of Liver transplant recipients 
The 14 liver transplant recipients from organ donors with ITP and recipients of 
livers from those without ITP were of similar age, gender, ethnicity, UKELD 
score, primary liver disease, and had the same proportion of recipients that 
were listed urgently for a liver transplant (Table 4.1).   
Platelet counts were recorded for all liver transplant recipients on day zero 
and day three post transplantation, with a median platelet count on day three 
of 49 x 10 9/l (IQR 24-76) and a median platelet count drop of 38 x 109/l (IQR 
17-70) from day zero to day 3 (figure 4.2).  The platelet count of liver 
transplant recipients fell in 12 of the 14 cases (86%) (Figure 4.2).  These 
platelet counts were compared to the last 3 years of liver transplant recipients’ 
day 0 and day 3 platelet counts at Addenbrooke’s hospital in Cambridge 
(n=259). The median day 3 platelet count in this cohort was 44 x 109/l (IQR 
30-58) and when the platelet counts dropped post liver transplantation, the 
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median platelet count drop was 18x109/l (IQR 10-31), which was not 
significantly different to the drop observed in liver recipients from organ 
donors with ITP (p=0.456). None of the liver transplant recipients from 
Cambridge had a platelet count <10x 109/L on day 3-post transplantation.  
 
Figure 4.2. Liver transplant recipients from donors with Immune thrombocytopenia 
day 0 and day 3 platelet counts 
In all cases the recipient centres were contacted regarding any possible 
diagnosis of TMAT.  One of the liver recipients, a 61-year-old male, developed 
TMAT post transplantation. His platelet count dropped on day three to 
2 x 109/l, and he subsequently died 18 days post liver transplantation 
secondary to pulmonary haemorrhage and multi-organ failure. Platelet 
antibodies specific to GPIb\XI identified in the donor were also found in the 
recipient following transplantation, but were absent from the recipient’s serum 
sample taken 14 days prior to transplantation. The donor liver time-zero 
biopsy showed marked extramedullary haematopoiesis. There was no 
evidence of TMAT in the recipient of a single kidney from the same donor. 
One liver transplant recipient developed hepatic artery thrombosis and 
needed urgent re-transplantation and one died secondary to haemorrhage 
from a ruptured vascular aneurysm (Table 4.1).  Graft and patient survival 
were inferior in recipients of livers from donors with ITP compared to those 
who received livers from all other deceased donors (Figure 4.3), although, 
when the death of the single patient with TMAT was excluded, patient and 
graft survival were similar in recipients of livers from donors with ITP and all 
other deceased donors (p=0.19) (Figure 4.3).  None of the other early causes 
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of death or graft failure in the liver recipients from donors with ITP were 













Figure 4.3 Patient and death censored Graft survival of liver transplant recipients 
from organ donors with ITP and from all other deceased organ donor 
1.25.5 Heart Recipients 
The four recipients of hearts from organ donors with ITP were of similar age 
(median 43.0, p=0.736) ethnicity (75% white vs. 90% white, p=0.307), and 
gender (75% male vs. 62% male, p= 0.604) to all other deceased donor heart 
transplant recipients. The day three platelet counts were 143, 96, 53, and 
96 x 109/l respectively. Two of the recipients developed thrombocytopenia 
more than three days post-transplant.  In one case, this was attributed to use 
of anti-thymocyte globulin (ATG). The other was investigated extensively for 
their low platelet count, and anti-platelet antibodies were absent (anti-
GPIIb/IIIa, GPIa/IIa, GPIb/IX, HLA, CD109). The nadir of their 
thrombocytopenia was a platelet count of 34 x 109/l seven days post cardiac 
transplantation. The recipient died 12 days post- cardiac transplantation from 
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allograft dysfunction and donor organ failure. The thrombocytopenia was 
thought to be secondary to continuous haemofiltration. 
Table 4.1.  Clinical Characteristics of liver transplant recipients from deceased organ 
donors with Immune thrombocytopenia (ITP) and all deceased donors without ITP 
 Transplant 
recipients from 
donors with ITP  
  (n = 14) 
All transplants from 
donors without ITP 
 (n =10499) 
P value 
Age (y) 46.0 (28-51) 50.0 (36-58) 0.190 
Gender   0.642 
Male/Female (%) 10 (71%)/4 (29%) 6201 (59%)/4297 (41%)  
Not Stated 0 1 (<0.5%)  
Ethnicity   0.374 
White/ Other/Not specified 13 (93%)/ 1 (7%) 8839 (84%)/ 1660 (16%)  
UKELD 55 ± 3 54 ± 6 0.69 
MELD 16.5 ± 4.4 16.8 ±7.1 0.867 
Urgent status 3 (21%) 1580 (15%) 0.50 
Primary Liver Disease   0.999 
Primary Sclerosing 
Cholangitis 
2 (14%) 778 (7%)  
Hepatitis C liver cirrhosis 0 1350 (13%)  
Alcoholic Liver disease 2 (14%) 1837 (18%)  
Other/Not stated 10 (71%) 6534(62%)  
Cause of Graft failure   <0.001 
Hepatic Artery thrombosis 1 (14%) 235 (8%)  
Chronic Rejection 1 (14%) 214 (7%)  
Biliary Complications 1 (14%) 91 (3%)  
Death with functioning graft  2 (28%) 1115 (38%)  
Primary Graft Failure 1 (14%) 181 (6.1%)  
TMAT 1 (14%) 0   
Cause of Death   <0.001 
Haemorrhage from ruptured 
vascular aneurysm 
1 (20%) 8 (<0.5%)  
Pulmonary Infection 2 (40%) 118 (4%)  
TMAT 1 (20%) 0  
Metabolic Brain Injury 1 (20%) 0  
Other 0 2425 (91%)  
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1.26 Discussion 
The analysis in this Chapter has described, for the first time, a national 
experience of using donors with ITP and has established that clinically 
significant TMAT is not a common occurrence in organ transplant recipients. 
Although donors with ITP make up a very small proportion of the total donor 
pool (0.15%), they made a significant contribution to organ transplantation 
with a total of 49 organ transplants, and because of the discrepancy between 
organ supply and demand it is imperative that organs from donors are not 
rejected unnecessarily (137).  
The absence of TMAT in 31 kidney and 4 heart transplant recipients from the 
series is consistent with three previous TMAT cases following liver 
transplantation, in which recipients of other organs (5 kidneys and a heart) 
from the same donors with ITP did not develop TMAT (130,132). Passenger 
lymphocyte induced haemolysis is most frequent following haematopoietic 
stem cell transplantation and progressively less likely following heart and lung 
transplantation, then liver/small bowel/pancreas then kidney transplantation in 
proportion to the number of transplanted lymphocytes (138). A larger number 
of lymphocytes transmitted to the recipient in the donor graft may therefore 
explain why TMAT has occurred following liver but not kidney or heart 
transplantation.  
With only one TMAT case in this series it is not possible to identify 
characteristics of donors with ITP that could distinguish those whose organs 
carry the greatest risk of TMAT. In this case series, and in all five previous 
TMAT cases, the donors all died of ICH and had platelets <20 x 109/l prior to 
death. Of the five ITP donors with a reported clinical history three had been 
refractory to multiple therapies including splenectomy, but two died as result 
of ICH as part of their acute ITP presentation. Failure of the donor with ITP to 
respond to splenectomy suggests that their liver is a major site of platelet 
destruction by the reticuloendothelial system(75,76,77).  In our series, one 
recipient of a liver from a donor with ITP who had required splenectomy 
developed TMAT and one did not. Extramedullary haematopoiesis in the 
donor liver represents a greater burden of transplanted haematopoetic tissue. 
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There were a limited number of time zero liver biopsies available, but the 
degree of extramedullary haematopoiesis and its significance in predicting 
TMAT could be explored in future studies.  
The progressive thrombocytopenia at day zero and three in liver recipients 
was expected. The platelet count is usually reduced post orthotopic liver 
transplantation, typically falling to a nadir around post-operative day four, 
followed by a gradual recovery (139). This thrombocytopenia is thought to be 
caused by factors such as reduced thrombopoietin production, haemodilution 
and platelet sequestration in the reperfused liver graft. There may also be 
patient specific variables such as sepsis, bleeding or disseminated 
intravascular coagulation (increased platelet consumption), medication, viral 
infection or heparin induced thrombocytopenia (80). Hence other causes of 
thrombocytopenia must therefore be considered in cases of suspected TMAT. 
Furthermore, like ITP, TMAT remains a clinical diagnosis. Serological testing 
may be supportive if the same anti-platelet antibodies are found in recipient 
and donor. However, the significance of these antibodies is unclear since it is 
unknown whether they can be detected in liver recipients of donors with ITP 
unaffected by TMAT. Secondly, platelet-associated IgG can be elevated in 
non-immune thrombocytopenia and antibodies to specific platelet 
glycoproteins cannot always be detected in patients with ITP (81). Hence 
negative serological testing of donor and recipient does not exclude the 
presence of TMAT.  
The natural history and optimal treatment of TMAT is unclear. In three cases 
the platelet counts had improved within 1-3 weeks with only IVIg ± steroids 
(130,132). In two cases refractory to multiple therapies including splenectomy, 
the platelets recovered following liver retransplantation day 11 for rejection in 
one case and following retransplantation day 43 for refractory TMAT in the 
other (131).  
The kidney transplant recipient that developed ITP after 8 years post 
transplantation is not likely to be a donor derived TMAT since lymphocytes do 
not persist following solid organ transplantation (128). The incidence of ITP is 
approximately 4 per 100,000 person years but occurs more frequently on the 
background of immune dysregulation (136). In a series of 256 liver transplant 
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recipients, 8 (0.7%) cases of new ITP occurred at a median time from 
transplant of 53.5 months (range 1.9-173) (100). 
There are some limitations to this analysis. The retrospective nature of the 
registry analysis may limit the accuracy and completeness of the donor and 
recipient data; the numbers presented in this analysis are likely an 
underestimate of the actual number of donors who had ITP as well as the 
impact of TMAT, as other than the single TMAT case there were no recipients 
with severe day three thrombocytopenia. However, we cannot exclude the 
possibility of milder episodes of TMAT that were not recognized as such by 
the treating teams.  
 
 96 
The potential to increase organ donation from deceased 
organ donors with a history of increased risk behaviour for 
the transmission of blood-borne viral infection 
Publications from this work: Trotter et al. Deceased organ donors with a history of increased 
risk behaviour for the transmission of blood-borne viral infection: The UK experience. 
Transplantation. 2017; 101(7):1679-1689. 
1.27 Introduction 
Unintended HCV, HBV, HIV and HTLV from deceased organ donors is a rare 
but serious complication of organ transplantation (113). This risk is minimised 
by performing relevant laboratory screening investigations in deceased 
donors prior to implantation of their organs. Currently available screening 
strategies cannot completely discount the presence of a recently acquired 
viral infection, and considerable importance is attached to the identification of 
donors with a history of increased risk behaviour (IRB) associated with the 
acquisition of HCV, HIV, HBV and HTLV (57,66,113,140). While the discard of 
organs from those with a history of IRB would minimize disease transmission, 
it would markedly reduce the number of transplants performed. Consequently, 
the risk of disease transmission from donors with IRB needs to be balanced 
against the potential benefits of organ transplantation. 
Solid organ donors who have a history of prior or current intravenous drug use 
(IVDU), or of recent or historical imprisonment, and those who have a history 
of high-risk sexual behaviour are viewed at greatest risk of transmission of 
BBV (140,141). In the UK, current guidance from SaBTO and the European 
Directive on Organ Donation requires that detailed information on ‘behavioural 
history that could have put the donor at an increased risk of blood borne 
viruses’ be obtained (62) The information needed includes ‘questions about 
risk behaviours such as recreational drug use, men who have sex with men 
(MSM), and risks such as accidental body fluid exposure’ (123). UK guidance 
on donor assessment is consistent with that in the US where the need to 
assess behavioural risk factors for a donor to be at increased risk of 
transmitting HIV, HBV and HCV is highlighted (57). The donor history with 
respect to such IRB also provides an important context for the interpretation of 
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the results from microbiological screening for HIV, HCV, HBV and HTLV 
(123,140,142). Current screening tests for viral markers have limited 
sensitivity, and serological screening may result in an infective window period 
of up to 70 days following infection when antibodies to virus are undetectable 
(142). 
In this chapter I analyse the UK experience of deceased organ donors, both 
potential and actual, with a history of IRB, highlighting the overall prevalence 
and types of IRB. My aim was to establish the impact of IRB on organ 
donation and utilization, as well as on their transplant recipient outcomes. 
1.28 Methods 
1.28.1 Identification of deceased organs donors with increased-risk 
behaviour 
The UKTR was examined to identify all deceased organ donors between 
1st January 2003 and 31st December 2015, who had a history of any one of 
the following IRB: IVDU, current or previous imprisonment, MSM, sex in 
exchange for money or drugs, and high risk sexual partner (defined as a 
sexual relationship with any of the previously mentioned increased risk 
groups). For the purposes of this study, “potential donors” were defined as 
deceased donors for whom consent/ authorization for organ donation had 
been obtained, “actual organ donors” as deceased donors who had one or 
more solid organs removed for transplantation on the basis that recipient 
centres had provisionally agreed to use them for transplantation, and “utilised 
organ donors” as actual organ donors whose organs were eventually 
transplanted. The decision as to whether or not a potential donor proceeds to 
organ donation is dependent on transplant clinicians at individual transplant 
centres indicating that they are willing to accept the organs for transplantation. 
There are no centralized clinical advisors involved in this decision.  
In the UK, a donor transplant coordinator (designated in 2008 as a SNOD) is 
required to enquire from the next of kin, medical notes and the potential 
donor’s family doctor, whether there is a history of IRB and record these 
findings. Additional UK guidance published in 2000 highlighted the 
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requirement to screen potential organ donors for behaviour associated with 
BBV.  
Free text entries of all potential donors were searched using the terms 
‘intravenous drug use’, ‘sex worker’, ‘Men who have sex with men’ and 
‘prison’. All common abbreviations, misspellings, synonymous terms and 
colloquialisms of the above search terms were also searched. Donors with a 
history of IVDU and imprisonment were sub-categorised based on whether or 
not they had been an IVDU or imprisoned during the preceding 12 months. 
Donors with a history of high-risk sexual behaviour were sub-categorised 
according to the type of behaviour into any one of ‘high risk partner’, ‘sex 
worker’, and ‘prior high risk partner’.  
It is important to note that a number of patients did not fall into the category of 
potential donors because formal consent for donation was not sought for a 
variety of reasons that included a belief by the clinicians caring for the patient 
that the patient’s IRB would exclude organ and tissue donation. Information 
on the number of patients who did not progress to become potential donors 
for the entire study period (2003-2015) was not available but the PDA was 
interrogated to obtain information on patients excluded from the present 
analysis. Between 1st January 2009 and 31st December 2015 there were 
12,040 potential donors which were included in the present analysis, and 
during the same period the PDA showed that 1,022 patients with an identified 
IRB (89% IVDU) did not get consented for organ donation for a variety of 
reasons that included IRB. For 86 patients excluded from the present 
analysis, IVDU was stated explicitly as a reason why the patient’s family was 
not approached for consent for organ donation.  
1.28.2 Identification of recipients of organs from donors with increased-risk 
behaviour 
The UKTR was examined to identify recipients of organs from donors with IRB 
and information on outcome (patient and graft survival) obtained. UK 
transplant centres are required to notify NHSBT of any potential donor-derived 
disease transmission and adverse events relating to the donation process. 
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Details of any donor transmitted infections were collected from a designated 
transplant incident reporting registry held by NHSBT.  
1.28.3 Statistical Analysis 
Univariate analysis comparing clinical characteristics between IRB and non-
IRB potential donors, who were seronegative for BBV, was carried out using 
Student’s t-test for approximately normal continuous data, and the Mann-
Whitney U test for non-normal continuous data. Categorical comparisons 
were made using the χ2–squared test.  
Kaplan-Meier curves were used to show death-censored graft survival and 
patient survival and the univariate log-rank test was used to compare 
unadjusted survival rates.  
Cox proportional hazards regression model and a logistic regression model 
were fitted in a stepwise selection method in order to control for potentially 
confounding factors. Donor related variables considered for inclusion in the 
multivariate model were donor age, donor type, ethnic group, sex, past 
medical history of diabetes and hypertension, liver disease, cardiac disease, 
smoking history and whether the donor had a history of IRB. Recipient factors 
included were age, ethnicity, sex, primary renal disease, HLA mismatch level 
and cold ischaemic time.  
1.29 Results 
One or more IRB was identified in 659 (3.8%) potential deceased donors, and 
454 (3.6%) actual organ donors. Of the potential donors with a history of IRB, 
47% had a history of IVDU, 33% a history of imprisonment, 10% were MSM, 
and 9.9% a history of high risk sexual behaviour. For actual donors with a 
history of IRB, 41% had a history of IVDU, 37% had a history of imprisonment, 
and 21% had a history of high risk sexual behaviour, and these proportions 
did not differ significantly from the behaviours in potential donors (p=0.147).  
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1.29.1 Organ donors who were seropositive for HIV, HCV, HBV and HTLV 
Overall, 285 (1.7%) potential organ donors were found to be seropositive for 
BBV markers. 104 (36.5%) seropositive potential donors proceeded to organ 
donation; in contrast to the 78% conversion rate observed in seronegative 
potential donors (p<0.001). Organs from 81 (77.8%) of the seropositive organ 
donors were subsequently transplanted, compared to 95.7% of seronegative 
organ donors (p<0.001).  
Half (50.5%) of potential donors who were seropositive for viral infection had a 
history of IRB, and in most (78.5%) this included IVDU. A history of 
imprisonment, MSM and high risk sexual behaviour was less common 
(16.7%, 2.7% and 2.1% respectively). The clinical characteristics of potential 
and actual seropositive donors are shown in Table 5.1. Positive serology for 
HCV was more common in donors with a history of IRB. In contrast, markers 
of HIV, HBV and HTLV were all more common in seropositive donors with no 
history of IRB (Table 5.1).  
The types of organs from seropositive organ donors that were used for 
transplantation differed according to whether or not there was a history of IRB. 
The 62 organ donors with a history of IRB provided 48 livers and 11 kidneys 
that were used for transplantation, whereas the 42 donors with no history of 
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26  (61.3%)/ 
16 (38.7%) 
0.044 
White Ethnicity (%) 79 (96.3%) 56 (91.8%) 89 (89.9%) 36 (85.7%) 0.128 
HIV antibody 3 (3.7%) 2 (3.2%) 8 (8.5%) 1 (2.4%) 0.420 
HCV antibody 77 (93.9%) 59 (95.1%) 62 (62.6%) 27 (64.2%) <0.001 
HBsAg positive 3 (3.7%) 3 (4.8%) 13 (14.3%) 12 (28.6%) <0.001 
HTLV 1 (0.7%) 0 19 (17%) 2 (4%) <0.001 
Increased-risk 
behaviour- All 82 62    
High risk sexual 
behaviour 5 (6.1%) 2 (3.2%)    
IVDU 61 (74.3%) 52 (83.9%)    
Prison 16 (19.5%) 8 (12.9%)    
Organs 
Transplanted     <0.001 
Liver  48  25  
Kidney  11  32  
Other organs  0  0  
Table 5.1. Clinical characteristics of potential and proceeding organ donors that were 
seropositive for HIV, HCV, HBsAg and HTLV 
1.29.2 Increased-risk behaviour and organ donation in donors who were 
seronegative for viral infection 
To examine the association between IRB and organ donation, all seropositive 
potential donors were excluded from subsequent analysis. After exclusion, 
there were 16,977 remaining potential donors of which 12,737 (75%) 
proceeded to organ donation (Figure 5.1). A history of IRB was identified in 
515 (3%) of potential and 392 (3%) of actual organ donors, suggesting that 
overall, a history of IRB did not adversely influence the decision to proceed to 
organ donation. 25% of potential donors with no history of IRB and 24% of 
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those with a history of IRB did not proceed to donation (p=NS). Potential 
donors with a history of IRB were, when compared to those with no history of 
IRB, much younger, and significantly less likely to have hypertension, cardiac 
disease and diabetes (Table 5.2). Potential donors with IRB were more likely 
to be smokers and to have a history of alcohol abuse. 
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Unknown/ Unstated 24 (5%) 1394 (8%)  








Unknown/ Unstated 20 (4%) 1175 (7%)  








Unknown/Unstated 13 (3%) 1158 (7%)  
Table 5.2. Clinical Characteristics of seronegative potential donors with increased-
risk behaviour compared with all other deceased organ donors.     
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Figure 5.1. Flow diagram for seronegative organ donors identified with increased-
risk behaviour 
There were significant differences in the conversion rate from potential to 
actual donors according to the type of IRB (Figure 5.2). Potential donors with 
a history of IVDU were less likely to proceed to organ donation than donors 
with no history of IRB and this effect was most marked in potential donors with 
a history of recent rather than historical IVDU. Those with a history of high risk 
sexual behaviour alone were as likely to proceed to donation as those with no 
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history of high risk sexual behaviour (Figure 5.2). History of imprisonment 
alone (previous or current) was associated with an increased rate of 
proceeding to donation compared to donors with no history of IRB (Figure 
5.2).  However, when a logistic regression model was fitted to adjust for the 
significant differences in age and co-morbidity between donors with or without 
a history of IRB, IRB was associated with significantly fewer potential organ 
donors becoming actual organ donors (odds ratio=1.580 (95% CI 1.273-
1.962, p<0.001).When the logistic regression model was fitted for the different 
types of IRB, IVDU (both recent and historical) was associated with 
significantly fewer potential organ donors becoming actual organ donors 
(Recent IVDU, odds ratio=3.552 (95% CI (2.373-5.315), p<0.001 and 
historical IVDU, odds ratio =1.984 (95% CI 1.205-3.268) p=0.007, 
respectively) (Table 5.3). 
The number of potential donors with a history of IRB increased markedly over 
the 13-year study period and the percentage of donors proceeding to donation 
also rose in the latter part of the study period (Figure 5.3).  
 Odds Ratio (95% 
Confidence Intervals) 
p-value 
Donor age (y) 1.035 (1.033 -1.038) <0.001 
Past medical history of hypertension vs. 
No past medical history of hypertension 
1.192 (1.094-1.29) <0.001 
High-risk sexual behavior vs.  
No high-risk sexual behaviour 
1.373 (0.900-2.094) 0.141 
Imprisonment vs.  
No history of Imprisonment 
0.859 (0.570-1.295) 0.468 
Historical IVDU vs.  
No history of IVDU 
1.984 (1.205-3.268) 0.007 
Recent IVDU vs. No history of IVDU 3.551 (2.373-5.315) <0.001 
Table 5.3. The likelihood of potential donors not proceeding to become actual organ 
donors based on the presence of selected risk factors. 
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Figure 5.2. Proceeding and non-proceeding seronegative consented organ donors according to whether or not they had history increased-risk 
behaviour. All p-values refer to category of IRB compared to all donors with no history of IRB.
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Figure 5.3. Number of seronegative potential donors with increased-risk behaviour 
whose organs were used for transplantation and those whose were not used for 
transplantation. 
Proportion of potential organ donors with a history of increased risk behaviour who 
did not proceed to organ donation is shown above each column. 
1.29.3 Clinical characteristics of actual organ donors with history increased-
risk behaviours 
Potential donors with a history of IRB, who proceeded to become actual organ 
donors were younger (39.8 ± 12.6 years vs. 44.3 ± 11.6 years, p<0.001) and 
more likely to be DBD than DCD donors (36.2% DCD vs. 82.9% DCD, 
p<0.001) than those potential donors with IRB who did not proceed to organ 
donation. 
The clinical characteristics of the 392 actual organ donors with a history of 
IRB, along with the clinical characteristics of all other deceased organ donors 
are shown in table 5.4. Actual organ donors with a history of IRB were 
younger, more often males and more likely to be of an ethnic minority other 
than white. Organ donors with a history of IRB were more likely to have a 
history of smoking and of alcohol abuse (table 5.4). 
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 Proceeding donors with 
a history of increased-
risk behaviour (n= 392) 




Age (y)  39 (30-48) 50 (38-61) <0.001 

























Body Mass Index (BMI) 24.4 (22.0-27.5) 25.7 (22.9-29.0) <0.001 























































Table 5.4. Clinical Characteristics of deceased seronegative proceeding organ 
donors with increased-risk behaviour compared with all other deceased organ 
donors.    
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1.29.4 Clinical characteristics of recipients receiving organs from donors with 
increased-risk behaviour 
Over the 13-year study period, a total 1,091 transplants were carried out using 
organs from seronegative deceased donors with a history of IRB (624 kidney, 
278 liver, 63 heart, 39 lung (including one lung pair), 2 heart and lung 
transplants, 84 pancreases, and 1 bowel transplant).  
Recipients of kidneys from donors with a history of IRB were younger, more 
often of non-white ethnicity and less well matched for HLA than recipients of 
kidneys from donors with no IRB (Table 5.5). Recipients of kidneys from 
donors with IRB spent a similar amount of time on the transplant waiting list 
and had a similar duration of dialysis pre-transplant when compared to those 
who received kidneys from donors without IRB. Recipients of kidneys from 
donors with IRB had similar graft and patient survival to those who received 
kidneys from all other deceased donors (Figure 5.4a). When the recipients of 
the different types of IRB were compared to all other recipients, a donor 





 Increased Risk 
Behaviour Donors  
(n= 624) 




Age (y) 48 (38-56) 50 (39-60) <0.001 
Gender    





Not stated 1 (<0.5%) 38 (<0.5%)  
Ethnicity    
White/Not white (%) 460 (73.8%)/ 163 
(26.2%) 
14663 (77.7%)/ 4208 
(22.3%) 
0.009 
Not stated 1 (<0.5%) 38 (<0.5%)  
*cRF >85% 63 (10.0%) 1800 (9.5%) 0.889 
HLA Group   0.256 
1 74 (11.9%) 2719 (14.4%)  
2 215 (34.5%) 6654 (35.3%)  
3 288 (46.2%) 8198 (43.4%)  
4 46 (7.4%) 1310 (7.0%)  
Missing/Not stated 1 (<0.5%) 29 (<0.5%)  
Primary Renal 
Disease 
  0.522 
Diabetic 
Nephropathy 
43 (6.9%) 1544 (7.6%)  
Glomerulonephritis 110 (17.6%) 3347 (17.7%)  
Pyelonephritis 50 (8.1%) 1437 (5.3%)  
Polycystic Kidney 
Disease 
70 (11.2%) 2261 (12.0%)  
Other/ Not stated 351 (56.3%) 10292 (57.4%)  
Time on dialysis 
(days) 
1295 (727-1994) 1252 (706-1955) 0.552 
Waiting time 
(days) 
827 (361-1370) 832 (354-1450) 0.489 
Table 5.5. Clinical characteristics of recipients of seronegative deceased donor 




Figure 5.4a and b.  Patient and death censored Graft survival of kidney transplant 
recipients from seronegative organ donors with increased-risk behaviour and from all 
other seronegative deceased organ donors. P-value corresponds to score test of the 
overall null hypothesis that there are no differences in survival curves for all groups 
i.e. comparing survival across all groups   
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Recipients of livers from donors with a history of IRB were older, more often 
male, had a lower UKELD score, and more often HCV positive than recipients 
of livers from donors with no IRB (Table 5.6). Similarly, patient and graft 
survival following liver transplantation was comparable for recipients of livers 
from donors with and without IRB (Figure 5.5a and Figure 5.5b).  
 
 Increased-risk 
behaviour Donors  
(n= 278) 




Age (y) 53 (43-59) 51 (37-59) 0.111 








Unknown/ Unstated 0 5(<0.5%)  
Ethnicity   0.148 
White (%) 244 (87.8%) 7404 (84.6%)  
Non-White (%) 34 (12.2%) 1348 (15.4%)  
Unknown/Unstated  4 (<0.5%)  
Urgent Status 42 (15.1%) 1483 (16.9%) 0.421 
UKELD score 53 (50-58) 55 (51-59) 0.016 
Recipient HCV 
antibody positive 
12 (4.3%) 484 (5.5%) <0.001 
Primary Liver 
Disease 
  0.012 
HCV cirrhosis 38 (13.7%) 950 (10.7%)  
ALD 67 (24%) 1561 (17.7%)  
Other/Not stated 173 (62.2%) 6245 (71.3%)  
Table 5.6. Clinical characteristics of recipients of deceased donor livers according to 
whether or not the donor had a history of increased-risk behaviour  
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Figure 5.5a and b. Patient and death censored graft survival of liver transplant 
recipients from seronegative organ donors with increased-risk behaviour and all 
other seronegative deceased organ donors.  P-value corresponds to score test of the 
overall null hypothesis that there are no differences in survival curves for all groups 
i.e. comparing survival across all groups  
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Because of the differences in donor and recipient demographics between 
recipients that received organs from donors with a history of IRB compared to 
those that did not, a Cox proportional hazards regression model was fitted to 
adjust for donor and recipient age, donor history of hypertension, HLA 
mismatch, cold ischaemic time and primary recipient disease. This showed 
that patient survival after kidney transplantation was not adversely affected by 
a donor history of IRB (Table 5.7). After assessing whether the different sub-
types of IRB adversely impacted on transplant outcome, the multivariate 
analysis indicated recipients of kidneys from donors with high-risk sexual 
behaviour had significantly worse patient survival than those who received 
kidneys from donors with no history of high-risk sexual behaviour, even after 
adjusting for donor and recipient factors. Each of the high-risk sexual 
behaviours was assessed in turn, and this revealed that it was only those who 
received kidneys from donors with a high-risk sexual partner that had worse 
patient survival. 
1.29.5 Disease transmission 
From the 1,091 organ transplants from donors with IRB, one liver recipient 
and two renal recipients (all from the same organ donor) developed donor-
derived HCV infection.  The donor of the organs had a history of recent IVDU, 
and tested negative for HCV antibody at time of donation. Retrospective 
testing of the donor serum obtained at donation was positive for HCV 
Ribonucleic Acid. The liver recipient was known to be HCV positive at time of 
transplantation, but it was noted that the predominant HCV genotype changed 
from genotype 1 pre-transplant to donor genotype 3 after transplant. The two 
renal recipients were both HCV negative prior to transplantation. There were 





 Hazard Ratio p-value 
Donor Age (y) 1.009 (1.005-1.012) <0.001 
Recipient Age (y) 1.056 <0.001 
DBD vs. DCD 1.151 (1.042-1.272) 0.006 
Cold Ischaemic Time 1.009 (1.002-1.016) 0.012 
HLA Mismatch   
1 0.840 (0.696-0.999) 0.0599 
2 0.857 (0.729-1.001) 0.0573 
3 0.883 (0.757-1.019) 0.1052 
4 1.00 - 
Male vs. Female 1.101 (1.010-1.200) 0.028 
Primary renal disease   
All other causes 1.00 - 
Glomerulonephritis 0.823 (0.731-0.927) <0.001 
Diabetic Neprhopathy 1.595 (1.409-1.805) <0.001 
Pyelonephritis 1.041 (0.896-1.221) 0.609 
Polycystic kidney disease 0.661 (0.578-0.763) <0.001 
History of Hypertension   
No history of hypertension 1.00 - 
Hypertension 1.186 (1.079-1.305) <0.001 
Unknown history of 
hypertension 
1.243 (1.037-1.491) 0.02 
Increased risk behaviour vs. 
No history of Increased risk 
behaviour 
1.102 (0.833-1.457) 0.498 
Sub-Types of Increased Risk 
Behaviour 
  
Recent IVDU 0.482 (0.136-1.713) 0.230 
Historical IVDU 0.763 (0.326-1.787) 0.534 
Imprisonment 0.804 (0.514-1.256) 0.338 
High-risk sexual behaviour 1.897 (1.253-2.872) 0.003 
Sub-types of High risk 
sexual behaviour 
  
High risk partner 3.004 (1.592-5.667) <0.001 
Men who have sex with men 1.376 (0.770-2.461) 0.281 
Not specified  3.819 (0.944-15.450) 0.060 
Prior high-risk partner 2.510 (0.351-17.930) 0.359 




Routine screening of all potential organ donors for a history of IRB to 
determine risk of transmission of BBV infection is routinely undertaken in most 
countries to help inform the decision on organ usage. The present analysis 
provides insight on the impact of this policy on organ donation and utilization 
in the UK, where the prevalence of blood borne viral infection is slightly lower 
than that in the USA and broadly similar to Western Europe (77,80,143).  
Around 4% of all potential organ donors, for whom consent for donation was 
obtained, had a history of IRB and 22% of these (2% of all potential donors) 
were seropositive for blood borne viral infection (mostly HCV), at the time 
organ donation was being considered and over half had a history of IRB. This 
again is lower than that observed in the US, where an estimated 20% of 
deceased donors have an increased risk for BBV (144). Positive serology for 
blood borne viruses may indicate a very high risk of disease transmission 
during transplantation, and enables an informed decision on whether to 
proceed with organ donation, and if so, to allocate organs to appropriate 
potential recipients; in the majority of cases the recipients are likely to be 
selected on the basis that they already have infection corresponding to that 
identified in the donor.  
In the present analysis, we were particularly interested in the extent to which 
IRB in seronegative potential donors impacted on organ donation and 
transplantation. Overall, around three quarters of all potential organ donors in 
the UK proceeded to become actual organ donors, on the basis that 
transplant implanting centres had provisionally accepted them for 
transplantation. A history of IRB (all types) was not associated with a 
reduction in the proportion of potential donors that proceeded to become 
organ donors. However, a history of IVDU accounted for nearly half of all IRB 
and was associated with a relatively small but significant reduction in the 
proportion of potential donors proceeding to donation, especially when the 
drug use may have been recent.   
Potential donors with IRB were significantly younger and had less additional 
comorbidity than those with no IRB, and when these variables were taken into 
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account by logistic regression analysis, IVDU (both recent and historical) were 
associated with donors not proceeding to become actual organ donors. Our 
analysis of the PDA (a prospective registry of all patients aged <80 years who 
died in critical care units of acute UK hospitals, irrespective of their medical 
suitability to become organ donors) indicated that a large number of these 
identified registry patients did not get consented for organ donation because 
of their history of IRB (in particular IVDU).  
The number of potential donors with IRB in the present analysis increased 
markedly over the 13-year study period. This likely reflects, for the most part, 
a true increase in the number of such donors over time, in line with the 
general trend towards increased consideration of organs from other types of 
high-risk donor (145). However, it is also likely that some of the increase in 
potential donors with IRB over time may be attributable to a bias in data 
capture, as clinical practice in organ donor screening by transplant 
coordinators and documentation became more standardised.  
While the risk of disease transmission in seronegative donors with IRB is very 
low, not all transplant centres routinely assess recipients for graft-derived 
acquisition of blood borne viral disease and consequently the present analysis 
may provide an underestimate of disease transmission from donors with IRB. 
Although seronegative donors with a history of IRB represent a small 
proportion of the total donor population they made a significant contribution to 
organ transplantation in the UK over the 13-year study period, providing 
organs for over a thousand transplants.  
There were three confirmed transmissions of HCV to two renal transplant 
recipients and one liver transplant recipient. All three episodes of disease 
transmission originated from the same donor, who was known to be an active 
IVDU at time of donation. Using standard serological testing the window 
period from infection with HCV to detection by antibody assays is around 70 
days (142,146-148) and with NAT is 3-5 days (142,146,148). Both serological 
testing and NAT testing carry the risk of false positive results and hence the 
unnecessary discard of potentially infection free organs from potential donors. 
NAT testing is only currently available in selected UK centres and recent 
evidence suggests that NAT testing would improve utilization of organs from 
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IRB donors, but not from donors with no history of IRB (142). Hence even 
when NAT testing is available a thorough history regarding IRB is still 
important to aid interpretation of positive results.  
As might be expected, recipients of organs from seronegative donors with IRB 
had transplant outcomes (patient and graft survival) comparable to recipients 
of organs from deceased donors with no history of IRB, even after adjustment 
for differences in donor and recipient demographics. However, those who 
received kidneys from donors with a high-risk sexual partner had worse 
patient survival than all other deceased donors. The exact cause of this 
remains unclear. When the causes of renal recipient death in this cohort were 
examined, no deaths (n=8) were attributable to disease transmission from the 
donor (2 post transplant proliferative disease, and one each of gastro-
intestinal haemorrhage, haemorrhage from graft site, septicaemia, viral 
hepatitis, non-lymphoid malignant disease, and ischaemic heart disease). The 
case of viral hepatitis was fulminant liver failure secondary to HCV genotype 
1b, which was already present in the recipient prior to transplantation. There 
was no significant difference in graft or patient survival in recipients of livers 
from donors with high-risk sexual behaviour and all other deceased donors.  
The comparison of recipient characteristics according to whether or not they 
received a kidney from a donor with a history of IRB revealed that recipients 
of kidneys from donors with IRB were significantly younger and significantly 
more likely to be of non-white ethnicity. Donors with a history of IRB were also 
significantly younger and of non-white ethnicity than all other deceased 
donors, and kidney allocation and acceptance policies in terms of age, blood 
group and HLA matching would likely explain the differences observed in 
recipient demographics. In support, it was notable that for liver transplant 
recipients, where HLA-matching is not undertaken, there was no significant 
difference in the ethnicity of recipients according to whether or not they 
received a liver from a donor with IRB. Because kidney donors with IRB were 
significantly younger than other deceased kidney donors, and recipients of 
kidneys from younger donors have improved transplant outcomes, it might 
have been expected that transplant outcomes would have been better in 
recipients of kidneys from donors with IRB (145,149). The number of 
 118 
recipients of kidneys from donors with IRB in the present analysis may not 
have been sufficient to demonstrate the advantage of younger donor age on 
transplant outcome. 
The analysis is the first to report in detail on different categories of IRB in a 
national cohort of deceased organ donors, and provides important information 
on which to base future transplant policy for managing the risk of disease 
transmission. The numbers presented likely represent an underestimate of 
potential donors with IRB in the donor population, because of underreporting. 
This is evidenced by the small number of reported MSM in the registry 
(0.44%), whilst estimates from a recent US census analysis and meta-
analysis estimated that around 3.9% of the US adult male populations are 
MSM, and in the UK it is estimated that 2.0-2.5% of the adult male population 
are MSM (150,151).  
Research suggests that a patient would be willing to accept a kidney from a 
donor with IRB if the organ was deemed otherwise healthy (152): individuals 
are more concerned about the perceived poor quality of the organ and the risk 
of disease transmission rather than having a prejudice or concern about a 
particular type of increased risk behaviour per se (152). 
While the present analysis indicates that a history of IRB, particularly IVDU, in 
seronegative potential donors is associated with a reduction in organs being 
accepted for transplantation, such donors represent a valuable source of 
organs for transplantation and the risk of disease transmission in the context 
of UK blood borne virus epidemiology is relatively small. Moreover, recent 
advances in the management of transmissible viruses particularly HCV, 
means that even if viral disease transmission occurs it can in many cases be 
successfully managed (2). It has also been suggested that kidneys from 
seronegative donors with a history of IRB may be a valuable source of organs 
for potential recipients with an increased likelihood of death whilst on the 
waiting list (82,153,154).  When organs from donors with a history of IRB are 
used for transplantation it would be prudent for all centres to test recipients 
within an appropriate time period following transplantation in order to exclude 
donor derived infection.   
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Potential and actual deceased donors with HCV 
Publications from this work: Trotter et al. Use of organs from hepatitis C virus positive donors 
for uninfected recipients: a potential cost-effective approach to save lives?  
Transplantation. 2018:102(4):664-672. 
1.31 Background 
Currently around 200,000 people in the UK are infected with HCV and with 
increasing demand for organs for transplantation selected HCVpos donors 
may represent an additional source of organs for transplantation (77,155). 
At present, organs from HCVpos deceased donors are usually declined for 
transplantation because of the high probability of disease transmission, with 
an accelerated risk of cirrhosis and liver failure; even in recipients who are 
HCV positive there is often reluctance to use organs from HCVpos donors. In 
many cases HCV antibody positive recipients have received treatment and 
cleared the virus. National guidance in the US and UK cautions against the 
use of organs from HCVpos donors (55,62,64,141). 
Until recently, treatment of HCV in allograft recipients was expensive, toxic 
and relatively ineffective (84). The advent of highly effective direct acting anti-
viral agents (DAA) has greatly improved the outcome for HCV infected 
patients, with sustained virological response (SVR) rates in excess of 95% 
(84-86,156-159). Hence, a large number of patients who would have required 
transplantation secondary to the end organ liver and/or kidney damage 
associated with chronic HCV infection are now being treated effectively prior 
to the need for transplantation (159). This will result in greater consideration 
being given to the use of HCVpos donor organs for HCV negative recipients, 
as a large proportion of the HCVpos recipients, who could have previously 
received the HCVpos donor organs, is reduced due to successful treatment 
with DAA (159). The safety of using HCVpos donor organs varies depending 
on the organ being transplanted, with much of the current evidence 
demonstrating efficacy of DAA in the transplant population following donor 
transmission of HCV pertaining to kidney transplantation (50,160,161,162). 
There is concern regarding the use of livers from HCVpos donors because of 
the increased rate of progression to cholestatic hepatitis observed in liver 
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transplant candidates with HCV (163,164). However, there is evidence to 
suggest that DAA use in the liver cohort also achieves SVR and reversal of 
hepatic decompensation (164,165). It was hypothesised that there were a 
large number of non-proceeding HCVpos donors whose organs would 
otherwise have been considered of good quality for transplantation.  
The aims of this analysis were to identify the seroprevalence of HCV in the 
UK deceased potential organ donor population, to determine the extent to 
which the presence of HCV impacted on their likelihood to proceed to organ 
donation, and to establish the quality of the donor organs that were not used 
for transplantation. I also aimed to estimate the impact that the use of organs 
from such donors would likely have in terms of additional transplants 
performed, transplant outcome, and specifically the cost benefit of using 
HCVpos donor kidneys for HCV negative recipients compared to a patient 
remaining on haemodialysis. 
1.32 Methods 
1.32.1 Identification of patients dying in UK critical care units who were not 
considered for donation because of the risk of HCV transmission 
Many patients who die in critical care units and might be suitable organ 
donors are not considered for organ donation because the team caring for the 
patient do not consider donation as an option. To determine the number of 
patients who died in critical care and could have potentially donated organs 
but were not considered eligible as donors because of the presence of HCV 
or of increased risk behaviour posing an increased risk for HCV transmission 
(such as IVDU), the UK PDA was examined. A potential eligible donor is 
defined as a patient with no absolute contra-indications to organ donation who 
met the requirements for brain-stem death testing or if death is thought likely 
to occur within 4 hours of withdrawal of treatment (166).The PDA was 
searched to identify deaths occurring from 1st October 2009 (when information 
in the PDA was made more comprehensive) to 1st January 2016. Patients 
with HCV were identified in the PDA by searching through the free text entries 
using the search terms ‘hepatitis’, ‘hepatitis C’, ‘HCV’ and ‘HepC’. All common 
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abbreviations and misspellings of these search terms were also searched. 
Patients with a history of intravenous drug use (IVDU) were identified from the 
free text entries in the PDA using the search terms ‘intravenous drug use’, 
‘IVDU’, ‘Needle’, ‘Heroin’, ‘Overdose’, ‘Injected’, ‘IVDA’. All common 
abbreviations, misspellings, synonymous terms and colloquialisms of the 
above search terms were also searched. 
1.32.2 Identification of consented potential and proceeding organ donors in 
the UK who were hepatitis C positive 
The UKTR includes information on all deceased potential donors for whom 
consent for organ donation had been obtained irrespective of whether or not 
they proceeded to donate organs for transplantation. The UKTR was 
examined to identify HCVpos potential and actual deceased donors in the UK 
between 1st January 2000 and 1st January 2016. HCVpos donors were 
identified by the presence of anti-HCV antibody in the serum at time of referral 
for organ donation; only a minority of the donor cohort had reported HCV RNA 
status in the UKTR as part of donor characterisation. Consented potential 
donors were categorised as “non-proceeding organ donors” when, for 
whatever reason, organ donation did not occur, as “proceeding organ donors” 
when one or more of their solid organs were retrieved for transplantation 
irrespective of whether they were subsequently used for transplantation, and 
“actual organ donors” when one or more of their organs were used for 
transplantation.  
1.32.3 Identifying recipients of organs from hepatitis C positive donors 
The UKTR was used to identify all recipients of organs from deceased 
HCVpos donors, and to obtain data on recipient survival, death censored graft 
survival and recipient HCV status. 
1.32.4 Estimation of non-proceeding donor organ quality 
The quality of non-proceeding donor organs, in terms of their suitability for 
transplantation was assessed by eGFR calculated using the MDRD equation, 
liver tests (LT), the UKKDRI and the UK DLI (104,105,107). 
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1.32.5 Cost analysis of haemodialysis versus kidney transplantation from a 
HCVpos donor together with antiviral therapy 
To assess whether kidney transplantation along with the use of DAA to treat 
transmitted HCV would be cost effective compared to haemodialysis, a cost 
analysis was carried out using the current estimated costs of renal 
transplantation in the UK (£53,288 first year plus £8,526 for each additional 
year), haemodialysis (£29,841) and a 12-week course of DAA therapy 
(sofosbuvir and ledipasvir +/- ribavirin depending on the HCV genotype, 
£38,980) (167,168). This combination of anti-viral agents was selected based 
on the National Institute for Health and Care Excellence (NICE) 
recommendations published in 2015. While the present analysis used only the 
combination of sofosbuvir and ledipasvir in the cost analysis, it is important to 
note that many more therapies have subsequently been approved by NICE 
(168-170). 
1.32.6 Statistical analysis 
Continuous parametric variables were compared using Student’s t-test and 
continuous non-parametric variables were compared using Mann-Whitney U 
test. Categorical variables were compared using Chi-squared test. Survival 
analysis was assessed using Kaplan-Meier tables.  All analyses were 
performed using SAS.  
1.33 Results 
1.33.1 Patients dying in UK critical care units who were not considered for 
donation because of the risk of HCV transmission 
Between 2009 and 2016, 274,600 patients who died in UK critical care units 
and were not considered for organ donation for a variety of reasons were 
identified from the PDA, of which 780 (0·3%) patients were reported to have 
HCV infection and 882 (0.3%) had a history of IVDU. Of the 780 patients 
reported to have HCV, 277 (35.5%) also had a history of IVDU. Compared to 
all other patients not considered for donation in the PDA, those with reported 
HCV infection were younger (median 48 years IQR 41-57 vs. median 68 years 
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IQR 56-76, p<0·001), were more likely to be male (69·5% male vs. 59·3% 
male, p<0.001), and were more likely to be of Asian descent compared to all 
other patients (7·3% vs. 4·4%, p<0·001) (Table 6.1).  
Of the 780 patients with reported HCV infection, 370 had no other primary 
contraindication to organ donation, and met the requirements for brain stem 
death testing or could have been considered as a DCD donor. In 120 of the 
370 patients, it was stated explicitly in free text entries of the PDA that the risk 
of HCV transmission was the reason that donation was considered not 
appropriate. 
Clinical Characteristics Non- proceeding 
potential donors 
with HCV   






Age (y) 48 (41-57) 67 (55-76) <0.001 
Male/Female (%) 542 (69.5%)/ 
237 (30.4%) 




















Hypoxic Brain Damage 
Liver failure 


















HIV or HIV related disease 
Multi-Organ Failure 
Other medical contraindication 
Donor specific contraindication 
















Table 6.1. Clinical Characteristics of non-proceeding potential organ donors 
identified as being HCV positive and all other non-proceeding potential donors 
 124 
1.33.2 Proceeding and non-proceeding organ donors who were hepatitis C 
virus seropositive 
Analysis of the UKTR for the period 2000-2015, identified 19,692 deceased 
potential organ donors. Of these, 244 (1·2%) were identified as anti-HCV 
antibody positive. Whereas only 98 (40·2%) of the HCVpos potential donors 
proceeded to become actual donors, 15,068 (76·5%) of the HCV seronegative 
(HCVneg) donors proceeded to donate one or more organs for transplantation 
(p<0.001). Organs from 76 (77·6%) of the 98 HCVpos proceeding organ 
donors were used for transplantation, whereas organs from 14,458 (95·9%) of 
HCVneg donors were subsequently transplanted (p<0·001). The number of 
potential HCVpos deceased donors increased over the study period, but the 
percentage proceeding to donate organs did not show any clear trend (Figure 
6.1). 
Figure 6.1. Total number of Hepatitis C positive donors whose organs were used for 
transplantation and those that were not. Proportion of Hepatitis C positive donors 
whose organs were used for transplantation shown above each column 
 
Over half (60·4%) of the 244 HCVpos potential organ donors had a history of 
increased-risk behaviour for blood borne viral disease. Only 6 (2·5%) 
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consented HCVpos donors were co-infected with other blood borne viruses 
(Human Immunodeficiency Virus (n=2), Hepatitis B Virus (n=2) or Human 
T cell Lymphotropic virus (n=2)).  
The clinical characteristics of proceeding HCVpos donors were compared to 
those of non-proceeding HCVpos donors and to all proceeding HCVneg 
donors (Table 6.2). Proceeding HCVpos donors were significantly younger 
than non-proceeding HCVpos donors and all other proceeding HCVneg 
negative donors (median age 41.5 years (IQR 32-51) vs. 48.5 years (39-54) 
and 49.0 years (37-60), respectively, p=0.010). Both proceeding and non-
proceeding HCVpos donors were less likely to have a medical history of 
hypertension compared to all proceeding HCVneg donors (12 (12.2%), 
24(16.4%) and 3717 (24.7%), respectively, p=0.004). However, both 
proceeding and non-proceeding HCVpos had significantly higher reported 
rates of alcohol abuse, drug abuse, liver disease and smoking history 




































White ethnicity 95 (96·9%) 136 (93·2%) 14431 (95·8%) 0·248 
BMI 25·0 (21·9-27·4) 25·0 (22·6-28·3) 25·4 (22·7-28·7) 0·077 
Diabetes    0·111 
Yes 1 (1·0%) 10 (6·8%) 908 (6·0%) 
No 93 (94·9%) 111 (76·0%) 13707 (91·0%) 













Hypertension    0·004 
Yes 12 (12·2%) 24 (16·4%) 3717 (24·7%) 
No 86 (87·8%) 122 (83·6%) 11347 (75·3%) 
Missing/Unknown 0 0 0 
Cardiac Disease    0·618 
Yes 8 (8·2%) 13 (8·9%) 1410 (9·4%) 
No 84 (79·3%) 110 (75·3%) 13047 (86·6%) 
Missing/unknown 6 (11·1%) 25 (17·1%) 606 (4·0%) 
Liver disease    <0·001 
Yes 22 (26·7%) 45 (30·8%) 418 (2·8%) 
No 68 (60·0%) 73 (50·0%) 13944 (92·5%) 
Missing/unknown 8 (25·2%) 28 (19·2%) 702 (4·7%) 
Alcohol Abuse    <0·001 
Yes 30 (43·0%) 72 (55·4%) 1975 (13·1%) 
No 60 (61·2%) 57 (43·9%) 12546 (83·3%) 
Missing/Unknown 8 (7·4%) 16 (7·4%) 547 (3·6%) 
Drug abuse    <0·001 
Yes 63 (44·4%) 85 (66·9%) 790 (5·2%) 
No 32 (45·2%) 42 (33·1%) 13686 (90·8%) 
Missing/Unknown 3 (10·4%) 19 (10·4%) 6 (<0.5%) 
Smoking history    <0·001 
Yes 77 (78·6%) 107 (73·3%) 6622 (43·9%) 
No 15 (15·3%) 21 (14·4%) 7960 (52·8%) 
Unknown/Missing 6 (6·3%) 18 (12·3%) 486 (3·2%) 
Table 6.2. Clinical characteristics of HCV seropositive (HCVpos) organ donors 
compared to those of HCV seronegative (HCVneg) organ donors 
 
1.33.3 Outcomes of recipients of HCVpos donor organs 
Of the 98 HCVpos proceeding organ donors, organs were used from 76 
donors and this resulted in a total of 92 solid organ transplants (63 liver, 27 
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kidneys, 2 heart). Patient and graft survival in recipients of livers and kidneys 
from HCVpos donors was no different to that observed in recipients of such 
organs from HCVneg deceased donors (Figure 6.2 and Figure 6.3). One of 
the heart transplant recipients died 7years 7 months after transplantation 
secondary to coronary occlusive disease, whilst the other heart transplant 
recipient is alive with a functioning graft (4 years 8 months).  
Of the liver transplant recipients, 96.8% (n=61) were known to be or have 
been HCVpos. The 2 liver transplant recipients that were not known to have 
HCV required a liver transplant urgently. Of the 27 kidney transplant 
recipients, 8 (29.6%) were reported to be HCV antibody positive, 11 (40.7%) 
HCVneg, and 8 (29.6%) of unknown status. Of the heart transplant recipients 
both recipients were recorded as being HCVneg. One of the heart transplant 
recipients fulfilled the criteria for super-urgent listing. 
 
Figure 6.2. Patient survival and death censored graft survival of recipients who 
received livers from hepatitis C virus seronegative (HCVneg) donors compared to 
those who received livers from HCV seropositive (HCVpos) donors 
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Figure 6.3. Patient survival and death censored graft survival of recipients of kidneys 
from hepatitis C negative donors compared to those who received kidneys from 
hepatitis C positive donors 
1.33.4 Estimation of non-proceeding donor organ quality 
The most common reason given for consented HCVpos donors not 
proceeding to become actual organ donors was the presence of positive 
donor virology (76·0%); only 15 (8·9%) of such donors were declined because 
of poor organ function (Table 6.3).  
The quality of organs in non-proceeding HCVpos consented donors was 
similar to that of HCVneg proceeding donors (Table 6.3). Of the non-
proceeding HCVpos potential donors, 42% had an eGFR>90mls/min and a 
similar proportion had liver tests within normal range. UKKDRI calculated for 
non-proceeding HCVpos donors showed that half (49·9%) of the donors were 
in the best two UKKDRI quartiles. The DLI scores calculated indicated that 42 




Reported Reason for Decline  
Donor Unsuitable-Virology 120 (71·4%) 
Donor Unsuitable-History 77 (45·6%) 
Non-Heart Beating donor 62 (36·9%) 
Family refusal 23 (13·6%) 
Poor function 15 (8·9%) 
Other/Not Stated 92 (54·7%) 
UK Kidney Donor Risk Index  
≤ 0.87 34(23·3%) 
0.871-1.02 38(26·0%) 
1.021-1.34 40(27·4%) 
≥1.341 26 (17·8%) 
Missing 8(5·5%) 
eGFR (ml/min) 103·0 (70·5-144.5) 
Creatinine at time of donation 67·5 (51-101) 
Bilirubin (μmol/L) 13·0(8-22) 
Alanine Transferase (IU/l) 53(29-111) 
Alkaline Phosphatase (IU/l) 92·5 (70-133) 
UK Donor Liver Index  
<0.96 25 (17·1%) 
0.96<LRI ≤1.11 17 (11·6%) 
1.11<LRI ≤1.32 21 (14·4%) 
LRI >1.32 83 (56·9%) 
 
Table 6.3. Estimation of organ quality of HCVpos deceased donors who did not 
proceed to organ donation 
1.33.5 Cost analysis 
We assessed if kidney transplantation and routine treatment with DAA would 
be cost effective compared to haemodialysis. As expected kidney 
transplantation from a HCVneg donor was cost effective compared to 
haemodialysis (Figure 6.4). While the use of routine anti-viral therapy in 
recipients of kidneys from HCVpos donors increased the cumulative cost of 
transplantation at 5 years by £38,979 per patient transplantation remained 
cost effective compared to haemodialysis at 5 years (Figure 6.4). 
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Figure 6.4. Cumulative cost analysis of haemodialysis compared to receiving either 
a kidney from a HCVneg donor or receiving a kidney from a HCVpos donor and 
receiving combination sofosbuvir and ledipasvir for 12 weeks.  
1.34 Discussion 
This chapter explored the opportunities for increasing organ donation and 
transplantation in the UK through the use of organs from HCVpos donors by 
analysing the entire organ donation pathway from patients dying in critical 
care units who were not considered for donation through to donors whose 
organs were removed but subsequently declined for transplantation. Our 
findings confirm that many patients dying in UK critical care units are not 
considered as potential donors because of a history of HCV, and the majority 
of consented, deceased potential donors with HCV do not proceed to organ 
donation because of the high risk of disease transmission.  
The rationale for undertaking the present analysis was that the availability of 
DAA now provides a treatment that allows for safe transplantation of organs 
from HCVpos donors(162,171,172). DAA are small-molecule inhibitors of the 
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HCV viral replication cycle that target non-structural viral 
proteins(85,173,174). Genotypic coverage varies among the agents, but 
combination therapy permits the use of highly effective interferon-free 
regimens achieving SVR at 12 weeks in more than 95% of infected 
individuals. Several studies have shown successful HCV clearance using a 
variety of interferon-free, DAA-based regimens in genotype 1 and 2 infected 
kidney and liver transplant recipients with preserved allograft function, and the 
DAAs were safe, effective, and well tolerated (85,86,171-174). A recent open 
label, single group, pilot trial also demonstrated the feasibility of using 
HCVpos kidneys for HCVneg recipients (175). Studies are underway 
assessing the use of liver grafts from HCV viraemic donors for HCVneg 
recipients but there are no published findings as yet. Several studies have 
demonstrated high rates of SVR in both cirrhotic and non-cirrhotic liver 
transplant recipients with DAA, suggesting that if HCV was transmitted with 
the graft, treatment with combination DAA would likely achieve SVR also 
(85,164,165,176). 
An important consideration in the proposition to use organs from donors with 
HCV for HCV naïve recipients is the possible legal implications of intentionally 
transmitting an infection. In the UK, the use of HCV infected organs is not 
prohibited, although guidance stipulates that recipients must give fully 
informed and specific consent and antiviral treatment must be made freely 
available. Similarly, in the US, federal law does not prohibit the use of HCV 
infected organs for transplantation (177). 
The present analysis of the PDA identified 370 patients with a history of HCV 
over an 8-year period that were eligible to donate organs but where consent 
for donation was not sought. In 120 of these, infection by HCV was stated 
explicitly as the reason for the patient not proceeding to become a potential 
donor. The patients identified from the PDA with a history of HCV/IVDU were 
significantly younger and a greater proportion were of non-white ethnicity 
compared to all other patients identified in the PDA. These results are 
consistent with those reported by other studies investigating the clinical 
characteristics of deceased donors with HCV or a history of increased risk 
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behaviour for the transmission of blood borne viral 
disease(15,82,140,159,178).  
The present analysis showed that for patients for whom consent for organ 
donation had been obtained, the presence of anti-HCV antibody was 
associated with a high likelihood (69%) that their organs would be declined for 
transplantation because of concern about disease transmission. In other 
respects, the declined HCVpos donors would have been considered 
satisfactory organ donors. They were of similar age to all other proceeding 
deceased donors and a significantly smaller proportion had a past medical 
history of hypertension. However, it is important to note that non-proceeding 
HCVpos donors were significantly more likely to be smokers, abuse alcohol, 
and have diabetes, all of which can detrimentally impact allograft survival. 
Nevertheless, the use of organs from donors with such conditions is accepted 
in current transplant practice. 
It should also be noted that there is a possibility of co-infection of other blood 
borne viral infections in HCVpos donors. In this cohort of non-proceeding 
deceased HCVpos donors, 6 (2.5%) were co-infected with HIV, HBV or HTLV. 
Although this represents a small proportion of the total, it is important to 
consider that if increased numbers of donors with HCV were to be consented 
and then used for transplantation the risk of missing a recent HIV or HBV 
infection may possibly increase, although with current organ donor screening 
practice this risk is likely to be small (141). 
Declined HCVpos donors often had good renal and liver function and based 
on validated UK Donor Risk Indices, 77% of kidneys and 80% of livers from 
the non-proceeding HCVpos donors would be predicted to be functioning at 5 
years if they had been transplanted.  
The majority of implanted HCVpos organs were livers and most of the liver 
recipients (96.8%) were known to already have had HCV infection prior to 
transplantation. Only a small minority of kidneys were used from proceeding 
HCVpos donors, yet were it not for the presence of HCV they would generally 
be considered good quality kidney donors: compared to HCVneg donors, 
proceeding HCVpos donors were younger and a smaller proportion had a 
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history of hypertension. Although the number of transplant recipients of 
organs from HCVpos donors was small, their outcomes in terms of patient 
and graft survival were comparable to those in recipients of organs from 
HCVneg donors. 
While the routine use of HCVpos donors for transplantation would represent a 
major change in clinical practice, there are already precedents in the case of 
CMV and EBV, where it is accepted that transplantation may result in the 
transmission of viral disease and protocols are in place to mitigate their 
impact by prophylactic or pre-emptive therapy (69,72). With the use of DAA, 
acquisition of HCV through the transplanted graft, may become viewed in a 
similar light (179). 
The use of antiviral therapy in recipients of kidneys from HCVpos donors 
would add considerably to the cost of renal transplantation in the first 12 
months. However, the cost analysis performed in the present analysis 
demonstrated that despite the high costs of combination sofosbuvir and 
ledispavir, their use to clear transmitted HCV from the renal allograft recipient 
would be cost effective compared to dialysis at 5 years. Similarly, a recent US 
publication described the costs of haemodialysis being between $40,000 and 
$73,000 and the cost of a combination of elbasvir/grazoprevir being $63,000 
indicating that similar cost benefit from transplanting HCVpos kidneys would 
be seen in the US (172,180). It is likely that the costs of DAA therapy will fall 
so the cost benefit may become greater in the future. Based on the last year 
of data in this analysis, and if the use of organs from HCVpos donors became 
part of UK practice, we could expect an additional 21 deceased donors with 
HCV. If each of these donors donated on average 2.3 organs for 
transplantation, like other UK deceased donors, we would expect 48 
transplants of which 2-3 may be expected to fail treatment with current DAA 
therapy. However, it is important to note that many salvage therapies are in 
practice or in development, meaning that even those who do not clear the 
virus with first line treatment will still likely achieve SVR (181). 
SaBTO, has suggested that the use of organs from such donors in some 
circumstances be permitted, and this advice has been accepted. National 
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clinical guidelines have been drawn up by a consortium of interested 
professional bodies.  
There are limitations to the present analysis. The first concerns determination 
of the HCV status of potential donors. Because the identification of HCVpos 
patients dying in critical care units through the PDA is based on entry of free 
text in the audit rather than a requirement to state the outcome of viral tests, it 
is likely that the number of patients classified as HCVpos is an underestimate. 
In the case of the UKTR of all consented potential donors, the presence of 
HCV infection was based on the results of serology and not on the presence 
of HCV RNA. In the UK, deceased donors who test positive for anti-HCV 
antibodies will be subsequently tested for HCV RNA with the result available 
after donation and transplantation. However, it is important to note that an 
increasing number of deceased organ donors who test positive for anti-HCV 
will be HCV RNA negative secondary to increased use of DAA. Although, 
centres in the UK may still not be able to test deceased donors for HCV RNA 
pre-transplant, it is important to consider that a proportion of anti-HCV 
antibody positive donors will not transmit HCV to the recipient. 
Data from the UK blood donor service, where both HCV serology and NAT 
testing are performed on all blood donors, indicates that approximately 20% of 
the potential organ donors who are seropositive for HCV are likely to be RNA 
negative and therefore unlikely to transmit infection (155) . The second 
limitation concerns the cost analysis of routine anti-viral therapy in recipients 
of kidneys from HCVpos donors. The cost analysis performed was based on 
current costing by NICE using only the DAA currently recommended in their 
guidance, but in this rapidly moving field many such treatments have now 
been approved (168-170). However, there are now a number of novel DAA 
and these may be more or less cost effective in transplantation. Also, it has 
not been possible to comment on the expected extra costs associated with 
routine testing of transplant recipients for the presence of HCV.  Thirdly, there 
is currently no information regarding the distribution of HCV genomes in the 
UK organ donor population as genotype determination is not part of routine 
organ donation screening. However, currently approved treatments include 
combinations that are active across all genotypes, with variable but usually 
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high SVR of >95%. Data from the UK general population can be used to infer 
the expected proportion of different genotypes in the UK organ donor 
population. In the UK, 90% of infected strains belong to genotype 1 or 3 with 
the latter being more common than the former (155).  This analysis cannot 
assess the likelihood of consent for transplantation in those potential donors 
where there was no attempt to determine their wishes. A further limitation of 
this analysis is not knowing the HCV status of all renal transplant recipients. 
However, given the time period that these transplants were performed over it 
is unlikely that these kidneys would have been transplanted into HCVneg 
recipients without confirmation of either recipient HCV status or further testing 
(not available in the UKTR) to confirm that the donor did not have HCV RNA.  
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Transplantation of organs from deceased organ donors who 
died following ligature asphyxiation. 
 
Publications from this work: Trotter et al. Transplantation of kidneys from DCD and DBD 
donors who died after ligature asphyxiation: the UK experience.  
American Journal of Transplantation. June 2018. Epub ahead of print. 
1.35 Introduction 
Kidneys from deceased donors who have undergone ligature asphyxiation are 
often used for transplantation, although there is little information on whether 
this mode of death influences transplant outcomes. Ligature asphyxiation is 
usually the result of attempted suicide by hanging and is one of the most 
common methods of suicide. Moreover, suicide remains a common cause of 
death worldwide, especially in the younger population (97,182,183). In 
situations where attempted resuscitation and hospitalization has occurred 
following ligature asphyxiation, individuals may become potential DBD or DCD 
organ donors. However, ligature asphyxiation in these circumstances is 
associated with a period of global tissue hypoxia, often of an unknown 
duration, which may cause warm ischaemic injury of the transplantable 
organs (94,95,184). During ligature asphyxiation there is compression of the 
carotid arteries, jugular veins and the trachea, resulting in raised intracranial 
pressure, cerebral oedema and catastrophic brain injury (98). In addition to 
the above, the victims of ligature asphyxiation may also develop pulmonary 
oedema and multi-organ failure secondary to global tissue hypoxia (98). While 
hypoxic tissue injury following ligature asphyxiation is a concern in DBD 
donors, it may have an even greater impact on organs from DCD donors 
where the organs are also subjected to a second period of warm ischaemic 
injury between cardiac arrest and cold perfusion of the organs (29). However, 
many potential donors who die following ligature asphyxiation are relatively 
young and previously healthy and therefore might be a source of good quality 
kidneys that can be used safely for transplantation (185). 
The evidence on which to base decisions regarding the use of organs from 
deceased donors following ligature asphyxiation is limited and comprises case 
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reports and single centre experiences (94,95,184). Moreover, the published 
experience relates almost exclusively to DBD donors, with little or no 
published evidence for DCD donors who are becoming an increasingly 
important source of organs for transplantation (94,95,184).  
To improve the evidence base and aid decision making on the use of organs 
from donors who die following ligature asphyxiation, I undertook a 
retrospective national UK cohort analysis of all kidney transplants performed 
using organs from DBD and DCD donors. 
1.36 Methods 
1.36.1 Identification of recipients who received organs from donors who died 
from ligature asphyxiation 
The UKTR was examined to identify the recipients of kidneys (both single and 
dual kidney transplant recipients) from donors who died secondary to ligature 
asphyxiation in the UK between 1st January 2003 and 31st December 2016 
and information on death-censored graft survival and patient survival was 
collected. In recipients of renal allografts, 1 year eGFR was calculated (107).  
All-cause graft failure was taken as time from transplantation to graft 
nephrectomy or return to permanent dialysis, whichever was earlier, or to 
death of the patient with a functioning graft. Survival of the patient was 
defined as time from transplantation until death. We defined PNF as failure of 
a graft to ever function. DGF was defined as the need for dialysis within the 
first 7 days after transplantation (excluding recipients with PNF). Graft survival 
was censored at 5 years. Warm ischaemic time was defined as the time from 
circulatory arrest to cold perfusion of the kidneys. Downtime was defined as 
either time from discovery of cardiac arrest until return of circulation following 
resuscitation or when the free text entries in the registry referred to the time 
as downtime. 
1.36.2 Statistical analysis 
Univariate analysis was carried out using the Student’s t-test for parametric 
continuous data and the Mann–Whitney U test for non-parametric continuous 
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data. Comparisons between groups were made using the 2 test for 
categorical data. Kaplan–Meier tables were used to compare death-censored 
graft survival and patient survival. The univariate log-rank test was used to 
test differences in survival.  
Cox proportional hazards regression model was fitted with factors known to 
impact on patient and graft survival. Patient and graft survival were censored 
at 1 year to determine factors associated with 1 year survival and at 5 years to 
determine the factors associated with 5-year survival. This was performed as 
a large proportion of donors who died following ligature asphyxiation had 
kidneys used for transplantation in the last 3 years. Patients without graft or 
patient follow-up (n=79 (0.4%)) were not included in the analysis. Log 
cumulative hazard plots were drawn and proportionality of hazards was 
checked using log–log plots.  
Multivariable linear regression modelling was carried out to assess the impact 
that donor cause of death from ligature asphyxiation had on 1 year eGFR and 
creatinine. Logistic regression analysis was performed to assess the impact of 
donor cause of death by ligature asphyxiation on potential donors proceeding 
to kidney donation and the impact of this cause of death on DGF and PNF 
rates.  
Multiple imputation was used to account for missing donor and recipient 
variables. There were no missing data for donor type, ethnicity and whether or 
not cause of death was by ligature asphyxiation. Missing information about 
past medical history of hypertension and/or diabetes was 7.1%. For past 
medical history of cardiac disease and smoking there were 0.98% and 2.3% 
missing data respectively. In terms of recipient characteristics, there were 
<1% missing data for recipient gender, HLA mismatch level, ethnicity and 
recipient sex, <2% for CIT and 37% for warm ischaemic time in DCD donors. 
Missing data were assumed to be missing at random and the missing 
variables had an arbitrary missing pattern. The imputed variables were all 
independent variables. Missing data were estimated by a discriminant function 
approach for categorical variables, a logistic regression approach for ordinal 
variables and linear models for cumulative variables. The FCS method was 
used to impute missing values of both continuous and class variables in the 
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dataset with an arbitrary missing pattern. For each analysis requiring multiple 
imputation, 20 imputed datasets were created.  
Donor-related variables considered for inclusion in the multivariable models 
were donor age, donor type, ethnic group, sex, cause of death, past medical 
history of diabetes, hypertension and cardiac disease, previous drug abuse 
and smoking history, and blood group. Recipient factors included were 
recipient age, ethnicity, sex, sensitization, primary renal disease (five 
categories), blood group (O, A, B, AB), HLA mismatch and CIT. Other factors 
considered for inclusion were renal transplant unit, which was included as a 
random effect, and year of transplant (as an ordinal variable).  
An addition to the above multivariable analyses, a case-control propensity 
score matched analysis was also performed to examine transplant outcomes 
in recipients of kidneys from donors who died following ligature asphyxiation. 
Propensity scores were calculated using logistic regression on the probability 
of a recipient receiving a kidney from a donor who died following ligature 
asphyxiation. The scores were then used to match recipients of kidneys from 
donors who died following ligature asphyxiation to recipients of kidneys from 
all other deceased donors with similar propensity scores. This was 
accomplished with 1:1 matching. The following covariates were included in 
the estimation of propensity scores since they have been shown in previous 
analyses of the UK dataset to impact on transplant outcomes: donor age, 
recipient age, donor past medical history of hypertension, primary renal 
disease, HLA mismatch grade, cold ischaemic time, donor weight, donor type 
(DBD and DCD) and transplant year (149,186). 
1.37 Results 
1.37.1 Potential and proceeding kidney donors who died secondary to 
ligature asphyxiation 
Over the 14-year study period (1st January 2003 to 31st December 2016), 
2.7% (n=521) of all potential UK organ donors died secondary to ligature 
asphyxiation. Nearly all (98.7%) were a result of attempted suicide, but a 
small proportion (1.3%) were accidental. From this pool of potential donors, 
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409 (78.5%) subsequently proceeded to donate one or more kidneys for 
transplantation. By comparison, only 69.9% of potential donors who died from 
all causes other than ligature asphyxiation proceeded to donate kidneys for 
transplantation (p<0.001). Of the potential donors who died from ligature 
asphyxiation and proceeded to kidney donation, 192 (46.9%) were DBD 
donors and 217 (53.1%) were controlled DCD donors. 
The proportion of potential DBD donors who died after ligature asphyxiation 
and proceeded to donate kidneys was similar to that for all other types of 
potential DBD donors (91.4% vs 87.6% respectively, p=0.092). Compared to 
potential DBD donors, a lower proportion of all potential DCD donors 
proceeded to kidney donation, irrespective of whether the cause of death was 
from ligature asphyxiation (50.1% vs 87.7%, p<0.001). However, more 
potential DCD donors proceeded to donate organs after ligature asphyxiation 
than after causes of death other than ligature asphyxiation (69.8% vs 49.4%, 
p<0.001). 
Relatively little information was available in the transplant registry regarding 
the physiological events occurring around the time of ligature asphyxiation. A 
total of 203 (39.0%) potential donors who died following ligature asphyxiation 
were reported to have had a cardiac arrest at the time of ligature asphyxiation 
and had a recorded ‘downtime’ (i.e. the length of time following cardiac arrest 
until return of circulation at the time of resuscitation). Of these, 73.8% 
proceeded to donate kidneys for transplantation compared to 80.7% of 
potential donors with no stated downtime (p=0.125). The median recorded 
downtime was 25 minutes (IQR 15–40 minutes). Of donors who died from 
ligature asphyxiation, DCD donors had significantly shorter recorded 
downtimes compared to DBD donors (median 22 minutes (IQR 15–34.5) vs 
median 33 minutes (IQR 19–45.5), p=0.0151). 
1.37.2 Factors associated with potential deceased donors proceeding to 
donate kidneys for transplantation 
A multivariable analysis was undertaken on all potential donors (n=19,310) to 
determine whether death from ligature asphyxiation was independently 
associated with a potential donor proceeding to donate one or more kidneys 
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for transplantation. As shown in Table 7.1a, the following donor factors were 
associated with proceeding to donate kidneys: donor age; DBD donor type; no 
past medical history of diabetes, hypertension or cardiac disease; and white 
ethnicity. Following adjustment for the above donor variables, ligature 
asphyxiation in potential donors remained strongly associated with an 
increased likelihood of kidney donation for transplantation (odds ratio 1.211 
(95% confidence interval 1.080–1.357), p<0.001).  A further multivariable 
analysis was performed to assess what factors influenced donors who died 
following ligature asphyxiation to proceed to kidney donation. Table 7.1b, 
demonstrates that younger donor age, DBD donor type, no history of smoking 
or liver disease, no history of intravenous drug use, and having been 
imprisoned were all independently associated with a donor who died following 
ligature asphyxiation proceeding to donate a kidney for transplantation.  
1.37.3 Clinical characteristics of proceeding kidney donors (DBD and DCD) 
who died from ligature asphyxiation 
The clinical characteristics of proceeding kidney donors who died after 
ligature asphyxiation and those who died from all other causes are shown in 
Table 7.2; the data are shown separately for DBD and DCD. Both DBD and 
DCD kidney donors who died from ligature asphyxiation were significantly 
younger and a greater proportion were male than those DBD and DCD donors 
who died from other causes. Four (<0.5%) DBD donors who died from causes 
other than ligature asphyxiation did not have gender known. 
Donors who died following ligature asphyxiation (both DBD and DCD donors) 
had a markedly lower incidence of hypertension and cardiac disease than 
donors who died from causes other than ligature asphyxiation. The proportion 
of kidney donors who died following ligature asphyxiation who had diabetes 
mellitus was numerically lower than that of donors who died from all other 
causes, but the difference was only significant in the case of DCD donors. 
More kidney donors (both DBD and DCD) who died following ligature 
asphyxiation had a history of smoking compared to all other deceased donors. 
DBD and DCD donors who died following ligature asphyxiation had 





(95% Confidence Interval) 
p-value 
Donor Age 0.983 (0.981-0.986) <0.001 
Donor ethnicity   
White 1.00 - 
Non-white  0.794 (0.731- 0.863) <0.001 
Donor Type   
DCD 1.00 - 
DBD  2.536 (2.444-2.631) <0.001 
Past medical history of 
diabetes 
  
No 1.00 - 
Yes  0.753 (0.707- 0.803) <0.001 
Past medical history of 
hypertension 
  
No 1.00 - 
Yes  0.902 (0.863-0.942) <0.001 
Past medical history of 
cardiac disease 
  
No 1.00 - 
Yes 0.863 (0.819-0.908) <0.001 




No 1.00 - 
Yes 0.970 (0.933-1.01) 0.115 
Donor cause of death   
No ligature asphyxiation 1.00 - 
Ligature asphyxiation  1.211 (1.080-1.357) 0.001 
Table 7.1a. Factors associated with potential deceased donors proceeding to donate 
one or more kidneys for transplantation. 19, 310 potential deceased donors were 
analysed by logistic regression. 
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Donor characteristics (n=521) Odds Ratio (95% Confidence Interval) p-value 
Donor Age (years) 0.975 (0.965-0.985) <0.001 
Donor ethnicity   
White 1.00 - 
Non-white 1.259 (0.829-1.911) 0.279 
Donor Type   
DCD 1.00 - 
DBD 1.973 (1.664-2.340) <0.001 
Past medical history of 
diabetes 
  
No 1.00 - 
Yes 0.951 (0.630-1.436) 0.811 
Past medical history of 
hypertension 
  
No 1.00 - 
Yes 1.223 (0.850-1.758) 0.278 
Past medical history of 
cardiac disease 
  
No 1.00 - 
Yes 0.901 (0.514-1.580) 0.716 




No 1.00 - 
Yes 0.829 (0.706-0.973) 0.022 
History of IVDU   
No 1.00 - 
Yes 0.543 (0.412-0.715) <0.001 
History of imprisonment   
No 1.00  
Yes 1.438 (1.055-1.961) 0.022 
History of liver disease   
No 1.00  
Yes 0.479 (0.324-0.709) <0.001 
Downtime (minutes) 1.005 (0.994-1.016) 0.387 
Pre-donation creatinine 
(umol/l) 
1.000 (0.999-1.002) 0.911 
Table 7.1b. Factors associated with potential donors who died following ligature 
asphyxiation proceeding to donate one or more kidneys for transplantation
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 DBD donors who died 
following ligature 
asphyxiation (n=192) 
DBD donors who died 




DCD donors who died 
following ligature 
asphyxiation (n=217) 
DCD donors who died 




Age (y) 32 (22-43) 49 (37-59) <0.001 34 (24-47) 54 (43-65) <0.001 
Male/Female (%) 113 (58.9%)/79 (41.1%) 4448 (50.3%)/ 4394(49.7%) 0.074 160 (73.7%)/57 (26.3%) 2583 (60.2%)/1708 (39.8%) <0.001 




5 (2.6%)/  
187 (97.4%) 
2172 (24.6%)/  
6480 (73.3%) 





Unknown/Unstated 0 194 (2.2%)  6 (2.8%) 289 (6.7%)  
History of Cardiac 
disease  
Yes/ No  
1 (0.5%) 
 189 (98.4%) 
746 (8.4%)  
7900(89.3%) 
<0.001 5 (2.3%)  
199 (91.7%) 
598 (13.9%)  
3359 (78.3%) 
<0.001 
Unknown/Unstated 2 (1.0%) 200 (2.3%)  13 (5.9%) 334 (7.8%)  
History of Diabetes 
 Yes/No 
8 (4.2%)/  
183 (95.3%) 
480 (5.4%)/  
8272(93.5%) 
0.565 5 (2.3%)/  
201 (92.6%) 
325 (7.6%)/  
3696 (86.1%) 
0.007 
Unknown/Unstated 1 (0.5%) 94 (1.1%)  11 (4.9%) 270 (6.3%)  
Smoking History  
Yes/ No  
125 (65.1%)/  
65(33.9%) 
4231 (47.8%)/  
4522 (51.1%) 
<0.001 140 (64.5%)/  
74 (34.1%) 
1802 (42.0%)/  
2233 (52.1%) 
<0.001 
Unknown/Unstated 2 (1.0%) 93 (1.1%)  3 (1.4%) 256 (6.0%)  
Pre-donation serum 
creatinine (umol/l) 
121 (93-162) 84 (67-107) <0.001 101 (80-129) 84 (65-108) <0.001 
Missing 0 9 (<0.5%)  3 (1.4%) 223 (5.2%)  
Table 7.2. Clinical Characteristics of proceeding kidney donors who died from ligature asphyxiation compared to all other deceased donors. 
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1.37.4 Clinical characteristics of recipients of kidneys from donors who died 
following ligature asphyxiation 
Donors who died following ligature asphyxiation provided kidneys for 650 
kidney only transplants. The clinical characteristics of recipients of kidneys 
from DBD and DCD donors who died following ligature asphyxiation and 
those who died from all other causes are shown in Table 7.3. Recipients of 
kidneys from donors who died following ligature asphyxiation were 
significantly younger than those receiving kidneys from donors who died from 
other causes, but were of similar gender and ethnicity. There was no 
difference in the crf or HLA mismatch between recipients of kidneys from 
deceased donors who died following ligature asphyxiation and those who died 
from all other causes. The primary renal disease in recipients of kidneys from 
DBD and DCD donors who died following ligature asphyxiation was broadly 
similar to that for recipients of kidneys from other DBD and DCD donors. The 
CITs of kidneys from DBD donors who died following ligature asphyxiation 
were significantly shorter than those for kidneys from all other DBD donors. 
CITs were similar for kidneys from DCD donors who died following ligature 
asphyxiation and all other DCD donors.  
Over the 14-year study period there was a marked increase in the number of 
deceased donor kidney transplants performed in the UK, predominantly 
because of an increase in transplants using kidneys from DCD donors (Figure 
7.1a). The number of kidney transplants performed from both DBD and DCD 
donors who died following ligature asphyxiation increased progressively over 
the study period (Figure 7.1b), such that half of the transplants using kidneys 
from such donors were performed in the last 4 of the 14-year study period.  
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Table 7.3. Clinical Characteristics of renal transplant recipients from organ donors who died from ligature asphyxiation compared to those who 
died of all other causes. *Missing data was <1% gender and HLA Mismatch level ethnicity and recipient sex and <2% for cold ischaemic time, 
37% for warm ischaemic time. 
 DBD donors following ligature 
asphyxiation(n=294) 




DCD donors following ligature 
asphyxiation(n=356) 




Age (y) 43 (29-53) 48 (37-58) <0.001 47 (38-57) 55 (46-63) <0.001 
MaleFemale (%) 182 (61.9%)/ 112(38.1%) 8774 (61.0%)/ 5599 (39.0%) 0.879 211 (59.3%)/ 143(40.2%) 4406 (66.2%)/ 2250 (33.8%) 0.001 
White ethnicity (%) 203 (69.1%) 11006 (76.5%) 0.003 284 (79.8%) 5167 (77.6%) 0.396 
Dual kidney transplant (%) 0 (0) 101(0.7%) 0.352 3 (0.8%) 318 (4.7%) 0.01 
cRF >85% 44 (15.0%) 1805 (12.6%) 0.217 20 (5.6%) 293 (4.4%) 0.304 
HLA Mismatch Grade   0.638   0.168 
1 58 (19.7%) 2728 (19.0%)  9 (2.5%) 226 (3.4%)  
2 124 (42.2%) 5841 (40.6%)  96 (26.7%) 1581 (23.7%)  
3 106 (36.1%) 5327 (37.1%)  216 (59.8%) 3889 (58.4%)  
4 6 (2.0%) 481 (3.3%)  40 (11.0%) 965 (14.5%)  
CIT   <0.001   0.248 
<12hours 78 (27.1%) 2662 (18.5%)  110 (31.3%) 1977 (30.0%)  
12 to 18 hours 129 (44.8%) 6820 (47.5%)  162 (46.4%) 2973 (45.1%)  
18 to 24 hours 65 (22.6%) 3354 (23.3%)  68 (19.5%) 1320 (20.0%)  
>24 hours 16 (5.6%) 1395 (9.7%)  9 (2.6%) 322 (4.9%)  
WIT (min) - -  7 (6-10) 8 (6-10) 0.796 
Primary Renal Disease   0.040   0.192 
Diabetic Nephropathy 19 (6.4%) 1004 (7.0%)  26 (7.5%) 637 (9.5%)  
Glomerulonephritis 38 (12.8%) 2497 (17.4%)  73 (20.8%) 1256 (18.8%)  
Pyelonephritis 19 (6.4%) 1218 (8.5%)  24 (6.7%) 462 (7.0%)  
Polycystic Kidney Disease 25 (8.5%) 1515 (10.5%)  42 (11.6%) 1011 (15.2%)  
Other 193 (65.7%) 8147 (56.6%)  191 (53.5%) 3295 (49.5%)  
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Figure 7.1. Number of renal transplants carried out from 2003-2015 from  
A) all deceased donors by donor type (DBD and DCD) and  
B) Donors who died following ligature asphyxiation and donor type (DBD and DCD) 
1.37.5 Outcomes in recipients of kidneys from donors who died following 
ligature asphyxiation  
The results of analyses of patient and graft survival are shown in Figures 7.2–
7.5. For these and the multivariable analyses the median follow-up of kidney 
transplant recipients was 48 months (IQR 24–96 months). For kidney 
transplant recipients transplanted in 2016, the median follow-up was 96 days 
(IQR 88–356 days).  
For transplant outcomes when comparing recipients of kidneys from donors 
who died following ligature asphyxiation with those who did not I chose to 
analyse recipients of kidneys from DBD and DCD donors separately. For 
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recipients of kidneys from DBD donors, graft survival was superior for those 
who received kidneys from donors who died following ligature asphyxiation, 
but there was no difference in patient survival (Figure 7.2). For recipients of 
kidneys from DCD donors, both patient and graft survival were better for those 
who received kidneys from donors who died following ligature asphyxiation 
(Figure 7.3). A comparison of recipients of kidneys from DBD and DCD 
donors who died following ligature asphyxiation showed similar patient and 
graft survival (Figure 7.4). Finally, a comparison of recipients of kidneys from 
all kidney donors (DBD and DCD) who died following ligature asphyxiation 
and those who received kidneys from all other deceased kidney donors 
demonstrated better patient and graft survival for those who received kidneys 
from donors who died following ligature asphyxiation (Figure 7.5).   
As already shown, significant differences were identified in donor and 
recipient demographics between recipients of kidneys from donors who died 
following ligature asphyxiation and all other deceased kidney donors. The 
factors considered in the analyses included donor and recipient age, CIT, 
donor type (DBD or DCD), HLA mismatch level, recipient primary renal 
disease and donor comorbid diseases.  
The results for the multivariable analyses (both unadjusted and adjusted) are 
shown in Table 7.4. Numerically, 1 year and 5-year patient and graft survival 
were superior when the donor cause of death was by ligature asphyxiation 
than by other causes, both before and after confounder adjustment (Table 
7.4). DGF and PNF rates were comparable between recipients of kidneys 
from donors who died of ligature asphyxiation and those who received 
kidneys from all other deceased donors after adjustment for donor and 




Figure 7.2. Kaplan-Meier estimates of A) Patient survival from renal transplantation 
from DBD donors who died following ligature asphyxiation and all other DBD donors 
and B) Death censored graft survival from renal transplantation from DBD donors 
who died following ligature asphyxiation and all other DBD donors 
 
Figure 7.3. Kaplan-Meier estimates of A) Patient survival from renal transplantation 
from DCD donors who died following ligature asphyxiation and all other DCD donors 
and B) Death censored graft survival from renal transplantation from DCD donors 
who died following ligature asphyxiation and all other DCD donors  
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Figure 7.4. Kaplan-Meier estimates of A) Patient survival from renal transplantation 
from donors who died following ligature asphyxiation (both DBD and DCD) and all 
other deceased donors and B) Death censored graft survival from renal 
transplantation from donors who died following ligature asphyxiation (both DBD and 
DCD) and all other deceased donors  
 
Figure 7.5. Kaplan-Meier estimates of A) Patient survival from renal transplantation 
from DCD and DBD donors who died following ligature asphyxiation and B) Death 
censored graft survival from renal transplantation from DCD and DBD donors who 
died following ligature asphyxiation  
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Of the 21,682 deceased donor kidney transplants performed, 18,059 (83.4%) 
were first-time kidney transplant recipients. In a sensitivity analysis of first 
kidney only transplants, patient and graft survival were similar for those who 
received their first kidney transplant from donors who died following ligature 
asphyxiation and for those who received kidneys from all other deceased 
donors.  
Of the 21,682 deceased donor kidney only transplant recipients, 18,258 
(82.3%) had 12 month post-transplant serum creatinine recorded and, of 
these, data were available to calculate eGFR for 18,216. Twelve month eGFR 
was significantly higher for those who received kidneys from donors who died 
from ligature asphyxiation (both DCD and DBD) (Figure 7.6).  
To examine the impact that donor death by ligature asphyxiation had on 12-
month post-transplant eGFR, a multivariable linear regression model was 
fitted. Following adjustment for donor and recipient factors, death by ligature 
asphyxiation was not an independent predictor of 12 month eGFR (p=0.452). 
 
Figure 7.6. 12 month eGFR by donor type and whether the donor died secondary to 
ligature asphyxiation. *p<0.05 
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Table 7.4. Comparison of kidney transplant outcomes by donor type (DBD and DCD) and donor death secondary to ligature asphyxiation. 
OR= Odds Ratio. HR= Hazard Ratio. PE=Parameter estimate. 
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To assess whether the additional warm ischaemic insult from ligature 
asphyxiation in DCD donors impacted on transplant outcomes, a separate 
multivariable analysis of such donors was performed. This revealed that even 
after adjusting for warm ischaemic time in DCD donors there was no 
difference between transplant outcomes for recipients of kidneys from DCD 
donors who died following ligature asphyxiation and all other DCD donors 
(Table 7.5). 
Renal transplant 
recipients from DCD 
donors 
Unadjusted ratio  




Adjusted ratio  






Primary-non-function OR 0.972  (0.473- 1.996) 
OR 1.196 
(0.823-1.739) 0.348 
Delayed graft function OR 0.849  (0.670- 1.074) 
OR 0.988  
(0.887-1.101) 0.827 
1-year death censored 
graft survival 
HR 0.666  
(0.383-1.158) 
HR 0.890  
(0.505-1.570) 0.688 
5-year death censored 
graft survival  
HR 0.608  
(0.389-0.948) 
HR 0.827  
(0.524-1.305) 0.413 
1-year patient survival 
from transplantation 




5-year patient survival 
from transplantation 
HR 0.564  
(0.353-0.902) 
HR 0.961  
(0.593-1.556) 0.871 
1-year first kidney death 
censored graft survival 
HR 0.666  
(0.383-1.158) 
HR 0.890  
(0.505-.1.568) 0.688 
5-year first kidney death 
censored graft survival 
HR 0.608  
(0.389-0.948) 
HR 0.827  
(0.524-1.305) 0.413 
12-month eGFR PE 11.185  (8.798-13.572) 
PE 1.858  
(-0.426- 4.141) 0.111 
Table 7.5. Comparison of DCD kidney transplant outcomes by donor death 
secondary to ligature asphyxiation. 
 
To reduce the impact of potential bias from confounding variables, a case-
control propensity score matched analysis was also performed. Recipients of 
kidneys from donors who died following ligature asphyxiation (n=622) were 
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matched to controls based on propensity scores generated using selected 
donor and recipient variables (see methods). This analysis showed all 
transplant outcomes of recipients of kidneys from donors who died following 
ligature asphyxiation were similar to those in the matched control group 
(Table 7.6). An additional case-control propensity score matched analysis was 
performed comparing outcomes in recipients of kidneys from DCD donors 
who died following ligature asphyxiation and controls who received DCD 
donor kidneys. This also confirmed that kidneys from donors who died 
following ligature asphyxiation had similar outcomes to matched controls. 
 155 
 Recipients of kidneys from 
donors dying after ligature 
asphyxiation (n=622) 




Median Propensity score  
(0.060 (0.030- 0.105) 
Propensity score matched 
ligature asphyxiation vs. 
non-ligature asphyxiation 
p-value 
PNF 9/570 (1.6%) 11 /580 (1.9%) OR 1.083 (0.456-2.569) 0.897 
DGF 152/570 (26.7%) 132/580(22.8%) OR 0.810 (0.619-1.060) 0.687 
1-year death censored graft survival 96.1% 96.3% HR 1.051 (0.593-1.862) 0.865 
5-year death censored graft survival  91.3% 89.2% HR 0.805 (0.537-1.208) 0.295 
1-year patient survival from transplantation 97.5% 97.8% HR 0.664 (0.347-1.273) 0.218 
5-year patient survival from transplantation 90.7% 92.5% HR 0.985 (0.640-1.515) 0.945 
1-year first kidney, death censored graft 
survival  (n=1077) 96.6% 96.8% HR 1.06 (0.544-2.046) 0.875 
5-year first kidney, death censored graft 
survival   (n=1077) 92.9% 90.9% HR 0.800 (0.499-1.282) 0.353 
12-month eGFR  (n=1104) 61 (47-74)(n=535) 59 (47-74)(n=557) PE 1.575 (-3.392-2.788) 0.848 
Table 7.6. Transplant outcomes in a 1-1 case-control propensity score matched analysis of recipients of kidneys from donors who died 
following ligature asphyxiation and their matched controls
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1.38 Discussion 
Organ donors who die following ligature asphyxiation represent a relatively 
small but important proportion of the overall deceased donor population (~3% 
in the present analysis). Most of these deaths result from attempted suicide by 
hanging and tragically the incidence of this continues to increase, 
predominantly among younger males where suicide is the second most 
common cause of death (185,187). The mode of death following ligature 
asphyxiation results in global tissue hypoxia and the effect that this has on 
end-organ function following kidney transplantation has never been fully 
assessed. The results of the present national cohort analysis clearly 
demonstrate that the outcomes for recipients of kidneys from both DBD and 
DCD donors who have died following ligature asphyxiation are comparable to 
those for recipients of kidneys from donors who have died from all other 
causes.  
In the present analysis, approximately half of the donors who died following 
ligature asphyxiation were DBD donors. Recipients of kidneys from such 
donors had similar patient survival and significantly better graft survival up to 
5 years to those of recipients of kidneys from all other DBD donors. Moreover, 
DGF and 12 month eGFR were significantly better in recipients of kidneys 
from DBD donors who died following ligature asphyxiation. The superior 
outcomes seen in recipients of kidneys from DBD donors who died following 
ligature asphyxiation is likely attributable to the fact that such donors were 
younger and had less comorbid disease than all other DBD donors. Indeed, 
after case-mix adjustment in a multivariable analysis, 12 month eGFR 
outcomes were similar. The case controlled propensity score matched 
analysis also confirmed that transplant outcomes were comparable in 
recipients of kidneys from donors dying from ligature asphyxiation and their 
matched controls. 
It is now widely accepted that while recipients of kidneys from DCD donors 
have increased rates of PNF and DGF, the long-term clinical outcomes are 
comparable to those observed in recipients of kidneys from DBD donors 
(149,187). As observed with DBD donors who died following ligature 
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asphyxiation, recipients of kidneys from DCD donors who died following 
ligature asphyxiation had superior transplant outcomes compared to those 
seen in recipients of kidneys from all other DCD donors. The additional warm 
ischaemic insult from ligature asphyxiation was not associated with an 
increase in either PNF or DGF. The additional analyses of DCD donors who 
died following ligature asphyxiation demonstrated that even after adjustment 
for warm ischaemic time, kidneys from such donors were not associated with 
poorer transplant outcomes than recipients of kidneys from all other DCD 
donors. This conclusion was confirmed by a case-control propensity score 
matched analysis of recipients of kidneys from DCD donors who died 
following ligature asphyxiation and their matched controls. 
There is little information in the literature concerning the outcome following 
transplantation with kidneys from either DBD or DCD donors who died 
following ligature asphyxiation. A major strength of the present registry 
analysis is that it provides the first comprehensive analysis of transplant 
outcome in recipients of kidneys from donors who died following ligature 
asphyxiation. The analysis included a relatively large national cohort of kidney 
donors who died following ligature asphyxiation with a large proportion of 
DCD donors.  
As for all retrospective transplant registry analyses, some degree of caution is 
required in the interpretation of the results because residual confounding 
factors not included in the analysis may have influenced the findings, such as 
significant recipient comorbidity. In the present analysis, some degree of 
selection bias is likely to have occurred. For example, it is possible that only 
kidneys from younger previously healthy donors who died following ligature 
asphyxiation were selected for transplantation, thereby limiting the general 
applicability of the present findings. If the selection criteria for use of kidneys 
from potential donors following ligature asphyxiation were to be made less 
stringent, it cannot be assumed that the clinical outcomes would be equally 
favourable. Interestingly, the present analysis showed that potential organ 
donors who died following ligature asphyxiation were more likely to donate 
one or more kidneys for transplantation than all other potential deceased 
donors, even after adjustment for key favourable donor factors including 
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donor age. For those donors who died following ligature asphyxiation who had 
a cardiac arrest and an estimated ‘downtime’ before restoration of circulation, 
the data available suggested that this did not influence whether or not a 
potential donor proceeded to kidney donation. Donors who died following 
ligature asphyxiation were more likely to proceed to kidney donation if they 
had a history of imprisonment (7.4% of such donors had a history of 
imprisonment). This may be because donors who died by hanging whilst 
incarcerated had a shorter time to resuscitation but this is speculation.  
Another potential weakness of the analysis is that donor cause of death from 
ligature asphyxiation was not one of the 65 reportable causes of death 
recorded in the transplant registry and so identification of such donors relied 
on manual review of the free text entries for all deceased organ donors using 
specific search term variables. It is unlikely that a significant number of donors 
who died following ligature asphyxiation were not identified, but it is possible 
that the numbers presented represent an underestimate of potential donors 
who died following ligature asphyxiation. The dataset used in the present 
analysis had very little missing data for most of the key variables. However, a 
further limitation of the analysis is that for some variables missing data may 
impact on the results and their interpretation. There were very few missing 
data on graft and patient survival (<0.5% overall and 0% for recipients of 
kidneys from donors who died from ligature asphyxiation). In the case of 12 
month eGFR, data were missing in 17.8% of the entire study cohort, but this 
was distributed equally between recipients who received kidneys from donors 
who died following ligature asphyxiation and those who did not, making bias 




Variations in risk appetite between UK kidney transplant 
centres and their impact on patient and graft outcomes 
1.39 Introduction 
Over the last 10 years there have been marked changes in deceased donor 
kidney transplant practice, with an increasing number of deceased donors 
with co-morbid diseases such as hypertension and diabetes, higher risk 
scores (as calculated by validated donor risk score indices) and around 30% 
of the UK deceased donor population are aged greater than 60 years old 
(30,188). 
It has been apparent that there is variation between kidney transplant centres 
in the UK demonstrated through the wide variations in first offer decline rates 
and median time on the transplant waiting list (149,189). Hence, it is evident 
that different centres may be utilising different approaches to the changes in 
the deceased donor populations. These variations have also been observed 
in the US, where the impact of variation in centre risk appetite and its impact 
on liver and kidney transplant survival has been assessed (190,191). The 
extent to which a transplant centre’s risk appetite impacts on patients’ 
outcomes has never been fully assessed in a UK population.  To address this, 
we need to know how we assess risk appetite. Risk is currently assessed 
through using validated donor risk indices (186,192,193). These risk scores 
do not encompass all aspects of donor risk, where the use of an organ may 
not necessarily impact on graft survival but may carry the risk of disease 
transmission or have a perceived risk of disease transmission 
(15,145,194,195).  
The aims of this analysis were to develop a broader metric of risk, reflecting 
clinicians’ concerns about both donor-related and organ-related risks. Then to 
use this metric to identify centres that accept kidneys from higher risk donors, 
and to describe changes in centre risk-taking behaviour over time and then 




1.40.1 Determining risk attitudes of centres over time 
In 2006, a new allocation scheme (NKAS) for DBD kidneys was developed in 
the UK in order to address inequalities in access to transplantation. This 
NKAS improved access to transplantation generally however it was accepted 
that geographical variation and inequality to access would take several years 
to address (38,196). There are 23 adult kidney transplant centres in the UK, 
and in order to assess their appetites with regards to risk, ten donor and 
transplant factors were selected and analysed from 1st January 2006 to 31st 
December 2015. These factors were selected based on factors known to 
impact on graft survival but also to reflect putative factors and factors known 
to impact on offer acceptance. The factors selected were: Donor age ³70 
years, DCD donors, UKKDRI score ³1.60, presence of donor malignancy 
(both past and present), increased infectious risk behaviour (IIRB), meningitis 
and encephalitis (ME) (both known and unknown causes), diabetes mellitus 
(DM), hypertension, Acute Kidney Injury Network (AKIN) score 2 and 3. A final 
factor of dual adult kidney transplantation (DAKT) was selected to reflect the 
surgical/clinical decision that the kidneys from these donors should be 
implanted as a dual in place of a single kidney. The proportion of renal 
transplants carried out from donors with these factors or that were implanted 
as DAKT were determined for all 23 adult kidney transplant centres in the UK 
over the 10-year study period. For each factor, for the whole 10-year study 
period, and the two 5-year time periods (2006-2010, 2011-2015), a median 
and interquartile range (IQR) of the percentage of renal transplants performed 
at each centre were calculated, and centres were attributed a score from 1 to 
4 based on the quartile in which they sat (4 representing highest proportion of 
use). For example, figure 8.1 demonstrates the total number of deceased 
donor kidney transplants that were performed by UK renal transplant centres 
from 2006-2015 from donors with DM, with the median and centre separation 
shown by the dotted lines.  
A single scoring system was developed called Score A. Score A was 
calculated based on the quartile each centre was in for each factor and these 
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scores were added to together for all 10 factors giving an overall score 
(maximum 40, minimum 10). From score A centres were again separated into 
quartiles around a median score, and analysed as a group (i.e. high risk 
centres for higher quartiles and low-risk centres for lower quartiles). 
Figure 8.1. Proportion of renal transplants carried out from deceased donors with 
diabetes mellitus in the UK from January 1st 2000 to 31st December 2015 
1.40.2 Identifying deceased kidney donors from the UK transplant registry 
The UKTR was used to identify all recipients of kidneys from deceased organ 
donors from 1st January 2006 to 31st December 2015. Paediatric donors 
(age<10 years) and paediatric recipients (<18 years) were excluded from the 
analysis. Information on the donor’s past-medical history of hypertension, DM 
(type 1, type 2 and unspecified), presence of malignancy (both past and 
present), donor type (DCD and DBD), and donor age were collected. 
Information on the deceased donors’ change in serum creatinine and urine 
output was collected and used to calculate the donor’s acute kidney injury 
network (AKIN) score as per methods described in Boffa et al (197). The 
UKKDRI was calculated for the deceased donors (198). Information on patient 
survival from transplantation and death censored graft survival was collected. 
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Recipients without graft or patient survival data were excluded from the 
analysis (n =12 (0. 08%)). Graft function was assessed via eGFR, calculated 
with 3-month and 12-month recipient serum creatinine by 4 variable MDRD 
equation (107).  
1.40.3 Identifying deceased kidney donors with a history of increased risk 
behaviour and meningitis/ encephalitis 
To identify deceased kidney donors with a reported history of IIRB (defined 
as: IVDU; imprisonment; donors who were MSM; and those with other high-
risk sexual behaviours) and donors who died from ME the UKTR was 
examined. The free text entries of all identified deceased donors were 
searched using the terms ‘intravenous drug use’, ‘sex worker’, ‘Men who have 
sex with men’ and ‘prison’. All common abbreviations, misspellings, 
synonymous terms and colloquialisms of the above search terms were also 
searched. All UK deceased donors whose cause of death was coded in the 
UKTR as ‘meningitis’ were readily identified. However, the designated codes 
for cause of death in the UKTR are limited to any one of 65 possible causes 
and there is no code for encephalitis in the registry. Deceased kidney donors 
who died secondary to ME were also identified through searching of free text 
entries using the search terms ‘meningitis’, ‘encephalitis’, and 
‘meningoencephalitis’ as previously described in chapters 3 and 5.  
1.40.4 Determining patient survival from listing 
Information on adult patients listed for a kidney only transplant in the UK, who 
either subsequently received a kidney transplant, were removed from the list 
or died whilst on the list were collected from 1st January 2006 to 
31st December 2015. Patients who were listed for a kidney transplant who 
received a living kidney transplant were excluded from this analysis.  
If a patient was removed from the list with no information on outcome they 
were censored at time of suspension or removal. Information on patient 
mortality was collected from the UKTR and the Office of National Statistics to 




Missing observations were observed in kidney transplant recipient serum 
creatinine follow-up at 3 and 12 months. The proportion of data missing was 
9.8% and 8% for 3-month and 12-month serum creatinine respectively. 
Multiple imputation based on chained equations was used to impute for 
missing values in 20 copies of the original first kidney transplant dataset. 
Linear models were used to estimate for this missing continuous data. Both 3-
month and 12-month recipient creatinine were log transformed to account for 
skewness and to ensure no negative imputed values. Stepwise variable 
selection process was performed on the imputed datasets and variables 
selected for inclusion in the final linear regression model had a significance 
level <0.05. The results of outcomes of the linear regression of the 20 imputed 
datasets were then combined to account for any variation between the 
datasets.  
1.40.6 Statistical Analysis 
Principal univariate analysis was carried out using Student’s t-test for 
parametric continuous data and Wilcoxon sums rank test for non-parametric 
continuous data. Categorical data was analysed using c2 test. 
Multivariate analysis was carried out using logistic regression for determining 
likelihood of receiving a kidney transplant, and Cox proportional hazards 
regression was carried out to determine the effects of variables on death 
censored graft survival and patient survival from transplantation and from 
listing.  
Cox proportional hazards regression model, logistic regression model and the 
linear regression model were fitted in a stepwise selection method to control 
for potentially confounding factors. Many donor factors known to impact on 
transplant outcome could not be adjusted for in our multivariate analysis as 
they were used to determine the risk scores for each centre (e.g. donor age 
and donor past medical history of hypertension). Hence, donor related 
variables considered for inclusion not already being adjusted for in our newly 
developed centre risk score were ethnic group, sex, past medical history liver 
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disease, cardiac disease, and smoking history. Recipient factors considered 
for inclusion were age, ethnicity, sex, primary renal disease, HLA mismatch 
level and cold ischaemic time. Similarly, recipient factors considered for 
analysis in our survival from listing analysis included the above plus receiving 
a transplant, time on the waiting list, and ABO blood group. If the factor was 
significant on step-wise selection method (p<0.05) the factor was included in 
the model.  
1.40.7 Results 
From 1st January 2006 to 31st December 2015 there were 8,888 deceased 
donors who donated at least one kidney for transplantation. These donors 
resulted in 15,024 kidney transplants (single kidneys and DAKT), of which 
12,654 were recipients receiving their first kidney transplant.  
The clinical characteristics of the deceased kidney donors and the kidney 
transplant recipients are shown in table 8.1.  
 Number of deceased kidney 
donors  
(n= 8,888) 
Age (y) (median + IQR) 52 (41-62) 
Ethnicity  
White/ Other 8035 (93%)/597 (7%) 
Donor Type  
DBD/ DCD 5515 (64%)/3117 (36%) 
BMI (median + IQR) 26 (23-29) 
Past Medical History of Diabetes  
Yes 546 (6%) 
No 7854 (92%) 
Unknown/ Not stated 114 (1%) 
Missing 118 (1%) 
Past Medical History of Hypertension  
Yes 2178 (27%) 
No 5855 (71%) 
Unknown/ Unstated 195 (2%) 
Missing 118 (1%) 
Past Medical History of Cancer  
Intracranial 148 (2%) 
Cancer-not intracranial 178 (2%) 
No cancer 8306 (96%) 
Known Increased risk behaviour  
Yes/ No 315 (4%)/8317 (96%) 
Diagnosis of Meningitis/ Encephalitis  
Known Cause 139 (2%) 
Unknown Cause 42 (<0.5%) 
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Cause of death  
Cerebrovascular accident 2180 (25%) 
Intracranial Haemorrhage 4829 (56%) 
Trauma 719 (8%) 
Other 904 (37%) 
CMV status  
Positive 4268 (50%) 
Negative 4251 (49%) 
Unknown/ Not stated 38 (<0.5%) 
Missing 75(<0.5%) 
Acute Kidney Injury Network Score  
1 816 (9.2%) 
2 461 (5.2%) 
3 212 (2.4%) 
Missing 591(6.6%) 
UKDRI (median + (IQR) 1.06 (0.97-1.48) 




Number of deceased donor 
kidney transplant recipients 
(n=15024) 
Age (y) (median + IQR) 52 (42-62) 
Ethnicity  
White 11175 (76%) 
Other 3444(24%) 
HLA Mismatch level  
1 2028(14%) 
2 4484 (31%) 
3 7095 (49%) 
4 1011(7%) 
Crf>85% 1502 (10%) 
Double Kidney Transplants (%) 341 (2%) 
Cold Ischaemic Time (hours) (median 
+ IQR) 
15.0 (12.0- 18.4) 
Cold Ischaemic Time DBD 15.3 (12.4-18.8) 
Cold Ischaemic Time DCD 14.3 (11.3-17.8) 
BMI (median + IQR) 26 (23-29.5) 
Primary Renal Disease  
Glomerulonephritis 2604  (18%) 
Diabetic Nephropathy 1217 (8%) 
Polycystic Kidney Disease 1868 (13%) 
Pyelonephritis 1111  (8%) 
Other 7819 (53%) 
Table 8.1. Clinical characteristics of Adult Deceased Organ Donors and their 
recipients in the UK from January 1st 2006 to December 31st 2015 
Overall, there was a proportional increase in the number of deceased donor 
kidney transplants being performed from donors with risk attributes, however 
variation over time was noted (Figure 8.2a-8.2j). 
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Over the 10-year period there were marked changes in individual centre 
deceased donor kidney transplant practice (Figure 8.3a). Overall, there was a 
trend towards an increasing proportion of renal transplants being performed 
from donors with the selected risk attributes (Figure 8.3a-8.3i). However, 
when each risk attribute was assessed over the 5-year time periods some 
centres appeared to reduce their risk appetite for selected factors. As an 
example, Guy’s and St Thomas’ hospital, in the first 5-year time-period was in 
either the second lowest or lowest risk quartile for all 10 donor risk attributes, 
but in the later 5-year time-period they had dramatically changed practice and 
are now in the highest risk quartiles for over half of the selected risk attributes 
(Figure 8.4a, 8.4b, 8.4c). 
From the information generated, risk score A was calculated (Table 8.2). 
From these scores, the UK median Risk Score A was calculated (median 25 
(IQR 20-32). Centres were then separated into their respective quartiles and 
analysed as a group based on these quartiles. 
 
 
Figure 8.2a. Proportion of adult renal transplants carried out from deceased donors 
with increased infection risk behaviour from 1st January 2006 to 31st December 2015. 
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Figure 8.2b. Proportion of adult renal transplants carried out from deceased donors 
















Figure 8.2c-8.2f. Proportion of adult renal transplants carried out from deceased donors with Diabetes Mellitus, 8.2d) Age ≥70, 


















Figure 8.2g-8.2j)Proportion of adult renal transplants carried out from deceased donors that were 8.2g) DAKT, from donors with a 8.2h) 


















Figure 8.3a-8.3d. Proportion renal transplants carried out from deceased organ donors with IIRB, 8.3b) UKKDRI ≥1.60 , 8.3c) Age ≥70, 8.3d) 



















Figure 8.3e-8.3i. Proportion renal transplants carried out from deceased organ donors with hypertension, 8.3f) that were DAKT, 8.3g) who 
were DCD donors, 8.3h) with malignancy, 8.3i) AKIN stage 2 and 3 UK by transplant centre from 01/01/2006 to 31/12/2015 
8.3e) 8.3f) 




Figure 8.4a-c. Heat map of UK Renal transplant units by the quartile of the proportion of deceased donor renal transplants carried out from 
donors with risk behaviours or attributes from A)1st January 2006 to 31st December 2015, B) 1st January 2006 to 31st December 2010, and C) 


















Table 8.2. UK adult renal transplant centre risk score A 
1.40.8 Impact of centre risk appetite on transplant outcome 
In order to establish what effect centre risk appetite was having on transplant 
outcomes, the risk scores were used to stratify first kidney transplant death 
censored graft survival for the whole-time period and the two 5-year time 
periods for the 12654 recipients of a first kidney only transplant. Analysis of 
the two 5-year time periods indicated that there was no significant difference 
in 5-year death graft survival between those recipients transplanted in the 
first-time period compared to the second (88.4% graft survival (95% CI 87.5-
89.3%) vs. 86.9% graft survival (95% CI 85.5-88.1%) respectively, p =0.330).  
Each transplant centre was analysed depending on the quartile of risk score A 






























over the 10-year study period in death censored graft survival based on 
centre risk score (Figure 8.5). Following adjustment for recipient age, CIT, 
primary renal disease, HLA-mismatch level and year of transplant, centre risk 
score A was not an independent predictor of death censored graft survival 
(Table 8.3). Three month and 12-month eGFR was noted to be marginally 
poorer at centres with higher risk scores following adjustment for CIT, HLA 
mismatch level, recipient age, donor and recipient ethnicity and primary renal 
disease (Table 8.3).  
DGF rates were noted to be higher at centres with higher risk scores before 
and after adjustment for recipient factors (Table 8.3).  
Patient survival from transplantation was assessed and demonstrated no 
significant difference in outcome based on centre risk score (p= 0.301) 
(Figure 8.6)  Following adjustment for recipient age, CIT, primary renal 
disease, HLA mismatch level, and year of transplant, it demonstrated that 
patient survival from transplantation was significantly worse if you received a 
kidney transplant at centres in the 3rd highest risk score group (1.188 (1.050-
1.345), p=0.006). The exact explanation for this could not be elicited, and 
investigation of individual centres within this cohort did not demonstrate 
significantly worse outcomes at these centres.  
 
Figure 8.5 and 8.6. 10-year death censored first kidney transplant graft survival and 
patient survival from transplantation by centre risk appetite score A. P-value 
corresponds to score test of the overall null hypothesis that there are no differences 
in survival curves for all groups i.e. comparing survival across all groups 
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  Unadjusted 












    
Risk score group 1 
vs 2 
HR 1.037  
(0. 882-1.219) 
0.662 1.080  
(0.917-1.271 
0.3030 




0.806 1.010  
(0.881-1.157) 
0.3576 











    
Risk score group 1 
vs 2 
OR 0.678  
(0.586-0.785) 
<0.001 0.692  
(0.597-0.803) 
<0.001 
Risk score group 3 
vs 2 
OR 1.339  
(1.207-1.486) 
<0.001 1.350  
(1.215-1.501) 
<0.001 
Risk score group 4 
vs 2 
OR 1.784  
(1.611-1.975) 








    




0.853 1.123  
(0.961-1.312) 
0.146 




0.0981 1.188  
(1.050-1.345) 
0.006 




0.325 1.017  
(0.897-1.153) 
0.794 
3 month eGFR 
(mls/minutes per 
1.73m2)¡ 
Cohort size  
(n= 12654) 
    




0.001 PE 0.032 
(0.007 - 0.058) 
0.012 
Risk score group 3 
vs 2 
PE -0.028 
(-0.051--0.006)    
0.015 PE -0.039 
(-0.061--0.017) 
0.001 
Risk score group 4 
vs 2 
PE -0.050 
(-0.069--0.031)    
<0.001 PE -0.045  
(-0.065--0.026) 
<0.001 





    




0.798 PE -0.015 
(-0.040-0.009) 
0.2117 




0.005 PE -0.041 
(-0.063--0.019) 
<0.001 




<0.001 PE -0.041 
(-0.05- -0.023) 
<0.001 
Table 8.3. Comparison of transplant outcomes by centre risk appetite score 
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1.40.9 Likelihood of receiving a kidney transplant 
Information on the 22,801 people who were listed for a kidney transplant from 
1st January 2006 to 31st December 2015 was collected and analysed in order 
to determine the impact that centre risk appetite had on the likelihood of 
patients listed at these centres of receiving a kidney transplant. Logistic 
regression analysis demonstrated, in comparison to risk score quartile 2, that 
centres with risk scores in the 1st quartile were significantly less likely to 
receive a kidney transplant (OR 0.920 (95% CI 0.849-0.998 p<0.001), and 
centres with risk scores in quartile 3 and 4 were significantly more likely to 
receive a kidney transplant (OR 1.367 (95% CI 1.266-1.476), p<0.001 and 
OR1.578 (95% CI 1.478-1.684), p<0.001 respectively). Following adjustment 
for recipient blood group, recipient ethnicity, primary renal disease at time of 
listing, recipient age of registration, centre risk score remained an 
















Risk score group 
1 vs 2 
0.920  
(0.849- 0.998) 
<0.001 0.811  
(0.745-0.884) 
<0.001 
Risk score group 
3 vs 2 
1.367  
(1.266-1.476) 
<0.001 1.310  
(1.204-1.414) 
<0.001 
Risk score group 
4 vs 2 
1.578  
(1.478-1.684) 




Table 8.4. Logistic regression analysis of patients listed for a kidney only transplant 
in the UK’s likelihood of receiving a kidney transplant following adjustment for 
recipient factors 
 
As expected, analysis demonstrated that patients listed for a kidney transplant 
at lower risk score centres spent significantly longer on the transplant waiting 
list compared to those listed at centres with higher risk scores. Patients listed 
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for a kidney transplant at lowest risk scored centres 1 and 2 spend 
significantly longer on the kidney transplant waiting list compared those listed 
for a kidney transplant at risk score centres in 3 or 4 (risk score A quartile 1 
(median 786 days (IQR 410-1232), risk score A quartile 2 (median 662 days 
(IQR 335-1077), risk score quartile 3 (median 627 (IQR 307-1027), and risk 
score quartile 4 (median 560 (IQR 261-932), p<0.0001).  
1.40.10 Patient survival from listing 
To determine the impact that a centre’s risk appetite has on a patient’s 
survival following listing for a renal only transplant, information on mortality of 
all patients listed for a kidney only transplant in the UK was analysed. This 
demonstrated that patients listed for a kidney transplant at centres with a 
lower risk score had similar patient survival from listing compared to those 
listed at centres with higher risk scores (Figure 8.7). Following adjustment for 
time on the waiting list, recipient age, recipient blood group, primary renal 
disease, and centre risk score, a centres risk appetite was not an independent 
predictor of patient survival from listing (Table 8.5). 
 
Figure 8.7. 10-year patient survival from listing by centre risk score A. P-value 
corresponds to score test of the overall null hypothesis that there are no differences 

















group 1 vs 2 
0.788  
(0.712- 0.873) 




group 3 vs 2 
0.997  
(0.916- 1.086) 




group 4 vs 2 
0.894  
(0.828- 0.965) 
0.004 1.011  
(0.937-1.092) 
0.772 
Table 8.5. Unadjusted and adjusted 10 year patient survival from listing based on 
centre risk score A quartile 
1.41 Discussion 
This chapter has described the changing nature of deceased donor kidney 
transplant practice in the UK over the last 10 years and has described the 
impact that these changes have had on transplant outcome for recipients 
across the UK. Firstly, it has importantly demonstrated that despite the 
increasing use of kidneys from more marginal donors, with factors that are 
known to negatively impact transplant outcome, kidney recipient graft and 
patient survival has remained good (30,188). This suggests that educated 
approaches to using kidneys from donors with risk factors, and careful 
recipient selection and management allow for successful transplantation of 
seemingly marginal organs. Secondly, it has also demonstrated that there is 
marked variation between UK adult kidney transplant centres with regards to 
their risk appetite for donor and organ related factors. Despite this variation, 
centres with greater appetites for risk have comparable transplant outcomes, 
and result in quicker transplantation for patients listed at those centres.  
Over the last 10 years there have been marked changes in the clinical 
characteristics of deceased kidney donors in the UK. Firstly, we have seen a 
marked increase over time in the number of deceased kidney donors who are 
DCD donors, have a past medical history of hypertension, diabetes, or a 
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reported history of IIRB (15,149). These changes in transplant practice have 
resulted in wide variations in the proportion of organs used from these donors 
between centres. Variations in risk appetite have anecdotally been apparent 
in UK kidney transplant practice, as demonstrated in the variations in time 
spent on the waiting list between centres (188,189) However, it remained to 
be seen whether or not avoiding donor risk factors and accepting only the 
highest quality organs was the optimum strategy for your patients. This 
analysis has demonstrated that there may be benefits in adopting a pro-risk 
strategy, but that the benefits of this strategy may be influenced by individual 
centre characteristics which we are unable to fully comment on. This analysis 
has demonstrated that centres with higher risk appetites had similar risk 
adjusted 10-year death censored graft survival and patient survival from 
transplantation and had clinically similar 3-month and 12 month eGFR post 
kidney transplantation, despite these centres using organs from donors with 
characteristics that are known to negatively impact on graft function following 
transplantation.  
An important outcome measure in transplantation is patient survival from 
listing, as this allows us to reflect not only on the survival of patients following 
transplantation, but that of all of those who need a kidney transplant. The 
analysis in this paper demonstrated that centres using higher risk strategies 
had similar patient survival from listing to those centres using lower-risk 
strategies. The analysis also importantly demonstrated that patients listed at 
higher risk centres were more likely to receive a kidney transplant and spend 
significantly less time on the transplant waiting list. Hence, variations in centre 
risk appetite are impacting on a patient’s likelihood of receiving a kidney 
transplant, and therefore importantly the patients time spend on renal 
replacement therapy. Research has demonstrated the quality of life benefit, 
along with health economic benefit of kidney transplantation over renal 
replacement therapy in patients with end stage renal failure (199)(200,201).  
This current research has limitations. Firstly, we are unable to comment on 
specific changes made at each centre over this study period. These specific 
changes, potentially in staffing or management, may elucidate further the 
variation we are observing the deceased donor kidney transplant practice 
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between centres. Secondly, there are many aspects of transplant practice not 
accurately captured in a registry analysis which again may explain the 
variations in transplant outcomes observed in this analysis.  
 
 181 
Development of the UK aide memoire 
1.42 Background 
The decision to use an organ from a donor with a transmissible or potential 
transmissible infection, as described before, can be incredibly complex. The 
previous chapters of this thesis have demonstrated not only the complexities 
in accepting organs from donors with risk attributes and the potential dangers 
involved in this, but also that marked variations exist in this practice across 
the different UK transplant centres. The reasons why accepting an organ from 
a ‘higher risk’ donor can be difficult is that offers of organs from such donors 
may occur out of normal working hours, and given the scarcity of some of the 
donor attributes (e.g. ITP (0.7%) of the total donor population) no one 
accepting clinician or centre will have enough experience to confidently 
decide one way or another. The current SaBTO guidance published in 2018, 
is very thorough and contains guidance on several transmissible 
microbiological diseases. However, reading and interpreting this document 
can be difficult, and as the prior analysis has shown results in marked 
variations in decision making across the UK. In response to this and to 
summarise some of the main findings from this body of work the UK aide 
memoire was developed. The aide memoire aims to assist clinician decision 
making. The aide memoire summarises guidance on the use of organs from 
donors with infection, malignancy, autoimmune conditions and other donor 
attributes believed to confer risk to the recipients into a single easy to use 
online tool.  
1.43 Aim 
Produce a simple guide for clinicians to encourage appropriate matching of a 
donor organ to recipient, increase transplant rates with consequent benefit to 
recipients and donor families as well as reassure clinicians that they are 





All available guidance from NHSBT, SaBTO and BTS on the use of organs 
from donors with infection (bacterial, viral, fungal, etc), malignancy, 
autoimmune disease/metabolic disease and donor risk attributes, such as 
cause of death or increased risk behaviour prior to donation were collated. 
Where guidance was not in place in the UK but present in Europe or the 
United States their guidance was used as a reference.   
Original research articles assessing the risk of disease transmission from 
donors with meningitis/encephalitis, increased risk behaviour, immune 
thrombocytopaenia and donor death secondary to ligature asphyxiation were 
used to inform guidance on these conditions. 
The document of collated guidance was then circulated round the chairs of 
the advisory committee, medical team at ODT and NHSBT Consultant 
Virologist and Microbiologist (figure 9.1). 
1.44.2 Matching organ to recipient 
In order to ensure that appropriate risks are being taken in the use of organs 
from donors with potential transmissible diseases, or conditions that will 
adversely impact organ quality, the aide memoire sought to classify organ 
transplant recipients into categories that reflected their overall risk of morbidity 
and mortality from not receiving a transplant. The categories were as follows: 
Ø Exceptional - implies death without a transplant in 7 days; 
Ø Urgent - implies death without a transplant within 1month. Examples 
include renal candidate with very limited vascular access; Patient with 
primary liver cell cancer approaching exclusion criteria;  hepatic artery 
thrombosis with intra-hepatic sepsis; a highly sensitised kidney 
candidate;  a long waiting heart or lung candidate with the option of a 
well-matched donor organ or a candidate under major psychological 
stress awaiting a graft.  
Ø Routine implied all other candidates.  
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Figure 9.1. Timeline of development of the aide memoire
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Each class of recipient for each donor disease/attribute was then attributed a 
symbol based on whether the organ should be used for transplantation for this 
recipient. The first, indicated the organ should not be used at all for 
transplantation. The second indicates that the transplanting clinician should 
think about using this organ for this recipient, and the final symbol indicates 
that in most situations this organ should be used for transplantation for this 
recipient.  
The document was then separated into sections based on the broad groups of 
donor diseases/attributes. The sections are: 
Infection:  
• Viral infections 
• Bacterial infections 
• Protozoal infections 
• Mycobacterium 
• Fungi 
• Other infectious agents 
• Neurological conditions including Meningitis, Encephalitis and 
Meningoencephalitis.  
• Malignancy  
• Increased risk behaviours 
• Autoimmune diseases 
• Metabolic diseases. 
1.44.3 NHS Online tool development: 
• Work with NHS Web development team and NHSBT Clinical 
Informatics Lead  
• Prototype online tool developed: http://www.txtools.net/sabto/.  
• User feedback required by NHSBT Web team before they will start 
work on the tool (Figure 9.1). 
1.45 Discussion 
The development of a UK aide memoire will help streamline decision making 
in organ transplantation and will allow for greater use of organs from donors 
with risk attributes that currently are unnecessarily discarded. The aide 
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memoire will also help prevent the transmission of diseases that may result in 
significant patient morbidity or even mortality. This aide memoire is the first of 
its kind in transplantation in the UK.  
The creation of this aide memoire will also allow NHSBT to audit the use of 
organs from donors with risk attributes covered by the aide memoire and see 
whether any improvements/changes have been made in response to its 
publication.  
The aide memoire will also have a feature allowing transplant clinicians 
across the UK to report donor diseases/conditions that there is currently no 
guidance for, alerting NHSBT to the need to carry out research into these 
conditions and asses their safety in organ donation and transplantation.  
A major limitation of this piece of work is the large number of diseases / 
conditions identified in the deceased donor population; in particular donor 
malignancies currently have little evidence as to whether a clinician should 
accept organs from such donors for transplantation. In these situations, 
guidance already in place in the EU and US have been used in conjunction 
with the UK guidance to create what is seen in the aide memoire. Expert 
clinical opinion was also sought, but it is clear that further research into the 





The research described in this thesis has explored the risks involved in using 
organs from donors dying with potentially transmissible diseases and with 
different risk profiles.  It has demonstrated that organ donors who die from 
meningitis and encephalitis represent a relatively small but important cohort of 
donor organs. In donors where the causative agent of meningitis is known to 
be bacterial, the risk of disease transmission is very low, although it is 
important to ensure that recipients of organs from such donors receive 
appropriate prophylactic anti-microbial therapy. For organs where the 
causative agent is not known, the risk of disease transmission is greater, and 
more caution should be exercised in the use of such organs, as highlighted in 
various clinical guidelines. The risk of potentially fatal disease transmission 
should be balanced against the clinical benefit of an organ transplant and the 
present analysis provides national data that may help guide this decision. 
It has also been demonstrated, that although the exact mechanism of 
Transplant Mediated Alloimmune Thrombocytopaenia (TMAT) is not fully 
understood, there is no evidence from UK experience of using kidneys, 
pancreata and hearts from donors with ITP to suggest it is unsafe. There is a 
small risk of TMAT following liver transplantation and this thesis has 
demonstrated inferior recipient survival following liver transplantation from 
donors with ITP. Transplant teams will have to consider the severity of liver 
disease and health of a potential recipient when balancing the risk of 
accepting the liver of a donor with ITP against the risk of further delay in 
transplantation. The risk might be lessened if the liver is biopsied before 
implantation and shown not to contain evidence of extramedullary 
haematopoiesis 
Around 4% of UK deceased donors have an identifiable history of behaviour 
associated with an increased risk of blood borne transmissible viral infection, 
but are seronegative at time of donation. Three quarters of such donors 
provide organs for transplantation with good transplant outcomes, and 
apparently low risk of disease transmission. Recent advances in the treatment 
 187 
of viral disease, particularly HCV, further reduce the risks associated with 
disease transmission. Donors with a history of IRB provide a valuable source 
of organs for transplantation with good transplant outcomes and there is 
scope for increasing the use of organs from donors with IRB, in particular for 
donors with a history of IVDU. 
The use of DAA raises the possibility that organs from HCVpos donors can be 
used with safety in HCVneg recipients. It is important to emphasise that 
experience of this practice is still limited and while it appears safe and 
effective some recipients may suffer adverse effects from antiviral therapy and 
it cannot be assumed that anti-viral treatment will invariably be effective. 
Nevertheless, as the present analysis demonstrates, the use of organs from 
donors with HCV offers considerable scope for increasing the number of 
organ transplants performed. Should such an approach be adopted, it is of 
course essential that the recipients gave fully informed consent prior to 
transplantation.  
The findings from this thesis also show that use of kidneys from both DBD 
and DCD donors who died following ligature asphyxiation results in excellent 
transplant outcomes. In view of this, increasing consideration should be given 
to the use of kidneys from potential donors who die following ligature 
asphyxiation and whose kidneys are currently declined for transplantation. To 
inform the increased use of such kidneys, the concept of total global tissue 
hypoxia from initiation of ligature asphyxiation to cold perfusion of the kidney 
with preservation solution may be helpful. Global hypoxia begins shortly after 
hanging is initiated and extends until discovery and initiation of resuscitation: 
its duration is highly variable and in many cases unknown. In most patients in 
the present cohort, this was followed by a period of “downtime” extending 
from discovery of a patient with no cardiac output until cardiac output is 
successfully re-established and the patient transferred to a critical care unit.  
Currently a minority of patients have recorded “downtimes” and there is a 
need for improved documentation. These two periods of global tissue hypoxia 
are, in the case of DCD donors, followed by a third period of tissue hypoxia 
from the time of withdrawal of life supporting treatment to cold perfusion of the 
kidneys, the duration of which is usually well documented. Although making 
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an assessment of the total duration of global tissue hypoxia is often 
problematic, incorporating this concept into decision making on the use of 
kidneys from donors who die following ligature asphyxiation may provide a 
basis for the safe utilisation of kidney from selected donors currently being 
declined for transplantation 
Continuing to research the proportion of the donor population and the 
corresponding transplant recipient outcomes of organ donors with ‘risk’ 
attributes will help to inform the transplant community of the risks of using 
organs from such donors. This research will also aim to increase the number 
of organs used from such donors and hence substantially increase the 
number of transplants in the UK. 
This thesis has also described the changes that have taken place in deceased 
donor kidney transplant practice in the UK over the last 10-years. It has 
shown that there is marked centre variation in risk appetite, with significant 
changes over time observed in some centres. Centres with higher risk 
appetites had shorter waiting times, were more likely to transplant their 
patients and there was no difference in death censored graft survival or 
patient survival compared to centres with lower risk appetites. This suggests 
that higher risk strategies may be of benefit to patients, and that centres with 
higher risk appetites may have attributes that enable their outcomes to be 
better than expected. 
The aide memoire developed during my PhD will help aide decision making in 
organ transplantation, and potentially increase organ utilisation in the UK.  
Overall, the work from my thesis has helped to inform policy on the use of 
organs from donors with risk attributes, in particular infections. The work on 
risk variation will allow UK transplant centres to audit their own practice and 
increase the use of organs from donors with risk attributes safely. 
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   Future work 
 
As mentioned in Chapter 1, the role of infectious diseases in transplantation is 
constantly changing. One area of particular importance to transplantation is 
the rise in multi-drug resistant organisms (MDRO). The increasing incidence 
of MDRO is a growing threat to public health (202-204). The frequency of 
antibiotic resistance to bacterial organisms results in over a hundred thousand 
deaths worldwide every year (202-204). Without effective antimicrobials for 
the effective treatment or prevention of infection, organ transplantation will 
become very high risk (202-204). The hope of mitigating this problem with the 
development of new antibiotics has been hindered by the low rate of antibiotic 
development and the likelihood that the pathogen will evolve to become 
resistant to this new antimicrobial (203,205). Hence, there is a pressing need 
to determine the scope of the problem and develop an effective response to 
antimicrobial resistance (AMR). Increasing numbers of cases of MDRO are 
being reported in solid organ transplant recipients, and one of the most 
common reported post-transplant infections is urinary tract infection (UTI) 
(205). An increasing number of studies are reporting a large incidence of UTI 
in renal transplant patients that are secondary to MDRO, in particular 
extended spectrum beta-lactamases (ESBL), and the other emerging MDRO 
are often gram negative organisms which are known to readily colonise the 
urinary tract (207-209). Transplant recipients receive multiple antimicrobials 
following transplantation but it is unknown what effect this antimicrobial 
prophylaxis has on the development of MDRO in organ transplant recipients 
and what impact this has on the transplant recipient’s microbiome, which is 
known to interact in a dynamic way the host immune system and may help 
contribute to infective and immunological sequelae in the recipient (210). 
There is also increasing evidence that dysbiosis can contribute to diseases 
outside the GI tract, including cardiovascular disease and malignancy, two 
major causes of death of renal transplant recipients with a functioning graft 
(188,211). There is now also evidence that changes in the microbiome can 
also influence susceptibility to organ rejection (212). The transmission of a 
 190 
MDRO from deceased organ donors to transplant recipients is thought to be a 
rare, but serious consequence of transplantation (59,60). 
Currently, there has been no description of the incidence of MDRO isolates in 
UK deceased organ donors and what impact these isolates have to transplant 
recipients.  
Another project investigating the role of donor disease transmission would be 
the effect of EBV transmission from organ donor to transplant recipient. EBV 
infection is associated with  the development of PTLD (68-70). PTLD is 
associated with significant morbidity, graft dysfunction and mortality. The 
incidence, risk factors and natural history of PTLD in the UK population of 
solid organ allograft recipients is poorly understood. Routine matching of 
donor and recipient for EBV is not routinely done in the UK, or elsewhere (68-
70). An improved understanding of the factors responsible for the 
development of PTLD and their association with EBV is essential for not only 
for identifying those transplant recipients who are at increased risk for the 
development of PTLD but will also allow the development of effective and 
cost-effective surveillance and interventions and will also ensure the 
transplant recipient gives adequately informed consent (68-70). 
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1.46 Appendix 1: Free text search code 
*NEW CATEGORIES -  
Cause of death - Poisoning/overdose, drowning, hanging. 
history - depression, alcohol abuse, cocaine abuse, other oral drug 
abuse, other intrvenous drug abuse, HRSB, imprisonment. 
infection - active, recent, treated in past, encephalitis. 
travel - outside europe.; 
 
%let store = F:\Stats & Audit\Shared\Donation\Projects\High-risk 
donors; 
libname store "&store."; 
 











if dcountry = 'UNITED KINGDOM'; 
if "&date1."d <= ddate < "&date2."d ; 











if record_type ne 2; 
if note_type in (40,30,35,374,386); 
note_text=compbl(" "||note_text); 
note_text=TRANWRD(note_text,'.',' '); *replace full stops with spaces 
so that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,',',' '); *replace comma with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,'/',' '); *replace slashes with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,'\',' '); *replace slashes with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,'(',' '); *replace bracket with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,')',' '); *replace bracket with dashes so 





if note_type in (40,30,35,374,386); 
note_text=compbl(" "||note_text); 
note_text=TRANWRD(note_text,'.',' '); *replace full stops with spaces 
so that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,',',' '); *replace comma with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,'/',' '); *replace slashes with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,'\',' '); *replace slashes with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,'(',' '); *replace bracket with dashes so 
that use of prxmatch function is easier; 
note_text=TRANWRD(note_text,')',' '); *replace bracket with dashes so 
that use of prxmatch function is easier; 
run; 
 
proc sort data=donor_comment1 out=donor_comment_nodup1; 
by donor_id descending note_type descending note_date; 
run; 
proc sort data=donor_comment_nodup1 nodupkey; 
by donor_id descending note_type; 
run; 
proc sort data=donor_comment2 out=donor_comment_nodup2; 
by donor_id descending note_type descending note_date; 
run; 
proc sort data=donor_comment_nodup2 nodupkey; 
by donor_id descending note_type; 
run; 
 
proc transpose data=donor_comment_nodup1 





proc transpose data=donor_comment_nodup2 














if note1_40=note2_40 then note1_40=' '; 
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if note1_30=note2_30 then note1_30=' '; 
if note1_35=note2_35 then note1_35=' '; 
if note1_374=note2_374 then note1_374=' '; 




%macro search(nums, group, terms); 
 
 %local i num field; 
 
  %let i=1; 
  %let num=%scan(&nums,&i,%str( )); 
  %do %while (&num ne); 
 
   %if &num=40 %then %let 
field=cod; 
   %if &num=30 %then %let 
field=pmh; 
   %if &num=386 %then %let 
field=contra; 
   %if &num=35 %then %let 
field=gen; 
   %if &num=374 %then %let 
field=coroner; 
 
   ind_1_&group._&field. = 
min(1, prxmatch( "m /&terms./ oi" , note1_&num.)); 
   ind_2_&group._&field. = 
min(1, prxmatch( "m /&terms./ oi" , note2_&num.)); 
     
  
   %let i=%eval(&i+1); 
   %let 
num=%scan(&nums,&i,%str( )); 
  %end; 
  
 risk1_&group.=0; 
 if sum(of ind_1_&group._:)>0 then risk1_&group.=1; 
 risk2_&group.=0; 
 if sum(of ind_2_&group._:)>0 then risk2_&group.=1; 
 
 risk_&group.= max(risk1_&group., risk2_&group.); 






%macro wrap (); 
 
%search (40 374    386   , overdose, 
 (OVERDOSE|OVER-DOSE| COCAIN| COCCAIN| 





POISON|CO POISON)  ); 
     
     
     
    ); 
%search (40 374 30 386 35,  depression, 
 (DEPRESSION|ANTIDEPRESS|ANTI-
DEPRESS|SUICIDE|SUICIDAL| JUMPED|SELF-POISON|SELF 
POISON|SELF-HARM|SELF HARM)   
     
    ); 
%search (40 374 30 386 35,  alcohol, 
 (ALCOHOLIC|ALCOHOL LIVER DISEASE|ALCOHOL 
DISEASE|ALCOHOL ABUSE|ALCOHOL EXCESS|HEAVY 
DRINK|DRINKS HEAVILY|DRUNK HEAVILY|DRANK HEAVILY|HIGH 
ALCOHOL|ALCOHOL EXCESS|ALCOHOL DEPEND|ALCOHOL 
MISUSE|ELEVATED ALCOHOL|ETOH |EXCESSIVE ALCOHOL) 
     
    ); 
%search (40 374 30 386 35,  drugs,  
 (DRUG ABUSE|HEROIN| ECSTACY| EXTACY| 
KETAMINE| AMPHETAMINE| OPIOID| BARBITURATE| 
BENZODIAZEPINE)    
     
 ); 
%search (40 374 30 386 35,  cocaine, 
 (COCAIN| COCCAIN)   
     
     
     ); 
%search (40 374 30 386 35,  other,  
 (ECSTACY| EXTACY| KETAMINE| AMPHETAMINE| 
OPIOID| BARBITURATE| BENZODIAZEPINE)  
     
     
     
 ); 
%search (40 374 30 386 35,  cannabis, 
 (MARIJUANA|CANNAB|CANABIS)  
   ); 
%search (40 374 30 386 35,  IV,  
  (HEROIN|IV-DRUG| IV DRUG| 
INTRAVENOUS DRUG| INTRA-VENOUS DRUG| INTRAVENOUS-
DRUG| INTRA-VENOUS-DRUG|IVDU|IVDA|IV DA|IV DU|INJECTED)
   ); 
%search (40 374 30 386 35,  HRSB,  
 (SEX-WORKER|SEXWORKER|SEX 
WORKER|PROSTITUTE|HIGH-RISK SEX|HIGH RISK SEX|HIGH-
RISK-SEX| MSM| GAY| HOMOSEXUAL| HOMO-SEXUAL) 
     ); 
%search (40 374 30 386 35,  prison,  
 (PRISON| CUSTODY| JAIL| GAOL| INMATE| CONVICT)
     
     
     
   ); 
  
%search (40 374 30 386 35,  infection,  ( 




MENINGITUS|BACTERIAL-MENENGITUS|PNEUMOCOCCAL| TB | 
TB-| MTB | MTB-| TUBERCULOSIS|PNEUMONIA|SEPSIS 
   ); 
%search (40 374 30 386 35,  encephalitis,
 (ENCEPHALITIS|ENCEPHALITUS|ENCEPHULITIS) 
  
%search (40 374 30 386 35,  travel,  
 (MALARIA| ASIA|AFRICA|SOUTH AMERICA|S 
AMERICA|INDIA)    
  ); 
if dcod in (30,85) then risk_depression=1; 
if dcod = 54 then risk_overdose=1; 
if dcod = 80 then risk_alcohol=1; 
if dcod = 81 then risk_overdose=1; 




%macro wrapdetail (); 
 
%search (40 374 30 386 35,  inftub,  
 ( TB | MTB | TUBERCULOSIS)  ); 
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%search (40 374 30 386 35,  infflu,  
 ( FLU |INFLUENZA|H1N1| SWINE)  ); 
%search (40 374 30 386 35,  travel,   ( 
MALARIA | AFRICA | ALGERIA | ANGOLA | BENIN | BOTSWANA | 
BURKINA FASO | BURUNDI | CAMEROON | CAPE VERDE | 
CENTRAL AFRICAN REPUBLIC | CHAD | DEMOCRATIC REPUBLIC 
OF CONGO | DRC | REPUBLIC OF CONGO | IVOIRE | IVORY | 
DJIBOUTI | EGYPT | EQUATORIAL GUINEA | ERITREA | ETHIOPIA | 
GABON | GAMBIA | GHANA | GUINEA | GUINEA BISSAU | KENYA | 
LESOTHO | LIBERIA | LIBYA | MADAGASCAR | MALAWI | MALI | 
MAURITANIA | MAURITIUS | MOROCCO | MOZAMBIQUE | NAMIBIA 
| NIGER | NIGERIA | REUNION | RWANDA | SAO TOME AND 
PRINCIPE | SENEGAL | SEYCHELLES | SIERRA LEONE | SOMALIA 
| SOUTH AFRICA | SOUTH SUDAN | SUDAN | SWAZILAND | 
TANZANIA | TOGO | TUNISIA | UGANDA | ZAMBIA | ZIMBABWE | 
SOUTH AMERICA | ARGENTINA | BOLIVIA | BRAZIL |  CHILE | 
COLOMBIA | ECUADOR | FRENCH GUIANA | GUYANA | PARAGUAY 
| PERU | SURINAME | URUGUAY | VENEZUELA | CENTRAL 
AMERICA | BELIZE | COSTA RICA | EL SALVADOR | GUATEMALA | 
HONDURAS | NICARAGUA | PANAMA | MEXICO | CARIBEAN | 
CARRIBEAN | CARIBBEAN | JAMAICA | CUBA | HAITI | BARBADOS | 
BAHAMAS | DOMINICAN | ARUBA | SAINT LUCIA | PUERTO RICO | 
TRINIDAD | TOBAGO | GUADELOUPE | MARTINIQUE | GRENADA | 
DOMINICA | ANTIGUA | BARBUDA | ASIA | AFGHANISTAN | 
BAHRAIN | BANGLADESH | BHUTAN | BRUNEI | CAMBODIA | 
CHINA | EAST TIMOR | HONG KONG | INDIA | INDONESIA | IRAN | 
IRAQ | ISRAEL | JAPAN | JORDAN | KAZAKHSTAN | KOREA | 
KUWAIT | KYRGYZSTAN | LAOS | LEBANON | MALAYSIA | 
MALDIVES | MONGOLIA | MYANMAR | BURMA | NEPAL | OMAN | 
PAKISTAN | PHILIPPINES | PHILLIPINES | QATAR | RUSSIA | SAUDI 
ARABIA | SINGAPORE | SRI LANKA | SYRIA | TAIWAN | TAJIKISTAN 
| THAILAND | TURKEY | TURKMENISTAN | UNITED ARAB 
EMIRATES | UAE | UZBEKISTAN | VIETNAM | YEMEN | AUSTRALIA | 
NEW ZEALAND)); 
%search (40 374 30 386 35,  malaria,        ( MALARIA | MALARONE | 
MALARAI )    ); 
%search (40 374 30 386 35,  travelinfe,      ( TRAVEL 
|ZIKA|CHIKUNGUNYA|CHICKENGUNYA|CHIKUN|EBOLA|ARBOVIRU
S|WNV|WEST NILE VIRUS|DENGUE|H1N1|SWINE 
FLU|HTLV|YELLOW FEVER|LASSA FEVER|VIRAL HAEMORRHAGIC 
FEVER|CHAGAS|TRYPANASOMA CRUZI)  
  ); 







|MATO GROSSO|PARA|RONDONIA|RORAMIA AND 




if risk_codparv=1 then risk_codpar=1; 
if dcod = 30 then risk_histsuic=1; 
if dcod = 85 then risk_histself=1; 
if dcod = 85 then risk_histsuic=1; 
if dcod = 54 then risk_codco=1; 
if dcod = 80 then risk_codalc=1; 
if dcod = 81 then risk_codpar=1; 
if dcod = 81 then risk_codOD=1; 
if dcod = 82 then risk_codother=1; 
if dcod = 51 then risk_infpneu=1; 
if dcod = 71 then risk_infsep=1; 
if dcod = 70 then risk_infmen=1; 
risk_infother=(dcod=72); 
if past_alcohol_abuse=2 then risk_histalc=1; 






*if sum(of ind_:)>0 or dcod in (30,54,70,80,81,82,85); 
/*if risk_TB OR risk_sex or risk_prison or risk_IV or risk_flu or 
risk_meningitis then viral_risk=1;*/ 
/*if risk_drugs or risk_alcohol or risk_paracetamol or risk_CO or 
risk_MSM or risk_hanging or risk_drowning or risk_suicide or 




proc freq data=all_donors; table risk_:; where sod=1; run; 
 213 
 




if dtype in (1,2); 
if dCountry='UNITED KINGDOM'; 
if sod=1; 
run; 




if dcountry='UNITED KINGDOM'; 
if donor_id in 
(list of donor ids);if sod=1; 
run; 
ods graphics on; 
run; 




if dtype in (1,2); 
if txCountry='UNITED KINGDOM'; 
run;  
proc sort data=kidney; 
by donor_id; 
run; 





if donor_id in 
(as above)’’not actual code –abreviated for this thesis’’ 







proc sort data=donorsUKM; 
by donor_id; 
proc sort data=kidneyUKM; 
by donor_id; 
run; 
data  kidneyUKM2; 
merge kidneyUKM donors; 
by donor_id; 
if recip_id=. then delete; 
run; 
proc freq data=kidneyUKM2; 
table UKM; 
run; 

















merge missing all; 
by recip_id; 




if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 













if patientdays=>duration then psurvfinal=patientdays-duration; 
run; 








merge kidneyUKM2 missing5; 
by recip_id; 
run; 





if psurv=. then psurv=psurvfinal; 
if pcens=. then pcens=patientsurvival; 
run; 





if psurv=>3650 then psurvival=3650; 
else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650; 
else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0; 
else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0; 
else gcensor=gcens; 
if rage>40 then rage_grp=2; 
else recip_age_grp=1; 
if dage>40 then dage_grp=2; 
else donor_age_grp=1; 
run; 









if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_absue in (7,8) then drug=3; 
run; 
 





if UKM='0' and dage<40 and dtype=1 then Adjust=1; 
if UKM='1' then adjust=2; 
run; 





if donor_id in(as above ‘’not actual code-abreviated for this thesis’’) 
); 
run; 
proc print data=analysisy; 
title 'Recipient ID from UKME donors'; 














/*proportionality of hazards*/ 
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proc phreg data=analysis3; 
class UKM; 
model psurvival*pcensor(0)=UKM UKMt; 
UKMt=UKM*log(psurvival); 
test_proportionality: test UKMt; 
run; 
 
proc phreg data=analysis2; 
class UKM; 
model psurvival*pcensor(0)= UKM; 






proc loess data=schoen; 
model schUKM=psurvival/smooth=(0.2 0.4 0.6 0.8); 
run; 
proc loess data=schoen plots=scoreplot; 
model schUKM=logpsurvival/smooth=(0.2 0.4 0.6 0.8); 
run; 
/*Cox Hazards Model*/ 
proc phreg data=analysis3; 
class UKM rsex rage_grp dage_grp HLA_GRP; 
model psurvival*pcensor(0)=UKM rsex rage_grp dage_grp cld_isch 

























2,106494,77900, 96615) then KM='0'; 
if txcountry= 'UNITED KINGDOM'; 
run; 





if km='1' then meningitis='2'; 
if ukm='1' then meningitis='1'; 
run; 
proc freq data=km3; 
table meningitis; 
run; 
data kidneywhoelse;set standard.kidney_tx;if donor_id in 125687 
140709 
 
data kmearly;set km3;if psurv<=30 and pcens=1 then early=1;run; 
data kmearlyX;set kmearly; if donor_id=108133;run; 
proc freq data=kmearly;table meningitis;run; 
data kmearly2;set kmearly; if meningitis=2;run; 
data notes;set database.recipient_note;if recip_id=111812;run; 
data notes2;set database.grafted_organ_note;if tx_id=240198;run; 
data notes3;set database.recip_ext_agency_death;if 
recip_id=111812;run; 
data kmnew;set km3;if psurv<=30 and pcens=1 then early=1;else 
early=0;if meningitis=. then meningitis=3;run; 
data kmnew2;set kmnew; if meningitis in (1,2)then menin=1;if 
meningitis=3 then menin=2;run; 
proc freq data=kmnew2;table menin*early/fisher;run; 
proc freq data=kmnew; table meningitis*early/fisher;run; 
data kmnew2;set kmnew; if meningitis in (1,2);if early=1;run; 
proc freq data=kmnew2; table meningitis*rcod;run; 
data kmnewstr;set kmnew;if rcod=522 then stroke=1;run; 
data kmnewstroke;set kmnewstr;if pcens=1;if stroke=. then 
stroke=0;run; 
proc freq data=kmnewstroke; table meningitis*stroke/chisq;run; 
I25.9; 
data icds;set database.icd_code;if icd_code='E14.9';run; 
data km4; 
set km3; 
if meningitis=. then meningitis='3'; 
if KM='0' and dage<40 and dtype=1 then adjusted='1'; 
if KM='1' then adjusted='2'; 
run; 





if km='1' and dage<=40 then kmage=1; 
if km='1' and dage>40 then kmage=2; 
if km='0' and dage<=40 then kmage=3; 
if km='0' and dage>40 then kmage=4; 
run; 





if past_diabetes=. then diabetes=3;run; 
/*Survival Analysis Known Meningitis*/ 





proc phreg data=km6; 
class meningitis(ref='3') dtype(ref='1')HLA_GRP (ref='1') 
diabetes(ref='1'); 
model psurvival*pcensor(0)=dage rage meningitis dtype HLA_GRP 
diabetes;run; 
data temp1; 
a=1-CDF('CHISQUARE',43946.360 - 43941.697,2); 
put a; 
run; 
proc phreg data=km5; 
class kmage rsex meningitis HLA_GRP ethnic dtype diabetes cardio 
hypertension past_smoker recip_ethnic ; 
model psurvival*pcensor(0)=kmage rsex rage dage cld_isch HLA_grp 
ethnic dtype diabetes cardio prd hypertension past_smoker 
recip_ethnic prd; 
run; 








proc freq data=km5; table rec_unit*meningitis/chisq;run; 
data kmnew;set km5;if meningitis in (1,2) then test=1;else test=0; 
run; 
 








if UKM=1 then menin=1;if km=1 THEN MENIN=2; 
IF ukm=0 AND km=0 THEN MENIN=0; 
run; 










if alternate in (0,1) then transplant=1; 
run; 
 













/*data updated tables*/ 





proc freq data=km4; 
table meningitis*rsex/chisq; 
run; 
proc freq data=km4; 
table meningitis*recip_ethnic/chisq; 
run; 
proc freq data=km4; 
table meningitis*sensitised/chisq; 
run; 









proc freq data=km4; 
table meningitis*Tx/chisq; 
run; 
proc freq data=km4; 
table meningitis*HLA_grp/chisq; 
run; 
proc freq data=km4; 
table meningitis*prd; 
run; 








 proc npar1way data=km4; 
 class meningitis; 
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 var prd; 
 run; 






proc freq data=analysis3; 
table UKM; 
run; 
proc univariate data=analysis3; 
class UKM; 
var rage dage cld_isch crf_tx wait_time; 
histogram; 
run; 









proc freq data=analysis3; 
table UKM*rsex/chisq; 
where rsex in (1,2); 
run; 
proc freq data=analysis3; 
table UKM*Dsex/chisq; 
run; 
proc freq data=analysis3; 
table UKM*recip_ethnic/chisq; 
run; 








proc freq data=analysis3; 
table UKM*Tx/chisq; 
run; 
proc freq data=analysis3; 
table UKM*sensitised/chisq; 
run; 
proc freq data=analysis3; 
table UkM*gcensor; 
where gcensor=1 and gsurvfinal<365.25; 
run; 
proc freq data=analysis3; 
table UkM*gcensor; 
run; 
proc freq data=analysis3; 
table UKM*pcensor; 
run; 









proc freq data=analysis3; 
table UKM*COF; 
run; 




proc freq data=analysis3; 
table UKM*PRD; 
run; 









proc freq data=analysis3; 
table UKM*RCOD; 
run; 




proc freq data=analysis3; 
table UKM*dtype/chisq; 
run; 


















proc freq data=analysis3; 
table UKM*hypertension/chisq; 
run; 
proc freq data=analysis3; 
table UKM*diabetes/chisq; 
run; 
proc freq data=analysis3; 
table UKM*liver/chisq; 
run; 
proc freq data=analysis3; 
table UKM*drug/chisq; 
run; 
proc freq data=analysis3; 
table UKM*alcohol/chisq; 
run; 






proc sort data=wcc; 
by donor_id; 
run; 




merge wcc analysis3; 
by donor_id; 
if UKM=. then delete; 
run; 
proc sort data=wccukm nodupkey; 
by recip_id; 
run; 



















if rcod=534 then cardiff=1; 
else cardiff=0; 
run; 





/*Data for tables-KM-Donors*/ 
proc freq data=KM2; 
table KM; 
run; 
proc univariate data=KM2; 
class KM; 
var rage dage cld_isch crf_tx wait_time; 
histogram; 
run; 








proc freq data=Km2; 
table KM*rsex/chisq; 
run; 
proc freq data=KM2; 
table KM*Dsex/chisq; 
where dsex in (1,2); 
run; 
proc freq data=KM2; 
table KM*ethnic/chisq; 
run; 
proc freq data=KM2; 
table KM*recip_ethnic/chisq; 
run; 












proc freq data=Km2; 
table KM*sensitised/chisq; 
run; 
proc freq data=Km2; 
table KM*COF; 
run; 




proc freq data=KM2; 
table KM*RCOD; 
run; 




proc freq data=km2; 
table KM*prd; 
run; 

























if pcens=1 and psurv<365.25; 
run; 






proc sort data=wcc; 
by donor_id; 
run; 




merge km2 wcc; 
by donor_id; 
if km=. then delete; 
run; 
proc sort data=km2allinfo nodupkey; 
by recip_id; 
run; 


















proc sort data=wait; 
by recip_id; 
run; 














if psurvival=>0 and wtime=>0 then survivaltime=psurvival + wtime; 
if wtime=>0 and psurvival=. then survivaltime=wtime; 





if pcenslisting=1 and survivaltime>3652.5 then pcens10=0 and 
survivaltime=3652.5; 
if pcenslisting=0 and survivaltime>3652.5 then pcens10=0; 






if UKM=1 then unknown=3; 
if UKM=0 then unknown=2; 























/*Survival from listing Known meningitis Kidney*/ 














if psurvival=>0 and wtime=>0 then survivaltime=psurvival + wtime; 
if wtime=>0 and psurvival=. then survivaltime=wtime; 




if pcenslisting=1 and survivaltime>3652.5 then pcens10=0; 
if survivaltime>3652.5 then survivaltime=3652.5; 






if KM=1 then known=3; 
if Km=0 then known=2; 
if km=. then known=1; 
run; 





if survival10=. then delete; 
run; 
proc lifetest data=knownwaitkidney5 notable plots=(S,LLS); 
time survival10*pcens10(0); 
strata known; 







if dtype in (1,2); 
run; 










merge liver liverethnic; 
by donor_id; 
if recip_id=. then delete; 
run; 
 





if donor_id in 
(as above-‘’not actual code-abreviated for this thesis’ 
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merge livermissing allliver; 
by recip_id; 




if psurv=. then delete; 
rename tx_date=first_tx_date psurv=patientdays pcens=patientsurvival; 
keep recip_id donor_id tx_date psurv pcens; 
run; 
proc sort data=livermissing2; 
by recip_id; 
run; 




merge liverukm livermissing2; 
by recip_id; 








if psurv=. then psurv=psurvfinal; 




if psurv>1826.5 then psurvival=1826.5; 
else psurvival=psurv; 
if gsurv>1826.5 then gsurvival=1826.5; 
else gsurvival=gsurv; 
if pcens=1 and psurv>1826.5 then pcensor=0; 
else pcensor=pcens; 
if gcens=1 and gsurv>1826.5 then gcensor=0; 
else gcensor=gcens; 






if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abusee in (7,8) then drug=3; 
if rhcv=1 then rhepc=1; 
if rhcv=2 then rhepc=2; 
if rhcv in (3,4,5,6,7,8) then rhepc=3; 
if hcv=1 then hepC=1; 
if hcv=2 then hepC=2; 






proc print data=lukmsa2; 
title 'liver recip_id ukme donors'; 
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var recip_id ukm donor_id; 
run; 
 
/*SA for Liver UKM*/ 








/*Proportionality of Hazards*/ 
 
proc phreg data=analysis2; 
class UKM; 
model psurvival*pcensor(0)=UKM UKMt; 
UKMt=UKM*log(psurvival); 
test_proportionality: test UKMt; 
run; 
 
/*Liver Tx Known Cause Meningitis*/ 
data liverKM; 
set lUKMSA; 
if dcod=70 or donor_id in (as above-not actuial code abbreviated for 
this thesis’’) 





if donor_id in 
(as above, not actual code abbreviated for this thesis’’) 
);run; 
 
proc freq data=liverkm6;table recip_id*rcod;run; 
/*updated tables*/ 





proc freq data=liverkm4; 
table meningitis*urgent/chisq; 
run; 










proc freq data=liverkm4; 
table meningitis*rsex/chisq; 
where rsex in (1,2); 
run; 
proc freq data=liverkm4; 
table meningitis*recip_ethnic/chisq; 
run; 
proc freq data=liverkm4; 
table meningitis*rhepc/chisq; 
run; 
proc freq data=liverkm4; 
table meningitis*graft_no/chisq; 
run; 
proc freq data=liverkm4; 
table meningitis*pld;  
run; 













/*data for Tables-Liver UKM*/ 
proc freq data=LUKMSA; 
table UKM; 
run; 
proc freq data=LUKMSA; 
table UKM*past_diabetes/chisq; 
where past_drug_abuse in (1,2); 
run; 
 
proc freq data=liverKM2; 
table KM; 
run; 
proc univariate data=LUKMSA; 
class UKM; 
var rage dage cit; 
run; 




proc freq data=lukmsa; 
table UKM*rsex/chisq; 
where rsex in (1,2); 
run; 





proc freq data=LUKMSA; 
table UKM*dsex/chisq; 
where dsex in (1,2); 
run; 
proc freq data=LUKMSA; 
table UKM*dtype/chisq; 
run; 






if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if dethnic=1 then donor_ethnic=1; 
else donor_ethnic=2; 
if RHCV=1 then HCV=1; 
if RHCV=2 then HCV=2; 
if RHCV in (6,7,8,9) then HCV=3; 
run; 
proc freq data=lukmsas; 
table UKM*recip_ethnic/chisq; 
run; 
proc freq data=lukmsas; 
table UKM*donor_ethnic/chisq; 
run; 









proc freq data=lukmsa; 
table UKM*COF; 
run; 









if ukm=1 and pcens=1 and psurv<365.25; 
run; 
 
/* Known Meningitis Data*/ 
proc freq data=liverkm2; 
table KM; 
run; 
proc freq data=liverKM2; 
table KM; 
run; 
proc univariate data=liverkm2; 
class KM; 
var rage dage cit; 
run; 








proc freq data=liverkm2; 
table KM*dsex/chisq; 
where dsex in (1,2); 
run; 
proc freq data=liverkm2; 
table KM*rsex/chisq; 
where rsex in (1,2); 
run; 




proc freq data=liverkm2; 
table KM*dtype/chisq; 
run; 








proc freq data=liverkm2; 
table KM*pcens; 
where pcens=1 and psurv<365.25; 
run; 
proc freq data=liverkm2; 
table KM*gcens; 




if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
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if dethnic=1 then donor_ethnic=1; 
else donor_ethnic=2; 
if RHCV=1 then HCV=1; 
if RHCV=2 then HCV=2; 
if RHCV in (6,7,8,9) then HCV=3; 
run; 
proc freq data=liverkm2s; 
table KM*recip_ethnic/chisq; 
run; 













proc freq data=liverkm2; 
table KM*COF; 
run; 














if endstat in ('D','DA','DS'); 
run; 
proc sort data=waitlist; 
by recip_id; 
run; 















if psurvival=>0 and rwtime=>0 then survivaltime=psurvival + rwtime; 
if psurvival=>0 and suwtime=>0 and rwtime=. then 
survivaltime=psurvival+suwtime; 
if rwtime=>0 and psurvival=. then survivaltime=rwtime; 




if pcenslisting=1 and survivaltime>1826.25 then pcens10=0 and 
survivaltime=1826.25; 
else pcens10=pcenslisting; 





if UKM=1 then Unknown=3; 
if UKM=0 then unknown=2; 
if UKM=. then unknown=1; 
run; 
proc freq data=ukmwaitlist5; 
table Unknown*pcens10; 
run; 





/*known meningitis listing*/ 















if psurvival=>0 and rwtime=>0 then survivaltime=psurvival + rwtime; 
if psurvival=>0 and suwtime=>0 and rwtime=. then 
survivaltime=psurvival+suwtime; 
if rwtime=>0 and psurvival=. then survivaltime=rwtime; 





if pcenslisting=1 and survivaltime>1826.25 then pcens10=0 and 
survivaltime=1826.25; 
else pcens10=pcenslisting; 





if KM=1 then known=3; 
if KM=0 then known=2; 
if Km=. then known=1; 
run; 
proc freq data=ukmwaitlist5; 
table known*pcens10; 
run; 








































/*Liver Unknown Meningitis-Patient and Graft Survival*/ 








/*liver Known Meningitis-Patient and Graft Survival*/ 













if dtype in (1,2); 
run; 





if dcod=70 or donor_id in (as above 





if donor_id in 
(as above 




if donor_id in 
(as above) 
) then UKM=1; 
else UKM=0; 
run; 











proc sort data=heartall; 
by recip_id; 
run; 




merge heartukm2 heartall; 
by recip_id; 




if psurv=. then delete; 
rename tx_date=first_tx_date psurv=patientdays pcens=patientsurvival; 
keep recip_id donor_id tx_date psurv pcens; 
run; 
proc sort data=heartmissing; 
by recip_id; 
run; 




merge heartuk heartmissing; 
by recip_id; 








if psurv=. then psurv=psurvfinal; 




if psurv>1826.25 then psurvival=1826.25; 
else psurvival=psurv; 
if gsurv>1826.25 then gsurvival=1826.25; 
else gsurvival=gsurv; 
if pcens=1 and psurv>1826.25 then pcensor=0; 
else pcensor=pcens; 







if dnation='OVERSEAS' then delete; 
if Txnation='OVERSEAS' then delete; 
if pcensor=. then delete; 
if km='1' then meningitis='2'; 
if ukm='1' then meningitis='1'; 
if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abusee in (7,8) then drug=3; 
if rhcv=1 then rhepc=1; 
if rhcv=2 then rhepc=2; 
if rhcv in (3,4,5,6,7,8) then rhepc=3; 
if hcv=1 then hepC=1; 
if hcv=2 then hepC=2; 
if hcv in (3,4,5,6,7,8) then hepc=3; 
run; 










if ukm=1 then meningitis=1; 
if km=1 then meningitis=2; 
run; 
proc freq data=heartall7;table meningitis;run; 
proc print data=heartall7; 
title 'heart recip-id ukme donors'; 
var recip_id ukm donor_id; 
run; 
proc freq data=heartall5; 
table KM*tx_type; 
run; 
/*updated heart table*/ 
proc freq data=heartall7; 
table meningitis; 
run; 





proc freq data=heartall6; 
table meningitis*rsex/chisq; 
run; 
proc freq data=heartall6; 
table meningitis*recip_ethnic/chisq; 
run; 
proc freq data=heartall6; 
table meningitis*graft_no/chisq; 
run; 
proc freq data=heartall6; 
table meningitis*urgent/chisq; 
run; 
proc freq data=heartall6; 
table meningitis*pcd/chisq; 
run; 




data donornotes;set database.donor_comment;if donor_id in (70730, 
84772);run; 
data heartall7;set heartall6;if psurv<=30 then early=1;else early=0;run; 
proc freq data=heartall7; table meningitis;run; 
data heartall8;set heartall7;if meningitis in (1,2);if early=1;keep recip_id 
psurv pcens meningitis donor_id rcod;run; 
data heartall8;set heartall7; if donor_id in  (70730, 
84772);run; 
data heartall9;set heartall8;if pcens=1;if stroke=. then stroke=0;run; 
proc freq data=heartall9;table meningitis*stroke/fisher;run; 
data heartall10;set heartall9;if stroke=1; if meningitis in (1,2);run; 
data notes;set database.recipient_note;if recip_id in 
(122117 
182170);run; 





if donor_id in 
(70730, 
84772);run; 
/*SA known cause Meningitis Heart Tx*/ 


















/*Lung known meningitis*/ 
proc lifetest data=heartall5  plots=(S,LLS); 
time ptsurv*pcensor(0); 
strata KM; 
where tx_type in (60,61,62,63,65,66); 
run; 





/*SA unknown cause Meningitis heart Tx*/ 










proc lifetest data=heartall5 notable plots=(s,LLS); 
time ptsurv*pcensor(0); 
strata UKM; 
where tx_type in (60,61,62,63,64,65,66); 
run; 
proc freq data=heartall5; 
table UKM*rcod; 
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where pcens=1 and ptsurv<1; 
run; 
proc freq data=heartall5; 
table UKM*cof; 















if donor_id in (59041, 71714, 88848, 78835, 109174, 105726); 
run; 
/*Heart Data Tables*/ 




proc freq data=heartall5; 
table KM*COf; 
run; 













if rethnic=1 then ethnic=1; 
else ethnic=2; 
run; 
proc freq data=heartall6; 
table KM*dsex/chisq; 
where dsex in (1,2); 
run; 
proc freq data=heartall6; 
table UKM; 
run; 
proc freq data=heartall6; 
table KM*dtype/chisq; 
run; 








proc freq data=heartall6; 
table KM*rsex/chisq; 
where rsex in (1,2); 
run; 
proc freq data=heartall6; 
table KM*ethnic/chisq; 
run; 
proc freq data=heartall6; 
table KM*urgent/chisq; 
run; 
proc freq data=heartall6; 
table UKM*urgent/chisq; 
run; 








proc freq data=heartall6; 
table UKM*dsex/chisq; 
where dsex in (1,2); 
run; 
proc freq data=heartall6; 
table UKM*dtype/chisq; 
where dsex in (1,2); 
run; 








proc freq data=heartall6; 
table UKM*ethnic/chisq; 
run; 
proc freq data=heartall6; 
table UKM*rsex/chisq; 











if donor_id in 
(as above 





if dcod=70 or donor_id in (as above 





if donor_id in 
(list of appropriate donor-ids) 
) then KM='0'; 
run; 





if ukm=1 then meningitis=1; 




if meningitis=. then meningitis=3; 
run; 
data kmpanc3;set kmpanc2; if psurv<=30 then early=1;else 
early=0;run; 
proc freq data=kmpanc3;table meningitis;run; 
data kmpanc4;set kmpanc3;if early=1;if meningitis in (1,2)then 
delete;keep recip_id psurv pcens rcod1;run; 
data notes; 
set database.recipient_note;if recip_id=72686;run; 
data km3;set km2;if early=1;if km=1;run; 
proc freq data=km3;table rcod;run; 








if donor_id in 









if dcod=70 or donor_id in (list of corresponding donor ids) 





if donor_id in 
(list of corresponding donor ids) 
) then KM='0'; 
run; 
proc freq data=intestineKM2; 
table KM*tx_type; 
run; 
data intestinekm3;set intestinekm2;if ukm=1 or km=1 then 
meningitis=1;run; 
data intestinekm4;set intestinekm3;if meningitis=. then meningitis=0;if 
psurv<=30 then early=1;else early=0;run; 
proc freq data=intestinekm4;table meningitis*early/fishers;run; 
data intestinekm5;set intestinekm4;if early=1;run; 



















merge pda pdanote; 
by pda_id; 
if cod=. then delete; 











merge pda2 pdanote; 
by pda_id; 
if contraindications=. then delete; 
















merge pdapilot pdapilotnote; 
by pda_id; 










merge pdapilot3 pdanote; 
by pda_id; 









proc sort data=donorunused; 
by donor_id; 
run; 




merge donorunused donorcomment; 
by donor_id; 
if utilised=. then delete; 
if note_type=. then delete; 
if note_type=300; 







/*table of patient from cardiff*/ 
data wcc; 
set database.dcsd_organ_donor; 
if donor_id in 
(list of corresponding donor ids) 
)then UKM='1'; 
else UKM='0'; 
keep donor_id temperature white_cells secretions 
causative_organisms UKM warm_isch_time; 
run; 





if donor_id in (list of corresponding donor ids) 
) ; 
keep note_text note_date note_type donor_id; 
run; 












if donor_id in 
(list of corresponding donor ids) 
)then UKM='1'; 
else UKM='0'; 
if dtype in (1,2); 
where sod=1; 








proc freq data=donors; 
table dcod; 
run; 
proc freq data=donors; 
table ukm; 
run; 
proc freq data=donors; 
table dyr*ukm; 
run; 




proc sort data=donors; 
by descending dyr; 
run; 
proc chart data=donors; 








merge wcc donors; 
by donor_id; 
if ddate=. then delete; 
run; 
proc sort data=donorwcc nodupkey; 
by donor_id; 
run; 





if temperature=>38.0  then fever=2; 
if temperature<38.0 then fever=1; 
if temperature=. then fever=0; 
if white_cells=>12.0 then WCC=2; 
if white_cells<12.0 then wcc=1; 
if white_cells=. then wcc=0; 
if dethnic=1 then ethnic=1; 
else ethnic=2; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abuse in (7,8) then drug=3; 
if past_smoker=1 then smoker=1; 
if past_smoker=2 then smoker=2; 




if dcod=70 or donor_id in (list of corresponding donor ids) 





if donor_id in 





if UKM='1' then meningitis='1'; 
if KM='1' then meningitis='1'; 
If UKM='0' and KM='0' then meningitis='0'; 
run; 
proc univariate data=donormeningitis;class meningitis;var dage;run; 










if donation_year=2003 then dyear='2003'; 
if donation_year=2004 then dyear='2004'; 
if donation_year=2005 then dyear='2005'; 
if donation_year=2006 then dyear='2006'; 
if donation_year=2007 then dyear='2007'; 
if donation_year=2008 then dyear='2008'; 
if donation_year=2009 then dyear='2009'; 
if donation_year=2010 then dyear='2010'; 
if donation_year=2011 then dyear='2011'; 
if donation_year=2012 then dyear='2012'; 
if donation_year=2013 then dyear='2013'; 
if donation_year=2014 then dyear='2014'; 
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if donation_year=2015 then dyear='2015'; 




if meningoencephalitis=1 then meningitisused=0; 
death_year=year(death_date); 
run; 
data therest5;set theresttx2; 
if death_year=2003 then dyear='2003'; 
if death_year=2004 then dyear='2004'; 
if death_year=2005 then dyear='2005'; 
if death_year=2006 then dyear='2006'; 
if death_year=2007 then dyear='2007'; 
if death_year=2008 then dyear='2008'; 
if death_year=2009 then dyear='2009'; 
if death_year=2010 then dyear='2010'; 
if death_year=2011 then dyear='2011'; 
if death_year=2012 then dyear='2012'; 
if death_year=2013 then dyear='2013'; 
if death_year=2014 then dyear='2014'; 
if death_year=2015 then dyear='2015'; 
run; 
proc sort data=therest5;by dyear;run; 
data allinfo; 
merge donmenon therest5; 
by dyear; 
if death_year=2003 then dyear='2003'; 
if death_year=2004 then dyear='2004'; 
if death_year=2005 then dyear='2005'; 
if death_year=2006 then dyear='2006'; 
if death_year=2007 then dyear='2007'; 
if death_year=2008 then dyear='2008'; 
if death_year=2009 then dyear='2009'; 
if death_year=2010 then dyear='2010'; 
if death_year=2011 then dyear='2011'; 
if death_year=2012 then dyear='2012'; 
if death_year=2013 then dyear='2013'; 
if death_year=2014 then dyear='2014'; 
if death_year=2015 then dyear='2015'; 
run; 










if donor_id=. then donor_age=age_years; 
if donor_id=. then donor_sex=sex; 
run; 
data allinfo4;set allinfo3; 
donor_years=dage; 
donorsex=dsex;run; 
data allinfo5;set allinfo4; 
if pda_id=. then donor_age=donor_years; 
if encephalitis=1 then UKM=2; 
run; 
data allinfoX;set allinfo5;if pda_id=. then donor_sex=donorsex;run; 
data allinfo6;set allinfox; if UKM in (1,2) then ME=1;run; 
data allinfo7;set allinfo6;if ME=. then ME=0;run; 
proc freq data=allinfo7;table meningitisused*ME/chisq;run; 
proc ttest data=allinfo5;class meningitisused;var donor_age;run; 
proc freq data=allinfo7;table meningitisused*donor_sex/chisq;run; 
proc univariate data=donormeningitis; 
class meningitis;var dage;run; 




proc freq data=donormeningitis; 
table meningitis*dsex/chisq; 
where dsex in (1,2); 
run; 
proc freq data=donormeningitis; 
table meningitis*dtype/chisq; 
run; 
















proc freq data=donormeningitis; 
table meningitis*past_diabetes/chisq; 
run; 
proc freq data=donormeningitis; 
table meningitis*past_hypertension/chisq; 
run; 
proc freq data=donormeningitis; 
table meningitis*cardio/chisq; 
run; 




proc freq data=donormeningitis; 
table meningitis*alcohol/chisq; 
run; 
proc freq data=donormeningitis; 
table meningitis*drug/chisq; 
run; 
proc freq data=donormeningitis; 
table meningitis*smoker/chisq; 
run; 
















if dcod=70 or donor_id in (list of corresponding donor ids) 
) then KM='1'; 
else KM='0'; 
if dtype in (1,2); 




if donor_id in 











if donor_id=105726 then cardiff='1'; 
else cardiff='0'; 
run; 










merge cardiff2 basics; 
by donor_id; 
if ukm=. then delete; 
keep donor_id forename surname dcent ddate; 
run; 
 
proc sort data=basicscardiff nodupkey; 
by donor_id; 
run; 








proc freq data=cardiff2; 
table cardiff*dsex; 
run; 
proc freq data=cardiff2; 
table cardiff*past_liver_disease; 
run; 
proc freq data=cardiff2; 
table cardiff*past_alcohol_abuse; 
run; 
proc freq data=cardiff2; 
table cardiff*past_diabetes; 
run; 
proc freq data=cardiff2; 
table cardiff*dethnic; 
run; 
proc freq data=cardiff2; 
table cardiff*past_hypertension; 
run; 







proc sort data=donorencph2; 
by donor_id; 
run; 




merge donorEncph2 DonorComment; 
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by donor_id; 






proc sort data=donorencph2; 
by donor_id; 
run; 




merge donorencph2 unused; 
by donor_id; 
keep donor_id dcod note_text note_type; 
if km='1'; 
run; 








proc freq data=donorwcc2; 
table ukm*wcc/chisq; 
run; 




proc freq data=donorwcc2; 
table UKM*dtype/chisq; 
run; 




proc freq data=donorwcc2; 
table UKM*diabetes/chisq; 
run; 
proc freq data=donorwcc2; 
table UKM*hypertension/chisq; 
run; 
proc freq data=donorwcc2; 
table UKM*cardio/chisq; 
run; 
proc freq data=donorwcc2; 
table UKM*drug/chisq; 
run; 
proc freq data=donorwcc2; 
table UKM*liver/chisq; 
run; 
proc freq data=donorwcc2; 
table UKM*alcohol/chisq; 
run; 









proc sort data=donorwcc nodupkey; 
by donor_id; 
run; 
proc freq data=donors; 
table UKM; 
run; 













proc freq data=donors; 
table UKM*past_diabetes; 
run; 
proc freq data=donors; 
table UKM*past_hypertension; 
run; 
proc freq data=donors; 
table UKM*past_alcohol_abuse; 
run; 
proc freq data=donors; 
table UKM*past_liver_disease; 
run; 
proc freq data=donors; 
table UKM*past_smoker; 
run; 





    LENGTH 
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        D_id               8 
        'Event History'n $ 267 
        'LP done'n       $ 14 
        CSF              $ 133 
        temperature        8 
        WCC              $ 4 
        PMH              $ 202 ; 
    FORMAT 
        D_id             BEST12. 
        'Event History'n $CHAR267. 
        'LP done'n       $CHAR14. 
        CSF              $CHAR133. 
        temperature      BEST12. 
        WCC              $CHAR4. 
        PMH              $CHAR202. ; 
    INFORMAT 
        D_id             BEST12. 
        'Event History'n $CHAR267. 
        'LP done'n       $CHAR14. 
        CSF              $CHAR133. 
        temperature      BEST12. 
        WCC              $CHAR4. 
        PMH              $CHAR202. ; 
    INFILE 'E:\SASWork\_TD10380_MSVSAS01_\#LN04585' 
        LRECL=455 
        ENCODING="WLATIN1" 
        TERMSTR=CRLF 
        DLM='7F'x 
        MISSOVER 
        DSD ; 
    INPUT 
        D_id             : BEST32. 
        'Event History'n : $CHAR267. 
        'LP done'n       : $CHAR14. 
        CSF              : $CHAR133. 
        temperature      : BEST32. 
        WCC              : $CHAR4. 
        PMH              : $CHAR202. ; 
RUN; 
 




















merge Meningitissummary cardiffdonor; 
by donor_id; 
if sod=. then delete; 
keep 'Event History'n 'LP done'n dsex CSF temperature WCC  PMH 
past_liver_disease past_drug_abuse past_alcohol_abuse 
past_diabetes past_hypertension ddate dage donor_id cardiff; 
run; 




proc freq data=cardiffmen; 
table cardiff*past_liver_disease; 
run; 
proc freq data=cardiffdonor; 
table cardiff*past_alcohol_abuse; 
run; 
proc freq data=cardiffdonor; 
table cardiff*past_smoker; 
run; 
proc freq data=cardiffdonor; 
table cardiff*past_drug_abuse; 
run; 
proc freq data=cardiffdonor; 
table cardiff*ORGANS_OFD; 
run; 
proc freq data=cardiffdonor; 
table cardiff*ORGANS_TXD; 
run; 
proc univariate data=cardiffdonor; 
class cardiff; 




















proc sort data=pda; 
by pda_id; 
run; 




merge pda pdanote; 
by pda_id; 
if cod=. then delete; 










proc sort data=pdamen; 
by pda_id; 
run; 




merge pdamen  pdanote; 
by pda_id; 
if cod=. then delete; 





















proc freq data=pdanote; 
table note_date; 
run; 
proc sort data=pdaother; 
by pda_id; 
run; 




merge pdaother pdanote; 
by pda_id; 
if cod=. then delete; 















proc freq data=pdanote; 
table note_date; 
run; 
proc sort data=pdaunknown; 
by pda_id; 
run; 




merge pdaunknown pdanote; 
by pda_id; 
if cod=. then delete; 






















merge pdainfection pdanote; 
by pda_id; 
if cod=. then delete; 
keep pda_id note_text admission_date note_type; 
run; 







proc sort data=pdanew; 
by pda_id; 
run; 




merge pdanew pdanote; 
by pda_id; 
if cod=. then delete; 
keep pda_id note_text admission_date note_type; 
run; 
 







proc sort data=pdanew2; 
by pda_id; 
run; 




merge pdanew2 pdanote; 
by pda_id; 
if cod=. then delete; 










proc sort data=pdanew98; 
by pda_id; 
run; 




merge pdanew98 pdanote; 
by pda_id; 
if cod=. then delete; 
keep pda_id note_text admission_date note_type; 
run; 
 






proc sort data=pdaMennew 
by pda_id; 
run; 




merge pdaMennew pdanote; 
by pda_id; 
if cod=. then delete; 








if dcod=70 or donor_id in (list of donor ids)od=0; 
if dcountry='UNITED KINGDOM'; 
if mdy(01,01,2003)<=ddate<mdy(01,01,2015); 
run; 





if donor_id in 








proc sort data=notes; 
by donor_ID; 
run; 











merge donors1 notes; 
by donor_id; 
if sod=. then delete; 
keep donor_id dcent dsex ddate dregion hospname note_type 
note_text sod; 
run; 




merge notesunused basics; 
by donor_id; 
if sod=. then delete; 




   Code generated by a SAS task 
    
   Generated on Saturday, November 07, 2015 at 8:31:07 PM 
   By task:     Import Data Wizard 
    
   Source file: \\msfile1\home$\dsummers\My 
   Documents\Meningitis%20for%20Prof-2(1).xlsx 
   Server:      Local File System 
    
   Output data: WORK.Meningitis_20for_20Prof_2_1_ 
   Server:      SASApp 
    
   Note: In preparation for running the following code, the Import 
   Data wizard has used internal routines to transfer the source data 
   file from the local file system to SASApp. There is no SAS code 
   available to represent this action. 
   -------------------------------------------------------------------- */ 
 
/* -------------------------------------------------------------------- 
   This DATA step reads the data values from a temporary text file 
   created by the Import Data wizard. The values within the  
   text file were extracted from the Excel source file. 
   --------------------------------------------------------------temporary------ */ 
data knewdata; 
merge donors Meningitissummary; 
by donor_id; 
if UKM=0 then delete; 
keep donor_id CSF temperature sod dbmi ddate dage WCC PMH 
past_liver_disease past_hypertension past_diabetes past_smoker 
past_drug_abuse  'LP done'n   'Event History'n;  
if donor_id=105726 then cardiff='1'; 
else cardiff='0'; 















































merge othercauses notes; 
if cod=. then delete; 
iF potential_donor_id in 
(list of donor ids) 
)  THEN MENINGITIS=1; 
run; 
DATA COMBINED2; 
SET COMBINED; IF MENINGITIS=1;keep potential_donor_id 
note_text note_type;RUN; 
PROC SORT DATA=COMBINED2 NODUPKEY;BY 
POTENTIAL_DONOR_ID;RUN; 






if cod=70 or pda_id in  
(list of donor ids) 
) then meningitis='1'; 
else meningitis='0'; 
run; 
proc freq data=allpdameningitis; 
table meningitis; 
run; 






proc freq data=pdanote; 
table note_date; 
run; 




merge allpdameningitis pdanote; 
by pDa_id; 
if meningitis=1; 






if pda_id in 
(list of donor ids) then encephalitis=1; 
else encephalitis=0; 
run; 
proc sort data=allpdamenin2; 
by death_date; 
run; 






if meningitis=1 or encephalitis=1 then meningoencephalitis=1; 
else meningoencephalitis=0; 
run; 





if meningitis=1 then meningoencephalitis=1; 
if encephalitis=1 then meningoencephalitis=2; 
run; 
proc freq data=allpdameninx;table meningoencephalitis;run; 
 










if meningoencephalitis in (1,2); 
if death_year=2003 then dyear='2003'; 
if death_year=2004 then dyear='2004'; 
if death_year=2005 then dyear='2005'; 
if death_year=2006 then dyear='2006'; 
if death_year=2007 then dyear='2007'; 
if death_year=2008 then dyear='2008'; 
if death_year=2009 then dyear='2009'; 
if death_year=2010 then dyear='2010'; 
if death_year=2011 then dyear='2011'; 
if death_year=2012 then dyear='2012'; 
if death_year=2013 then dyear='2013'; 
if death_year=2014 then dyear='2014'; 




if dyear='2015' then delete; 
run; 









proc freq data=allpdamenin3; 
table meningoencephalitis*death_year; 
run; 
/* reason for refusal*/ 
data allpdamenin4; 
set allpdamenin3; 
if pda_id in  
(list of pda ids 
) then reason=1; 
if pda_id in 
(list of pda ids 
) then reason=2; 
If pda_id in 
(188885 
194555) then reason=3; 
if pda_id in 
(list of pda ids) then reason=4; 
if pda_id in 
(list of pda ids) then reason=5; 
if pda_id in 
(list of pda ids) then reason=6; 
if pda_id in 
(list of pda ids) then reason=7; 
if pda_id in 
(list of pda ids 
) then reason=8; 
if pda_id in  
(list of pda ids) then reason=9; 
if pda_id in 
(list of pda ids) then reason=10; 
if pda_id in 
(list of pda ids 
) then reason=13; 
run; 
 





/*new reasons for TID publication*/ 
data allpdamenin5; 
set allpdamenin4; 
if pda_id in 
(list of pda ids) then encephalitis=1; 
run; 
proc freq data=allpdamenin5;table encephalitis;run; 
data allpdamenin6; 
set allpdamenin5; 
if pda_ID IN 
(list of pda ids 
) then reason=8; 
if pda_id in 
(list of pda ids 
) then reason=11; 
if pda_id in 
(list of pda ids) then reason=13; 
if pda_id in  









if meningitis in (1,3) then meningoencephalitis=1;else 
meningoencephalitis=0; 
run; 
data therest3;set therest2;if meningoencephalitis=1;run; 
data therest4; 
set therest3; 
if reason=8 then newreason='Not Stated'; 
if reason in (11,7) then newreason='Secondary to 
meningitis/encephalitis'; 
if reason =13 then newreason='Family refusal'; 
if reason=2 then newreason='Treatment Not Withdrawn'; 
if reason in (1,4,5,6,9,10,12) then newreason='Other'; 
run; 








proc sort data=therest4; 
by pda_id; 
run; 










keep pda_id note_type note_text reason; 
if reason in (1,4,5,6,9,10,12); 
run; 
proc freq data=othereason2;table reason; 
run; 
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1.48 Appendix  3: ITP code 
data names; 
set database.donor_basics; 
if donor_id in 
(49500, 58575,59122,71187,79663, 90012, 92051, 92211, 92340, 
104535, 105671, 108560, 62345, 71536, 104396, 105599, 107337, 
72766, 83330, 96590, 55688, 108320, 95864, 109545); 
keep donor_id forename surname donation_date hospital_id nhs_no 
birth_date; 
run; 

































keep donor_id note_text; 
if note_date=>mdy(01,01,2000); 
run; 




merge donors donorcomment; 
by donor_id; 
if dcod=. then delete; 





if dtype in (1,2); 
if dcod in (10,11,13,73,90,98,99) then delete; 
run; 










merge donors2 donorcomment; 
by donor_id; 
if dcod=. then delete; 





if donor_id not in 
(49500, 58575,59122,71187,79663, 90012, 92051, 92211, 92340, 
104535, 105671, 108560, 62345, 71536, 104396, 105599, 107337, 




if donor_id  in (49500, 58575,59122,71187,79663, 90012, 92051, 
92211, 92340, 104535, 105671, 108560, 62345, 71536, 104396, 
105599, 107337, 72766, 83330, 96590, 55688, 108320, 95864, 
109545)then ITP=1;else ITP=0; 
run; 
 
proc sort data=blood nodupkey; 
by donor_id;run; 
data blood2;set blood;keep donor_id haemoglobin platelets ITP;run; 
proc univariate data=blood;class ITP;var platelets;run; 
 




if dtype in (1,2); 
if dcountry='UNITED KINGDOM'; 
if donor_id in (49500, 58575,59122,71187,79663, 90012, 92051, 
92211, 92340, 104535, 105671, 108560, 62345, 71536, 104396, 
105599, 107337, 72766, 83330, 96590, 55688, 108320, 95864, 
109545) then ITP=1; 
else ITP=0; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (3,4,5,6,7,8,9,.) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (3,4,5,6,7,8,9,.) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (3,4,5,6,7,8,9,.) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (3,4,5,6,7,8,.) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (3,4,5,6,7,8,9,.) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abuse in (3,4,5,6,7,8,9,.) then drug=3; 
IF PAST_SMOKER=1 THEN SMOKER=1; 
IF PAST_SMOKER=2 THEN SMOKER=2; 
IF PAST_SMOKER IN (3,4,5,6,7,8,9,.) THEN SMOKER=3; 
if sod=1; 
run; 
proc sort data=itptable;by donor_id;run; 
data blood; 
set database.donor_blood_result; 
if donor_id  in (49500, 58575,59122,71187,79663, 90012, 92051, 
92211, 92340, 104535, 105671, 108560, 62345, 71536, 104396, 
105599, 107337, 72766, 83330, 96590, 55688, 108320, 95864, 
109545)then ITP=1;else ITP=0; 
run; 
proc sort data=blood; by donor_id;run; 
data platelets;merge itptable blood; by donor_id;if dtype=. then 
delete;run; 
proc sort data=platelets nodupkey;by donor_id;run; 
proc univariate data=platelets;class itp;var platelets;histogram;run; 
proc npar1way data=platelets;class itp; var platelets;run; 
data why;set itptable;if sod=1;if itp=1;run; 




proc freq data=itptable;table itp;run; 
proc ttest data=itptable;class itp;var dage;run; 
proc univariate data=itptable;class itp;var dage;run; 
proc freq data=itptable;table itp*dsex/fisher;run; 
proc freq data=itptable;table itp*dcod;run; 
data cod; set itptable; if dcod =10 then cause=1;if dcod=11 then 
cause=2; if dcod=19 then cause=3; if dcod=20 then cause=4;run; 
data cod2;set cod; if cause=. then cause=5;run; 
proc freq data=cod2;table itp*cause/fisher;run; 
proc univariate data=itptable;class itp;var dage;run; 
PROC NPAR1WAY DATA=ITPTABLE;CLASS ITP;VAR DCOD;RUN; 
PROC FREQ DATA=ITPTABLE;TABLE ITP*DTYPE/fisher;RUN; 
PROC FREQ DATA=ITPTABLE;TABLE 
ITP*HYPERTENSION/fisher;RUN; 
PROC FREQ DATA=ITPTABLE;TABLE ITP*DIABETES/fisher;RUN; 
PROC FREQ DATA=ITPTABLE;TABLE ITP*CARDIO/fisher;RUN; 
PROC FREQ DATA=ITPTABLE;TABLE ITP*SMOKER/fisher;RUN; 
PROC FREQ DATA=ITPTABLE;TABLE ITP*DRUG/fisher;RUN; 




PROC NPAR1WAY DATA=ITPTABLE;CLASS ITP;VAR 
ORGANS_TXD;RUN; 
PROC NPAR1WAY DATA=ITPTABLE;CLASS ITP;VAR 
ORGANS_DNTD;RUN; 





data fup;set database.rcs_liver_fup_annual;if donor_id in (49500, 
58575,59122,71187,79663, 90012, 92051, 92211, 92340, 104535, 
105671, 108560, 62345, 71536, 104396, 105599, 107337, 72766, 
83330, 96590, 55688, 108320, 95864, 109545); 
run; 
proc sort data=fup;by donor_id;run; 








if dtype in (1,2); 
run; 










if donor_id  in 
(49500, 58575,59122,71187,79663, 90012, 92051, 92211, 92340, 
104535, 105671, 108560, 62345, 71536, 104396, 105599, 107337, 
72766, 83330, 96590, 55688, 108320, 95864, 109545) then 
ITP=1;ELSE ITP=0; 
if recip_id=. then delete; 
run; 
data liveritpX;set liveritp2;if itp=1; 
run; 
data liverdetails;set database.recipient;if recip_id=132368;run; 
proc sort data=liveritpx;by rec_unit;run; 
data organnote; 
set database.recipient_status_history_note; 











if recip_id in (89677,177120,175466); 
run; 
proc sort data=note; 
by recip_id; 
run; 




merge liveritp2 note; 
by recip_id; 
if dcod=. then delete; 

















merge livermissing allliver; 
by recip_id; 




if psurv=. then delete; 
rename tx_date=first_tx_date psurv=patientdays pcens=patientsurvival; 
keep recip_id donor_id tx_date psurv pcens; 
run; 
proc sort data=livermissing2; 
by recip_id; 
run; 




merge liveritp2 livermissing2; 
by recip_id; 








if psurv=. then psurv=psurvfinal; 




if psurv>1826.5 then psurvival=1826.5; 
else psurvival=psurv; 
if gsurv>1826.5 then gsurvival=1826.5; 
else gsurvival=gsurv; 
if pcens=1 and psurv>1826.5 then pcensor=0; 
else pcensor=pcens; 
if gcens=1 and gsurv>1826.5 then gcensor=0; 
else gcensor=gcens; 






if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abusee in (7,8) then drug=3; 
if rhcv=1 then rhepc=1; 
if rhcv=2 then rhepc=2; 
if rhcv in (3,4,5,6,7,8) then rhepc=3; 
if hcv=1 then hepC=1; 
if hcv=2 then hepC=2; 
if hcv in (3,4,5,6,7,8) then hepc=3; 
run; 
proc freq data=litp; 
table ITP; 
run; 
proc univariate data=litp;class itp;var rage;run; 
PROC TTEST DATA=LITP;CLASS ITP;VAR RAGE;RUN; 
PROC FREQ DATA=LITP;TABLE ITP*RSEX/CHISQ;RUN; 
PROC FREQ DATA=liTP; TABLE ITP*pLd/CHISQ;RUN; 
PROC NPAR1WAY DATA=LITP; CLASS ITP; VAR PLD;RUN; 
PROC FREQ DATA=LITP; TABLE ITP*RECIP_ETHNIC/CHISQ;RUN; 
PROC FREQ DATA=LITP;TABLE ITP*URGENT/CHISQ;RUN; 
PROC NPAR1WAY DATA=LITP;CLASS ITP;VAR UKELD;RUN; 
PROC UNIVARIATE DATA=LITP;CLASS ITP;VAR rplatelets;RUN; 
PROC NPAR1WAY DATA=LITP;CLASS ITP;VAR rplatelets;RUN; 
PROC FREQ DATA=LITP;TABLE gcens;where itp=1;RUN; 
data litp2;set litp; if recip_id=177120 then delete;run; 
data litp3;set litp; if rcod=526 then recip_death=1; 
if rcod in (530,531,532,533) then recip_death=2; 
if rcod=511 then recip_death=3; 
if rcod=0 then recip_death=5; 
run; 
 
proc freq data=litp3;table rcod;run; 
data litp4; set litp3; if recip_death=. then recip_death=4;run; 
proc freq data=litp4; table itp*recip_death/fisher;run; 












1. 1 364 
1. 3 51 
2. 1 53.  
2. 3 24. 
3. 1 72.  
3. 3 2 
4. 1 23.  
4. 3 56. 
5. 1 73.  
5. 3 36. 
6. 1 304 
6. 3 153 
7. 1 131  
7. 3 83. 
8. 1 64.  
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8. 3 47. 
9. 1 54.  
9. 3 15. 
10 1 197  
10 3 74. 
11 1 267  
11 3 342 
12 1 41.  
12 3 24. 
13 1 101  
13 3 76. 
14 1 103  
14 3 44. 
; 
run; 
proc  univariate data=Platelets; 









proc transpose data=platelets out=diff name=days prefix=out;by recip; 




































































keep recip_id donor_id dtype dage rage rsex rethnic psurv pcens 
rplatelets rcod cof; 
if itp=1; 
run; 




































if dtype in (1,2); 
run; 
proc sort data=itp; 
by donor_id; 
run; 





if donor_id  in 
(49500, 58575,59122,71187,79663, 90012, 92051, 92211, 92340, 
104535, 105671, 108560, 62345, 71536, 104396, 105599, 107337, 
72766, 83330, 96590, 55688, 108320, 95864, 109545)then ITP=1; 
else ITP=0;run; 
data kidneyitp3;set kidneyitp2;if itp=1;run; 
proc freq data=kidneyitp2; 
table itp*recip_id;where ITP=1; 
run; 
data why; 















merge missing all; 
by recip_id; 
if itp=. then delete; 
run; 





if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 




merge missing missing2; 
by recip_id; 
run; 











if patientdays=>duration then psurvfinal=patientdays-duration; 
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run; 
proc sort data=missing5; 
by recip_id; 
run; 




merge kidneyitp2 missing5; 
by recip_id; 
run; 









if psurv=. then psurv=psurvfinal; 
if pcens=. then pcens=patientsurvival; 
run; 





if psurv=>3650 then psurvival=3650; 
else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650; 
else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0; 
else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0; 
else gcensor=gcens; 
if rage>40 then rage_grp=2; 
else recip_age_grp=1; 
if dage>40 then dage_grp=2; 
else donor_age_grp=1; 
run; 







if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abuse in (7,8) then drug=3; 
if rECIP_ID IN (101160,108100)THEN ITP=2; 
run; 
DATA ANALYSIS4;SET ANALYSIS3; IF itp IN (1,2) THEN 
IDIOPATHIC=1;ELSE IDIOPATHIC=0; 
RUN; 
PROC FREQ DATA=ANALYSIS4; TABLE IDIOPATHIC;RUN; 







/*READS IN YOUR DATASET AND CHANGES THE SURVIVAL 
VARIABLES READY FOR USE*/ 
/*ALSO CHANGES THE DATA TO YEARS OR MONTHS OR DAYS*/ 
data surv; 
set &data; 
if &surv <0 then delete; 
cens = &cens; 
if lowcase("&period") = "months" then surv = &surv / 30.44; 
if lowcase("&period") = "years" then surv = &surv / 365.25; 
if lowcase("&period") = "days" then surv = &surv / 1; 
if surv > &end then do; surv = &end; cens = 0; end; 
fup = 0; 
if surv = &end or cens ne 0 then fup = 1; 
run; 
 
/*GETS THE COUNT FOR EACH STRATA*/ 
proc freq data = surv noprint; table &var / out = num; run; 
 
/*GETS THE COUNT FOR FOLLOW UP*/ 
proc freq data = surv noprint; table &var * fup / out = fup; run; 
 
/*OPENS THE FILE TO SAVE THE PLOT*/ 
filename gsasfile "&file.\&cgm..emf"; 
 
/*RUNS THE LIFETEST PROCEDURE TO OUTPUT THE DATA 
NEEDED FOR THE PLOT*/ 
ODS OUTPUT homtests=homtests; 
proc lifetest data=surv plots=(s) outsurv=surv1; 




/*SORTS OUT THE LAYOUT OF THE PLOT AND CHOOSES 
COLOURS FOR THE LINES*/ 
goptions reset=all reset=symbol htext=1.8 cback=white colours=(black)  
/*ftext=HWCGM005*/ ftext='Arial/bold' 
noborder hsize=8.5 vsize=9.5 Gaccess=GSASFILE;run; 
axis1 minor=none order=&yaxis to 100 by 10 label=(ANGLE=90 "% 
&survival survival"); 
axis2 minor=none order=0 to &end by &end1 label=("&period post-
transplant"); 
symbol; 
symbol1 c=CXFF6600 i=steplj w=4 l=1 v=none; 
symbol2 c=CX99CCFF i=steplj w=4 l=2 v=none; 
symbol3 c=CXFFCC00 i=steplj w=4 l=1 v=none; 
symbol4 c=CX339966 i=steplj w=4 l=1 v=none; 
symbol5 c=black    i=steplj w=4 l=1 v=none; 
symbol6 c=CXFF6600 i=steplj w=4 l=2 v=none; 
symbol7 c=CX99CCFF i=steplj w=4 l=2 v=none; 
symbol8 c=CXFFCC00 i=steplj w=4 l=2 v=none; 
symbol9 c=CX339966 i=steplj w=4 l=2 v=none; 
symbol10 c=black   i=steplj w=4 l=2 v=none; 
 
 LEGEND1 ACROSS=1 
         POSITION=(BOTTOM INSIDE CENTER) 
         MODE=SHARE 
         OFFSET=(0,1.5) 
         SHAPE=SYMBOL(5,1) 
   CBORDER=Black 
         LABEL=(POSITION=(TOP) 
                JUSTIFY=CENTER H=1.2 "&var") 
   VALUE=(H=1.2); 
 
/*PRODUCES THE PLOT*/ 
data splot1; set surv1; retain lag_s; drop=lag_s; if survival=. then 
survival=lag_s; 
lag_s=survival; run; 
data splot2; set splot1; survival=survival*100; 
proc gplot data=splot2; plot survival * surv = &var /legend=legend1 
noframe vaxis=axis1 haxis=axis2;  
title ' '; run; quit; 
 
/*USES THE DATA TO OBTAIN THE SURVIVAL ESTIMATES FOR 
THE STRATA*/ 
data surv2; set surv1; if _censor_ = 0; run; 
proc sort data = surv2; by &var survival; run; 
proc sort data = surv2 nodupkey; by &var; run; 
 
data surv3; set surv2; surv = (survival*100); lcl = (sdf_lcl*100); ucl = 
(sdf_ucl*100); 
format surv lcl ucl 10.1; run; 
 
data surv4; merge surv3 num; by &var; run; 
 
/*OBTAINS THE P-VALUE FOR THE STRATA*/ 
data _null_; 
set homtests; 
where test = 'Log-Rank'; 
call symput ("logrank",trim(left(put(ProbChiSq,PVALUE6.4)))); 
run; 
 
/*PRINTS THE ESTIMATES, COUNT AND P-VALUE FOR THE 
DATA*/ 
title1"&survival survival by &var p=&logrank";                                                                                                                                                                                         
proc print data = surv4; var &var count surv lcl ucl;  run; 
%mend survival; 
 
/*MACRO VARIABLES REQUIRED*/ 
/*%survival(data,surv,cens,time,end,end1,censor,var,survival,period,cg
m);*/ 
/*WHERE data=dataset with survival variables 
  surv=name of survival variable - eg gsurv 
  cens=name of censoring variable - eg 
gcens 
  period=years, months, days 
  end=put 10 if wanting 10 year survival, 12 
for 12 month survival, 30 for 30 day survival 
  end1=how big you want your x-label gap eg 
1 if you want 10 years by 1 year 
  var=variable you want to strata by - eg 
centre 
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  survival=either graft, patient or transplant 
  yaxis=point at which you want the yaxis to 
start, 40 is standard 








/*DATA TABLES KIDNEY RECIPIENTS*/ 
proc univariate data=analysis4;class idiopathic;var rage;run; 
PROC TTEST DATA=ANALYSIS4;CLASS IDIOPATHIC;VAR 
RAGE;RUN; 
PROC FREQ DATA=ANALYSIS4;TABLE 
IDIOPATHIC*RSEX/CHISQ;RUN; 
PROC FREQ DATA=ANALYSIS4; TABLE 
IDIOPATHIC*HLA_GRP/CHISQ;RUN; 
PROC FREQ DATA=ANALYSIS4; TABLE 
IDIOPATHIC*prd/CHISQ;RUN; 
PROC NPAR1WAY; CLASS IDIOPATHIC; VAR PRD;RUN; 
PROC FREQ DATA=ANALYSIS4; TABLE 
IDIOPATHIC*RECIP_ETHNIC/CHISQ;RUN; 






keep donor_id recip_id pcens rec_unit psurv gcens gsurv rcod cof dage 
rage tx_date ddate dtype; 
run; 
 
proc freq data=analysis3; 
table rec_unit*recip_id; 
run; 










proc sort data=leeds; 
by recip_id; 
run; 




merge leeds recip_names; 
by recip_id; 














proc sort data=note; 
by recip_id; 
run; 




merge analysis3 note; 
by recip_id; 
if dcod=. then delete; 





proc sort data=grafted; 
by donor_id; 
run; 




merge grafted analysis3; 
by donor_id; 
if dcod=. then delete; 







if dtype in (1,2); 
run; 
proc sort data=itp; 
by donor_id; 
run; 




merge heartitp itp; 
by donor_id; 
if sod=. then delete; 
if donor_id  in 
(49500, 58575,59122,71187,79663, 90012, 92051, 92211, 92340, 
104535, 105671, 108560, 62345, 71536, 104396, 105599, 107337, 
72766, 83330, 96590, 55688, 108320, 95864, 109545) then ITP=1; 
if recip_id=. then delete; 
run; 
proc univariate data=heartitp2;var rage;run; 
pROC FREQ DATA=HEARTITP2;TABLE RSEX;RUN; 
pROC FREQ DATA=U;TABLE RSEX;RUN; 
pROC FREQ DATA=HEARTITP2;TABLE RECIP_ID*PCD;RUN; 





proc sort data=heartitp2; 
by recip_id; 
run; 




merge heartitp2 note; 
by recip_id; 
if dcod=. then delete; 
if recip_id =132754; 
run; 
 
proc freq data=heartinfo; 
table rcod; 
run; 



















proc sort data=note; 
by recip_id; 
run; 




merge heartitp2 note; 
by recip_id; 
if dcod=. then delete; 






proc sort data=itp; 
by donor_id; 
run; 




merge itp plt; 
by donor_id; 
if sod=. then delete; 
run; 









if dtype in (1,2); 
if dcountry='UNITED KINGDOM'; 
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merge mgdonors2 kindeymg; 
by donor_id; 
if MG=1; 
if recip_id=. then delete; 
run; 



















proc sort data=livermg; 
by donor_id; 
run; 





merge mgdonors2 livermg; 
by donor_id; 
if MG=1; 
if recip_ID=. THEN DELETE; 
run; 













































































































































































































































































proc univariate data=cambridgeplatelets; 
var day3; 
run; 
data new;set cambridgeplatelets; 
new=day0-day3;run; 
data new2;set new; 
if new=>1 then new2=new; 
if day0=>1 then itpseries=0; 
run; 













53  24. 
372 2 
23  56. 












data plat;set platelets; 
if day0=>1 then ITPseries=1; 
run; 
data new2;set new2;run; 
proc sort data=new2;by itpseries; 
run; 
data together; 
merge plat new2; 
by itpseries; 
run; 





1.49 Appendix 4: Increased risk behaviour code 
data risk; 
set standard.donors; 
if dtype in (1,2); 






if donor_id in 











) then HRSB=1; 














) then HRSB=2; 
if donor_id in 
(117857,110250,100375,60864,65391,68140,68929,80495,92918,933
82,94416,95615,100064,100375, 
100500,106178) then HrsB=3; 
if donor_id in 
(108989,106611,103899,87004,95478,100566,101759, 
103899) then HrsB=4; 
if donor_id in 
(117391,112783,109881,109142,106279,104587,100319,72941,80501
,83817,98976,100319,104587, 
106279,106839) then HrsB=5; 
run; 





data sexualbehaviour2;set sexualbehaviour;if hrsb=>1;run; 
proc sort data=sexualbehaviour2; by ddate;run; 
proc freq data=sexualbehaviour;table hrsb;run; 
data IVDU; 
set sexualbehaviour; 

































































proc freq data=IVDU;table IVDU;run; 
data prison; 
set IVDU; 


















































) then prison=2; 
donation_year=year(ddate); 
run; 
data barchartforpaper1;set prison;if IVDU or prison or HRSB =>1 then 
high_risk=1; 
else high_risk=0; 
if donation_year=2000 then dyear='2000'; 
if donation_year=2001 then dyear='2001'; 
if donation_year=2002 then dyear='2002'; 
if donation_year=2003 then dyear='2003'; 
if donation_year=2004 then dyear='2004'; 
 249 
if donation_year=2005 then dyear='2005'; 
if donation_year=2006 then dyear='2006'; 
if donation_year=2007 then dyear='2007'; 
if donation_year=2008 then dyear='2008'; 
if donation_year=2009 then dyear='2009'; 
if donation_year=2010 then dyear='2010'; 
if donation_year=2011 then dyear='2011'; 
if donation_year=2012 then dyear='2012'; 
if donation_year=2013 then dyear='2013'; 
if donation_year=2014 then dyear='2014'; 
if donation_year=2015 then dyear='2015'; 
if dethnic=1 then ethnic=1; 
else ethnic=2; 
if past_diabetes=1 then diabetes=1;if past_diabetes=2 then 
diabetes=2;if past_diabetes in (3,4,5,6,7,8,9,.) then diabetes=3; 
if past_hypertension=1 then hypertension=1;if past_hypertension=2 
then hypertension=2;if past_hypertension in (3,4,5,6,7,8,9,.) then 
hypertension=3; 
if past_cardio_disease=1 then cardio=1;if past_cardio_disease=2 then 
cardio=2;if past_cardio_disease in (3,4,5,6,7,8,9,.) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1;if past_alcohol_abuse=2 then 
alcohol=2;if past_alcohol_abuse in (3,4,5,6,7,8,9,.) then alcohol=3; 
if past_liver_disease=1 then liver=1;if past_liver_disease=2 then 
liver=2;if past_liver_disease in (3,4,5,6,7,8,9,.) then liver=3; 
if past_drug_abuse=1 then drug=1;if past_drug_abuse=2 then 
drug=2;if past_drug_abusee in (3,4,5,6,7,8,9,.) then drug=3; 
if hcv=1 then hepC=1;if hcv=2 then hepC=2;if hcv in (3,4,5,6,7,8,.) then 
hepc=3; 
if past_smoker=1 then smoker=1;if past_smoker=2 then smoker=2;if 












/*data PHE data collection*/ 
data phe; 
set barchartforpaper1; 








proc sort data=names; 
by donor_id; 
run; 















keep donor_id surname forename sod dregion hospname IVDU prison 
HRSB HCV HIB HBV ddate; 
run; 





/*for Q-Pulse */ 
data Q;set barchartforpaper1;if high_risk=1;if 









proc sort data=unused;by donor_id;run; 
proc sort data=unusednote;by donor_id;run; 
data unused2;merge unused unusednote;by donor_id;run; 
data notdonated;set viralnone; if sod=0;if high_risk=1;run; 
proc sort data=notdonated;by donor_id;run; 
proc sort data=unused2; by donor_id;run; 
data sod; merge notdonated unused2;by donor_id; if high_risk=1;keep 
ddate donor_id primary_reason secondary_reason high_risk donor_id 
organ_type HBCAB note_type note_text;run; 




proc sort data=sod2 nodupkey; by donor_id;run; 
proc freq data=sod2;table organ_type*primary_reason;run; 
 
/*number high_risk*/ 
proc freq data=barchartforpaper1;table high_risk;run; 






data barchartforpaper2;set barchartforpaper1; if high_risk=1 or 
hCV=2;run; 






keep donor_id HCV ddate trust_name new_dtc_team ddob high_risk; 
run; 












merge ines basics; 
by donor_id; 
if high_risk=. then delete; 
















/*table for Ines*/ 
data barchartforpaperX;set barchartforpaper2;keep donor_id ddate 
IVDU prison HRSB sod trust_name HCV ethnic;run; 
 
data barchartpaper3;set barchartforpaper2;if sod=1;run; 
data barchartIVDU;set barchartforpaper1;if IVDU=>1;run; 
data barchartPrison;set barchartforpaper1;if prison=>1;run; 
proc freq data=prison; table prison*IVDU*HRSB;run; 
 
 
/*data Tables-How many of each type of high risk donor-how many 
multiple?*/ 
proc freq data=barchartforpaper2; table high_risk*sod;run; 
proc freq data=barchartforpaper2; table IVDU*sod;run; 
proc freq data=barchartforpaper2; table prison*sod;run; 
proc freq data=barchartforpaper2; table HRSB*sod;run; 
proc freq data=barchartforpaper2; table HRSB*IVDU;where 
sod=1;run; 
proc freq data=barchartforpaper2; table HRSB*prison;where 
sod=1;run; 
proc freq data=barchartforpaper2; table IVDU*prison;where 
sod=1;run; 
proc freq data=barchartforpaper2; table HRSB*IVDU;where 
sod=0;run; 
proc freq data=barchartforpaper2; table HRSB*prison;where 
sod=0;run; 




/*number of viral positive in each group*/ 
data virus;set barchartforpaper1;if HCV=2 or HIV=2 or HBSAG=2 or 
HTLV=2;run; 
data viralcombination; set virus;if hcv=2 and htlv=2;run; 
proc freq data=virus;table sod*risk/chisq;run; 
 
data alldata;set final2;if HCV=2 or HIV=2 or HBSAG=2 or HTLV=2 then 
viral=1;else viral=0;IF SOD=1;run; 
proc freq data=ALLDATA;table virAl*UTILISED/CHISQ;run; 
 
/*Ines to request samples*/ 
data hospitals;set final2;if high_risk=1;keep donor_id hospname 
dregion ddate risk HCV;run; 
proc sort data=hospitals;by dregion;run; 
proc freq data=hospitals;table DREGION;run; 
 
 
proc sort data=hospitals nodupkey;by dregion;run; 
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input behaviour 1 type 3 percent 5-7; 
datalines; 
1 1 133  
1 2 97. 
2 1 311 
2 2 188 
3 1 215 
3 2 169 
run; 
proc freq data=compare; 
weight percent; 
table behaviour*type/chisq;run; 
data viralonly;set final2;if HCV=2 or HIV=2 or HBSAG=2 or 
HTLV=2;run; 
proc univariate data=viralonly;class high_risk;var organs_ofd;run; 
data compare2; 
input organ highrisk number; 
datalines; 
1 1 32 
1 2 11 
2 1 29 
2 2 44 
run; 







if hTLV=2 then HTV=2; 
if HTLV=1 then HTV=1; 
if hTLV in (3,4,5,6,7,8,9,.) then HTLV=3; 
run; 
 





proc freq data=viralonly1;table sod*risk/chisq;run; 
DATA FINAL3;SET FINAL2;IF DDATE=>MDY(01,01,2013);RUN; 




data viralnone;set final2;if HCV=2 or HIV=2 or HBSAG=2 or HTLV=2 
then delete;if donor_id=. then count=0;else count=1; 
if IVDU=. then IVDU=0;run; 
proc freq data=viralnone;table high_risk*sod;run; 
 
/*new data table-all potential with no viral positivity*/ 
proc univariate data=viralnone;class high_risk;var 
dage;histogram/normal;run; 
proc npar1way data=viralnone;class high_risk;var dage; 
run; 
proc freq data=viralnone;table dsex*high_risk/chisq;run; 
proc freq data=viralnone;table diabetes*high_risk/chisq;run; 
proc freq data=viralnone;table smoker*high_risk/chisq;run; 
 
















proc freq data=viralnone2; 
table dtype*high_risk/chisq; 
run; 
proc freq data=viralnone2; 
table ethnic*high_risk/chisq; 
run; 
proc freq data=viralnone2; 
table alcohol*high_risk/chisq; 
run; 
proc freq data=viralnone2; 
table smoker*high_risk/chisq; 
run; 
proc freq data=viralnone2; 
table cardio*high_risk/chisq; 
run; 
































/*bonferonni adjustment without viral disease present*/ 
 
ods output chisq(persist)=chisq(where=(statistic="Chi-squared") 
                                rename=(Prob=Raw_P)); 
proc freq data=viralnone; 
where risk in (0,1); 
weight count; 
table sod*risk/chisq cellchi2 nopercent; 
run; 
proc freq data=viralnone; 
where risk in (0,2); 
weight count; 
table sod*risk/chisq cellchi2 nopercent; 
run; 
proc freq data=viralnone; 
where risk in (0,3); 
weight count; 
table sod*risk/chisq cellchi2 nopercent; 
run; 
proc freq data=viralnone; 
where risk in (0,4); 
weight count; 
table sod*risk/chisq cellchi2 nopercent; 
run; 
proc freq data=viralnone; 
where IVDU in (1,0); 
weight count; 
table sod*IVDU/chisq cellchi2 nopercent; 
proc freq data=viralnone; 
where IVDU in (2,0); 
weight count; 
table sod*IVDU/chisq cellchi2 nopercent; 
proc freq data=viralnone; 
where IVDU in (2,1); 
weight count; 
table sod*IVDU/chisq cellchi2 nopercent; 
ods output clear; 
 
proc print data=chisq noobs; 
var value raw_p; 
run; 
proc multtest pdata=chisq bon; 
run; 





/*with extra IVDU variable*/ 
data viralIVDU;set viralnone;if IVDU=. then IVDU=0;run; 
proc freq data=viralivdu; 
table sod*IVDU/chisq;where IVDU in (2,0);run; 
data viralnone2; 
set viralnone; 
if ivdu=1 then risk=4; 
if ivdu=2 then risk=2; 
run; 
proc freq data=viralnone2; 
table HRSB*sod; 




proc logistic data=viralnone2; 
class risk(ref='0') hypertension(ref='1')/param=ref;           
model sod=risk dage hypertension; 
run; 









contrast 'Risk1 V Risk0' 1 -1 0; 
contrast 'Risk2 V Risk0' ; 
contrast 'Risk3 V Risk0'; 





/*Data tables-High-risk solid organ donors vs. All other deceased 
donors*/ 
data donortests;set barchartforpaper1;run; 
proc freq data=donortests;table high_risk;run;proc freq 
data=donortests;table smoker*high_risk/chisq;run; 
proc univariate data=donortests;class high_risk;var 
dage;histogram;run; 
proc ttest data=donortests;class high_risk;var dage;run; 
proc freq data=donortests;table dsex*high_risk/chisq;run; 
proc freq data=donortests;table ethnic*high_risk/chisq;run; 
proc freq data=donortests;table HepC*high_risk/chisq;run; 
proc freq data=donortests;table HIV*high_risk/chisq;where HIV in 
(1,2,3);run; 
proc freq data=donortests;table alcohol*high_risk/chisq;run; 
proc freq data=donortests;table diabetes*high_risk/chisq;run; 
proc freq data=donortests;table smoker*high_risk/chisq;run; 
proc freq data=donortests;table cardio*high_risk/chisq;run; 
proc npar1way data=donortests;class high_risk;var dbmi;run; 
proc univariate data=donortests;class high_risk; var dbmi; 
histogram;run; 
proc freq data=donortests;table HBSAG*high_risk/chisq;where 
HBSAG in (1,2,3);run; 
 
/*Individual risk factors vs. all other deaceased donors*/ 
data donortestsone;set donortests;if IVDU=1 then HRSB=6;if IVDU=2 
then HRSB=7; if prison=1 then HRSB=8; if prison=2 then HRSB=9; 
run; 
data final;set donortestsone; if HRSB in (1,2,3,4,5) then SB=1;else 
SB=0;If IVDU in (1,2) then IV=1; else IV=0; 
if prison in (1,2) then Jail=1;else jail=0;run; 
proc freq data=final;table IV;run; 
data finals;set final; if SB=1 then Risk=1;;if Jail=1 then risk=3;if IV=1 
then risk=2;run; 
data final2;set finals;if risk=. then risk=0;run;proc freq 
data=final2;table risk;run; 
data IV;set final2;if IV=1;run; 
data donortesttwo;set donortestsone;if HRSB=>1;run; 
proc anova data=donortestsone; class HRSB; model dage=HRSB; 
means HRSB;run; 
proc freq data=final2;table risk;run; 
 
data barchartforpapervirus;set barchartforpaper1;if high_risk=1 and 
HCV=2 or HIV=2 or HBV=2 then delete;run; 
proc freq data=barchartforpapervirus;table sod*ivdu/chisq;run; 
 
/*Donor Data Table-4 sub groups*/ 
proc univariate data=final2;class risk;var dbmi;run; 
proc anova data=final2; class risk; model dage=risk; means risk;run; 
proc anova data=final2; class risk; model dage=risk; means risk/ 
tukey;run; 
proc freq data=final2;table dsex*risk/chisq;run; 
proc freq data=final2;table dtype*risk/chisq;run; 
proc freq data=final2; table ethnic*risk/chisq;run; 
proc npar1way data=final2;class risk;var dbmi;run; 
proc univariate data=final2;class risk;var dbmi;run; 
proc freq data=final2; table HepC*risk/chisq; where HepC in (1,2);run; 
proc freq data=final2; table HBSAG*risk/chisq; where HBSAG in 
(1,2,3);run; 
proc freq data=final2; table HIV*risk/chisq;where HIV in (1,2,3);run; 
proc freq data=final2;table alcohol*risk/chisq;run; 
proc freq data=final2;table liver*risk/chisq;run; 
proc freq data=final2;table smoker*risk/chisq;run; 
proc freq data=final2;table risk;run; 
 
/*offers table/figure for the paper*/ 
data offers;set standard.current_offers;run; 
proc sort data=offers;by donor_id;run; 
proc sort data=barchartforpaper1;by donor_id;run; 
 
data alloffers;merge offers barchartforpaper1;by donor_id;if high_risk=. 
then delete;run; 
data alloffers2;set alloffers;if result=5 then outcome=1;if result=2 then 
outcome=2; 
if off_cent in ('G1501' 'G0101' 'G0501' 'G1403') then off_cent='G1111'; 
if off_cent in ('E1301' 'T0701') then off_cent='T2222'; 
if off_cent in ('F0708' 'F0835') then off_cent='F2222'; 
if off_cent in ('H1305' 'H1202') then off_cent='H3333'; 
if off_cent in ('D0921' 'E0425') then delete; 
run; 
data alloffers3;set alloffers2; 







if org_type in 
(10,11,12,13,29,30,31,32,33,34,40,41,42,45,46,47,50,51,52,53,60,61,6
2,63, 
64,65,66,67,68 ,69 ,70,81,82,83,84,85,99,100,101,102,105,109,110); 
if outcome=. then outcome=3; 
run; 
proc freq data=alloffers3;table high_risk*reason1/chisq;run; 
proc univariate data=alloffers3;class high_risk; 
proc sort data=alloffers3 nodupkey;by donor_id;run; /*number of 
donors in this analysis-16,112*/ 







data allofersnohighrisk;set alloffers3;if high_risk=0;run; 
data highriskonly;set alloffers3;if high_risk=1;run; 
proc freq data=highriskonly;table reason1;run; 
proc freq data=allofersnohighrisk;table outcome;run; 
 
proc freq data=alloffers3;table off_cent*outcome;run; 
 
/*logistic regression HepC*/ 
data model;set final2;if hepc=1 then yes=1;else yes=0;run; 
proc logistic data=model descending; 
class risk(ref='0')  /param=ref; 
model yes= dage; 
run; 
proc logistic data=model descending; 
class risk(ref='0')  /param=ref; 
model yes= dage risk; 
run; 
proc logistic data=model descending; 
class risk(ref='0')  /param=ref; 
model yes=  risk ; 
run; 
 
/* Renal Recipients High-risk Behaviour Donors*/  
/*Code taken from Meningitis Paper*/ 
proc sort data=viralnone2;by donor_id;run; 
data kidney;set standard.kidney_tx;if 
mdy(01,01,2003)<=tx_date<mdy(01,01,2016); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);if Tx_type in 
(10,11,12,13,14);run; 
proc sort data=kidney;by donor_id;run; 




/*Find missing patient survival data*/ 
proc freq data=kidneyrisk;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=kidneyrisk;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data kidneyrisk2;set kidneyrisk; if psurv=.;run; 
proc sort data=kidneyrisk2;by recip_id;run; 
data all;set standard.kidney_tx;run; 
proc sort data=all;by recip_id;run; 
data Allmissing;merge kidneyrisk2 all; 
by recip_id;if high_risk=. then delete;run; 
data Missing2;set allmissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=missing2;by recip_id;run; 
data missing3;merge kidneyrisk2 missing2;by recip_id;run; 
data missing4;set missing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data missing5;set missing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=missing5;by recip_id;run; 
proc sort data=kidneyrisk;by recip_id;run; 
data Kidneyall;merge kidneyrisk missing5;by recip_id;run; 
proc freq data=kidneyall;table high_risk;run; 
data Analysis;set kidneyall;if psurv=. then psurv=psurvfinal;if pcens=. 
then pcens=patientsurvival; 
run; 
proc freq data=analysis;table pcens;run;/*190 bits of data missing 
<10% total*/ 
 
/*Censor to 10 years graft and patient survival*/ 
 
data analysis2;set analysis; 
if psurv=>3650 then psurvival=3650;else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650;else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0;else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0;else gcensor=gcens; 
if rage>40 then rage_grp=2;else recip_age_grp=1; 
if dage>40 then dage_grp=2;else donor_age_grp=1; 





label date1="DATE with DATE9. format"; 























proc freq data=analysis2;table HIV;run; 












proc sort data=recipientinfo; 
by recip_id; 
run; 




merge analysis2 recipientinfo; 
by recip_id; 
if donor_id=. then delete; 
run; 
data KidneyFinal;set analysis3; 
if rethnic=1 then recip_ethnic=1;else recip_ethnic=2; 
if graft_no=1 then Tx=1;if graft_no=2 then Tx=2;if graft_no>2 then 
Tx=3; 
if crf_tx>85 then sensitised=1;else sensitised=0; 
if txcountry='UNITED KINGDOM';if pcensor=. then delete;if gcensor=. 
then delete; 
if rhcv=1 then rhepc=1;if rhcv=2 then rhepc=2;if rhcv in (3,4,5,6,7,8,9,.) 
then rhepc=3; 
if prd in (210,211,212,213,214,215,216,217,219) then renal=1; 
if prd in (220,221,222,223,224,225,229) then renal=2; 
if prd in (241,242) then renal=3; 
if prd in (280,281) then renal=4; 
run; 
 








/*READS IN YOUR DATASET AND CHANGES THE SURVIVAL 
VARIABLES READY FOR USE*/ 
/*ALSO CHANGES THE DATA TO YEARS OR MONTHS OR DAYS*/ 
data surv; 
set &data; 
if &surv <0 then delete; 
cens = &cens; 
/*survival analysis-Initially all High risk behaviour together*/ 
/*Survival macro used*/ 
if lowcase("&period") = "months" then surv = &surv / 30.44; 
if lowcase("&period") = "years" then surv = &surv / 365.25; 
if lowcase("&period") = "days" then surv = &surv / 1; 
if surv > &end then do; surv = &end; cens = 0; end; 
fup = 0; 
if surv = &end or cens ne 0 then fup = 1; 
run; 
 
/*GETS THE COUNT FOR EACH STRATA*/ 
proc freq data = surv noprint; table &var / out = num; run; 
 
/*GETS THE COUNT FOR FOLLOW UP*/ 
proc freq data = surv noprint; table &var * fup / out = fup; run; 
 
/*OPENS THE FILE TO SAVE THE PLOT*/ 
filename gsasfile "&file.\&cgm..emf"; 
 
/*RUNS THE LIFETEST PROCEDURE TO OUTPUT THE DATA 
NEEDED FOR THE PLOT*/ 
ODS OUTPUT homtests=homtests; 
proc lifetest data=surv plots=(s) outsurv=surv1; 




/*SORTS OUT THE LAYOUT OF THE PLOT AND CHOOSES 
COLOURS FOR THE LINES*/ 
goptions reset=all reset=symbol htext=1.8 cback=white colours=(black)  
/*ftext=HWCGM005*/ ftext='Arial/bold' 
noborder hsize=8.5 vsize=9.5 Gaccess=GSASFILE;run; 
axis1 minor=none order=&yaxis to 100 by 10 label=(ANGLE=90 "% 
&survival survival"); 
axis2 minor=none order=0 to &end by &end1 label=("&period post-
transplant"); 
symbol; 
symbol1 c=CXFF6600 i=steplj w=4 l=1 v=none; 
symbol2 c=CX99CCFF i=steplj w=4 l=1 v=none; 
symbol3 c=CXFFCC00 i=steplj w=4 l=1 v=none; 
symbol4 c=CX339966 i=steplj w=4 l=1 v=none; 
symbol5 c=black    i=steplj w=4 l=1 v=none; 
symbol6 c=CXFF6600 i=steplj w=4 l=2 v=none; 
symbol7 c=CX99CCFF i=steplj w=4 l=2 v=none; 
symbol8 c=CXFFCC00 i=steplj w=4 l=2 v=none; 
symbol9 c=CX339966 i=steplj w=4 l=2 v=none; 
symbol10 c=black   i=steplj w=4 l=2 v=none; 
 
 LEGEND1 ACROSS=1 
         POSITION=(BOTTOM INSIDE CENTER) 
         MODE=SHARE 
         OFFSET=(0,1.5) 
         SHAPE=SYMBOL(5,1) 
   CBORDER=Black 
         LABEL=(POSITION=(TOP) 
                JUSTIFY=CENTER H=1.2 "&var") 
   VALUE=(H=1.2); 
 
/*PRODUCES THE PLOT*/ 
data splot1; set surv1; retain lag_s; drop=lag_s; if survival=. then 
survival=lag_s; 
lag_s=survival; run; 
data splot2; set splot1; survival=survival*100; 
proc gplot data=splot2; plot survival * surv = &var /legend=legend1 
noframe vaxis=axis1 haxis=axis2;  
title ' '; run; quit; 
 
/*USES THE DATA TO OBTAIN THE SURVIVAL ESTIMATES FOR 
THE STRATA*/ 
data surv2; set surv1; if _censor_ = 0; run; 
proc sort data = surv2; by &var survival; run; 
proc sort data = surv2 nodupkey; by &var; run; 
 
data surv3; set surv2; surv = (survival*100); lcl = (sdf_lcl*100); ucl = 
(sdf_ucl*100); 
format surv lcl ucl 10.1; run; 
 
data surv4; merge surv3 num; by &var; run; 
 
/*OBTAINS THE P-VALUE FOR THE STRATA*/ 
data _null_; 
set homtests; 
where test = 'Log-Rank'; 
call symput ("logrank",trim(left(put(ProbChiSq,PVALUE6.4)))); 
run; 
 
/*PRINTS THE ESTIMATES, COUNT AND P-VALUE FOR THE 
DATA*/ 
title1"&survival survival by &var p=&logrank";                                                                                                                                                                                         
proc print data = surv4; var &var count surv lcl ucl;  run; 
%mend survival; 
 
/*MACRO VARIABLES REQUIRED*/ 
/*%survival(data,surv,cens,time,end,end1,censor,var,survival,period,cg
m);*/ 
/*WHERE data=dataset with survival variables 
  surv=name of survival variable - eg gsurv 
  cens=name of censoring variable - eg 
gcens 
  period=years, months, days 
  end=put 10 if wanting 10 year survival, 12 
for 12 month survival, 30 for 30 day survival 
  end1=how big you want your x-label gap eg 
1 if you want 10 years by 1 year 
  var=variable you want to strata by - eg 
centre 
  survival=either graft, patient or transplant 
  yaxis=point at which you want the yaxis to 
start, 40 is standard 







data analysis3;set analysis2; 
if risk in (0,4); 
run; 
 
proc lifetest data=analysis2 notable plots=(S,LLS); time 
psurvival*pcensor(0);strata risk;where risk in (0,4);run; 
 
/*Cox regression model*/ 
data model;set prd; 
if hypertension in (3,.) then hypertension=3;if diabetes in (3,.)then 
diabetes=3; 
if smoker in (3,.)then smoker=3;if alcohol in (3,.) then alcohol=3; if 
rhepc in (3,.)then rhepc=3; 
if hepc in (3,.) then hepc=3;if ethnic in (2,.) then ethnic=2; 
if risk in (0,.)then risk=0; 
if cardio in (3,.)then cardio=3; 
if prison=. then prison=0; 
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if hrsb=. then hrsb=0; 
if hrsb=1 then higher=1;if hrsb=2 then higher=2;if hrsb=3 then 
higher=3;if hrsb=4 then higher=4; if hrsb=5 then higher=5; 
run; 
 
data mod;set model;if hypertension in (3,.) then hypertension=3;if 
higher=. then higher=0;run; 
proc freq data=mod;table sexy*ivdu;run; 
proc phreg data=mod; 
class renal(ref='5')hypertension(ref='1') HLA_grp (ref='4') rsex(ref='2') 
dtype (ref='1') higher(ref='0'); 
model psurv*pcens(0)=dage rage renal hypertension risk cld_isch 




proc freq data=mod;table higher*rcod;run; 
 
























































proc sort data=recipcomment; 
by recip_id; 
run; 
proc sort data=mod2;by recip_id;run; 
data reciphigher; 
merge mod2 recipcomment; 
by recip_id; 













/*Kidney HCV Ines Table*/ 
data kidneyhcv;set kidneyfinal;if HCV=2;keep ddate tx_date rec_unit 
recip_id donor_id HCV RHCV HRSB IVDU Prison ethnic pld 
RHCV_RNA;run; 
proc sort data=kidneyHCV;by ddate;run; 
 
/*Clinical Characteristics of Kidney Recipients from High Risk Donors*/ 
proc freq data=KidneyFinal;table high_risk;run; 




proc npar1way data=kidneyfinal;class high_risk;var rage;run; 
 
 
proc anova data=kidneyfinal; class risk;model rage=risk;means 
risk;run; 
proc freq data=KidneyFinal;table rsex*high_risk/chisq;where rsex in 
(1,2);run; 
proc freq data=KidneyFinal;table recip_ethnic*high_risk/chisq;where 
rsex in (1,2);run; 
proc freq data=KidneyFinal;table sensitised*high_risk/chisq;run; 
 
proc univariate data=kidneyfinal;class risk;var 
wait_time;histogram;run; 
proc freq data=kidneyfinal;table rhepc*risk/chisq;run; 
proc freq data=KidneyFinal;table rhepc*risk/chisq;run; 
proc freq data=KidneyFinal;table HLA_grp*high_risk/chisq;run; 
proc anova data=kidneyfinal;class high_risk; model 
rage=high_risk;means high_risk;run; 
data barchartkidney; set kidneyfinal; txyear=year(tx_date);run; 
data kidneychart; set barchartkidney; if txyear=2000 then year='2000'; 
if txyear=2001 then tyear='2001'; 
if txyear=2002 then tyear='2002'; 
if txyear=2003 then tyear='2003'; 
if txyear=2004 then tyear='2004'; 
if txyear=2005 then tyear='2005'; 
if txyear=2006 then tyear='2006'; 
if txyear=2007 then tyear='2007'; 
if txyear=2008 then tyear='2008'; 
if txyear=2009 then tyear='2009'; 
if txyear=2010 then tyear='2010'; 
if txyear=2011 then tyear='2011'; 
if txyear=2012 then tyear='2012'; 
if txyear=2013 then tyear='2013'; 
if txyear=2014 then tyear='2014'; 




data prd;set kidneyfinal; if renal=. then renal=5;run; 
proc freq data=prd; table renal*high_risk/chisq;run; 
data kidneyealrier;set kidneyfinal;if hcv=2 or HIV=2 or HBSAG=2 or 
HTLV=2;if high_risk=0;run; 
proc freq data=kidneyealrier;table HTLV;run; 
 
/* Liver Recipients*/  
proc sort data=viralnone2;by donor_id;run; 
data liver;set standard.liver_tx;if 
mdy(01,01,2003)<=tx_date<mdy(01,01,2016); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);run; 
proc sort data=liver;by donor_id;run; 





/*Find missing patient survival data*/ 
proc freq data=liverrisk;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=liverrisk;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data liverrisk2;set liverrisk; if psurv=.;run; 
proc sort data=liverrisk2;by recip_id;run; 
data total;set standard.liver_tx;run; 
proc sort data=total;by recip_id;run; 
data totalmissing;merge liverrisk2 total; 
by recip_id;if high_risk=. then delete;run; 
data LiverMissing2;set totalmissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=Livermissing2;by recip_id;run; 
data Livermissing3;merge liverrisk2 livermissing2;by recip_id;run; 
data Livermissing4;set livermissing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data Livermissing5;set livermissing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=livermissing5;by recip_id;run; 
proc sort data=liverrisk;by recip_id;run; 
data liverall;merge liverrisk livermissing5;by recip_id;run; 
proc freq data=liverall;table high_risk;run; 
data liverAnalysis;set liverall;if psurv=. then psurv=psurvfinal;if pcens=. 
then pcens=patientsurvival; 
run; 
proc freq data=liveranalysis;table high_risk;run; 
 
/*5 year censor for Liver analysis*//*104 patients deleted due to no 
survival information=1%of data*/ 
 
data liveranalysis2;set liveranalysis; 
if psurv=>3650 then psurvival=3650;else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650;else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0;else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0;else gcensor=gcens; 
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if rage>40 then rage_grp=2;else recip_age_grp=1; 
if dage>40 then dage_grp=2;else donor_age_grp=1; 
if pcensor=. then delete; 
run; 




/*Data Tables Liver*/ 
data LiverFinal;set Liveranalysis2; 
if rethnic=1 then recip_ethnic=1;else recip_ethnic=2; 
if graft_no=1 then Tx=1;if graft_no=2 then Tx=2;if graft_no>2 then 
Tx=3; 
if crf_tx>85 then sensitised=1;else sensitised=0; 
if txcountry='UNITED KINGDOM';if pcensor=. then delete;if gcensor=. 
then delete; 
if dcountry='UNITED KINGDOM'; 




/*data liver Ines HCV*/ 
data liverhcv;set liverfinal;if HCV=2;keep recip_id donor_id HCV RHCV 
HRSB IVDU Prison ethnic pld RHCV_RNA;run; 
 
 
data barchartliver; set liverfinal; txyear=year(tx_date);run; 
data liverchart; set barchartliver; if txyear=2000 then year='2000'; 
if txyear=2001 then tyear='2001'; 
if txyear=2002 then tyear='2002'; 
if txyear=2003 then tyear='2003'; 
if txyear=2004 then tyear='2004'; 
if txyear=2005 then tyear='2005'; 
if txyear=2006 then tyear='2006'; 
if txyear=2007 then tyear='2007'; 
if txyear=2008 then tyear='2008'; 
if txyear=2009 then tyear='2009'; 
if txyear=2010 then tyear='2010'; 
if txyear=2011 then tyear='2011'; 
if txyear=2012 then tyear='2012'; 
if txyear=2013 then tyear='2013'; 
if txyear=2014 then tyear='2014'; 
if txyear=2015 then tyear='2015'; 
if high_risk=1; 
run; 
data liverchart2; set barchartliver; if txyear=2000 then year='2000'; 
if txyear=2001 then tyear='2001'; 
if txyear=2002 then tyear='2002'; 
if txyear=2003 then tyear='2003'; 
if txyear=2004 then tyear='2004'; 
if txyear=2005 then tyear='2005'; 
if txyear=2006 then tyear='2006'; 
if txyear=2007 then tyear='2007'; 
if txyear=2008 then tyear='2008'; 
if txyear=2009 then tyear='2009'; 
if txyear=2010 then tyear='2010'; 
if txyear=2011 then tyear='2011'; 
if txyear=2012 then tyear='2012'; 
if txyear=2013 then tyear='2013'; 
if txyear=2014 then tyear='2014'; 




set liverfinal;if risk=.;run; 
 
/* Clinical Characteristics of Liver Transplant Recipients*/ 
proc freq data=liverFinal;table high_risk;run; 
proc univariate data=liverfinal; class high_risk;var rage;run; 
proc npar1way data=liverfinal;class high_risk;var rage; 
run; 
proc freq data=liverfinal;table high_risk*rsex/chisq;run; 
 
proc anova data=liverfinal; class risk; model rage=risk; means risk/ 
tukey;run; 
proc ttest data=liverfinal;class high_risk;var rage;run; 
proc freq data=liverFinal;table rsex*risk/chisq;where rsex in (1,2);run; 
proc freq data=liverFinal;table rsex*HIGH_risk/chisq;where rsex in 
(1,2);run; 
proc freq data=LIVERFinal;table recip_ethnic*risk/chisq;run; 
proc freq data=LIVERFinal;table recip_ethnic*HIGH_risk/chisq;run; 
proc freq data=LIVERFinal;table URGENT*risk/chisq;run; 
Proc freq data=LIVERFinal;table URGENT*HIGH_risk/chisq;run; 
proc freq data=LIVERFinal;table recip_ethnic*HIGH_risk/chisq;run; 
proc freq data=LIVERfinal;table rhepc*high_risk/chisq;run; 
PROC npar1way DATA=liverfinal;class risk; var UKELD;run; 
PROC univariate DATA=liverfinal;class risk; var UKELD;run; 
PROC npar1way DATA=liverfinal;class high_risk; var UKELD;run; 
PROC univariate DATA=liverfinal;class high_risk; var UKELD;run; 
data pld;set liverfinal; if pld= 424 then liverd=1;if pld=419 then liverd=2; 




data pld2;set pld;if liverd=. then liverd=4; 
if hypertension in (3,.) then hypertension=3;if diabetes in (3,.)then 
diabetes=3; 
if smoker in (3,.)then smoker=3;if alcohol in (3,.) then alcohol=3; if 
rhepc in (3,.)then rhepc=3; 
if hepc in (3,.) then hepc=3;if ethnic in (2,.) then ethnic=2; 
if risk in (0,.)then risk=0; 
if cardio in (3,.)then cardio=3; 
if prison=. then prison=0; 
if hrsb=. then hrsb=0; 
if hrsb=1 then higher=1;if hrsb=2 then higher=2;if hrsb=3 then 
higher=3;if hrsb=4 then higher=4; if hrsb=5 then higher=5; 
run; 
data pld3;set pld2;if higher=. then higher=0;run; 
 
data mod;set model;if hypertension in (3,.) then hypertension=3;if 
higher=. then higher=0;run; 
proc freq data=mod;table sexy*ivdu;run;run; 
proc freq data=pld2;table liverd*high_risk/chisq;run; 
 
/*liver positive virology*/ 
data liverviral;set liverfinal;if HCV=2 or HIV=2 or HTLV=2 or 
HBSAG=2;if high_risk=0;run; 
proc freq data=liverviral;table hbsag;run; 
 
/*reviewer comment*/ 
data liversf;set liverfinal;if risk in (1,0);run; 
 




/*Liver multivariate model*/ 
 
proc phreg data=pld3; 
class liverd(ref='4') risk(ref='0') urgent (ref='0'); 














/* Heart Recipients from High risk behaviour donors*/ 
proc sort data=final2;by donor_id;run; 
data finalhcv;set final2;if hcv=2;run; 
data heart;set standard.cardio_tx;if 
mdy(01,01,2000)<=tx_date<mdy(01,01,2016); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);run; 
proc sort data=heart;by donor_id;run; 
data heartrisk;merge final2 heart;by donor_id;if recip_id=. then delete; 
run; 
 
/*Heart recipients from HCV positive donors*/ 
proc sort data=finalhcv;by donor_id;run; 
data hearthcv; merge heart finalhcv;by donor_id;if HCV=2;run; 
 
/*Find missing patient survival data*/ 
proc freq data=heartrisk;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=heartrisk;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data heartrisk2;set heartrisk; if psurv=.;run; 
proc sort data=heartrisk2;by recip_id;run; 
data complete;set standard.cardio_tx;run; 
proc sort data=total;by recip_id;run; 
data completemissing;merge heartrisk2 complete; 
by recip_id;if high_risk=. then delete;run; 
data heartMissing2;set completemissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=heartmissing2;by recip_id;run; 
data heartmissing3;merge heartrisk2 heartmissing2;by recip_id;run; 
data heartmissing4;set heartmissing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data heartmissing5;set heartmissing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=heartmissing5;by recip_id;run; 
proc sort data=heartrisk;by recip_id;run; 
data heartall;merge heartrisk heartmissing5;by recip_id;run; 
proc freq data=heartall;table high_risk;run; 
data heartAnalysis;set heartall;if psurv=. then psurv=psurvfinal;if 
pcens=. then pcens=patientsurvival; 
run; 
proc freq data=heartanalysis;table high_risk*tx_type;run; 
 
/*censor data at 5 years*/ 
 
data heartanalysis2;set heartanalysis; 
if psurv=>3650 then psurvival=3650;else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650;else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0;else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0;else gcensor=gcens; 
if rage>40 then rage_grp=2;else recip_age_grp=1; 
if dage>40 then dage_grp=2;else donor_age_grp=1; 
if pcensor=. then delete; 
run; 
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/*Data Tables heart*/ 
data heartFinal;set heartanalysis2; 
if rethnic=1 then recip_ethnic=1;else recip_ethnic=2; 
if graft_no=1 then Tx=1;if graft_no=2 then Tx=2;if graft_no>2 then 
Tx=3; 
if crf_tx>85 then sensitised=1;else sensitised=0; 
if txcountry='UNITED KINGDOM';if pcensor=. then delete;if gcensor=. 
then delete; 
if dcountry='UNITED KINGDOM'; 






/* Clinical Characteristics of Heart Tx recipients from high risk 
behaviour donors*/ 
data hearttable;set heartfinal;if tx_type=30;run; 
proc freq data=hearttable;table risk;run; 
proc freq data=hearttable;table HIGH_risk;run; 
proc anova; class risk; model rage=risk;means risk; run; 
proc anova; class risk; model rage=risk;means risk /tukey; run; 
proc ttest data=hearttable; class high_risk;var rage;run; 
proc univariate data=hearttable; class high_risk;var rage;run; 
proc freq data=hearttable;table rsex*risk/chisq;where rsex in (1,2);run; 
proc freq data=hearttable;table rsex*high_risk/chisq;where rsex in 
(1,2);run; 
proc freq data=hearttable;table recip_ethnic*risk/chisq;run; 
proc freq data=hearttable;table recip_ethnic*high_risk/chisq;;run; 
proc freq data=hearttable;table urgent*risk/chisq;run; 
proc freq data=hearttable;table urgent*high_risk/chisq;;run; 
 
 













/* All other organ transplants*/ 
proc sort data=final2;by donor_id;run; 
data pancreas;set standard.pancreas_tx;if 
mdy(01,01,2003)<=tx_date<mdy(01,01,2016); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);run; 
proc sort data=pancreas;by donor_id;run; 
data pancreasrisk;merge final2 pancreas;by donor_id;if recip_id=. then 
delete; 
run; 




proc sort data=final2;by donor_id;run; 
data GI;set standard.intest_tx;if 
mdy(01,01,2003)<=tx_date<mdy(01,01,2016); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);run; 
proc sort data=GI;by donor_id;run; 
data GIrisk;merge final2 GI;by donor_id;if recip_id=. then delete; 
run; 
proc freq data=GIrisk; table high_risk*tx_type;run; 
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if dtype in (1,2); 
run; 







if dcountry='UNITED KINGDOM'; 
if sod=1; 
run; 






proc sort data=liver1; 
by donor_id; 
run; 




merge liver1 liverHCV; 
by donor_id; 




if HCV=2 then hepatitis=1; 
else hepatitis=0; 
if RHCV=2 and HCV=2 then Super=2; 
if RHCV=1 and HCV=2 then Super=1; 








proc sort data=livermissingdata; 
by recip_id; 
run; 




merge livermissingdata liver; 
by recip_id; 




keep recip_id tx_id psurv pcens  tsurv tcens tx_date; 
if psurv=. then delete; 
rename psurv=survivaldays pcens=patient_survival; 
run; 





merge livermiss livermissingdata; 
by recip_id; 
run; 















merge livermissingdata liverlongtime; 
by recip_id; 




keep recip_id tx_id psurv pcens  tsurv tcens tx_date; 
keep recip_id tx_id psurv pcens  tsurv tcens tx_date; 
if psurv=. then delete; 
rename psurv=survivaldays pcens=patient_survival; 
rename tx_date=first_transplant_date; 
run; 















if duration<=survivaldays then Psurvfinal=survivaldays-duration; 
run; 
proc sort data=LiverPcens2; 
by donor_id; 
run; 
proc freq data=liverpcens2; 
table patient_survival; 
run; 
proc freq data=liverall2; 
table patient_survival; 
run; 
proc sort data=liverall2; 
by donor_id; 
run; 




merge liverPcens2 liverHCV3; 
by donor_id; 
run; 
proc freq data=liveranalysisfull; 
table patient_survival; 
run; 





if pcens=. then pcens=patient_survival; 
if psurv=. then psurv=Psurvfinal; 
run; 





if psurv=>1826.25 then psurvival=1826.25; 
else psurvival=psurv; 
if gsurv=>1826.25 then gsurvfinal=1826.25; 
else gsurvfinal=gsurv; 
if psurv=>1826.25 and pcens=1 then pcensor=0; 
else pcensor=pcens; 
if gsurv=>1826.25 and gcens=1 then gcensor=0; 
else gcensor=gcens; 
if rage>40 then recip_age_grp=2; 
else recip_age_grp=1; 







proc sort data=recipientinfo; 
by recip_id; 
run; 




merge liveranalysisfull3 recipientinfo; 
by recip_id; 
if donor_id=. then delete; 
run; 








if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
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if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 
if past_drug_abuse in (7,8) then drug=3; 
if RHCV=2 and hepatitis=1 then HCVmatch=1; 
if RHCV=2 and hepatitis=0 then HCVMatch=2; 
if RHCV=1 and hepatitis=1 then HCVMatch=3; 
if RHCV=1 and hepatitis=0 then HCVmatch=4; 
if RHCV in(.,3,4,5,6,7,8,9) and hepatitis=1 then HCVmatch=5; 




if HCV in (2,3); 
run; 
 
proc freq data=liveranalysis3; 
table rhcv; 
run; 
proc freq data=liveranalysis3; 
table HCVmatch; 
run; 
proc lifetest data=liveranalysis3 plots=(S,LLS); 
time ptsurv*pcensor(0); 
strata hcvmatch; 
where HCVmatch IN (1,2); 
run; 
proc lifetest data=liveranalysis3 plots=(S,LLS); 
time grsurv*gcensor(0); 
strata hcvmatch; 






proc freq data=liveranalysis3; 
table HCVmatch*urgent/chisq; 
where HCVmatch in (1,2); 
run; 
 
/*proportionality of Hazards*/ 
proc phreg data=liveranalysis3; 
class HCVmatch; 
model ptsurv*pcensor(0)=HCVmatch HCVmatcht; 
HCVmatcht=HCVmatch*log(ptsurv); 
test_proportionality: test HCVmatcht; 
run; 
 




proc sort data=livingwaitinglist; 
by recip_id; 
run; 




merge liveranalysis3 livingwaitinglist; 
by recip_id; 
if donor_id=. then delete; 
if hcvmatch=1; 
run; 




/*Cox Hazards regression model*/ 
 
proc phreg data=allanalysis; 
class rsex dtype renceph rab_surgery tx_type rascites hepatitis 
hcvmatch RHCV(ref='1') abomatch/param=ref; 
model ptsurv*pcensor(0)= pld hcvmatch cit tx_type dtype hepatitis 
abomatch rhcv rsodium rpotassium rsex rab_surgery renceph rascites 
ralbumin rinr diabetes dbmi dage rage dcod rbilirubin rwtime; 
run; 
 
proc phreg data=allanalysis; 
class rsex dtype renceph rab_surgery tx_type rascites hcvmatch 
RHCV(ref='9') abomatch/param=ref; 
model grsurv*gcensor(0)= pld hcvmatch cit tx_type dtype abomatch 
rhcv rsodium rpotassium rsex rab_surgery renceph rascites ralbumin 
rinr diabetes dbmi dage rage dcod rbilirubin rwtime; 
run; 
/* datA FOR TABLES*/ 
proc univariate data=allanalysis; 
class HCVMatch; 
var rage; 
where HCVmatch in (1,2); 
histogram; 
run; 
proc ttest data=allanalysis; 
class HCVmatch; 
var rage; 
where hcvmatch in (1,2); 
run; 
 
proc npar1way data=allanalysis; 
class hcvmatch; 
var rwtime; 
where hcvmatch in (1,2); 
run; 








where hcvmatch in (1,2); 
run; 
 






if endstat in ('D','DA','DS'); 
run; 
proc sort data=waitlist; 
by recip_id; 
run; 















if psurvival=>0 and rwtime=>0 then survivaltime=psurvival + rwtime; 
if psurvival=>0 and suwtime=>0 and rwtime=. then 
survivaltime=psurvival+suwtime; 
if rwtime=>0 and psurvival=. then survivaltime=rwtime; 




if pcenslisting=1 and survivaltime>1826.25 then pcens10=0 and 
survivaltime=1826.25; 
else pcens10=pcenslisting; 





if hepatitis=1 then hepatitisTx=3; 
if hepatitis=0 then hepatitisTx=2; 
if hepatitis=. then hepatitisTx=1; 
run; 
 
proc lifetest data=HepCwaitlist5 notable plots=(S,LLS); 
time survivaltime*pcens10(0); 
strata hepatitisTx; 

























proc sort data=kidney; 
by donor_id; 
run; 




merge kidney donorskidney; 
by donor_id; 
if recip_id=. then delete; 
run; 
 





if HCV=2 then hepatitis=2; 
if HCV=1 then hepatitis=1; 

















merge missing all; 
by recip_id; 




if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 














if patientdays=>duration then psurvfinal=patientdays-duration; 
run; 
proc sort data=missing5; 
by recip_id; 
run; 










if psurv=. then psurv=psurvfinal; 
if pcens=. then pcens=patientsurvival; 
run; 





if psurv=>3650 then psurvival=3650; 
else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650; 
else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0; 
else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0; 
else gcensor=gcens; 
if rage>40 then rage_grp=2; 
else recip_age_grp=1; 







if dethnic=1 then ethnic=1; 
else ethnic=2; 
if rethnic=1 then recip_ethnic=1; 
else recip_ethnic=2; 
if graft_no=1 then Tx=1; 
if graft_no=2 then Tx=2; 
if graft_no>2 then Tx=3; 
if crf_tx>85 then sensitised=1; 
else sensitised=0; 
if txcountry='UNITED KINGDOM'; 
if pcensor=. then delete; 
if gcensor=. then delete; 
if past_diabetes=1 then diabetes=1; 
if past_diabetes=2 then diabetes=2; 
if past_diabetes in (7,8) then diabetes=3; 
if past_hypertension=1 then hypertension=1; 
if past_hypertension=2 then hypertension=2; 
if past_hypertension in (7,8) then hypertension=3; 
if past_cardio_disease=1 then cardio=1; 
if past_cardio_disease=2 then cardio=2; 
if past_cardio_disease in (7,8) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1; 
if past_alcohol_abuse=2 then alcohol=2; 
if past_alcohol_abuse in (7,8) then alcohol=3; 
if past_liver_disease=1 then liver=1; 
if past_liver_disease=2 then liver=2; 
if past_liver_disease in (7,8) then liver=3; 
if past_drug_abuse=1 then drug=1; 
if past_drug_abuse=2 then drug=2; 














merge analysis3 recipientinfo; 
by recip_id; 
if donor_id=. then delete; 
if RHCV=2 and hepatitis=2 then HCVmatch=1; 
if RHCV=2 and hepatitis=1 then HCVMatch=2; 
if RHCV=1 and hepatitis=2 then HCVMatch=3; 
if RHCV=1 and hepatitis=1 then HCVmatch=4; 
if RHCV in(.,3,4,5,6,7,8,9) and hepatitis=2 then HCVmatch=5; 
if RHCV in (.,3,4,5,6,7,8,9) and hepatitis=1 then HCVmatch=6; 
if RHCV=2 and hepatitis=3 then HCVmatch=7; 











proc lifetest data=analysis4 notable plots=(S,LLS); 
time ptsurv*pcensor(0); 
strata Hcvmatch; 
where HCVmatch in (1,2,4); 
run; 





proc univariate data=analysis4; 
class hcvmatch; 
var dage; 
where hcvmatch in (1,2); 
run; 





if dtype in (1,2); 
if txcountry='UNITED KINGDOM'; 
run; 
proc sort data=heart; 
by donor_id; 
run; 




merge heart donorskidney; 
by donor_id; 
if recip_id=. then delete; 
run; 










if HCV in (2,3); 
if dcountry='UNITED KINGDOM'; 




















proc sort data=unused; 
by donor_id; 
run; 




merge HCV4 unused; 
by donor_id; 










/*differences between groups*/ 




proc freq data=HCV; 
table sod*dtype/chisq; 
run; 




proc print data=Hcv3; 
title 'Organs Utilised for SOT from HCV positive Donors'; 
var donor_id ddate dregion hospname organs_ofd organs_txd kidtxd 
livtxd hrttxd lngtxd pantxd dtype; 
run; 
proc print data=HCV4; 
title 'Organs Not Utilised for SOT from HCV positive Donors'; 
var donor_id ddate dregion hospname organs_ofd organs_txd kidtxd 
livtxd hrttxd lngtxd pantxd dtype; 
run; 
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1.51 Appendix 6: Ligature asphyxiation code 
data risk; 
set standard.donors; 
if dtype in (1,2); 
if dcountry='UNITED KINGDOM'; 
if mdy(01,01,2003)<=ddate<mdy(01,01,2017); 
run; 






































































































proc freq data=hanging;table hanging*sod;run; 
 














































data year2;set year; 
if donation_year=2000 then dyear='2000'; 
if donation_year=2001 then dyear='2001'; 
if donation_year=2002 then dyear='2002'; 
if donation_year=2003 then dyear='2003'; 
if donation_year=2004 then dyear='2004'; 
if donation_year=2005 then dyear='2005'; 
if donation_year=2006 then dyear='2006'; 
if donation_year=2007 then dyear='2007'; 
if donation_year=2008 then dyear='2008'; 
if donation_year=2009 then dyear='2009'; 
if donation_year=2010 then dyear='2010'; 
if donation_year=2011 then dyear='2011'; 
if donation_year=2012 then dyear='2012'; 
if donation_year=2013 then dyear='2013'; 
if donation_year=2014 then dyear='2014'; 
if donation_year=2015 then dyear='2015'; 
if dethnic=1 then ethnic=1; 
else ethnic=2; 
if past_diabetes=1 then diabetes=1;if past_diabetes=2 then 
diabetes=2;if past_diabetes in (3,4,5,6,7,8,9,.) then diabetes=3; 
if past_hypertension=1 then hypertension=1;if past_hypertension=2 
then hypertension=2;if past_hypertension in (3,4,5,6,7,8,9,.) then 
hypertension=3; 
if past_cardio_disease=1 then cardio=1;if past_cardio_disease=2 then 
cardio=2;if past_cardio_disease in (3,4,5,6,7,8,9,.) then cardio=3; 
if past_alcohol_abuse=1 then alcohol=1;if past_alcohol_abuse=2 then 
alcohol=2;if past_alcohol_abuse in (3,4,5,6,7,8,9,.) then alcohol=3; 
if past_liver_disease=1 then liver=1;if past_liver_disease=2 then 
liver=2;if past_liver_disease in (3,4,5,6,7,8,9,.) then liver=3; 
if past_drug_abuse=1 then drug=1;if past_drug_abuse=2 then 
drug=2;if past_drug_abusee in (3,4,5,6,7,8,9,.) then drug=3; 
 264 
if hcv=1 then hepC=1;if hcv=2 then hepC=2;if hcv in (3,4,5,6,7,8,.) then 
hepc=3; 
if past_smoker=1 then smoker=1;if past_smoker=2 then smoker=2;if 
past_smoker in (3,4,5,6,7,8,9,.) then smoker=3; 






111070) then hanging=.; 
run; 
proc freq data=year2; 
table hanging*sod;run; 
data year3;set year2;if hanging=1 and dtype=2 then hangdcd=1;if 
hanging=1 and dtype=1 then 
hangdcd=2;if hanging=. then hanging=0;run; 
proc freq data=year3;table hangdcd*sod/chisq;run; 
data year4;set year3; if sod=1;run; 









data hypoxicx; set year3; if hangdcd=. then hangdcd=0;run; 
/*add in warm ischsaemic time for dcd donors*/ 
/*try dcsd_donor_data + dcsd_donor_kidney*/ 
data perfusion; 
set database.dcsd_donor_kidney; 




keep donor_id atw_cert_death; 
run; 
proc sort data=perfusion; 
by donor_id; 
run; 


















proc freq data=warming3; 
table wit; 
run; 




 proc sort data=hypoxicx; 




 merge hypoxicx warming3; 
 by donor_id; 
 if hangdcd=. then delete; 
 run; 
proc sort data=hypoxic nodupkey; 
 by donor_id; 
  run; 












warm_isch= aortic_perfusion-atw_cert_death ; 
warm_isch2=perfusion_start_date-atw_cert_death; 
run;  
data warm3;set warm2;time1=warm_isch;label time1="time with time8. 
format"; 
format warm_isch time8.;run; 
data warm4;set warm3;time2=warm_isch2;label time2="time with 
time8. format"; 




 keep warm_isch wit time1 donor_id; 
 run; 
 proc sort data=warm5; 
 by donor_id; 
 run; 
 
 proc sort data=hypoxicx; 




 merge hypoxicx warm5; 
 by donor_id; 
 if hangdcd=. then delete; 
 run; 
proc freq data=hypoxic; 
table warm_isch*dtype; 
run; 
/*draw new bar chart*/ 
data barchart; 
 set hypoxic; 
  if hanging=0; 
 run; 
proc freq data=barchart; 
 table dtype*kiddonor*dyear; 
























proc npar1way data=hypoxicused;class hangdcd; 
var organs_txd; 
run; 
proc freq data=hypoxicused; 
table hangdcd*ethnic/chisq; 
run; 
/*compare proceeding rates DCD vs. DBD*/ 




/*Now compare DBD and DCD kidney donor characteristics*/ 
   /*first do DBD*/ /*new table saved as Table 1 kidney donor*/   
      /*remember hangdcd=1 is DCD*/ 
       /*separate by kiddonor=1 or kiddonor=0 in place of sod*/ 







if dtype=1;if kiddonor=1; 
run; 








proc freq data=hypoxic2; 
table hangdcd*dsex/chisq; 
run; 
proc freq data=hypoxic2; 
table hangdcd*dethnic/chisq; 
run; 
proc freq data=hypoxic2; 
table hangdcd*hypertension/chisq; 
run; 
proc freq data=hypoxic2; 
table hangdcd*cardio/chisq; 
run; 
proc freq data=hypoxic2; 
table hangdcd*diabetes/chisq; 
run; 








proc sort data=tests; 
by donor_id; 
run; 





merge hypoxic2 tests; 
by donor_id; 
if hangdcd=. then delete; 
run; 
proc sort data=hypoxictests; 





if first. donor_id; 
if sod=1; 
run; 








proc npar1way data=htests; 
     class hangdcd; 
  var creatinine; 
  run; 
 
 
/*remove missing data for logistic regression analysis*/ 
proc univariate data=hypoxic; 
var dage; 
run; 






if hypertension=3 then hypertension=.; 
if diabetes=3 then diabetes=.; 
if cardio=3 then cardio=.; 
if smoker=3 then smoker=.; 
if dage<40 then age_grp=1; 
if 40<=dage<53 then age_grp=2; 
if 53<=dage<64 then age_grp=3; 
if dage=>64 then age_grp=4; 
run; 






set remove;if diabetes=. then delete; 
if hypertension=. then delete; 
run; 






/*attempt at multiple imputation for missing variables*/ 
proc mi data=remove out=mi_mvn1 nimpute=20 seed=7654321; 
class kiddonor diabetes hypertension cardio dtype hanging smoker 
ethnic; 
fcs nbiter=5 discrim(Diabetes/details) discrim(Hypertension/details) 
discrim(Cardio/details) discrim(smoker/details); 
var kiddonor diabetes hypertension cardio dtype hanging smoker ethnic 
dage; 
run; 
proc logistic data=mi_mvn1 descending; 
class hanging(ref='0') dtype(ref='2') hypertension(ref='1') 
diabetes(ref='1') ethnic (ref='1') smoker(ref='1') cardio (ref='1'); 
model kiddonor= diabetes hypertension cardio dtype hanging smoker 
ethnic dage  dage; 
by _imputation_; 
ods output parameterestimates=lgsparms 
   CovB=lgscovb; 
 run; 
proc mianalyze parms(classvar=classval)=lgsparms ; 
class dtype hanging hypertension diabetes ethnic smoker cardio; 
modeleffects intercept dage dtype hanging hypertension diabetes 
ethnic smoker cardio; 
ods output ParameterEstimates=parms2; 
run; 









keep parm dage dtype hanging hypertension diabetes ethnic smoker 






proc logistic data=remove descending; 
class hanging(ref='0') dtype(ref='2')hypertension (ref='1') 
diabetes(ref='1') ethnic (ref='1') smoker (ref='1') cardio (ref='1') 
HepC(ref='1'); 
model kiddonor=dage dtype hanging hypertension diabetes ethnic 
smoker cardio ; 
run; 
proc logistic data=remove descending; 
class hanging(ref='0') age_grp(ref='2') dtype(ref='2')hypertension 
(ref='1') diabetes(ref='1') ethnic (ref='1') smoker (ref='1') cardio (ref='1') 
HepC(ref='1'); 










/*new logistic regression for reviewers*/ 
 /*first only including hanging donors*/ 








if donor_id in 










107995) then HRSB=1; 














) then HRSB=2; 
if donor_id in 
(117857,110250,100375,60864,65391,68140,68929,80495,92918,933
82,94416,95615,100064,100375, 
100500,106178) then HrsB=3; 
if donor_id in 
(108989,106611,103899,87004,95478,100566,101759, 
103899) then HrsB=4; 
if donor_id in 
(117391,112783,109881,109142,106279,104587,100319,72941,80501
,83817,98976,100319,104587, 



























































proc freq data=IVDU;table IVDU;run; 
data prisonnew; 
set IVDUnew; 























































if ivdu in (1,2) then drugs=1;else drugs=0; 
if prison in (1,2) then prisoner=1;else prisoner=0; 
run; 




proc logistic data=format descending; 
class dtype(ref='2')hypertension(ref='1') drugs(ref='0') alcohol 
(ref='1')prisoner(ref='0') diabetes(ref='1') ethnic (ref='1') smoker (ref='1') 
cardio (ref='1') HepC(ref='1'); 







/*assess role of downtime*/ 
    /*mport dataset of ligature donors wit hanging time and downtime*/ 




    LENGTH 
        Donor_id           8 
        'Hanging time'n    8 
        downtime           8 ; 
    FORMAT 
        Donor_id         F12. 
        'Hanging time'n  BEST12. 
        downtime         BEST12. ; 
    INFORMAT 
        Donor_id         BEST12. 
        'Hanging time'n  BEST12. 
        downtime         BEST12. ; 
    INFILE 'E:\SASWork\_TD8664_MSVSAS01_\#LN00024' 
        LRECL=15 
        ENCODING="WLATIN1" 
        TERMSTR=CRLF 
        DLM='7F'x 
        MISSOVER 
        DSD ; 
    INPUT 
        Donor_id         : BEST32. 
        'Hanging time'n  : BEST32. 














proc sort data=downtime; 
by donor_id; 
run; 
proc freq data=downtime; 
table 'Hanging time'n ; 
run; 
proc univariate data=downtime; 
var 'Hanging time'n ; 
run; 
proc sort data=hypoxic; 
by donor_id;run; 
 
/*merge data together*/ 
data hypoxictime; 




/*now remove those who didnt proceed*/ 









/*subanalysis of only those with recorded downtimes*/ 
data hypoxiatimes; 
set hangtimes; 
if downtime=. then delete; 
if downtime<15 then dt=1; 
if 15<=downtime<25 then dt=2; 
if 25<=downtime<40 then dt=3; 
if 40<=downtime then dt=4; 
run; 












proc sort data=tests; 
by donor_id; 
run; 





merge hypoxiatimes tests; 
by donor_id; 
if hangdcd=. then delete; 
run; 
proc sort data=hypoxictests; 





if first. donor_id; 
run; 
proc freq data=htests; 
table dt*dtype/chisq; 
run; 
ods graphics on; 
proc corr data=htests plots=all; 
var creatinine downtime; 
run; 
ods graphics off; 
 









proc npar1way data=htests; 
     class hangdcd; 
  var creatinine; 









if organs_Txd=>3 then used=3; 
else used=organs_txd; 
run; 













/*dcd only comparisons*/ 



























/*dcd only comparisons*/ 












/*combine with pre-donation blood tests*/ 
 
/*Checking reason for decline*/ 










proc sort data=notes;by donor_id;run; 
 
data unusedhypoxic; 
merge hypoxic unused notes; 
by donor_id; 
if hangdcd=. then delete; 
if organ_type in (10,11,12) then organ='Kidney'; 
if organ_type in (40,41,42,45,46,47) THEN ORGAN='Liver'; 
if organ_type in (50,51,52,53,130) then organ='Pancreas/SPK'; 
if organ_type in (60,61,62,63,64,65,66,67,68,69) then organ='Lung'; 
if organ_type=30 then organ='Heart'; 
run; 










proc freq data=unusedhypoxickidney;table 
NOTE_TEXT*hangdcd;where hangdcd in (1,2);run; 
data unusedhypoxicsod;set unusedhypoxic;if sod=0;run; 
 





If hangdcd in (1,2); 
keep donor_id primary_reason sod hangdcd dtype note_text; 
RUN; 
















keep donor_id primary_reason note_text; 
RUN; 
PROC FREQ DATA=KIDNEYdbd2; 
TABLE DONOR_ID*NOTE_TEXT; 
RUN; 












proc sort data=offers; 
by donor_id; 
run; 




merge unusedhypoxic2 offers; 
by donor_id; 
if hangdcd=. then delete; 






if org_type in (10,11,12) then organ='Kidney'; 
if org_type in (40,41,42,45,46,47) THEN ORGAN='Liver'; 
if org_type in (50,51,52,53,130) then organ='Pancreas/SPK'; 
if org_type in (60,61,62,63,64,65,66,67,68,69) then organ='Lung'; 





proc freq data=refused; 
table reason1*organ; 
run; 






proc sort data=donorsnotes; 
by donor_id; 
run; 
proc sort data=unusedhypoxic2; 
by donor_id; 
run; 
data haningnotes;merge unusedhypoxic2 donorsnotes; 
by donor_id; 









proc sort data=unusedhypoxiccheck; 
by donor_id; 
run; 




merge unusedhypoxiccheck names; 
by donor_id; 






 if sod=0; 
 IF PRIMARY_REASON=11; 
 run; 
proc freq data=unused2;table note_text;run; 





if organ_type in (60,61,62,63,64,65,66,67,68,69); 
run; 







proc freq data=unused2;table organ_type*note_text;where organ_type 
in (50,51,63,70);run; 
 
/*Blood tests of donors pre-donation*/ 
/*DCD first*/ 




proc sort data=tests; 
by donor_id; 
run; 




merge hypoxic3 tests; 
by donor_id; 
if hangdcd=. then delete; 
run; 
proc sort data=hypoxictests; 





if first. donor_id; 
if sod=1; 
run; 








proc npar1way data=htests; 
     class hangdcd; 
  var creatinine; 




 set database.donor_liver_function; 
  run; 
proc sort data=LFT;by donor_id;run; 
proc sort data=hypoxic3;by donor_id;run; 
data hypoxicLFT;  
   merge hypoxic3 LFT; 
   by donor_id; 
   if hANGDCD=. then delete; 
   run; 
proc sort data=hypoxiclft; 





if first. donor_id; 
if sod=1; 
run; 
proc univariate data=hlft; 
     class hANGDCD; 
  var Amylase; 
  run; 
proc npar1way data=hlft; 
     class hANGDCD; 
  var Amylase; 





proc sort data=hypoxic;by donor_id;run; 
data kidney;set standard.kidney_tx;if 
mdy(01,01,2003)<=tx_date<mdy(01,01,2017); 
if txcountry='UNITED KINGDOM';if dcountry='UNITED KINGDOM';if 
dtype in (1,2);if Tx_type in (10,11,12,13,14);run; 
proc sort data=kidney;by donor_id;run; 




/*Find missing patient survival data*/ 
proc freq data=kidneyrisk;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=kidneyrisk;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data kidneyrisk2;set kidneyrisk; if psurv=.;run; 
proc sort data=kidneyrisk2;by recip_id;run; 
data all;set standard.kidney_tx;run; 
proc sort data=all;by recip_id;run; 
data Allmissing;merge kidneyrisk2 all; 
by recip_id;if hangdcd=. then delete;run; 
data Missing2;set allmissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=missing2;by recip_id;run; 
data missing3;merge kidneyrisk2 missing2;by recip_id;run; 
data missing4;set missing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data missing5;set missing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=missing5;by recip_id;run; 
proc sort data=kidneyrisk;by recip_id;run; 
data Kidneyall;merge kidneyrisk missing5;by recip_id;run; 
proc freq data=kidneyall;table hangdcd;run; 
data Analysis;set kidneyall;if psurv=. then psurv=psurvfinal;if pcens=. 
then pcens=patientsurvival; 
run; 
proc freq data=analysis;table pcens;run; 
proc freq data=analysis;table hangdcd;run; 
 
/*46 graft surviva;l missing, 33 patient survival deleted*/  
 
/*Censor to 10 years graft and patient survival*/ 
 
data analysis2;set analysis; 
if psurv=>3650 then psurvival=3650;else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650;else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0;else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0;else gcensor=gcens; 
if rage>40 then rage_grp=2;else recip_age_grp=1; 
if dage>40 then dage_grp=2;else donor_age_grp=1; 
if pcensor=. then delete; 
run; 





















ods graphics on; 
proc logistic data=analysis2 descending plots=all; 
class hanging(ref='0') hypertension (ref='1') HLA_GRP rec_unit tx_yr; 




data KidneyFinal;set analysis2; 
if rethnic=1 then recip_ethnic=1;else recip_ethnic=2; 
if graft_no=1 then Tx=1;if graft_no=2 then Tx=2;if graft_no>2 then 
Tx=3; 
if crf_tx>85 then sensitised=1;else sensitised=0; 
if txcountry='UNITED KINGDOM';if pcensor=. then delete;if gcensor=. 
then delete; 
if rhcv=1 then rhepc=1;if rhcv=2 then rhepc=2;if rhcv in (3,4,5,6,7,8,9,.) 
then rhepc=3; 
if prd in (210,211,212,213,214,215,216,217,219) then renal=1; 
if prd in (220,221,222,223,224,225,229) then renal=2; 
if prd in (241,242) then renal=3; 
if prd in (280,281) then renal=4; 
if dgf in (3,4,5,6,7,8,9,.) then DGrF=3; 
else DGrf=DGF; 










/*check for time effect*/ 
data kidneyfinaltime; 
set kidneyfinal2; 
if mdy(01,01,2003)<=tx_date<mdy(01,01,2010) then time=1; 
if mdy (01,01,2010)<=tx_date<mdy(01,01,2017) then time=2;run; 
 









/*READS IN YOUR DATASET AND CHANGES THE SURVIVAL 
VARIABLES READY FOR USE*/ 
/*ALSO CHANGES THE DATA TO YEARS OR MONTHS OR DAYS*/ 
data surv; 
set &data; 
if &surv <0 then delete; 
cens = &cens; 
/*survival analysis-Initially all High risk behaviour together*/ 
/*Survival macro used*/ 
if lowcase("&period") = "months" then surv = &surv / 30.44; 
if lowcase("&period") = "years" then surv = &surv / 365.25; 
if lowcase("&period") = "days" then surv = &surv / 1; 
if surv > &end then do; surv = &end; cens = 0; end; 
fup = 0; 
if surv = &end or cens ne 0 then fup = 1; 
run; 
 
/*GETS THE COUNT FOR EACH STRATA*/ 
proc freq data = surv noprint; table &var / out = num; run; 
 
/*GETS THE COUNT FOR FOLLOW UP*/ 
proc freq data = surv noprint; table &var * fup / out = fup; run; 
 
/*OPENS THE FILE TO SAVE THE PLOT*/ 
filename gsasfile "&file.\&cgm..emf"; 
 
/*RUNS THE LIFETEST PROCEDURE TO OUTPUT THE DATA 
NEEDED FOR THE PLOT*/ 
ODS OUTPUT homtests=homtests; 
proc lifetest data=surv plots=(s) outsurv=surv1; 




/*SORTS OUT THE LAYOUT OF THE PLOT AND CHOOSES 
COLOURS FOR THE LINES*/ 
goptions reset=all reset=symbol htext=1.8 cback=white colours=(black)  
/*ftext=HWCGM005*/ ftext='Arial/bold' 
noborder hsize=8.5 vsize=9.5 Gaccess=GSASFILE;run; 
axis1 minor=none order=&yaxis to 100 by 10 label=(ANGLE=90 "% 
&survival survival"); 
axis2 minor=none order=0 to &end by &end1 label=("&period post-
transplant"); 
symbol; 
symbol1 c=CXFF6600 i=steplj w=4 l=1 v=none; 
symbol2 c=CX99CCFF i=steplj w=4 l=1 v=none; 
symbol3 c=CXFFCC00 i=steplj w=4 l=1 v=none; 
symbol4 c=CX339966 i=steplj w=4 l=1 v=none; 
symbol5 c=black    i=steplj w=4 l=1 v=none; 
symbol6 c=CXFF6600 i=steplj w=4 l=2 v=none; 
symbol7 c=CX99CCFF i=steplj w=4 l=2 v=none; 
symbol8 c=CXFFCC00 i=steplj w=4 l=2 v=none; 
symbol9 c=CX339966 i=steplj w=4 l=2 v=none; 
symbol10 c=black   i=steplj w=4 l=2 v=none; 
 
 LEGEND1 ACROSS=1 
         POSITION=(BOTTOM INSIDE CENTER) 
         MODE=SHARE 
         OFFSET=(0,1.5) 
         SHAPE=SYMBOL(5,1) 
   CBORDER=Black 
         LABEL=(POSITION=(TOP) 
                JUSTIFY=CENTER H=1.2 "&var") 
   VALUE=(H=1.2); 
 
/*PRODUCES THE PLOT*/ 
data splot1; set surv1; retain lag_s; drop=lag_s; if survival=. then 
survival=lag_s; 
lag_s=survival; run; 
data splot2; set splot1; survival=survival*100; 
proc gplot data=splot2; plot survival * surv = &var /legend=legend1 
noframe vaxis=axis1 haxis=axis2;  
title ' '; run; quit; 
 
/*USES THE DATA TO OBTAIN THE SURVIVAL ESTIMATES FOR 
THE STRATA*/ 
data surv2; set surv1; if _censor_ = 0; run; 
proc sort data = surv2; by &var survival; run; 
proc sort data = surv2 nodupkey; by &var; run; 
 
data surv3; set surv2; surv = (survival*100); lcl = (sdf_lcl*100); ucl = 
(sdf_ucl*100); 
format surv lcl ucl 10.1; run; 
 
data surv4; merge surv3 num; by &var; run; 
 
/*OBTAINS THE P-VALUE FOR THE STRATA*/ 
data _null_; 
set homtests; 
where test = 'Log-Rank'; 
call symput ("logrank",trim(left(put(ProbChiSq,PVALUE6.4)))); 
run; 
 
/*PRINTS THE ESTIMATES, COUNT AND P-VALUE FOR THE 
DATA*/ 
title1"&survival survival by &var p=&logrank";                                                                                                                                                                                         
proc print data = surv4; var &var count surv lcl ucl;  run; 
%mend survival; 
 
/*MACRO VARIABLES REQUIRED*/ 
/*%survival(data,surv,cens,time,end,end1,censor,var,survival,period,cg
m);*/ 
/*WHERE data=dataset with survival variables 
  surv=name of survival variable - eg gsurv 
  cens=name of censoring variable - eg 
gcens 
  period=years, months, days 
  end=put 10 if wanting 10 year survival, 12 
for 12 month survival, 30 for 30 day survival 
  end1=how big you want your x-label gap eg 
1 if you want 10 years by 1 year 
  var=variable you want to strata by - eg 
centre 
  survival=either graft, patient or transplant 
  yaxis=point at which you want the yaxis to 
start, 40 is standard 













if dtype=2 and hanging=0 then Hangtype=3; 
if dtype=1 and hanging=0 then Hangtype=4; 
else hangtype=hangdcd; 
if rsex in (3,4,5,6,7,8,9,.) then recip_sex=3; 
else recip_sex=rsex; 
if dgf in (4,5,6,7,8,9,.) then DeGF=4; 
else DeGF=DGf; 
if dgf in (1,3) then delayed=0; 
 270 
if dgf=2 then delayed=1; 
if dgf=3 then pnf=1;if dgf in (1,2) then pnf=0; 
if 0<cld_isch<12 then cit=1; 
if 12<=cld_isch<18 then cit=2; 
if 18<=cld_isch<24 then cit=3; 
if cld_isch=>24 then cit=4; 
transplant_year=year(tx_date); 










if delayed=. then delayed=2; 
if pnf=. then pnf=2; 
if  transplant_year=2000 then tyear='2000'; 
if  transplant_year=2001 then tyear='2001'; 
if  transplant_year=2002 then tyear='2002'; 
if  transplant_year=2003 then tyear='2003'; 
if  transplant_year=2004 then tyear='2004'; 
if transplant_year=2005 then tyear='2005'; 
if  transplant_year=2006 then tyear='2006'; 
if  transplant_year=2007 then tyear='2007'; 
if transplant_year=2008 then tyear='2008'; 
if  transplant_year=2009 then tyear='2009'; 
if transplant_year=2010 then tyear='2010'; 
if  transplant_year=2011 then tyear='2011'; 
if  transplant_year=2012 then tyear='2012'; 
if  transplant_year=2013 then tyear='2013'; 
if  transplant_year=2014 then tyear='2014'; 
if transplant_year=2015 then tyear='2015'; 
if transplant_year=2016 then tyear='2016'; 
IF RENAL=. THEN RENAL=5; 
run; 










proc freq data=kidneyfinal3; 
table hangtype*wit/chisq;where dtype=2; 
run; 







/*logistic regression of DGF and PNF*/ 
   /*start with DGF-missing data put into dummy missing variable*/ 
data kidneyfinal4; 
set kidneyfinal3; 
if pnf in (0,1); 
run; 











/*attempt at multiple imputation for missing variables*/ 
proc mi data=kidneyfinal4 out=MII nimpute=20 seed=7654321; 
class pnf hanging dtype hypertension HLA_GRP diabetes renal 
REC_UNIT TYEAR ; 
fcs discrim(Diabetes=dage rage cld_isch dweight); 
 
FCS discrim(Hypertension=dage rage cld_isch dweight); 
 
FCS logistic(HLA_GRP=dage rage hanging dtype hypertension 
diabetes renal rec_unit tyear cld_isch dweight); 
 
FCS reg(cld_isch= dage rage hanging dtype hypertension HLA_GRP 
diabetes renal rec_unit tyear  dweight); 
FCS reg(dweight= dage rage hanging dtype hypertension HLA_GRP 
diabetes renal rec_unit tyear);  
var dage rage pnf hanging dtype hypertension HLA_GRP diabetes 
renal rec_unit tyear cld_isch dweight; 
run; 
proc logistic data=miI descending; 
class hanging(ref='0') dtype(ref='2') hypertension(ref='1')rec_unit 
diabetes(ref='1') RENAL(ref='1') TYEAR HLA_GRP(REF='2') dbg rbg; 
model pnf= dage rage hanging dtype hypertension HLA_GRP diabetes 
renal tyear cld_isch dweight dbg rbg; 
by _imputation_; 
ods output parameterestimates=DGFPARM 
   CovB=lgscovb; 
 run; 
proc mianalyze parms(classvar=classval)= DGFPARM ; 
class hanging dtype hypertension rec_unit diabetes RENAL TYEAR 
HLA_GRP dbg rbg; 
modeleffects intercept dage rage hanging dtype hypertension 
HLA_GRP diabetes renal rec_unit dbg rbg tyear cld_isch dweight; 
ods output ParameterEstimates=combined; 
; 
run; 








keep parm dage rage hanging dtype hypertension HLA_GRP diabetes 
renal rec_unit dbg rbg tyear cld_isch dweight probt HR UCI LCI; 
run; 
 
/*attempt at multiple imputation for missing variables-now just DCD 
donors therefore includes warm ischaemic time*/ 
proc mi data=kidneydcdonly out=MII nimpute=20 seed=7654321; 
class delayed hanging hypertension HLA_GRP diabetes renal 
REC_UNIT TYEAR ; 
fcs discrim(Diabetes=dage rage cld_isch dweight); 
 
FCS discrim(Hypertension=dage rage cld_isch dweight); 
 
FCS logistic(HLA_GRP=dage rage hanging hypertension diabetes 
renal rec_unit tyear cld_isch dweight); 
 
FCS reg(cld_isch= dage rage hanging  hypertension HLA_GRP 
diabetes renal rec_unit tyear  dweight); 
FCS reg(dweight= dage rage hanging  hypertension HLA_GRP 
diabetes renal rec_unit tyear);  
FCS reg(logwarm= dage rage hanging  dweight cld_isch hypertension 
HLA_GRP diabetes renal rec_unit tyear);  
var dage rage delayed hanging logwarm hypertension HLA_GRP 
diabetes renal rec_unit tyear cld_isch dweight; 
run; 
proc logistic data=miI descending; 
class hanging(ref='0') hypertension(ref='1')rec_unit diabetes(ref='1') 
RENAL(ref='1') TYEAR HLA_GRP(REF='2') dbg rbg; 
model delayed= dage rage hanging logwarm hypertension HLA_GRP 
diabetes renal tyear cld_isch dweight dbg rbg; 
by _imputation_; 
ods output parameterestimates=DGFPARM 
   CovB=lgscovb; 
 run; 
proc mianalyze parms(classvar=classval)= DGFPARM ; 
class hanging hypertension rec_unit diabetes RENAL TYEAR 
HLA_GRP dbg rbg; 
modeleffects intercept dage rage hanging logwarm hypertension 
HLA_GRP diabetes renal rec_unit dbg rbg tyear cld_isch dweight; 
ods output ParameterEstimates=combined; 
; 
run; 








keep parm dage rage hanging logwarm hypertension HLA_GRP 











proc logistic data=kidneydcdonly2 descending plots=all; 
class hanging(ref='0') hanging(ref='0') hypertension(ref='1') 
HLA_GRP(ref='2') diabetes(ref='1') renal(ref='5') cit_hrs rec_unit tyear; 
model pnf=  hanging; 
run; 
 
proc logistic data=kidneyfinal4 descending plots=all; 
class hanging(ref='0') hanging(ref='0') hypertension(ref='1') 
HLA_GRP(ref='2') diabetes(ref='1') renal(ref='5') cit_hrs rec_unit tyear; 
model delayed= hanging hypertension dage HLA_GRP diabetes renal 
rec_unit tyear cld_isch dweight; 
run; 
/*compare DCD first*/ 










proc freq data=kidneyfinal2; 
table hangTYPE; 






















if gsurv > (5*365.25) then gsurv5=(5*365.25); 
else gsurv5=gsurv; 
if gsurv > (5*365.25) then gcens5=0; 
else gcens5=gcens; 
 
if gsurv > (1*365.25) then gsurv1=365.25; 
else gsurv1=gsurv; 




if psurv > (5*365.25) then psurv5=5; 
else psurv5=psurv/365.25; 
if psurv > (5*365.25) then pcens5=0; 
else pcens5=pcens; 
 
if psurv > (1*365.25) then psurv1=365.25; 
else psurv1=psurv; 
if psurv > (1*365.25) then pcens1=0; 
else pcens1=pcens; 
 
if gsurv=0 and gcens=1 then pnf1=1; 
else pnf1=0; 
if diabetes=3 then diabetes=.; 











proc phreg data=kidneydcdonly; 
class hanging(ref='0') ; 





proc freq data=mvadata; 
table cld_isch; 
run; 
proc mi data=kidneydcdonly out=five nimpute=20 seed=7654321; 
class hanging  hypertension HLA_GRP diabetes renal REC_UNIT 
TYEAR ; 
fcs discrim(Diabetes=dage rage cld_isch dweight); 
 
FCS discrim(Hypertension=dage rage cld_isch dweight); 
 
FCS logistic(HLA_GRP=dage rage hanging  hypertension diabetes 
renal rec_unit tyear cld_isch dweight); 
 
FCS reg(cld_isch= dage rage hanging hypertension HLA_GRP 
diabetes renal rec_unit tyear  dweight); 
FCS reg(dweight= dage rage hanging hypertension HLA_GRP 
diabetes renal rec_unit tyear);  
fcs reg(logwarm=dage rage hanging hypertension HLA_GRP diabetes 
renal rec_unit tyear); 
var dage rage  hanging logwarm hypertension HLA_GRP diabetes 
renal rec_unit tyear cld_isch dweight; 
run; 
 
proc phreg data=five outest=imputed covout; 
class hanging(ref='0') hanging(ref='0') hypertension(ref='1') 
HLA_GRP(ref='2') diabetes(ref='1') renal(ref='5')  rec_unit tyear; 
model Gsurv5*Gcens5(0)= dage hanging logwarm rage hypertension 
diabetes hla_grp cld_isch dweight tyear renal/covb; 
by _imputation_;  
random rec_unit; 
run; 
PROC MIANALYZE DATA=IMPUTED; 
MODELEFFECTS dage rage  HANGING1 LOGWARM  diabetes2 
hypertension2  HLA_GRP1 HLA_GRP3 HLA_GRP4 renal1 renal2 
renal3 renal4 renal6 cld_isch dweight tyear2003 tyear2004 tyear2005 
tyear2006 tyear2007 tyear2008 tyear2009 tyear2010 tyear2011 
tyear2012 tyear2013 tyear2014 tyear2015; 
; 
ODS OUTPUT PARAMETERESTIMATES=SURVIVE; 
RUN; 
proc mianalyze PARMS(CLASSVAR=FULL)=imputed; 
class hanging1 hypertension2 diabetes2 HLA_GRP1 HLA_GRP3 
HLA_GRP4 renal1 renal2 renal3 renal4 renal6 tyear2003 tyear2004 
tyear2005 tyear2006 tyear2007 tyear2008 tyear2009 tyear2010 
tyear2011 tyear2012 tyear2013 tyear2014 tyear2015; 
modeleffects  dage rage  HANGING1 LOGWARM  diabetes2 
hypertension2  HLA_GRP1 HLA_GRP3 HLA_GRP4 renal1 renal2 
renal3 renal4 renal6 cld_isch dweight tyear2003 tyear2004 tyear2005 
tyear2006 tyear2007 tyear2008 tyear2009 tyear2010 tyear2011 
tyear2012 tyear2013 tyear2014 tyear2015; 
ods output Parameterestimate=survival; 
run; 








keep parm dage rage hanging dtype hypertension HLA_GRP diabetes 
renal rec_unit dbg rbg tyear cld_isch dweight probt HR UCI LCI; 
run; 
 
proc mianalyze DATA=IMPUTED; 
modeleffects  dage rage hanging1 diabetes2 hypertension2  
HLA_GRP1 HLA_GRP3 HLA_GRP4 renal1 renal2 renal3 renal4 renal6 
cld_isch dweight tyear2003 tyear2004 tyear2005 tyear2006 tyear2007 
tyear2008 tyear2009 tyear2010 tyear2011 tyear2012 tyear2013 
tyear2014 tyear2015; 
ods output Parameterestimate=survival; 
run; 








keep parm dage rage hanging LOGWARM hypertension HLA_GRP 









proc phreg data=mvadata; 
class hanging(ref='0') hanging(ref='0') hypertension(ref='1') 
HLA_GRP(ref='2') diabetes(ref='1') renal(ref='5')  rec_unit 
tyear/param=ref; 







proc phreg data=kidneyfinal3; 
class hanging(ref='0')/param=reference; 
model gsurvfinal*gcensor(0)=  hanging; 
hazardratio hanging/diff=ref; 
run; 
proc phreg data=kidneyfirst2; 
class dtype (ref='1') 
hanging(ref='0')hypertension(ref='1')hla_grp(ref='2')renal(ref='5')/param
=ref; 









if gsurv=>1826.25 then firstfive=1826.25;else firstfive=gsurv; 
run; 
data kidneyfirst2; 




/*impact of hanging on delayed graft function and primary non-
function*/ 













PROC SORT DATA=CREATININE; 
BY TX_ID; 
RUN; 





MERGE kidneyDCDONLY CREATININE; 
BY TX_ID; 
IF hangdcd=. THEN DELETE; 
RUN; 






if SERUM12 ne . and RAGE ne . and Rsex ne . and Rethnic ne 9 then 
do; 
      * non-black males *; 
      if Rsex=1 and Rethnic ne 3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))));      
      end; 
      * black males *; 
      if RSex=1 and Rethnic=3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))*1.210));        
      end; 
      * non-black females *; 
      if Rsex=2 and Rethnic ne 3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))*0.742));        
      end; 
      * black females *; 
      if Rsex=2 and Rethnic=3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))*0.742*1.210));  




ods graphics on; 




ods graphics off; 
 
proc mi data=CAMCREAT out=five nimpute=20 seed=7654321; 
class hanging  hypertension HLA_GRP diabetes renal REC_UNIT 
TYEAR ; 
fcs discrim(Diabetes=dage rage cld_isch dweight); 
 
FCS discrim(Hypertension=dage rage cld_isch dweight); 
 
FCS logistic(HLA_GRP=dage rage hanging  hypertension diabetes 
renal rec_unit tyear cld_isch dweight); 
 
FCS reg(cld_isch= dage rage hanging  hypertension HLA_GRP 
diabetes renal rec_unit tyear  dweight); 
FCS reg(dweight= dage rage hanging  hypertension HLA_GRP 
diabetes renal rec_unit tyear);  
FCS reg(logwarm=dage rage hanging  hypertension HLA_GRP 
diabetes renal rec_unit tyear); 
var dage rage  hanging logwarm hypertension HLA_GRP diabetes 
renal rec_unit tyear cld_isch dweight MDRD; 
run; 




DIABETES REC_UNIT tyear; 
MODEL MDRD=dage rage  hanging  hypertension HLA_GRP diabetes 
renal rec_unit tyear cld_isch dweight/SOLUTION; 
random rec_unit; 




PROC FREQ DATA=CAMCREAT; 
TABLE MDRD;RUN; 
PROC GLM DATA=CAMCREAT; 
CLASS  hanging(ref='0'); 
MODEL MDRD= hanging /SOLUTION CLPARM; 














PROC SORT DATA=PARMS_GLM; 
BY PARAMETER _IMPUTATION_; 
RUN; 
 
proc mianalyze PARMS=PARMS_GLM2; 
modeleffects  PHANGING1 ; 
ods OUTPUT ParameterEstimates=PARMS_GLM3; 
run; 








keep parm dage rage hanging dtype hypertension HLA_GRP diabetes 
renal rec_unit dbg rbg tyear cld_isch dweight probt HR UCI LCI; 
run; 
 









proc sort data=hypoxic;by donor_id;run; 
data liver;set standard.liver_tx;if 
mdy(01,01,2003)<=tx_date<mdy(01,01,2017); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);run; 
proc sort data=liver;by donor_id;run; 
data liverrisk;merge hypoxic liver;by donor_id;if recip_id=. then delete; 
run; 
proc freq data=liverrisk;table hang; 
run; 
 
/*Find missing patient survival data*/ 
proc freq data=liverrisk;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=liverrisk;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data liverrisk2;set liverrisk; if psurv=.;run; 
proc sort data=liverrisk2;by recip_id;run; 
data total;set standard.liver_tx;run; 
proc sort data=total;by recip_id;run; 
data totalmissing;merge liverrisk2 total; 
by recip_id;if hangdcd=. then delete;run; 
data LiverMissing2;set totalmissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=Livermissing2;by recip_id;run; 
data Livermissing3;merge liverrisk2 livermissing2;by recip_id;run; 
data Livermissing4;set livermissing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data Livermissing5;set livermissing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=livermissing5;by recip_id;run; 
proc sort data=liverrisk;by recip_id;run; 
data liverall;merge liverrisk livermissing5;by recip_id;run; 
proc freq data=liverall;table hangdcd;run; 
data liverAnalysis;set liverall;if psurv=. then psurv=psurvfinal;if pcens=. 
then pcens=patientsurvival; 
run; 
proc freq data=liveranalysis;table hangdcd;run; 
 
/*5 year censor for Liver analysis*//*104 patients deleted due to no 
survival information=1%of data*/ 
 
data liveranalysis2;set liveranalysis; 
if psurv=>3650 then psurvival=3650;else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650;else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0;else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0;else gcensor=gcens; 
if rage>40 then rage_grp=2;else recip_age_grp=1; 
if dage>40 then dage_grp=2;else donor_age_grp=1; 
if pcensor=. then delete; 








proc lifetest data=liveranalysis2 notable plots=(S,LLS); 
time psurvival*pcensor(0); 
strata hangdcd;run; 






/*Data Tables Liver*/ 
data LiverFinal;set Liveranalysis2; 
if rethnic=1 then recip_ethnic=1;else recip_ethnic=2; 
if graft_no=1 then Tx=1;if graft_no=2 then Tx=2;if graft_no>2 then 
Tx=3; 
if crf_tx>85 then sensitised=1;else sensitised=0; 
if txcountry='UNITED KINGDOM';if pcensor=. then delete;if gcensor=. 
then delete; 
if dcountry='UNITED KINGDOM'; 
if rhcv=1 then rhepc=1;if rhcv=2 then rhepc=2;if rhcv in (3,4,5,6,7,8,9,.) 
then rhepc=3;if liverd=. then liverd=4; 
if dtype=2 and hangdcd=0 then Hangtype=3; 
if dtype=1 and hangdcd=0 then Hangtype=4; 
else hangtype=hangdcd; 
if rsex in (3,4,5,6,7,8,9,.) then recip_sex=3; 
else recip_sex=rsex; 
if renal=. then renal=5; 
run; 
 















proc freq data=liverfinal; 
table rec_unit*cof; 










proc phreg data=liverfinal plots=survival; 
class hanging(ref='0') hypertension smoker (ref='1') 
liverd(ref='4')/param=ref ; 





proc phreg data=liverfinal plots=survival; 
class hanging(ref='0') hypertension smoker (ref='1') 
liverd(ref='4')/param=ref ; 


















proc freq data=liverfinal; 
table hangtype; 
run; 








proc freq data=liverfinal2; 
table hangtype*livpd_grp/chisq; 
run; 












proc sort data=hypoxic;by donor_id;run; 
data heart;set standard.cardio_tx;if 
mdy(01,01,2000)<=tx_date<mdy(01,01,2016); 
if txcountry='UNITED KINGDOM';if dtype in (1,2);run; 
proc sort data=heart;by donor_id;run; 




/*Find missing patient survival data*/ 
proc freq data=heartrisk;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=heartrisk;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data heartrisk2;set heartrisk; if psurv=.;run; 
proc sort data=heartrisk2;by recip_id;run; 
data complete;set standard.cardio_tx;run; 
proc sort data=total;by recip_id;run; 
data completemissing;merge heartrisk2 complete; 
by recip_id;if hangdcd=. then delete;run; 
data heartMissing2;set completemissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=heartmissing2;by recip_id;run; 
data heartmissing3;merge heartrisk2 heartmissing2;by recip_id;run; 
data heartmissing4;set heartmissing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data heartmissing5;set heartmissing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=heartmissing5;by recip_id;run; 
proc sort data=heartrisk;by recip_id;run; 
data heartall;merge heartrisk heartmissing5;by recip_id;run; 
proc freq data=heartall;table hangdcd;run; 
data heartAnalysis;set heartall;if psurv=. then psurv=psurvfinal;if 
pcens=. then pcens=patientsurvival; 
run; 
proc freq data=heartanalysis;table hangdcd*tx_type;run; 
 
/*censor data at 5 years*/ 
 
data heartanalysis2;set heartanalysis; 
if psurv=>3650 then psurvival=3650;else psurvival=psurv; 
if gsurv=>3650 then gsurvfinal=3650;else gsurvfinal=gsurv; 
if psurv=>3650 and pcens=1 then pcensor=0;else pcensor=pcens; 
if gsurv=>3650 and gcens=1 then gcensor=0;else gcensor=gcens; 
if rage>40 then rage_grp=2;else recip_age_grp=1; 
if dage>40 then dage_grp=2;else donor_age_grp=1; 
if pcensor=. then delete; 
run; 








/*Data Tables heart*/ 
data heartFinal;set heartanalysis2; 
if rethnic=1 then recip_ethnic=1;else recip_ethnic=2; 
if graft_no=1 then Tx=1;if graft_no=2 then Tx=2;if graft_no>2 then 
Tx=3; 
if crf_tx>85 then sensitised=1;else sensitised=0; 
if txcountry='UNITED KINGDOM';if pcensor=. then delete; 
if dcountry='UNITED KINGDOM'; 
if rhcv=1 then rhepc=1;if rhcv=2 then rhepc=2;if rhcv in (3,4,5,6,7,8) 
then rhepc=3; 
run; 





if tx_type in (60,63,70); 
if hanging=1 then hypo=1; 
if drown=1 then hypo=2; 
if Co=1 then hypo=3; 
if hypoxic=0 then hypo=4; 
if psurvival >365 then psurvfinal=365;else psurvfinal=psurvival; 




/*coding for primary lung disease*/ 
data lungsurvival2; 
set lungsurvival; 
if pcd=327 then plungd=1; 
if pcd=322 then plungd=2; 
if pcd=323 then plungd=3; 
if pcd=325 then plungd=4; 
if past_smoker=1 then smoker=1; 
if past_smoker=2 then smoker=2; 
if past_smoker in (3,4,5,6,7,8,9,.) then smoker=3; 
run; 




data test;set lungsurvival2;if plungd=. then plungd=5;run; 
 
 










ods graphics on; 
proc phreg data=test plots= survival; 
class hangdcd(ref='0') smoker(ref='1')plungd(ref='2')/param=ref ; 




proc phreg data=test; 
 
 
/*Lung cause of death*/ 
data lungdeath; 
set lungsurvival; 
if hangdcd=1;if pcens=1; 
keep rcod rdod cof recip_id hangdcd psurv pcens; 
run; 
proc sort data=lungdeath;by recip_id;run; 
data recipient2;set database.recipient_note;run; 
proc sort data=recipient2;by recip_id;run; 
data together;merge lungdeath recipient2;by recip_id;if hangdcd=1;run; 
 
proc freq data=together;table rcof;run; 
 





























































































/*down time and hanging time*/ 
data donorinfo; 
set database.donor_comment; 
























































































keep donor_id note_text; 
run; 










































































124018) then delete; 
run; 












/* attempt at propensity score matching*/ 
proc logistic data=kidneyfinal3 descending; 
class dtype hypertension HLA_GRP  renal tyear; 
 model hanging=dage rage dtype hypertension HLA_GRP  
renal cld_isch dweight tyear; 
 output out=study pred=ps xbeta=logit_ps; 
 run; 
 
proc univariate data=study; 
 class hanging; 
  var ps; 










if ps=. then delete; 
if dtype=2; 
run; 
data prop_score_treated prop_score_untreated; 
set study2; 
if hanging=1 then output prop_score_treated; 
else if hanging=0 then output prop_score_untreated; 
run; 






%psmatch_multi(subj_dsn = prop_score_treated, 
subj_idvar = RECIP_id, 
subj_psvar = ps, 
cntl_dsn = prop_score_untreated, 
cntl_idvar = RECIP_id, 
cntl_psvar = ps, 
match_dsn = matched_pairs1, 
match_ratio = 1, 

























    LENGTH 
        recip_id           8 
        matched_recip_id   8 
        subj_score         8 
        cntl_score         8 ; 
    FORMAT 
        recip_id         F12. 
        matched_recip_id F12. 
        subj_score       BEST12. 
        cntl_score       BEST12. ; 
    INFORMAT 
        recip_id         BEST12. 
        matched_recip_id BEST12. 
        subj_score       BEST12. 
        cntl_score       BEST12. ; 
    INFILE 'E:\SASWork\_TD37152_MSVSAS01_\#LN00057' 
        LRECL=53 
        ENCODING="WLATIN1" 
        TERMSTR=CRLF 
        DLM='7F'x 
        MISSOVER 
        DSD ; 
    INPUT 
        recip_id         : BEST32. 
        matched_recip_id : BEST32. 
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        subj_score       : BEST32. 











proc sort data=matching; 
 





%macro psmatch_multi(subj_dsn =, /* Data set with subject data */  
subj_idvar=,   /* Subject ID variable in 
&SUBJ_DSN */  
subj_psvar=,   /* Propensity Score variable in 
&SUBJ_DSN */  
cntl_dsn=,     /* Data set with control data  */ 
cntl_idvar=,   /* Control ID variable in data set 
&CNTL_DSN */  
cntl_psvar=,   /* Propensity Score variable in 
&CNTL_DSN */  
match_dsn=,    /* Output data set */ 
match_ratio=,  /* Number of matches per subject  */ 
score_diff=,   /* Maximum allowable absolute 
differences between propensity 
scores*/  
opt=none,      /* Type of matching optimization -- 
by number of matches( = num), 
by closeness ( = close), 
or default none ( = none) */ 
seed=1234567890); /* Optional seed for random number  
generator */  
/*******************************************************************/  
/*  Delete final matched pairs dataset, if exists from a prior run 
/*******************************************************************/  





/*  Make all internal macro variables local 
/********************************************/ 
%local __dsid __varnum __cntl_type __rc __num; 
/**********************************************/ 
/* Control ID variable (numeric or character) 
/**********************************************/ 
%let __dsid      = %sysfunc(open(&cntl_dsn,i)); 
%let __varnum    = %sysfunc(varnum(&__dsid, &cntl_idvar)); 
%let __cntl_type = %sysfunc(vartype(&__dsid, &__varnum)); 
%let __rc        = %sysfunc(close(&__dsid)); 
%put &__cntl_type; 
/**************************/ 
/*  Subject Matching Data 
/**************************/ 




/*  Control Matching Data 
/**************************/ 




/*  Find all possible matches between subjects and controls 
/*  Propensity scores must match within +/- &match (radius) 
/************************************************************/ 
PROC SQL;  
create table __matches0 as 
select  
s.&subj_idvar as subj_idvar, 
c.&cntl_idvar as cntl_idvar, 
s.&subj_psvar as subj_score, 
c.&cntl_psvar as cntl_score, 
abs(s.&subj_psvar - c.&cntl_psvar) as diff_score 
from __subjmatch s left join __contmatch c 
on abs(s.&subj_psvar - c.&cntl_psvar) <= &score_diff 
order by subj_idvar; 
quit;  
/*************************************/ 





/*  Create a random number for each match 
/*-----------------------------------------*/ 
call streaminit(&seed); 
rand_num = rand('uniform'); 
/*-----------------------------------------------*/ 
/*  Remove subjects who had no possible matches 
/*-----------------------------------------------*/ 
%if &__cntl_type = C %then %do; 
if cntl_idvar ^= ''; 
%end;  
%else %if &__cntl_type = N %then %do; 
%end;  
if cntl_idvar ^= .;  
/*--------------------------------------------*/ 
/*  Round DIFF_SCORE to an order of magnitude 
/*--------------------------------------------*/ 
%if &opt = close %then %do; 
if . < diff_score < .000000001 then  
sort_diff_score = .000000001;  
else if .000000001 <= diff_score < .00000001 then  
sort_diff_score = round(diff_score, .000000001);  
else if .00000001 <= diff_score < .0000001 then  
sort_diff_score = round(diff_score, .00000001);  
else if .0000001 <= diff_score < .000001 then  
sort_diff_score = round(diff_score, .0000001);  
else if .000001 <= diff_score < .00001 then  
sort_diff_score = round(diff_score, .000001);  
else if .00001 <= diff_score < .0001 then  
sort_diff_score = round(diff_score, .00001);  
else if .0001 <= diff_score < .001 then  
sort_diff_score = round(diff_score, .0001);  
else if .001 <= diff_score < .01 then  
sort_diff_score = round(diff_score, .001);  
else if .01 <= diff_score < .1 then  
sort_diff_score = round(diff_score, .01);  
else if diff_score >= .1 then  
sort_diff_score = round(diff_score, .1);  
%end;  
/*---------------------------*/ 
/*  Create a dummy variable 
/*---------------------------*/ 
n = 1;  
run;  
/******************************************************************/  
/*  Find the number of potential control matches for each subject 
/******************************************************************/  
PROC FREQ data=__possible_matches noprint; 







/*  Only keep subjects with minimum number of possible matches 
/*------------------------------------------------------------*/ 
if count >= &match_ratio; 
run;  





/*  Count the number of entries in the file of possible matches 
/*****************************************************************/  
%let __dsid = %sysfunc(open(__matches_freq,i)); 
%let __num = %sysfunc(attrn(&__dsid,nobs)); 
%let __rc = %sysfunc(close(&__dsid)); 
%do %while (&__num >= 1);  
PROC SORT data=__matches_freq; 
by %if &opt = num %then %do; 
count  
%end;  






/*  Get first randomly selected subject 
/*  For options, with either the least number of matches or 
/*   the closest match 
/**************************************************************/ 
DATA __first_subj_idvar (keep = subj_idvar); 
set __matches_freq; 
by n;  
if first.n;  
run;  
/**************************************/ 
/*  Get all matches for that subject 
/***************************************/ 
PROC SORT data=__matches_freq; 
by subj_idvar %if &opt = num %then %do; 
count  
%end;  










num + 1;  
run;  
DATA __new_matched_pairs (keep = subj_idvar cntl_idvar 
   subj_score cntl_score); 
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 set __all_first_id; 
label subj_idvar = 
"Subject ID, original variable name &subj_idvar" 
cntl_idvar =  
"Matched Control ID, original variable name &cntl_idvar" 
subj_score =  
"Subject Propensity Score, original var name &subj_psvar" 
cntl_score =  
"Matched Control Propensity Score, orig var &cntl_psvar" 
;  
if num <= &match_ratio; 
run;  
/******************************************/ 
/*  Remove subjects with matched controls 
/******************************************/ 







by subj_idvar;  
if ^id;  
run;  
/************************************************************/ 
/*  Remove all matched pairs that include selected controls 
/************************************************************/ 











if ^id;  
run;  




/*  Add new matched pairs to set of final matched pairs 
/********************************************************/ 




/*  Find the number of potential control matches for each subject 
/****************************************************************/  
PROC FREQ data=__possible_matches noprint; 








/*  Only keep subjects with the minimum number of matches 
/*---------------------------------------------------------*/ 
if count >= &match_ratio; 
run;  
/********************************************************/ 
/*  Determine number of remaining possible matched pairs 
/********************************************************/ 
%let __dsid = %sysfunc(open(__matches_freq,i)); 
%let __num = %sysfunc(attrn(&__dsid,nobs)); 
%let __rc = %sysfunc(close(&__dsid)); 
%end;  /*  of " %do %while (&__num >= 1);  */ 
/*****************************************************************/  
/*  Create final output data set with one observation for each 
/*  original subject. 
/*  
/*  Variable names in output data set are: 
/*    SUBJ_IDVAR, SUBJ_SCORE, CNTL_IDVAR, CNTL_SCORE 
/*  
/*  If no match for subject ID (SUBJ_IDVAR), then CNTL variables 
/*    (CNTL_IDVAR, CNTL_SCORE) are missing. 
/*****************************************************************/  
PROC SORT data=__final_matched_pairs; 
by subj_idvar subj_score; 
run;  
DATA __subjmatch_orig; 
set __subjmatch (rename= (&subj_idvar = subj_idvar 
&subj_psvar = subj_score)); 
run;  
PROC SORT data=__subjmatch_orig; 
by subj_idvar subj_SCORE ; 
run;  
DATA &match_dsn (label="Final Matched Pairs for PS Matching"); 
merge __final_matched_pairs 
__subjmatch_orig; 
by subj_idvar subj_score; 
run;  
/***************************************************/ 
/*  Delete all temporary datasets created by macro 
/***************************************************/ 
PROC DATASETS nolist; 
delete __contmatch __final_matched_pairs __matches_freq0 
__matches_freq __match_pair0 __matchfreq 
__match_remove_cont __match_remove_subj 






%mend psmatch_multi;  
 
/*checking differenc in propensity scores*/ 
 
 
/*assess impact of macthed cohort on outcomes*/ 
data kidneypropatched; 
set kidneyfinal3; 




















proc freq data=propmatch; 
table hanging*graft_no; 
run; 








proc logistic data=propmatchdcd; 
model pnf=hanging; 
where pnf in (1,0); 
run; 
 








if gsurv > (5*365.25) then gsurv5=(5*365.25); 
else gsurv5=gsurv; 
if gsurv > (5*365.25) then gcens5=0; 
else gcens5=gcens; 
 
if gsurv > (1*365.25) then gsurv1=365.25; 
else gsurv1=gsurv; 




if psurv > (5*365.25) then psurv5=5; 
else psurv5=psurv/365.25; 
if psurv > (5*365.25) then pcens5=0; 
else pcens5=pcens; 
 
if psurv > (1*365.25) then psurv1=365.25; 
else psurv1=psurv; 
if psurv > (1*365.25) then pcens1=0; 
else pcens1=pcens; 
 
if gsurv=0 and gcens=1 then pnf1=1; 
else pnf1=0; 
if diabetes=3 then diabetes=.; 














proc sgplot data=propcheck; 
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PROC SORT DATA=CREATININE; 
BY TX_ID; 
RUN; 





MERGE propmatch2dcd CREATININE; 
BY TX_ID; 
IF hangdcd=. THEN DELETE; 
RUN; 






if SERUM12 ne . and RAGE ne . and Rsex ne . and Rethnic ne 9 then 
do; 
      * non-black males *; 
      if Rsex=1 and Rethnic ne 3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))));      
      end; 
      * black males *; 
      if RSex=1 and Rethnic=3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))*1.210));        
      end; 
      * non-black females *; 
      if Rsex=2 and Rethnic ne 3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))*0.742));        
      end; 
      * black females *; 
      if Rsex=2 and Rethnic=3 then do; 
            mdrd =round((186*((SERUM12/88.4)**(-1.154))*(Rage**(-
0.203))*0.742*1.210));  




ods graphics on; 




ods graphics off; 
 
PROC GLM DATA=camcreatpsdcd; 





PROC FREQ DATA=CAMCREAT; 
TABLE MDRD;RUN; 
 






PROC GLM DATA=CAMCREATps; 
CLASS  hanging(ref='0'); 
MODEL MDRD= hanging /SOLUTION CLPARM; 












if txcountry='UNITED KINGDOM';If dtype in (1,2);if rage=>18; 
if dcountry='UNITED KINGDOM';if tx_type in (10,11,12,13,14);if 
dage=>10; 
if recip_id=>0 then id=1; 
run; 
 
/*missing death data*/ 
proc freq data=kidney;table pcens;run; 
data donors;set standard.donors;run; 
proc sort data=kidney;by donor_id;run; 
proc sort data=donors;by donor_id;run; 
data kidney2;set kidney; if psurv=.;run; 
proc sort data=kidney2;by recip_id;run; 
data all;set standard.kidney_tx;run; 
proc sort data=all;by recip_id;run; 
data Allmissing;merge kidney2 all; 
by recip_id;if id=. then delete;run; 
data Missing2;set allmissing;if psurv=. then delete; 
rename tx_date=first_tx_date psurv=Patientdays 
pcens=patientsurvival; 
keep recip_id tx_date psurv pcens; 
run; 
proc sort data=missing2;by recip_id;run; 
data missing3;merge kidney2 missing2;by recip_id;run; 
data missing4;set missing3;if tx_date>first_tx_date then 
duration=tx_date-first_tx_date; 
run; 
data missing5;set missing4;if patientdays=>duration then 
psurvfinal=patientdays-duration; 
run; 
proc sort data=missing5;by recip_id;run; 
proc sort data=kidney;by recip_id;run; 
data Kidneyall;merge kidney missing5;by recip_id;run; 
proc freq data=kidneyall;table id;run; 
data Analysis;set kidneyall;if psurv=. then psurv=psurvfinal;if pcens=. 
then pcens=patientsurvival; 
run; 
proc freq data=analysis;table pcens;run; 
 
/*checking Guys survival*/ 
data Guys; 
set analysis; 
if mdy(01,01,2006)<=tx_date<mdy(01,01,2010)then group=1; 
















/*own attempt at doing survival form listing over set period*/ 
data history;set standard.kidwait; if 
mdy(01,01,2006)<=adate_on<mdy(01,01,2016);run; 
data history2; set history;surv=d_date-adate_on;if endstat in ('DA','DS', 
'D', 'DR') then died=1;if endstat='L' then delete;run; 
data history3;set history2;if surv=>0 then died=1;run; 
data history4;set history3;if died=. then newtimes=mdy(01,01,2016)-
adate_on;run; 
proc freq data=history4;table died;run; 
proc sort data=history4;by recip_id;run; 
proc sort data=analysis;by recip_id;run; 
 
data allhistory;merge analysis history4;by recip_id; if adate_on=. then 
delete;if mdy(01,01,2006)<=adate_on<mdy(01,01,2016);run; 
proc sort data=allhistory;by recip_id rsex tx_date;run; 
data allhistory allhistory2; 
  set allhistory; 
  by recip_id rsex tx_date; 
  if last.rsex then output allhistory; 








data ahistory4;set allhistory;time=tx_date-adate_on;run; 
data ahistory5;set ahistory4;timing=time+psurv;run; 
data ahistory6;set ahistory5;if pcens=1 then died=1;if donor_id=. then 
txd=0;else txd=1;run; 
proc freq data=ahistory6;table txd*tx_date;run; 
data ahistory7;set ahistory6;if died=1;times=surv;run; 
data ahistory8;set ahistory6;if txd=1 then times=timing; 
run; 
data ahistory9;set ahistory6;if txd=0 and died=. then 
times=newtimes;run; 
proc sort data=ahistory7;by recip_id;run; 
proc sort data=ahistory8;by recip_id;run; 
proc sort data=ahistory9;by recip_id;run; 
data aallhistory;merge ahistory7 ahistory8;by recip_id;run; 
data aallhistory2; merge ahistory9 aallhistory; by recip_id;run; 
proc sort data=analysis;by recip_id;run; 
proc sort data=ahistory9;by recip_id;run; 
data aallhistory;merge ahistory9 analysis;by recip_id;if adate_on=. then 
delete;run; 
data sorting;set aallhistory; run; 
data sorting2; set sorting;newtimes=tx_date-adate_on;run; 
data sorting3; set sorting2;timelisting=psurvfinal+newtimes;run; 
data sorting4; set sorting3;if timelisting=. then timelisting=surv;run; 
data sorting5; set sorting4; if timelisting=. then timelisting=times;run; 
data sorting6; set sorting5;if timelisting=. then timelisting=wait_time + 
psurvfinal;run; 
data sorting7;set sorting6;if timelisting=. then timelisting=wait_time + 
psurv;run; 
data sorting8;set sorting7; listingcentre=tx_cent; 
if dcountry='OVERSEAS' then delete; 




if tx_cent in ('G0501','G1501', 'G1403','G1401') THEN 
LISTINGcENTRE='G1501'; 
if tx_cent in ('H1305', 'H1202') then listingcentre='H1202'; 
if died=. then died=0;run; 
proc sort data=sorting8; by  listingcentre;run; 






/*import risk score data*/ 
 
DATA WORK.Book4; 
    LENGTH 
        Rec_Unit         $ 5 
        Score1             8 
        Score1b            8 
        Score1c            8 
        Score2a            8 
        Score2b            8 
        Score2c            8 
        EarlyScore1a       8 
        Earlyscore1b       8 
        Earlyscore1c       8 
        Earlyscore2a       8 
        Earlyscore2b       8 
        Earlyscore2c       8 
        Latescore1a        8 
        Latescore1b        8 
        Latescore1c        8 
        Latescore2a        8 
        Latescore2b        8 
        Latescore2c        8 ; 
    FORMAT 
        Rec_Unit         $CHAR5. 
        Score1           BEST12. 
        Score1b          BEST12. 
        Score1c          BEST12. 
        Score2a          BEST12. 
        Score2b          BEST12. 
        Score2c          BEST12. 
        EarlyScore1a     BEST12. 
        Earlyscore1b     BEST12. 
        Earlyscore1c     BEST12. 
        Earlyscore2a     BEST12. 
        Earlyscore2b     BEST12. 
        Earlyscore2c     BEST12. 
        Latescore1a      BEST12. 
        Latescore1b      BEST12. 
        Latescore1c      BEST12. 
        Latescore2a      BEST12. 
        Latescore2b      BEST12. 
        Latescore2c      BEST12. ; 
    INFORMAT 
        Rec_Unit         $CHAR5. 
        Score1           BEST12. 
        Score1b          BEST12. 
        Score1c          BEST12. 
        Score2a          BEST12. 
        Score2b          BEST12. 
        Score2c          BEST12. 
        EarlyScore1a     BEST12. 
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        Earlyscore1b     BEST12. 
        Earlyscore1c     BEST12. 
        Earlyscore2a     BEST12. 
        Earlyscore2b     BEST12. 
        Earlyscore2c     BEST12. 
        Latescore1a      BEST12. 
        Latescore1b      BEST12. 
        Latescore1c      BEST12. 
        Latescore2a      BEST12. 
        Latescore2b      BEST12. 
        Latescore2c      BEST12. ; 
    INFILE 'E:\SASWork\_TD6264_MSVSAS01_\#LN00023' 
        LRECL=86 
        ENCODING="WLATIN1" 
        TERMSTR=CRLF 
        DLM='7F'x 
        MISSOVER 
        DSD ; 
    INPUT 
        Rec_Unit         : $CHAR5. 
        Score1           : BEST32. 
        Score1b          : BEST32. 
        Score1c          : BEST32. 
        Score2a          : BEST32. 
        Score2b          : BEST32. 
        Score2c          : BEST32. 
        EarlyScore1a     : BEST32. 
        Earlyscore1b     : BEST32. 
        Earlyscore1c     : BEST32. 
        Earlyscore2a     : BEST32. 
        Earlyscore2b     : BEST32. 
        Earlyscore2c     : BEST32. 
        Latescore1a      : BEST32. 
        Latescore1b      : BEST32. 
        Latescore1c      : BEST32. 
        Latescore2a      : BEST32. 
        Latescore2b      : BEST32. 












proc sort data=riskscores; 
by rec_unit; 
run; 





merge guys riskscores; 
by rec_unit; 
run; 






if prd in (210,211,212,213,214,215,216,217,219) then renal=1; 
if prd in (220,221,222,223,224,225,229) then renal=2; 
if prd in (241,242) then renal=3; 
if prd in (280,281) then renal=4; 
if score1<20 then risky=1; 
if 20<=score1<25 then risky=2; 
if 25<=score1<30 then risky=3; 
if score1=>32 then risky=4; 
if score1b<48.5 then risky1b=1; 
if 48.5<=score1b<60 then risky1b=2; 
if 60<=score1b<75.0 then risky1b=3; 
if score1b=>75 then risky1b=4; 
if score1c<52 then risky1c=1; 
if 52<=score1c<66.5 then risky1c=2; 
if 66.5<=score1c<83.5 then risky1c=3; 
if score1c=>83.5 then risky1c=4; 
if score2a<90 then risky2a=1; 
if 90<=score2a<111 then risky2a=2; 
if 111<=score2a<160 then risky2a=3; 
if score2a=>160 then risky2a=4; 
if score2b<216 then risky2b=1; 
if 216<=score2b<269 then risky2b=2; 
if 269<=score2b<389.5 then risky2b=3; 
if score2b=>389.5 then risky2b=4; 
if score2c<237 then risky2c=1; 
if 237<=score2c<291.5 then risky2c=2; 
if 291.5<=score2c<438.5 then risky2c=3; 
if score2c=>438.5 then risky2c=4; 
if tx=. then tx=0; 




if renal=. then renal=5; 
run; 
proc  freq data=model2; 
table renal; 
run; 
proc phreg data=model2; 
class renal(ref='5') risky(ref='2')tx_yr graft_no (ref='1'); 
model psurv*pcens(0)=renal  rage wait_time risky tx_yr; 
hazardratio risky/diff=ref; 
run; 











if dcountry='OVERSEAS' then delete; 





if died=1 or pcens=1 or patientsurvival=1 then death=1;else death=0; 
if reg_age<18 then delete;run; 
DATA ; 
prOC UNIVARIATE DATA=ALL2;VAR score1;run; 







if score1=>30 then risky=4; 
if score1<20 then risky=1; 
if 20<=score1<25 then risky=2; 
if 25<=score1<30 then risky=3; 
run; 




data all4;set all3;if  donor_id=. then txde=0;else txde=1;run; 
proc freq data=all4;table txdE;run; 
 
data all5;set all4;run; 
 
proc freq data=all3;table risky*death;run; 
 
data external;set all5;if txde=0;run; 





proc sort data=death;by recip_id;run; 
 
data externaldeath;merge external death;by recip_id;if txde=. then 
delete;run; 
data new; set externaldeath; keep recip_id death death_date;run; 
proc freq data=new;table death;run; 
data new2;set new;if death=1 then deadly=1;run; 
data new3;set new2;if death_date=>0 then deadly=1;run; 
proc freq data=new3;table deadly;run; 
proc sort data=all5; by recip_id;run; 
proc sort data=new3;by recip_id;run; 
 
data alldeath;merge all5 new3;by recip_id;run; 
data alldeath2;set alldeath; if death=1 and deadly=. then deadly=1;run; 
 
data alldeath3;set alldeath2;if deadly=. then deadly=0;run; 
proc freq data=alldeath3;table listingcentre*risky;run; 
 
data alldeath4;set alldeath3; 
rec_unit=listingcentre;new_time=timelisting;if recip_id=. then 
real=0;else real=1;run; 
proc freq data= alldeath4;table new_time;run; 
 
data alldeathnow;set alldeath4;if new_time=. then 
new_time=wait_time+psurv;run; 
proc freq data=alldeathnow;table new_time;run; 
data checking;set alldeathnow;if new_time=.;run; 
data checking2;set checking; format death_time date9. ;run; 
 
 
data checking3;set checking2; new_time=death_time-adate_on;run; 
 
data checking4;set checking3; if new_time=. then new_time=wtime;run; 
proc sort data=checking4;by recip_id;run; 
proc sort data=alldeath4;by recip_id;run; 
proc freq data=alldeath4;table deadly;run; 
data alldeath5;merge alldeath4 checking4;by recip_id;run; 










survival=psurv + wtime; 
run; 































if tx_date=>0 and tx_date<mdy(01,01,2016) then txde=1 and 














proc sort data=infoxx4;by recip_id;run; 
data kidneyall;set standard.kidney_tx;run; 
proc sort data=kidneyall;by reciP_id;run; 
data sense; merge infoxx4 kidneyall;by recip_id;if txde=. then delete; 
if dage<10 then delete;if txcountry='UNITED KINGDOM';if rage=<18 
then delete;if tx_date<=mdy(01,01,2006);run; 
data sense2;set sense;survival=psurv+wtime;run; 
 
proc sort data=infoxx4;by recip_id;run; 
proc sort data=kidney; by recip_id;run; 





proc sort data=info2; by recip_id;run; 
proc sort data=infox3; by recip_id;run; 
data together; merge info2 infox3; by recip_id;run; 
proc sort data=infoxx5;by recip_id; run; 
proc sort data=together;by recip_id;run; 
data together2; merge together infoxx5; by recip_id;run; 
proc sort data=sense2;by recip_id;run; 
proc sort data=together2;by recip_id;run; 
data together3;merge together2 sense2;by recip_id; 
;run; 
proc freq data=together3;table survival;run; 
data news;set together3;if survival=. then delete;run; 
data letsee;set together3;if survival=.  ;death=datepart(death_date);run; 
data letsee2;set letsee;date1=death;label date1="DATE with DATE9. 
format"; 
format death date9.;run; 
data letsee3;set letsee2;survival2=death-adate_on;run; 
 
proc sort data=letsee3;by recip_id;run; 
proc sort data=news;by recip_id;run; 
data news2;merge letsee3 news;by recip_id;run; 
proc freq data=news2;table survival2;run; 
data news3;set news2;if survival2=. then surviving=survival;else 
surviving=survival2;if listingcentre=. then listingcentre=tx_cent; 
if tx_cent in ('G0501','G1501', 'G1403','G1401') THEN 
LISTINGcENTRE='G1501'; 
if tx_cent in ('H1305', 'H1202') then listingcentre='H1202';run; 
proc freq data=news3;table surviving;run; 
proc freq data=news3;table listingcentre;run; 
data keep; 
set news3; 







/*checking negative times*/ 
data checking; 
set together2; 
if new_time<0 then delete; 
run; 













ods graphics on; 












if risky in (1,3); 
run; 
 
/*Overall time period-Risk scores*/ 





if score1b<48.5 then risky1b=1; 
if 48.5<=score1b<57.5 then risky1b=2; 
if 57.5<=score1b<75.0 then risky1b=3; 
if score1b=>75 then risky1b=4; 
if score1c<52 then risky1c=1; 
if 52<=score1c<66.5 then risky1c=2; 
if 66.5<=score1c<83.5 then risky1c=3; 
if score1c=>83.5 then risky1c=4; 
if score2a<89 then risky2a=1; 
if 89<=score2a<111 then risky2a=2; 
if 111<=score2a<160 then risky2a=3; 
if score2a=>160 then risky2a=4; 
if score2b<216 then risky2b=1; 
if 216<=score2b<269 then risky2b=2; 
if 269<=score2b<389.5 then risky2b=3; 
if score2b=>389.5 then risky2b=4; 
if score2c<237 then risky2c=1; 
if 237<=score2c<291.5 then risky2c=2; 
if 291.5<=score2c<438.5 then risky2c=3; 
if score2c=>438.5 then risky2c=4; 
run; 





















if earlyscore1a<17 then early1a=1; 
if 17<=earlyscore1a<23 then early1a=2; 
if 23<=earlyscore1a<28 then early1a=3; 
if earlyscore1a=>28 then early1a=4; 
if earlyscore1b<39.5 then early1b=1; 
if 39.5<=earlyscore1b<53.0 then early1b=2; 
if 53.0<=earlyscore1b<68.5 then early1b=3; 
if earlyscore1b=>68.5 then early1b=4; 
if earlyscore1c<45.5 then early1c=1; 
if 45.5<=earlyscore1c<59.5 then early1c=2; 
if 59.5<=earlyscore1c<73.5 then early1c=3; 
if earlyscore1c=>73.5 then early1c=4; 
if earlyscore2a<75 then early2a=1; 
if 75<=earlyscore2a<114 then early2a=2; 
if 114<=earlyscore2a<143 then early2a=3; 
if earlyscore2a=>143 then early2a=4; 
 282 
if earlyscore2b<147.5 then early2b=1; 
if 147.5<=earlyscore2b<273.5 then early2b=2; 
if 273.5<=earlyscore2b<362.0 then early2b=3; 
if earlyscore2b=>362.0 then early2b=4; 
if earlyscore2c<191 then early2c=1; 
if 191<=earlyscore2c<305 then early2c=2; 
if 305<=earlyscore2c<381.5 then early2c=3; 
if earlyscore2c=>381.5 then early2c=4; 
run; 
 





proc freq data=checkinglate; 
table latescore1a; 
run; 





if latescore1a<21 then late1a=1; 
if 21<=latescore1a<24 then late1a=2; 
if 24<=latescore1a<32 then late1a=3; 
if latescore1a=>32 then late1a=4; 
if latescore1b<51.5 then late1b=1; 
if 51.5<=latescore1b<62.0 then late1b=2; 
if 62.0<=latescore1b<72.0 then late1b=3; 
if latescore1b=>72.0 then late1b=4; 
if latescore1c<55 then late1c=1; 
if 55<=latescore1c<64 then late1c=2; 
if 64<=latescore1c<84.5 then late1c=3; 
if latescore1c=>84.5 then late1c=4; 
if latescore2a<114 then late2a=1; 
if 114<=latescore2a<161 then late2a=2; 
if 161<=latescore2a<174 then late2a=3; 
if latescore2a=>174 then late2a=4; 
if latescore2b<221 then late2b=1; 
if 221<=latescore2b<277 then late2b=2; 
if 277<=latescore2b<367 then late2b=3; 
if latescore2b=>367 then late2b=4; 
if latescore2c<257.5 then late2c=1; 
if 257.5<=latescore2c<309.5 then late2c=2; 
if 309.5<=latescore2c<426.5 then late2c=3; 









/*READS IN YOUR DATASET AND CHANGES THE SURVIVAL 
VARIABLES READY FOR USE*/ 
/*ALSO CHANGES THE DATA TO YEARS OR MONTHS OR DAYS*/ 
data surv; 
set &data; 
if &surv <0 then delete; 
cens = &cens; 
/*survival analysis-Initially all High risk behaviour together*/ 
/*Survival macro used*/ 
if lowcase("&period") = "months" then surv = &surv / 30.44; 
if lowcase("&period") = "years" then surv = &surv / 365.25; 
if lowcase("&period") = "days" then surv = &surv / 1; 
if surv > &end then do; surv = &end; cens = 0; end; 
fup = 0; 
if surv = &end or cens ne 0 then fup = 1; 
run; 
 
/*GETS THE COUNT FOR EACH STRATA*/ 
proc freq data = surv noprint; table &var / out = num; run; 
 
/*GETS THE COUNT FOR FOLLOW UP*/ 
proc freq data = surv noprint; table &var * fup / out = fup; run; 
 
/*OPENS THE FILE TO SAVE THE PLOT*/ 
filename gsasfile "&file.\&cgm..emf"; 
 
/*RUNS THE LIFETEST PROCEDURE TO OUTPUT THE DATA 
NEEDED FOR THE PLOT*/ 
ODS OUTPUT homtests=homtests; 
proc lifetest data=surv plots=(s) outsurv=surv1; 




/*SORTS OUT THE LAYOUT OF THE PLOT AND CHOOSES 
COLOURS FOR THE LINES*/ 
goptions reset=all reset=symbol htext=1.8 cback=white colours=(black)  
/*ftext=HWCGM005*/ ftext='Arial/bold' 
noborder hsize=8.5 vsize=9.5 Gaccess=GSASFILE;run; 
axis1 minor=none order=&yaxis to 100 by 10 label=(ANGLE=90 "% 
&survival survival"); 
axis2 minor=none order=0 to &end by &end1 label=("&period post-
transplant"); 
symbol; 
symbol1 c=CXFF6600 i=steplj w=4 l=1 v=none; 
symbol2 c=CX99CCFF i=steplj w=4 l=1 v=none; 
symbol3 c=CXFFCC00 i=steplj w=4 l=1 v=none; 
symbol4 c=CX339966 i=steplj w=4 l=1 v=none; 
symbol5 c=black    i=steplj w=4 l=1 v=none; 
symbol6 c=CXFF6600 i=steplj w=4 l=2 v=none; 
symbol7 c=CX99CCFF i=steplj w=4 l=2 v=none; 
symbol8 c=CXFFCC00 i=steplj w=4 l=2 v=none; 
symbol9 c=CX339966 i=steplj w=4 l=2 v=none; 
symbol10 c=black   i=steplj w=4 l=2 v=none; 
 
 LEGEND1 ACROSS=1 
         POSITION=(BOTTOM INSIDE CENTER) 
         MODE=SHARE 
         OFFSET=(0,1.5) 
         SHAPE=SYMBOL(5,1) 
   CBORDER=Black 
         LABEL=(POSITION=(TOP) 
                JUSTIFY=CENTER H=1.2 "&var") 
   VALUE=(H=1.2); 
 
/*PRODUCES THE PLOT*/ 
data splot1; set surv1; retain lag_s; drop=lag_s; if survival=. then 
survival=lag_s; 
lag_s=survival; run; 
data splot2; set splot1; survival=survival*100; 
proc gplot data=splot2; plot survival * surv = &var /legend=legend1 
noframe vaxis=axis1 haxis=axis2;  
title ' '; run; quit; 
 
/*USES THE DATA TO OBTAIN THE SURVIVAL ESTIMATES FOR 
THE STRATA*/ 
data surv2; set surv1; if _censor_ = 0; run; 
proc sort data = surv2; by &var survival; run; 
proc sort data = surv2 nodupkey; by &var; run; 
 
data surv3; set surv2; surv = (survival*100); lcl = (sdf_lcl*100); ucl = 
(sdf_ucl*100); 
format surv lcl ucl 10.1; run; 
 
data surv4; merge surv3 num; by &var; run; 
 
/*OBTAINS THE P-VALUE FOR THE STRATA*/ 
data _null_; 
set homtests; 
where test = 'Log-Rank'; 
call symput ("logrank",trim(left(put(ProbChiSq,PVALUE6.4)))); 
run; 
 
/*PRINTS THE ESTIMATES, COUNT AND P-VALUE FOR THE 
DATA*/ 
title1"&survival survival by &var p=&logrank";                                                                                                                                                                                         
proc print data = surv4; var &var count surv lcl ucl;  run; 
%mend survival; 
 
/*MACRO VARIABLES REQUIRED*/ 
/*%survival(data,surv,cens,time,end,end1,censor,var,survival,period,cg
m);*/ 
/*WHERE data=dataset with survival variables 
  surv=name of survival variable - eg 
gsurv 
  cens=name of censoring variable - 
eg gcens 
  period=years, months, days 
  end=put 10 if wanting 10 year 
survival, 12 for 12 month survival, 30 for 30 day survival 
  end1=how big you want your x-label 
gap eg 1 if you want 10 years by 1 year 
  var=variable you want to strata by - 
eg centre 
  survival=either graft, patient or 
transplant 
  yaxis=point at which you want the 
yaxis to start, 40 is standard 








proc freq data=checking2;table listingcentre;run; 
data why; 
set checking2; 
if endstat in ('RS', 'R', 'S', 'RA') or deadly=1 then removed=1;else 
removed=0; 
run; 

























proc phreg data=alldeath5; 
class risky(ref='1')/param=ref; 
model new_time*deadly(0)=risky rage; 
hazardratio risky/diff=ref; 
run;
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